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Summary
Genotoxicology involves the assessment of a substance’s ability to induce DNA damage after 
exposure to humans. DNA damage is an underlying cause of mutations that are likely to 
initiate carcinogenesis. Furthermore, the investigation of low dose responses in 
genotoxicology testing helps to improve health risk assessment by establishing whether DNA 
reactive compounds follow linear or non-linear (thresholded) dose response relationships.
The current assumption for direct acting genotoxins is that the relationship between exposure 
to genotoxic chemicals, DNA damage formation and the induction of mutagenic changes is 
linear. However, it is known that mutations are not produced directly by DNA adducts as 
DNA repair activity limits the proportion of adducts processed into mutations. It is therefore 
possible, that no observed effect levels (NOEL) may exist for some genotoxins.
The main aim of this thesis was to improve in vitro genotoxicity testing by assessing the low 
dose response relationships for the genotoxic agents mitomycin-C (MMC), 4-nitroquinoline 
1-oxide (4NQO) and cytosine arabinoside (araC). Furthermore, the automated micronucleus 
slide scoring system Metafer was validated and used for these studies.
In addition, the mechanism of action of each test component was further investigated by 
follow up experiments to gain a better understanding of the processes involved in this type of 
damage.
The in vitro micronucleus assay for the detection of chromosomal damage revealed non­
linear dose response relationships following low dose exposure of MMC and araC, while 
4NQO revealed a weak clastogenic potential. The semi-automated scoring protocol for the 
Metafer-System proved to be a rapid and accurate system for scoring micronuclei.
DNA repair plays most likely a major role in these non-linear responses by removing genetic 
damage induced at low levels. Furthermore, p53 was shown to be involved in the DNA 
damage response in human lymphoblastoid cells, through cell cycle delay and the induction 
of apoptosis.
In addition, this work confirmed that a proper dosing regime, accurate toxicity measurements 
and the appropriate choice of cell type are cmcial criteria for defining the dose response 
relationships and the induction of genotoxicity and cytotoxicity.
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Chapter 1 
General Introduction
Genotoxicology involves the assessment of a substance’s ability to induce DNA damage, 
which is an essential consideration for human risk assessment, because DNA damage is an 
underlying cause of mutations that have the potential to initiate carcinogenesis. A mutation is 
defined as a permanent change in the amount or structure of the genetic material of a whole 
organism or a single cell (Dearfield et al., 2002; COM guideline, 2011). Mutations can range 
from alterations in genes to modifications of the number and/or structure of chromosomes. 
Gene mutations are changes in the nucleotide sequence, which involve single point mutation 
(substitutions or frameshift mutation), or small deletions or duplications. Chromosome 
mutations comprise alterations in segments of chromosomes through whole chromosomes or 
entire sets of chromosomes (COM guideline, 2011). Mutations in germ cells can cause 
heritable effects, which then may also have an impact on the offspring. Thus characterising 
DNA damage is crucial to minimising the detrimental impact of exposure to exogenous 
substances (COM guideline, 2011).
Compounds, which interact with DNA and cause mutations, are called mutagens and/or 
genotoxins. These compounds can interact with DNA by various mechanisms, such as direct 
interaction of the compound with DNA, interaction of the compound with cellular 
components that cause indirect DNA damage and DNA damage can be induced through 
activation of the compound by cellular metabolism to produce products, which are capable to 
interact with DNA (Parry and Parry, 2012). Examples of chemicals which directly interact 
with the DNA helix are mitomycin C and 4-nitroquinoline 1-oxide; while the production of 
reactive oxygen species is a mechanism as an example of the generation of secondary active 
molecules which are capable to react with DNA. The metabolism of benzo(a)pyrene by 
arylhydrocarbon hydroxylases into a diol epoxide, which then reacts with DNA, is an 
example for activation of a compound by cellular metabolism into a reactive metabolite 
(Levin et al., 1977; Parry and Parry, 2012).
1.1 DNA damage, mutagenesis and carcinogenesis
DNA damage plays a key role in mutagenesis and carcinogenesis as an important cause of 
genetic disease. Chemical events that can lead to DNA damage include hydrolysis, exposure 
to reactive oxygen species (ROS) and electrophilic attack (Mamett and Plastaras, 2001; De
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Bont and van Larebeke, 2004). These reactions are triggered through exposure to exogenous 
chemicals, such as environmental agents, food additives and constituents or are the result of 
endogenous reactive metabolites (Mamett and Plastaras, 2001).
Mutations due to DNA damage (exogenous and endogenous) play an essential role in 
carcinogenesis. Consequently knowledge of the types of endogenous DNA damage is crucial 
for the understanding of the interaction of exogenous agents and the influences of 
endogenous processes in the development of cancer and other diseases (De Bont and van 
Larebeke, 2004).
1.1.1 Endogenous DNA damage and mutation
Endogenous (spontaneous) mutations arise from a variety of sources, including DNA 
replication errors, spontaneous lesions and transposable genetic elements. Oxidation, 
methylation, deamination and depurination are major endogenous processes leading to 
significant DNA damage (Ames et al., 1993). Endogenous DNA damage occurs at a high 
rate, but specific DNA repair glycosylases for oxidative, methylated and deaminated adducts 
and a repair system for apurinic sites contribute to the low frequency of spontaneous 
I mutations, which is estimated to be 10' to 10' mutations per nucleotide per cell per
i
* generation (Drake et al., 1969; Ames et al., 1993).
I
| Errors in replication can occur due to misincorporation of bases during DNA replication
i
leading to base substitutions (Griffiths et al., 2000). Mispairs can lead to transition mutations,
i
! in which a purine substitutes for a purine or a pyrimidine for a pyrimidine, or to transversion
! mutations, where a pyrimidine substitutes for a purine and vice versa (Griffiths et al, 2000).
I
| Further replication errors can lead to frameshift mutations and deletions and duplications
constitute to a sizeable fraction of spontaneous mutations (Griffiths et al., 2000).
In addition to replication errors, spontaneous lesions can generate mutations, including 
apurinic/apyrimidic (AP) sites, deamination and oxidative DNA damage. AP sites often occur 
through the disruption of the glycosidic bond between the base and the desoxyribose and the 
subsequent loss of a base from the DNA leaving a gap in the DNA sequence (Griffiths et al., 
2000). The resulting AP sites, if not repaired, cannot specify a base complementary to the 
original base during replication.
Deamination of DNA bases can cause transition mutations. For instance, the deamination of 
cytosine produces uracil, which will pair with adenine during replication if unrepaired and 
result in the conversion of a G-C pair into an A-T pair (Griffiths et al., 2000).
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Reactive oxygen species (ROS), such as superoxide radicals, hydrogen peroxide and 
hydroxyl radicals are continuously formed as a consequence of metabolic and other 
biochemical reactions. ROS can oxidize DNA, which can lead to DNA damage, including 
oxidized bases and single- and double-strand breaks (De Bont and van Larebeke, 2004).
To summarize, endogenous mutations can be generated by different processes. Errors in 
replication and spontaneous lesions cause most of the significant DNA damage.
1.1.2 Exogenous DNA damage and mutation
Mutations can be caused through exposure to exogenous chemicals. Exogenous agents 
include aromatic amines, alkylating agents, radiation and other reactive chemicals.
Some chemical agents act as base analogs and are incorporated into the DNA in place of 
normal bases, where they can cause mispairs. For instance, 5-bromouracil is an analog of 
thymine, whereas 2-amino-purine is an analog of adenine (Griffiths et al., 2000). Alkylating 
agents, such as ethylmethanesulfonate can cause specific mispairing through alteration of a 
base. Ionizing radiation can lead to the formation of ionized and excited molecules that can 
cause damage to the DNA, including formation of AP sites or DNA strand breaks (Griffiths 
et al., 2000).
In conclusion, mechanisms by which these agents can cause mutation include mimicking 
normal bases and incorporation into the DNA, where they can mispair (Griffiths et al, 2000). 
The types of endogenous DNA damage are similar to those caused by exogenous agents.
1.1.3 Multiple mutations in cancer
The ability of substances to induce mutations and their ability to induce cancer are correlated, 
as mutations are essential for cancer to evolve (Loeb and Loeb, 2000). Cancer is a genetic 
disease and cancer cells contain multiple mutations, implying that tumour progression is 
driven by mutagenesis (Loeb and Loeb, 2000; Sarasin, 2003). It has been estimated that four 
to seven mutations in key genes are necessary for the induction of human cancers (Sarasin, 
2003). Early events of carcinogenesis involve mutations in genes that are key in maintaining 
genetic stability of cells, leading as a result to genetic instability in cancer cells and resulting 
in a cascade of mutations which enable cancer cells to bypass regulatory processes, such as 
cell cycle progression, apoptosis and gene expression (Loeb and Loeb, 2000; Jackson and 
Loeb, 2001).
Normal mutation rates followed by the selective advantage of mutated clones might be 
enough to produce the multiple mutations found in human cancers (Sarasin, 2003). However,
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mutations in normal cells only occur at a rate of 10'10 mutations per nucleotide per cell per 
generation. Therefore Loeb et a l (2003), proposed that normal mutation rates are insufficient 
to account for the numerous mutations found in tumours and that mutations increase the basal 
mutation rate and lead to multiple mutations (Loeb et al., 2003; Sarasin, 2003).
Several types of genetic modification have been identified in human tumours, including base 
substitutions, deletions or additions of a few nucleotides, losses or gains of whole 
chromosomes, chromosome translocation and gene amplification (Sarasin, 2003). The loss or 
gain of whole chromosomes results from a defective mitosis and leads to chromosomal non­
disjunction (Jackson and Loeb, 2001), while chromosome translocations result from fusion 
between two non-adjacent sequences on the same chromosome or on two different 
chromosomes (Sarasin, 2003).
Consequently, the ability to detect substances which cause DNA mutations is essential in the 
risk assessment for human populations. Assessing substances for their DNA damage 
capability might be a useful tool as a surrogate for carcinogenicity testing. To provide 
comprehensive coverage of the mutagenic potential of a chemical it is necessary to supply 
information on three levels of DNA damage: gene mutation, clastogenicity (i.e. structural 
chromosome aberrations) and aneuploidy (i.e. numerical chromosomal aberrations) (COM 
guideline, 2011). Consequently, genotoxicity testing was established to investigate the 
mutagenic potential of all new synthetic chemicals and regulatory bodies developed 
guidelines and assays for genotoxicity testing.
1.2 Regulatory authorities and testing
Many countries have developed guidelines for testing the genotoxicity of new chemicals. No 
single test alone can predict the entire spectrum of inducible mutations, because of the variety 
of genetic events that can occur (Cimino, 2006). Non-human test systems are able to predict 
the intrinsic mutagenicity of test chemicals because of the universality of DNA and the 
genetic code, even though differences in metabolism or DNA repair may exist (Dearfield et 
al., 2002). Furthermore, chemicals causing genetic effects in one species or test system (e.g. 
bacterial, insect, rodent) show largely similar effects in other species or systems (Dearfield et 
al., 2002).
Initial screens for genotoxic activity include a range of in vitro tests to cover the three main 
endpoints. Advantages of in vitro systems include easy and rapid culture conditions, exposure 
of target cells and most importantly no use of live animals for the exposure of toxic 
compounds. However disadvantages, like poor characterisation of the metabolic capability of
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cell lines or the fact that organ homogenates used in exogenous activation systems might be 
cytotoxic to mammalian cells in culture led to the conclusion that in vivo tests should be 
included in the standard test battery (Cimino, 2006).
1.2.1 History of testing strategies
Concerns about chemicals introducing deleterious alterations in the DNA of humans, which 
were demonstrated by Auerbach and Robson in the late 1940s (Auerbach and Robson, 1946) 
and concerns about germ line mutations, led to the formation of the Environmental Mutagen 
Society in 1969 in the United States. Subsequently, in the 1970s requirements for testing for 
mutagenic properties of chemicals were introduced (MacGregor et al., 2000). The publication 
of a key paper by McCann et al, “Carcinogens are Mutagens: Analysis of 300 Chemicals” 
showed a strong correlation of mutagenic activity in Salmonella with animal carcinogenicity 
(McCann et al., 1975; MacGregor et al., 2000). In vitro mutagenesis screening tests, like the 
Ames test, were then used to identify chemical carcinogens. Furthermore, regulatory 
guidelines for the bacterial gene mutation test were implemented during the 1970s and 1980s 
(MacGregor et al., 2000). However at that time it was also recognized that mutations could 
arise by multiple mechanisms and that the Ames test was not adequate to detect chromosomal 
interchanges or large chromosomal deletions. From this it followed that an in vitro test 
battery was devised to be able to detect all major classes of damage which could be fixed as 
heritable mutations (MacGregor et al., 2000). The first test batteries used included (1) a 
bacterial test for gene mutation, (2) an in vitro test for chromosomal aberrations or a 
mammalian cell mutagenesis test and (3) a general DNA damage test (MacGregor et al., 
2000).
During the 1970s, guidelines for testing environmental chemicals (and in 1982 for food 
additives) were drafted in the US (MacGregor et al. 2000). In 1993 the US Food and Drug 
Administration (FDA)-recommended testing battery was (1) a bacterial test for gene 
mutation, (2) an in vitro mammalian gene mutation test and (3) an in vivo cytogenetic damage 
assay, with preference for a rodent bone marrow assay (MacGregor et al, 2000). Similar 
recommendations, but with regional differences were made by the European, Japanese and 
Canadian authorities. An international consensus for a testing battery for pharmaceutical 
registration was achieved by the International Conferences on Harmonization of the 
Toxicological Requirements for Registration of Pharmaceuticals for Human Use (ICH) in the 
late 1990s and included (1) a bacterial test for gene mutation in bacteria, (2) an in vitro 
mammalian chromosome aberration test or the L5178Y mouse lymphoma mammalian cell
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mutagenesis test and (3) an in vivo chromosomal damage test in rodent hematopoietic cells 
(MacGregor et al., 2000). Since then great efforts in harmonization of testing strategies and 
testing standards have been undertaken. Recommendations for internationally harmonized 
testing protocols were developed by the Organization for Economic Cooperation and 
Development (OECD) (MacGregor et al., 2000).
1.2.2 Regulatory testing strategies in the United States, the United Kingdom and the 
European Union
Similar genotoxicity testing strategies, but with regional differences were developed for the 
detection of the mutagenic hazard of chemicals, which cover the endpoints of gene mutations 
and chromosome aberrations.
1.2.2.1 United States (US)
The regulatory agencies in the US include among others the US Environmental Protection 
Agency (EPA), the US Food and Drug Administration (FDA) and the US Consumer Product 
Safety Commission (CPSC).
The EPA evaluates environmental risks though a risk assessment process that combines 
analysis of a set of scientific data with the application of scientific judgement (Dearfield et 
al., 2002). The EPA estimates chemical risk via a four-step risk assessment paradigm 
(Dearfield et al., 2002; Cimino, 2006):
• Hazard identification: evaluates the inherent genotoxicity of an agent, 
including structure activity relationships (SAR) data to assess human 
genotoxicity
• Dose-response assessment: relationship between dose of an agent and the 
induction of an adverse effect (includes mechanisms and mode of action of the 
agent)
• Exposure assessment: extent of human exposure (route(s) of entry and levels 
of exposure)
• Risk characterization: nature and likelihood of genotoxicity risk to humans 
(including attendant uncertainty)
The current EPA test battery consists of a three-tiered system (Table 1.1), with the first tier 
including (1) the bacterial reverse mutation assay for gene mutation (Salmonella typhimurium 
and Escherichia coli), (2) an in vitro mammalian cell gene mutation assay and (3) the in vivo
Chapter 1
mammalian bone marrow chromosome aberration or the in vivo erythrocyte MN assay 
(Dearfield et al., 1991; Cimino, 2006). If the first tier studies show any genotoxicity, a second 
tier study is employed, investigating any genotoxic effects in the reproductive tissue of the 
intact mammal. Tests available include the in vivo unscheduled DNA synthesis (UDS), 
alkaline elution (AE), sister chromatid exchange (SCE) and chromosomal aberration assays, 
done in testicular tissues and the rodent dominant lethal assay (Cimino, 2006). Third tier 
studies are used to determine if any mutagenic effects are transmitted to the offspring by 
parents who were exposed to a chemical. Tests include biochemical or visible specific locus 
assays (Cimino, 2006).
The FDA is compromised of the following components:
1. Centre for Biologies Evaluation and Research (CBER)
2. Centre for Drug Evaluation and Research (CDER)
I 3. Centre for Devices and Radiological Health (CDRH)
| 4. Centre for Food Safety and Applied Nutrition (CFSAN)
i
5. Centre for Veterinary Medicine (CVM)
6. National Centre for Toxicological Research (NCTR)
7. Office of Regulatory Affairs (ORA)
8. Office of the Commissioner (OC)
iiIi
I Most centres of the FDA, which are involved in regulatory testing, follow the three test
| battery (Table 1.1) proposed for human drugs developed by the ICH (Cimino, 2006).
| CPSC is an independent regulatory agency and relies upon existing genotoxicity data, when
assessing the need to regulate a consumer product (Cimino, 2006).
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1.2.2.2 United Kingdom (UK)
Regulatory bodies in the UK are advised by the Committee on Mutagenicity of Chemicals in 
Food, Consumer Products and the Environment (COM). COM is an independent expert 
advisory committee (COM, 2000). Advised regulatory bodies include:
1. UK Department of Health (DOH)
2. Food Standard Agency (FSA)
3. Department of Environment, Transport and the Regions (DETR)
4. Health and Safety Executive (HSE)
5. Pesticides Safety Directory (PSD)
6. Veterinary Medicines Directory (VMD)
7. Medicines Control Agency (MCA)
8. Scottish Executive
9. Welsh Assembly
10. Northern Ireland Executive
The current COM test strategy consists of a staged system (Table 1.2). Stage 0 includes 
preliminary considerations, such as physico-chemical properties of the test agent, structure 
activity relationships (SAR) and information from screening tests (COM guideline, 2011). 
Stage 1 is the core-test battery, which is based on in vitro tests including (1) a bacterial gene 
mutation assay (Ames test) combined with (2) the in vitro MN test to require information for 
gene mutation, chromosome damage and aneuploidy (COM guidelines, 2011). If any 
genotoxic effects were observed in Stage 1, then Stage 2 is employed.
Stage 2 investigates if any genotoxic effects are expressed in somatic or germ cells using in 
vivo testing. The assays mainly used are the rodent MN/chromosome aberration assays, to 
investigate aneuploidy and clastogenicity and the rodent transgenic gene mutation assay 
and/or comet assay for DNA damage induction (COM guideline, 2011). However based on 
information on the compound, the UDS assay and P-postlabelling assays might be used on a 
case-by-case basis (Cimino, 2006). To measure the induction of DNA lesions i.e. as a 
measure of exposure, uptake and reactivity to DNA, the comet assay or the P-postlabelling 
assay can be used in target tissues. The liver UDS can be used to measure the repair of DNA 
lesions, whereas transgenic animal models are useful to determine the induction of genetic 
changes (COM guideline, 2000). Assays available to analyse germ line mutations include 
MN induction in spermatocytes, the dominant lethal assay and mutation assays in the
Chapter 1
reproductive tissue of transgenic mice (Cimino, 2006). To further investigate the risk for 
heritable mutations, assays including the mouse specific locus test and/or heritable 
translocation test are available.
Table 1.2: Genotoxicity Testing Scheme for the UK
Proposed UK (COM) scheme
Stage 0: Preliminary considerations
• Physico-chemical properties of test agent
• Structure activity relationships (SAR)
• Screening tests
Stage 1: Two in vitro tests:
Bacterial gene mutation assay (Ames test) 
In vitro MN assay
Stage 2: In vivo tests (at least one)
In vivo MN assay
In vivo chromosome aberration assay 
Possible other in vivo tests include:
> Comet assay
O'}
> P-postlabeling assay
> UDS, SCE
> Transgenic animal models
SCE, sister chromatid exchange; UDS, unscheduled DNA synthesis
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1.2.2.3 European Union (EU)
The EU test battery consists of a three-tiered test system (Table 1.3). Initial screening consists 
mainly of in vitro testing. The type and amounts of tests are based upon the chemical type. In 
the first tier the EU requires two in vitro tests for industrial products (1) a bacterial gene 
mutation assay and (2) a mammalian cell assay. For biocides (pesticides), cosmetic products 
and food additives the EU requires three in vitro tests, including (1) a bacterial gene mutation 
assay, (2) either the chromosome aberration or the in vitro MN assay and (3) a mammalian 
cell gene mutation assay. For pharmaceuticals the following three tests are required: (1) a 
bacterial gene mutation assay, (2) an in vitro mammalian cell chromosome aberrations assay 
or an in vitro gene mutation assay in mouse lymphoma cells and (3) either the in vivo 
chromosome aberration test or the in vivo MN assay. Five in vitro tests are required for hair 
dye ingredients. These tests include (1) the bacterial gene mutation assay, (2) a mammalian 
cell mutation assay, (3) a mammalian cell chromosomal aberration assay, (4) a mammalian 
cell MN assay and (5) a mammalian cell UDS assay (Cimino, 2006). If any of these tests 
show genotoxic activity further in vivo studies are required. However due to the 7th 
amendment to the EU Cosmetics Directive testing ban, it is no longer possible to follow up 
positive in vitro results with in vivo genotoxicity tests of cosmetic ingredients (Pfuhler et al., 
2010). A second and third tier might be employed, which investigates effects in germ cells 
and effects in the offspring of exposed parents (Cimino, 2006).
Due to the prohibition of in vivo testing for cosmetic products and their ingredients in the EU 
and due to the general direction within the scientific community to reduce animal testing, in 
vitro genotoxicity testing will be the main tool to investigate and monitor human populations 
for genetic damage in the future (Kirkland et al., 2007; Pfuhler et al., 2010).
However, the sensitivity and specificity of a number of in vitro assays needs to be improved 
due to the high false positive rate observed for in vitro genotoxicity tests when compared 
with carcinogenicity in rodents (Kirkland et al., 2007; Pfuhler et al., 2010). The main areas of 
focus in the reduction of false positive results are: choices of cell type, toxicity measurements 
and maximum concentration to be tested (Pfuhler et al., 2010). Further new assays need to be 
developed to follow up positive results from in vitro assays, i.e. the use of 3D human 
reconstructed skin models and weight of evidence assessments (using information on the 
chemical itself, structural/functional analogues, metabolites, etc.) need to be conducted 
(Pfuhler et al.,2010).
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1.2.3 International Standardization
ICH and OECD attempt to standardize testing strategies for genotoxicity as well as test 
guidelines between different regulatory authorities and countries to produce useful and 
transparent data.
1.2.3.1 ICH Harmonization
The first meeting of the ICH took place in Tokyo in December 1992 (Cimino et al., 2006). 
The membership of the workgroup comprises two co-sponsors from each of three regions, 
Europe, Japan and the US. One co-sponsor represents the regulatory authority, whereas the 
second co-sponsor represented the pharmaceutical industry (Cimino, 2006). The six co­
sponsors are:
• Commission of the European Union
• European Federation of Pharmaceutical Industries and Associations (EFPIA)
• Ministry of Health and Welfare (MHW), Japan
• Japan Pharmaceutical Manufacturers Association (JPMA)
• U.S. Food and Drug Administration (FDA)
• Pharmaceutical Research and Manufacturers of America (PhRMA)
Furthermore the World Health Organization, the European Free Trade Area and Canada act 
as observers (Cimino, 2006).
Over the years the ICH workgroup developed two guidances for genotoxicity testing: S2A 
“Guidance on specific aspects of regulatory genotoxicity tests” (ICH, 1996b) and S2B 
“Genotoxicity: a standard battery for genotoxicity testing of pharmaceuticals” (ICH, 1997b), 
which provides general advice for genotoxicity testing and assessment of pharmaceuticals 
(Cimino, 2006).
The current ICH test battery consists of (1) a gene mutation test in bacteria, (2) an in vitro 
mammalian chromosomal damage test or the in vitro mouse lymphoma assay and (3) an in 
vivo test to investigate chromosomal damage in rodent hematopoietic cells (Cimino, 2006).
1.2.3.2 OECD Test Guidelines
OECD is an international organization with the aim to develop and coordinate environmental 
health and safety activities on an international level (Cimino, 2006), including:
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• Harmonizing chemical testing and hazard assessment procedures
• Harmonizing classification and labelling
• Developing principles for Good Laboratory Practices (GLPs)
• Cooperating on the investigation of existing chemicals
• Sharing and exploring cooperative activities on risk management
Over recent years OECD developed several guidelines for the testing of chemicals (OECD, 
2005; Cimino, 2006). The guidelines are internationally accepted and used by government, 
industry and independent laboratories. Furthermore the data produced in studies following the 
guidelines are accepted by all OECD member countries (30 countries) (Cimino, 2006).
1.3 Mutation assays
A battery of mutagenicity tests is used for the detection of gene, chromosome or genome 
mutations to assess human risk for genetic damage. As mentioned above, a battery of in vitro 
tests for hazard identification has been developed which employs a wide variety of 
organisms, including bacteria, yeast and other eukaryotic microorganisms as well as 
mammalian cells (COM guideline, 2000). These tests include the Ames test (mutation in 
bacteria), the gene mutation test (mutation in mammalian cells), chromosomal aberration or 
MN assays in cultured human or Chinese hamster cells.
Furthermore a battery of in vivo tests are available for hazard characterisation and can be also 
used for risk assessment, including the MN assay in rodent bone marrow, blood or liver for 
chromosomal aberrations, the comet assay for DNA damage, DNA adduct analysis in 
appropriate tissues or the MutaMouse model for mutation in target genes of transgenic 
animals (COM guideline, 2000).
1.3.1 In vitro gene mutation assays
In vitro gene mutation assays are commonly used in genotoxicity testing as initial screens for 
mutagenicity and carcinogenesis. Tests available include the bacterial reverse mutation assay 
as well as the in vitro mammalian cell gene mutation assay.
1.3.1.1 Bacterial Reverse Mutation Test
The short-term bacterial reverse mutation assay (Ames test) allows identifying substances 
that lead to gene mutations. The test is used as an initial screen for the mutagenic potential of
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new chemicals and drugs as there is a high predictive value for rodent carcinogenicity when 
the test shows a positive response (Mortelman and Zeiger, 2000).
The assay uses a number of auxotrophic amino acid-dependent strains of Salmonella 
typhimurium and Escherichia coli. Salmonella typhimurium strains have mutations in the 
histidine operon that leaves the bacteria unable to synthesize histidine, whereas the 
Escherichia coli strains used have mutations in the gene for the amino acid tryptophan, which 
leaves the bacteria unable to synthesize tryptophan (OECD, 1997a). In the absence of a 
histidine respectively tryptophan source, the cells are unable to grow to form colonies. 
Colony growth can be restored by new mutations at the site of the mutation or nearby in the 
genes allowing the cells to synthesize histidine or tryptophan respectively (Mortelman and 
Zeiger, 2000). Revertant cells grow on minimal agar that contains small amounts of histidine 
or tryptophan, whereas wild-type cells stop growing after depleting the traces of amino acid 
(OECD, 2008).
The bacterial reverse mutation test uses prokaryotic cells, which differ in certain factors, such 
as uptake, metabolism, chromosome structure and DNA repair processes from mammalian 
cells (OECD, 1997a). Therefore it is important to keep in mind that the Ames test does not 
provide direct information on the mutagenic and carcinogenic potency of substances in 
mammals (OECD, 1997a). Despite this, the Ames test is a commonly used and robust test for 
the initial screening of genotoxic activity.
1.3.1.2 In vitro mammalian cell gene mutation test
The in vitro mammalian cell gene mutation test identifies substances that lead to gene 
mutations in mammalian cells. The test detects mutated cells which are able to survive in the 
presence of a selective agent only after the new mutation occurs (Aaron et al., 1994).
Suitable cell lines for the test include the L5178Y mouse lymphoma cells, the CHO, AS52 
and V79 lines of Chinese hamster cells and the human lymphoblastoid cell line TK6 (OECD, 
1997e). Endpoints measured are mutation at thymidine kinase (TK), hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) and a transgene of xanthine-guanine phosphoribosyl 
transferase (XPRT) (Aaron et al., 1994; OECD, 1997e). The HPRT locus is on the X- 
chromosome, whereas the TK and XPRT locus lies on an autosome. Therefore these mutation 
tests detect different spectra of genetic events, for example the location of TK and XPRT 
allows detecting large deletions not detected at the HPRT locus (OECD, 1997e).
Cells deficient in TK, due to TK+/' to TK7’ mutation, are resistant to the cytotoxic effects of 
the pyrimidine analogue trifluorothymidine (TFT), whereas cells deficient in HPRT or XPRT
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are resistant to 6-thioguanine (6-TG) or 8-azaguanine (8-AG) (OECD, 1997e). Therefore 
mutant cells are able to proliferate in the presence of TFT, 6-TG or 8-AG, whereas the 
cellular metabolism of normal cells is inhibited and further cell divisions are put on hold 
(OECD, 1997e).
1.3.2 In vitro chromosome aberration assays
The in vitro chromosome aberration assays identify substances that cause chromosomal 
damage (OECD, 1997b), including chromosome loss or gain (aneuploidy) and/or 
chromosomal breakage (clastogenicity). Assays available are the in vitro mammalian 
chromosome aberration test or the in vitro MN assay (see section 1.4 for further detail).
1.3.2.1 The in vitro mammalian chromosome aberration assay
The in vitro mammalian chromosome aberration assay identifies substances that cause 
structural chromosome aberrations in cultured mammalian cells (OECD, 1997b). Suitable for 
the in vitro test are cultures of established cell lines, cell strains or primary cell cultures. 
These are selected by growth ability in culture, stability of karyotype, chromosome number 
and diversity as well as spontaneous frequency of chromosome aberrations (OECD, 1997b). 
Cell cultures are treated with a metaphase-arresting substance at predetermined intervals after 
exposure to the test compound with and without metabolic activation (Galloway et al., 1994; 
OECD, 1997b). This allows condensed chromosome preparations to be produced for easy 
analysis of chromosome defects. Afterwards cultures are harvested, stained and analysed (in 
the metaphase stage) microscopically for the presence of chromosome aberrations (Galloway 
et al., 1994; OECD, 1997b).
The in vitro mammalian chromosome aberration test is used to screen for possible 
mammalian mutagens and carcinogens since many compounds detected positive in the test 
are mammalian carcinogens. However it is important to keep in mind that there is not a 
perfect correlation between the test and carcinogenicity (OECD, 1997b). Further the assay is 
laborious and requires highly trained laboratory staffs, who are experienced in scoring 
chromosome aberrations.
1.3.3 In vivo assays for somatic cell gene mutation in endogenous and transgenic genes
In vivo assays for gene mutation in endogenous genes, like the mouse spot test, are not widely 
used for testing purposes because of the lack of effective methods and high costs (OECD,
16
2008). Mutation tests using endogenous genes, i.e. Hprt, Aprt, TKH'/' and Dlb-1 have been 
developed, but are not yet used for routine testing (OECD, 2008).
In vivo assays for gene mutation in transgenes are available for routine testing. With the help 
of transgenes, i.e. LacZ or LacI, mutations can be detected in almost every tissue. However 
they appear to have high background mutation rates, which are leading to relatively high 
background mutation frequencies that seem to lower the sensitivities for detecting induced 
mutations resulting from exogenous chemicals (Svenberg et al., 2008).
1.3.3.1 Mouse spot test
The mouse spot test is used to identify substances that cause gene mutations and re­
combinations in somatic cells of mice. In this test developing embryos are treated with a test 
chemical. The target cells are mouse melanoblasts, which are heterozygous for several 
recessive coat colour genes (OECD, 1986b; OECD, 2008). Mutations in or loss of the 
dominant allele in those colour genes produces varies coloured spots in the coat of the 
resulting mouse as a result of the expression of the recessive phenotype (OECD, 1986b).
1.3.3.2 Transgenic mutation detection systems
The transgenic rodent gene mutation assay allows detection of mutations in a range of 
somatic and germ cells. The assay uses transgenic mice and rats that contain multiple copies 
of chromosomally integrated plasmid or phage shuttle vectors. These transgenes harbour 
reporter genes, for example L a d  and LacZ, for the detection of gene mutations and/or 
chromosomal rearrangements (OECD, 2008).
Mutations arising in rodents are scored by recovering the integrated plasmid or shuttle vector 
and analysing the phenotype of the reporter gene in a bacterial host (OECD, 2008). The host 
is deficient for the reporter gene. Furthermore the mutant transgenes can be sequenced to 
determine the mutation spectrum (OECD, 2008). However, one of the disadvantages of the 
assay is the relatively high spontaneous mutant frequency in comparison with the endogenous 
targets (OECD, 2008).
1.3.4 In vivo assays for somatic cell chromosomal aberrations
The in vivo chromosomal aberration assays have the potential to detect substances that cause 
DNA damage at the chromosome level. The substances can either effect the chromosome 
structure or, by interfering with the mitotic apparatus, alter the chromosome number (OECD, 
2008).
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Tests available include the bone marrow chromosomal aberration assay and the rodent
erythrocyte MN assay (see in section 1.4 for further detail).
1.3.4.1 Mammalian bone marrow chromosome aberration test
The mammalian bone marrow chromosome assay identifies substances that cause 
chromosome aberrations in bone marrow cells of animals (OECD, 1997d). The mammalian 
bone marrow chromosome aberration test is used to assess mutagenic hazard and takes in 
vivo metabolism, pharmacokinetics and DNA repair processes into consideration, although 
these factors may vary among species and tissues (OECD, 1997d).
Mice, rats or Chinese hamsters are used for the test and administered with a test chemical.
Animals are then treated with a spindle inhibitor prior to bone marrow processing to arrest 
cells in metaphase (Tice et al., 1994). Chromosome preparations from the bone marrow are 
subsequently stained and scored for aberrations (Tice et al., 1994).
1.4 The micronucleus (MN) assay 
i  The MN assay is one of the most common assays used in genotoxicity testing to study DNA
damage at the chromosome level and is part of the initial screening batteries for mutationalj
| hazard of chemicals.
!
| MN are expressed in dividing cells and are derived from either chromosome fragments
| arising from asymmetrical structural aberrations lacking centromeres (acentric fragments) or
| represent whole chromosomes, which are not incorporated into the nucleus during DNA
j replication and nuclear division (Fenech, 1997; Fenech et al., 1999; Fenech, 2000). MN can
be measured in peripheral blood lymphocytes and to a lesser extent in epithelial cells, 
| erythrocytes and fibroblasts (Fenech et al., 1999). Chromosome specific probes for
centromeric, pericentromeric or telomeric regions of human, rat and mouse chromosomes 
allow further investigation of the origin of MN (chromosome breakage and/or chromosome 
loss) as well as the distribution of sister chromatids between daughter cells (chromosome loss 
or chromosome non-disjunction) (Figure 1.1) (Kirsch-Volders et al., 1997). Chromosome loss 
is caused by lagging chromosomes at the metaphase plate during the anaphase movement, 
while chromosome non-disjunction is the failure of two sister chromatids to segregate 
(Kirsch-Volders et al., 1997).
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micronucleus expression in a dividing cell
Figure 1.1: The origin of MN (chromosome breakage and/or chromosome loss) in a dividing 
cell at anaphase (from Fenech et al., 1999)
The advantage of using the MN assay is the relatively simple scoring procedure and the 
statistical power obtained from scoring large numbers of cells (Fenech et al., 2000). The 
diameter of the MN, which are morphologically identical to, but smaller than the main nuclei, 
varies between 1/16th and 1 /3rd of the mean diameter of the main nuclei (Figure 1.2) 
(Fenech, 2000; Fenech et al., 2003).
Figure 1.2: Appearance and relative size of MN in binucleated cells, a) Cell with two MN 
with l/3rd and l/9th the diameter of the main nuclei, b) MN touching the main nuclei, c) A 
binucleated cell with a nucleoplasmic bridge and MN. d) Cell with MN of various sizes (from 
Fenech, 2000).
1.4.1 History of the MN assay
MN have been described by many scientists for more than a century. In the late 1800s and 
early 1900s, Howell and Jolly described Feulgen-positive nuclear bodies, which represented 
chromosomes separated from the mitotic spindle (Howell-Jolly bodies) to haematologists 
(Howell, 1890; Jolly, 1905; Decordier et al., 2006). Cytogeneticists described similar 
structures after in vitro irradiation of cells (Thoday, 1951; Evans et al., 1959) and assumed 
that the structures originate from acentric fragments, which were excluded from the daughter 
nuclei during mitosis (Decordier et al., 2006).
(a) (b) (c) (d)
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In the early 1970s the term MN test was used for the first time by Boiler and Schmid (Boiler 
and Schmid, 1970) and Heddle (Heddle, 1973). They showed that the MN test system is a 
rapid method to detect chromosomal damage after in vivo exposure (X-rays) of animals using 
bone marrow erythrocytes (Heddle, 1973; Decordier et al., 2006). In 1976, Countryman and 
Heddle showed that the MN test could also be used for peripheral blood lymphocytes. The 
advantages of peripheral lymphocytes amongst others are availability, wide body distribution 
for in vivo studies and convenient culturing methods (Countryman and Heddle, 1976). 
Furthermore they suggested that the MN assay could be useful as a rapid screening method. 
The conventional MN methods did not discriminate between dividing and non-dividing cells. 
MN are expressed only in cells that have undergone a nuclear division. In the early 1980s, 
Fenech and Morley reported a method (cytokinesis-block micronucleus (CBMN) method), 
which could inhibit cytokinesis by using an inhibitor of microfilament assembly, called 
cytochalasin B (Fenech and Morley, 1986). Cytochalasin B is a known inhibitor of actin 
polymerisation, which is required for the formation of the microfilament ring that constricts 
the cytoplasm between the daughter nuclei during cytokinesis. This enabled reliable 
comparisons of chromosome damage between cell populations that may differ in their cell 
division kinetics by scoring binucleated cells only (Fenech and Morley, 1986; Fenech, 2000). 
The CBMN assay solved the problem of variation in the MN frequency caused by alterations 
in the proportion of dividing cells (Figure 1.3) (Fenech, 2000; Kirsch-Volders et al., 2003).
Figure 1.3: The origin of MN (A) from chromosome loss and chromosome breakage at 
anaphase. (B) Nucleoplasmic bridge formation from a dicentric chromosome. In the CBMN 
assay cells are identified by their binucleated appearance through cytochalasin B treatment. 
This method enables the distinction between cells that are not dividing and cells that are 
undergoing mitosis within a cell population (from Fenech, 2000)
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In 1980, Yamamoto and Kikuchi made a first attempt to distinguish clastogens from 
aneugens by measuring the diameter of the MN (Yamamoto and Kikuchiu, 1980; Kirsch- 
Volders et al., 1997) and in 1986, Vig and Sweamgrin showed that centromeres in MN could 
be immunologically visualized with anti-kinetochore antibodies from CREST-patients 
(calcinosis, Raynaud phenomenon, esophageal dismotility, sclerodactyly, and telangiectasia) 
(Vig and Sweamgrin, 1986; Kirsch-Volders et al., 1997). The CREST serum contains 
antibodies that bind specific to protein of the kinetochore region of chromosomes of 
mammalian cells (Kirsch-Volders et al., 1997). Further, in 1989 Vanderkerken et al. 
distinguished clastogens from aneugens with the C-banding technique, which is based on the 
detection of pericentromeric DNA. However the method cannot detect Y-chromosomes in 
mice because of its C-heterochromatin deficiency and is limited to animal species with 
chromosomes without intercalary C-heterochromatin (Vanderkerken et al., 1989, Kirsch- 
Volders et al., 1997).
In the late 1980s and in the early 1990s the use of DNA probes directed against repetitive 
sequences uniquely present in the centromeric region of the chromosomes became an 
accurate method to distinguish aneugenic from clastogenic agents (Kirsch-Volders et al., 
1997). These techniques, combined with the CBMN assay, allowed identification of 
chromosome breakage (MN with acentric fragments) versus failure of the mitotic apparatus 
(MN with whole chromosomes) as mechanisms responsible for MN induction (Decordier et 
al., 2006).
As a result of two “International Workshops on Genotoxicity Test Procedures” in 1999 and 
2002 a definite international protocol for the in vitro MN test was designed. At the 
Washington International Workshop in 1999, methodologies and data for the MN test were 
inspected and agreement was achieved on the following topics: cells, slide preparation, 
analysis, cytochalasin B, number of doses and treatment as well as harvest time (Kirsch- 
Volders et al., 2000). At the Plymouth International Workshop in 2002 a definite protocol for 
the in vitro MN test was finally designed after important validation studies were completed, 
the data were reviewed and agreement was reached on the following topics: demonstration of 
cell proliferation, assessment of toxicity and dose range finding, treatment schedule for cell 
lines, treatment schedule for lymphocytes, choice of positive controls, number of cells to be 
scored, repeat experiments and statistics (Kirsch-Volders et al., 2003). The harmonized 
protocol supported the release of guidelines for the MN assay by the OECD.
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1.4.2 Methodological variations
The MN assay can be carried out in vivo as well as in vitro.
1.4.2.1 In vivo MN assay
The in vivo MN assay is the most common in vivo genotoxicity test in rodents. Bone marrow 
and peripheral blood are acceptable tissues for analysis of MN induction in mice and rats and 
micronucleated cells in peripheral blood samples obtained at various times can give 
additional information about the time course of MN induction (Hayashi et al., 2000).
Animals have to be sacrificed at appropriate times after treatment if bone marrow is used for 
MN analysis. Bone marrow is extracted; smears are prepared and stained for the analysis 
(Hayashi et al., 2000). If peripheral blood is used for analysis, blood is collected at 
appropriate times after and/or during treatment, followed by smear preparation and staining 
(Figure 1.4) (Hayashi et al., 2000).
The majority of MN can be found in the group of youngest erythrocytes, since they expel 
their nucleus after completion of the last mitosis and the MN remain in the cytoplasm 
(Schmid, 1975). Furthermore young erythrocytes stain differently from older forms, since 
they are polychromatic for the duration of their adolescence (lasting approximately 24h) 
(Schmid, 1975). However the presence of MN can be analysed in either immature or mature 
erythrocytes.
Figure 1.4: Micronucleated immature erythrocytes. (A) Mouse bone marrow cells. (B) Rat 
bone marrow cells. Giemsa staining (upper panel) and acridine orange (lower panel). (C) 
Micronucleated mouse peripheral reticulocyte (from Heddle et al., 2011)
In studies with rodents, concurrent negative control animals treated with solvent or vehicle 
alone, as well as untreated controls should be included (Hayashi et al., 2000). One gender is
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adequate for screening unless gender-related differences in toxicokinetics are known and 
treated and control groups should include at least five animals per group each (Hayashi et al., 
2000). The test substance is administered by gavage, via drinking water, feed, intraperitoneal 
injection or intravenous injection normally at least once each day and treatments of up to four 
weeks are acceptable (Hayashi et al., 2000). Bone marrow samples should be collected no 
later than 24h after the last treatment, whereas peripheral blood should be collected no later 
than 40h after the last treatment (Hayashi et al., 2000). At least three dose levels should be 
used and they should cover a range from clear toxicity to little or no toxicity (Hayashi et al., 
2000).
For analysis, the proportion of immature cells among total erythrocytes is determined. 
Therefore, with bone marrow samples a total of at least 2000 erythrocytes should be counted 
for each animal, whereas for peripheral blood 1000 erythrocytes should be counted (Hayashi 
et al., 2000). In general at least four analysable animals and 2000 cells per animal should be 
scored to determine the incidence of micronucleated immature erythrocytes (Hayashi et al., 
2000).
Additionally, tissues other than bone marrow and blood can be used for the MN assay. 
Examples are colon, skin and young rodent liver as well as male germ cells (Morita et al., 
2011). These assays can be used for mechanistic studies to investigate specific issues 
(Hayashi et al., 2000; Hayashi et al., 2007; Morita et al., 2011).
1.4.2.2 In vitro MN assay
Different cell types are suitable for the in vitro MN assay, such as human lymphoblastoid 
cells, Syrian Hamster Embryo (SHE) cells or rodent cell lines, like CHO, V79 and L5178Y, 
which have a low and stable background frequency for MN formation (OECD, 2007). The 
assay can be performed with or without the actin polymerisation inhibitor cytochalasin B. 
When using cytochalasin B, appropriate concentrations need to be optimized for each cell 
type.
In the absence of a cytokinesis blocker it is necessary to demonstrate the analysed cells have 
undergone cell division during or after the exposure to the test substance (OECD, 2007).
For both, the in vitro MONOMn and the in vitro CBMN assay, cell lines and strains are 
seeded in an appropriate culture medium and incubated at 37°C. If the cells used are not 
metabolically competent then the use of an exogenous source of metabolic activation is 
needed. Often used is a co-factor-supplemented post-mitochondrial fraction (S9), which is 
prepared from the livers of rodents, treated with enzyme inducing agents (OECD, 2007).
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The test concentrations selected should cover a range producing 50±5% cytotoxicity to little 
or no cytotoxicity, because higher levels may induce chromosome damage as a secondary 
effect of cytotoxicity. Several different methods to measure cytotoxicity in the presence and 
absence of cytochalasin B are available. In the presence of cytochalasin B cytotoxicity can be 
determined with the help of the Cytokinesis-block proliferation index (CBPI) or the 
Replicative index (RI). In the absence of cytochalasin B, Relative population doubling 
(RPD), Relative increase in cell counts (RICC) or Relative cell counts (RCC) can be used to 
measure cytotoxicity (Fellows and O’Donovan, 2009).
Short-term treatments as well as extended treatments can be performed. The scoring for MN 
is usually done manually with a light or fluorescent microscope (according to cell stains 
selected). However, new semi-automated systems for scoring MN exist and are frequently 
used. The slides can be stained using various methods, such as Giemsa or fluorescent DNA- 
specific dyes like DAPI or acridine orange. For scoring cytochalasin B treated cultures, a 
minimum of 2000 binucleated cells per dose should be scored, whereas in cultures without 
cytochalasin B, analysis should include a minimum of 4000 mononucleated cells per dose.
A positive result from the MN assay indicates that the test substance induces chromosomal 
damage; whereas a negative result indicates no induction of chromosomal damage under the 
used test conditions.
1.4.2.2.1 The advantages and disadvantages of the CBMN method
MN will only be expressed in a DNA damaged cell after at least one round of nuclear 
division. From this it follows that cells that are not dividing cannot express MN as a sign of 
chromosome damage and so the level of MN observed is dependent on the proportion of cells 
that are dividing (Fenech, 1997). Furthermore it was reported that the MN frequencies 
decline when cells proceed through more than one nuclear division (Fenech, 1997). It is 
therefore important that the kinetics of nuclear division after a DNA insult are identical and it 
has to be noted that an absolute value for MN frequency can only be obtained if MN are 
scored in cells that have divided once only (Fenech, 1997).
The most frequently used method to score MN is in cells that have passed through one 
mitosis, but are prevented from undergoing cytokinesis due to the use of cytochalasin B 
(CBMN assay). This method enables distinction between cells that are not dividing and cells 
that are undergoing mitosis within a cell population by scoring only binucleated cells 
(Fenech, 2000). Cytochalasin B is added to cultured cells before the first mitotic wave after 
induction of DNA damage (Fenech, 1997). The advantage of cytochalasin B is that it inhibits
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cytokinesis without interfering with nuclear division (Carter, 1967; Fenech, 1997), while 
increased sensitivity and consistency in experiments are further advantages of the assay 
(Figure 1.5). Additionally, twice the numbers of mononucleated cells have to be scored to 
observe the same level of MN that would occur in binucleated cells (Fenech, 1997). 
Furthermore, the CBMN assays enables measurement of the nuclear division index, which 
provides information on cytostatic effects of a particular chemical or physical agent, and the 
test system also offers the possibility of detecting dicentric bridges as well as chromosome 
loss and non-disjunction events (Fenech, 1997).
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Figure 1.5: A schematic diagram to visualise the end-points that can be scored with the 
CBMN assay (from Fenech, 1997)
The disadvantage of the CBMN assay is that cytochalasin B itself might induce MN in 
binucleated cells. However, several studies have demonstrated that there is no dose-response 
effect for MN induction over the concentration range 1 to 6 pg/ml (Fenech, 1997). 
Furthermore the efficiency of cytochalasin B inhibition of cytokinesis is dependent on the
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concentration used. Therefore it is important to test the optimal concentration of cytochalasin 
B for each cell type to ensure the maximising cytokines is-blocking effect (Fenech, 1997). 
Further cytochalasin B might prevent the detection of chemicals that are also cytokinesis or 
microfilament polymerisation inhibitors (Fenech, 1997).
Nonetheless, in general, the CBMN technique is a robust assay that has enhanced the MN 
technique and enabled investigation of new parameters of genotoxicity and cell division 
kinetics.
1.4.3 Advent of automated technologies
Visual scoring of MN can be time consuming and the results depend on subjective 
interpretation. Therefore a high demand for automation of the MN assay exists. Two types of 
automated MN scoring are commonly used: flow cytometry and MN scoring by image 
analysis (Varga et al., 2004). With specific regard to image analysis, several systems are now 
commercially available, such as Metafer, IMSTAR and Cellomics (Decordier et al., 2011; 
Doherty et al., 2011).
Flow cytometry has been used to measure MN frequencies induced by ionising radiation and 
chemicals and in rat hepatocytes treated with carcinogens (Nusse and Marx, 1997). In 
addition, this technique can be used to measure and analyse the DNA distribution of MN, 
which allows investigation of the mechanisms of MN induction (Nusse and Marx, 1997). The 
advantages of using flow cytometry for measuring MN are that a large number of cells can be 
analysed in short time intervals, the objective criteria for identifying MN in suspension, or 
MN in erythrocytes as well as the automation during measurement and analysis of the 
measured data (Nusse and Marx, 1997). Disadvantages are that the results cannot be re­
checked after measurement and no data for individual cells can be obtained (Varga et al.,
2004). In addition, not all particles identified as MN during the measurement are actual MN, 
because of the necessity to lyse cells in this protocol. Consequently, these unspecific particles 
might be debris developed during the preparation of a suspension of MN or nuclei or 
fragmented nuclei as well as apoptotic bodies induced by certain chemicals (Nusse and Marx,
1997). Furthermore apoptotic and necrotic cells can cause MN artefacts.
Two advanced automated image analysis systems for application with the CBMN assay have 
been recently reported. The advantages of image analysis are that a large number of intact 
cells can be scored, which increases the statistical significance of the results (Verhaegen et 
al., 1994). In addition, repeated scoring of the same slide is possible.
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The first advanced automated system, the Metafer-System, introduced by MetaSystems, uses 
fluorescent dyes specific for DNA (DAPI) and has been shown to be a rapid and accurate 
system for scoring MN (Varga et al., 2004; Doherty et al., 2011). The Metafer-System can 
identify mononucleated or binucleated cells and MN in the vicinity of these cells due to a set 
of parameters (called classifier) (Rossnerova et al., 2011). Classifier settings determine the 
size and shape of the cells and MN and further allow analysis of the distance of the nuclei and 
their size ratio (Rossnerova et al., 2011).The Metafer-System, optimised and assessed for the 
use on lymphocyte cell lines in our laboratory, consists of a motorised scanning stage, 
coupled to an Olympus BX50 fluorescent microscope (Carl Zeiss), a Dell computer hub 
(loaded with Metafer4 Version 3.8.5 software) and a high resolution megapixel charge 
coupled device (CCD) camera for image capture.
The second system, the PathFinder™Cellscan™ (IMSTAR), described by Decordier et al, 
(2009), was developed for biomonitoring on Giemsa-stained slides. The detection and scoring 
process is separated in two steps: firstly the cells and nuclei are detected, followed by MN 
scoring in the detected cells (Decordier et al., 2009). The system described by Decordier et 
al. (2009) is applicable to the CBMN assay and can discriminate between mononucleated and 
polynucleated cells.
The visual scoring of MN of thousands of cells is time-consuming and it may result in 
subjective interpretation of scoring criteria (Rossnerova et al., 2011). Automation of MN 
analysis therefore enhances throughput and reliability of results. Furthermore, it reduces the 
scoring subjectivity of MN identification. However most automated systems need validation 
work to ensure maximum reproducibility. Minor difficulties have been encountered in our 
laboratory during automated scoring with the Metafer-System due to the loss of cytoplasmic 
boundaries. Consequently, careful attention is paid to the distance of MN from the main 
nuclei as well the staining pattern and intensities of the two nuclei within binucleated cells. 
However, it is important to note that automated technologies allow the assessment of 
chromosomal damage of large numbers of cells and thus they are very powerful tools for 
enhancing the statistical sensitivity of the MN assay and increasing sample throughput. 
Consequently, they are also a promising tool for improving risk assessment of human 
populations, which are exposed to mutagens (Rossnerova et al., 2011).
1.5 Genotoxic thresholds
The MN assay has been extensively used in genotoxicity studies and contributed to the 
understanding of the dose-response relationships of aneugens and clastogens (Elhajouji et al.,
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2011). It is important to investigate the biological significance of low dose exposures to 
improve health risk assessments, obtain sufficient safety data in the early stages of drug 
development and to establish if DNA reactive compounds follow linear or non-linear 
(thresholded) dose response relationships.
The concept of thresholds in genotoxicology has been discussed extensively and has been 
mainly accepted for aneuploidy based mechanistic experimental evidence (Elhajouji et al., 
2011). However the assumption for direct acting genotoxins (including clastogens) is that the 
relationship between exposure to genotoxic chemicals, DNA damage formation and the 
induction of mutagenic change is linear (Henderson et al., 2000). Recent studies with 
alkylating agents, however, support the existence of a threshold dose-response for clastogens 
(Doak et al., 2007; Gocke and Mueller, 2009). However, acceptance is based on a case-by- 
case basis together with strong experimental evidence and supported by an understanding of 
the mechanisms behind the mutagen-target interaction (Elhajouji et al., 2011).
1.5.1 History of the threshold concept
During the early decades of the twentieth century the threshold model was used in 
establishing radiation health standards and in 1928 the “International Committee for 
Radiation Protection” (ICRP) recommended a tolerance dose of 1/100 of an 600r erythema 
dose for occupational radiation exposure (Calabrese, 2009). The second radiation standards 
report, published by the “National Council on Radiation Protection and Measurement” 
(NCRPM) in 1934, stated that a safe whole body exposure is O.lr/day for hard x-rays 
(Calabrese, 2009).
Since the 1930s the linear dose response model was developed after the discovery of X-ray 
induced mutations in Drosophila by Hermann J. Muller (Muller, 1927; Calabrese, 2009). The 
hypothesis of a linear dose response relationship without a threshold at low doses was 
proposed for ionizing radiations on the basis of the one-hit model of action (Crebelli, 2000). 
The linear dose response relationship was then extended to chemical mutagens, because of 
the possible interaction of a single molecule of a mutagen with the DNA, which can lead to a 
genetic alteration and eventually trigger a carcinogenic process (Crebelli, 2000). This 
hypothesis was assured by demonstrating the linearity in the relationship between DNA 
adducts and doses over a wide exposure ranges for different mutagens, such as aflatoxin B l, 
benzo(a)pyrene and benzene (Crebelli, 2000). However mutations are not produced directly 
by DNA adducts as DNA repair activity potentially limits the proportion of adducts 
processed into mutational changes. A number of biological mechanisms, like metabolic
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detoxification and error-free DNA repair at low doses may lead to a deviation from the linear 
dose response relationship and support the threshold model (Jenkins et al., 2005). However, 
there is limited evidence available to confirm or refute the existence of thresholds. Thus, at 
present, most chemicals are assumed to have non-thresholded modes of action and thresholds 
of genotoxic activity have to be proven for each agent on a case-by-case basis.
1.5.2 Threshold definitions
A threshold is defined as a concentration below which no effect occurs (Lovell, 2000). The 
threshold is characterised by the inflection point, which is the point where the change in 
gradient is at its maximum (Figure 1.6) (Johnson et al., 2009). The no observed effect level 
(NOEL) is lower than the threshold dose and defined as the highest dose that does not cause 
an adverse effect, whereas the lowest observed effect level (LOEL) is defined at the lowest 
dose that causes an adverse effect (Johnson et al., 2009).
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Figure 1.6: A schematic diagram of the linear and threshold dose response model. NOEL (no 
observed effect level); LOEL (lowest observed effect level); Inflection point = point where 
the change in gradient is at its maximum (after Johnson et al., 2009)
Dose response thresholds for genotoxins have implications for the setting of safe exposure 
levels. The European Centre for Ecotoxicology and Toxicology of chemicals (ECETOC) has 
defined an “absolute (true) threshold” as a concentration below which a cell would not notice 
the presence of the chemical, whereas a “pragmatic threshold” is considered as a 
concentration below which any effect is considered biologically unimportant (Lutz et al.,
1998). A “statistical threshold” is the lowest concentration of a chemical that induces a 
statistically significant increase in the endpoint being measured (Kirsch-Volders et al., 2000),
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whereas a “biologically meaningful threshold” describes the threshold dose for a substance 
where there is appropriate supporting evidence to conclude that there is a biological 
explanation of a threshold dose for mutagenicity (Kirsch-Volders et al., 2009).
1.5.3 Arguments for a threshold dose response
The choice of endpoint is an important step in mutagenicity studies. A variety of test systems 
can be used as an endpoint. The simplest system is where the endpoint corresponds with the 
target, e.g. analysis of DNA adducts, DNA breakage or modified bases (Kirsch-Volders et al., 
2003). If the endpoint is different from the target three different levels can be considered at 
the cellular level: proximal is where the endpoint is close but still different, for example gene 
mutations or chromosomal structural mutations; intermediate is where the endpoint is 
separated by several steps from the target, e.g. analysis of repair and metabolic pathways; and 
distal is where the endpoint is a result of complex alterations of cellular activities, which 
happens after the initial interaction of the compound with the target, like apoptosis, necrosis 
and cell survival (Kirsch-Volders et al., 2003). The main endpoints analysed for threshold 
dose responses have been DNA adduct formation, gene mutation and chromosomal 
aberration. A threshold of genotoxic activity indicates that a compound will not produce 
mutations below a critical exposure level. Furthermore it reduces the risk for the induction of 
cancer or congenital abnormalities at these exposures.
Mammalian cells have a range of homeostatic mechanisms in vivo that provide protection to a 
certain extent until they become saturated and can therefore lead to threshold dose responses 
(Doak et al., 2007).
There are two main mechanisms which can lead to genotoxic thresholds. The first mechanism 
involves redundant targets. Examples for this mechanism are thresholds identified with 
spindle poisons, like colchicine or vinblastine (Jenkins et al., 2005). Multiple targets of 
tubulin monomers, of which the spindle consists, have to be damaged before a significant 
adverse effect occurs, thus at lower doses enough spindle fibres are intact to allow normal 
segregation (Jenkins et al., 2005). Non-DNA damaging substances can target mechanical 
components required for chromosome segregation (e.g. microtubules, kinetochores, 
centrioles), DNA synthesis (e.g. topoisomerases, DNA polymerases, imbalanced nucleotide 
pools) or DNA repair enzymes (e.g. polymerases, endonucleases, ligases) (Jenkins et al., 
2005).
The second mechanism involves protective mechanisms, such as exclusion of the chemical 
from the cell and or nucleus through the cellular membranes and epithelial barriers,
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detoxification of the genotoxic agent or DNA repair to remove damaged DNA sequences as 
well as apoptosis (Jenkins et al., 2005; Jenkins et al., 2010).
1.5.4 Experimental evidence for genotoxic thresholds
Experimental evidence (to date) of thresholded dose responses has only been demonstrated 
for spindle poisons, ionizing radiation, alkylating agents (methylmethanesulfonate (MMS), 
ethylmethanesulfonate (EMS)), topoisomerase II inhibitors and ROS inducers (Table 1.4).
Table 1.4: Examples of published data demonstrating genotoxic thresholds (after Jenkins et 
al., 2005)
Test agent Type of agent Test assay
Lindane, Malathion, 
Metacid
(Kumar et al., 1995)
Pesticides Clastogenicity, dominant 
lethality
Colchicine, Carbendazim, 
Mebendazole, Nocodazole,
(Elhajouji et al., 1995; 
Elhajouji et al., 1997)
Spindle poisons MN formation
Etoposide, Doxorubicin, 
Genistein, Ciprofloxacin
(Lynch et al., 2003)
Topoisomerase II inhibitors MN formation
Vinyl acetate
(Hengstler et al., 2003)
Industrial chemical Various
X-radiation
(Koana et al., 2004)
Ionizing radiation Drosophila somatic mutation 
analysis
PhIP
(Fukushima et al., 2004)
Cooked meat carcinogen DNA adduct, aberrant crypt 
foci
MelQX
(Wanibuchi et al., 2006)
Cooked meat carcinogen LacI mutation, pre-neoplastic 
liver foci formation
MMS
(Doak et al., 2007)
Alkylating agent MN formation; HPRT assay
EMS
(Doak et al., 2007; Gocke et 
al., 2009)
Alkylating agent MN formation; HPRT assay
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KBr03, Bleomycin, DNA-oxidizing agents MN formation
Hydrogen peroxide
(Platel, et al., 2009;
Seager et al., 2012)
Aneugens (non-DNA reactive genotoxins) show non-linear (thresholded) dose response 
curves. Low levels of the compounds are tolerated, because deactivation of multiple targets is 
required to induce aneuploidy. The non-DNA damaging substances may target mechanical 
components required for chromosome segregation (e.g. microtubules, kinetochores, 
centrioles), DNA synthesis (e.g. topoisomerases, DNA polymerases, imbalanced nucleotide 
pools) or DNA repair enzymes (e.g. polymerases, endonucleases, ligases) (Jenkins et al.,
2005).
Spindle poisons, like colchicine or vinblastine are good examples of aneuploidy inducing 
agents due to inhibition of tubulin polymerisation. The spindle consists of many tubulin 
monomers. Therefore multiple targets have to be damaged before a significant adverse effect 
occurs (Elhajouji et al., 1997).
DNA reactive genotoxins are believed to induce non-threshold curves, because they directly 
induce DNA lesions that have the potential to be fixed as point mutations or chromosomal 
aberrations. However, mammalian cells have a number of defence mechanisms, such as DNA 
repair or detoxification, which provide protection to a certain extent and therefore can 
theoretically result in a NOEL (Jenkins et al., 2010).
There is now evidence to support this theory; for example a study by Doak et al. (2007) 
demonstrated that direct acting genotoxins have thresholds for mutation induction and 
chromosome breakage in vitro (Doak et al., 2007). The human lymphoblastoid cell line 
AHH-1 was treated with alkylating agents (MMS, MNU, EMS and ENU) that have different 
mechanisms of action and DNA-targets. MNU and ENU showed linear dose responses, 
whereas MMS and EMS showed non-linear curves containing a range of non-mutagenic low 
doses (Doak et al., 2007). In addition EMS showed non-linear dose responses in vivo using 
the mouse-bone marrow MN test and point mutations at the LacZ locus as endpoints (Gocke 
et al., 2009), confirming the possible existence for genotoxic thresholds.
To summarize, it is likely that genotoxic thresholds for clastogens exist. However further 
investigations are needed to investigate the mechanisms of action of genotoxins and how they 
interact with DNA at low levels (Jenkins et al., 2010). If there is no elevation of genetic
3 2
damage above background levels, safe exposure levels may exist for some clastogens, and 
consequently regulatory bodies may have to adapt and modify their regulatory schemes 
accordingly (Jenkins et al., 2010, Elhajouji et al., 2011). However, it is important to note that 
variability in the experimental data, intra- and inter-species variation, differences in exposure 
and individual susceptibility have to be taken into account for the health risk assessment 
(Elhajouji et al., 2011).
1.6 The present study
The main aim of this thesis was to assess low dose response relationships in vitro for a 
number of genotoxic agents and to establish if the DNA reactive compounds follow linear or 
non-linear (thresholded) dose responses, since it is important to investigate the biological 
significance of low dose exposures to improve health risk assessments.
Mitomycin C (MMC), a crosslinking agent; 4-nitroquinoline 1-oxide (4NQO), a bulky adduct 
inducer and cytosine arabinoside (araC), a nucleoside analogue were investigated for DNA 
! damage induction. These agents had not been subject to robust low dose studies previously.i
I These studies used the newly installed semi-automated MN detection system Metafer
| (MetaSystems, Altlussheim, Germany) at Swansea University. RPD was used to measure
i
| cytotoxicity. In addition the mechanism of action of each test component was further
investigated by follow up experiments to gain mechanistic understanding of the dose 
response relationships, including DNA repair assays using Real-time PCR or protein analysis 
j  using Western blotting as well as cell cycle status analysis and p53 signalling studies.
I
i
I
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Chapter 2 
Material and Methods
2.1 Materials
2.1.1 Equipment
BD FACS Aria™ Flow Cytometer 
Biofreezing vessels 
Centrifuge Tubes (15ml/50ml)
Centrifuges:
BIOFUGE fiesco 
Centrifuge 581 OR 
ChemiDOC™ XRS+ System 
CO2 Air-Jacketed Incubators 
Comet IV capture system 
Cryovial®
Cytospin 4 
Fridge (4°C)
Freezer (-20°C)
Fume Hood 
Haemocytometer 
Heat block 
Hotplate & Stirrer 
Ice machine
Immun-Blot® PVDF membrane 
IQ5 Real-Time PCR System 
Microcentrifuge tubes 
Microscopes:
Axio Imager Z1 
Axiovert 40C 
TMS
Milli-Q Integral Water Purification System 
Mini Protean® 3 Cell 
Mini Trans-Blot® Cell
BD Biosciences 
Bicell
Fisherbrand
Heraeus
Eppendorf
BioRad
Nuaire™
Perceptive Instruments Ltd. 
Elkay Laboratories Products 
Thermo Shandon 
Liebherr 
Proline
Clean Air, Limited 
Hawksley 
Techne Di-Block 
Jen way 
Hoshizaki 
BioRad 
BioRad 
Eppendorf
Zeiss
Zeiss
Nikon
Millipore
BioRad
BioRad
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Multipurpose Container (20ml)
NanoDrop (ND-1000 Spectrophotometer) 
pH meter
Pipette with tip (5ml/10ml/25ml)
Pipettes 
Pipette tips 
Pipettors
Platform Shaker (innova™ 2100)
POLARstar Omega Microplate Reader 
Power Pac™ Basic Power Supply 
Purifier PCR Enclosure 
Scales:
LA 120S 
TE3102S 
T100™ Thermal Cycler 
Thick Blot Paper
Tissue Culture Flasks (25cm2/75cm2/175cm2)
Tissue Culture Hood
Ultra Low Temperature Freezer (-80°C)
Vortexer
Windsor Incubator 
Waterbaths:
SUB Aqua 18
The Belly Dancer®Hybridization Water Bath 
Z1 Coulter Particle Counter
2.1.2 Reagents
Acetic acid 
Acridine orange
30% AcrylamidelBis Solution, 37.5:1 
Albumin bovine serum 
Ammonium persulfate 
Buffer Tablets „Gurr“
Cytochalasin B
Greiner bio-one 
Labtech 
Mettler Toledo 
Greiner bio-one 
Gilson/ Eppendorf 
StarLAB
StarLAB/ Fisherbrand 
New Brunswick Scientific 
BMG Labtech 
BioRad 
Labconco
Sartorius
Sartorius
BioRad
BioRad
Cellstar
Scanlaf mars
New Brunswick Scientific 
Fisons
Raymond A Lamb 
Grant
Stovall Life Sciences Inc. 
Beckman Coulter, Inc.
Fisher Scientific
Sigma-Aldrich
BioRad
Sigma-Aldrich
Sigma-Aldrich
Gibco®
Merck
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Cytosine arabinoside Sigma-Aldrich
Dimethyl sulfoxide Fisher Scientific
DPX Mounting Medium Fisher Scientific
Ethanol Fisher Scientific
Formamide Fisher Scientific
Giemsa’ Stain Solution Gurr®, VWR International Ltd.
Glutamine Gibco®
Glycine Melford
Horse serum Gibco®
Hydrogen chloride Fisher Scientific
Hygromycin B Merck
Hypoxanthine-aminopterin-thymidine (HAT) Gibco®
Hypoxanthine-thymidine (HT) Gibco®
Isopropanol Fisher Scientific
Magnesium chloride Sigma-Aldrich
Methanol Fisher Scientific
Mitomycin C (Streptomyces caespitosus) Sigma-Aldrich
4-Nitroquinoline 1-oxide Sigma-Aldrich
N,N,N* ,N ’ -tetramethylethylenediamine Sigma-Aldrich
Pepsin Sigma-Aldrich
Phosphate buffered saline Gibco®
Phosphatase Inhibitor Cocktail 2 Sigma-Aldrich
Potassium chloride Fisher Scientific
Propidium iodide solution Sigma-Aldrich
Protein inhibitor cocktail Sigma-Aldrich
Ribonuclease A Sigma-Aldrich
RPM I1640 Gibco®
RTU Human Pan Centromeric Probe StarFISH (Cambio)
Sodium chloride Sigma-Aldrich
Sodium citrate Sigma-Aldrich
Sodium dodecyl sulfate Sigma-Aldrich
Staurosporine Sigma-Aldrich
6-Thioguanine Sigma-Aldrich
Tris Melford
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Tween® 20
Vectashield® Mounting Medium with DAPI 
Xylene
2.1.3 Buffer and Solutions
lOx Annexin V Binding Buffer (abeam)
10% (w/v) APS 
BSA Blocking Buffer
Buffer F pH 8.0
Electrophoresis buffer pH 13.0 
Laemmli Buffer (Sigma-Aldrich) pH 6.8
Lysis solution
Sigma-Aldrich 
Vector Laboratories 
Fisher Scientific
lg Ammonium persulphate 
ddH20  to 10ml
20mM Tris (pH 7.6)
137mM NaCl 
5% (w/v) BSA 
0.1% (v/v) Tween®20
40mM HEPES 
0.1MKC1 
0.5mM EDTA 
0.2mg/ml BSA
ImM Na2EDTA 
0.3M NaOH
0.0004% Bromphenol blue 
400mM DTT 
20% Glycerol 
4% SDS
2.5M NaCl 
lOOmM Na2EDTA 
lOmM Tris buffer (pH 10)
10% DMSO 
1% Triton X-100
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Neutralisation buffer pH 7.5 0.4M Tris-HCl
RIP A Buffer (Sigma-Aldrich) pH 8.0 150mM NaCl 
1.0% IGEPAL®CA-360 
0.5% Sodium deoxycholate 
0.1% (w/v) SDS 
50mM Tris
Protein Running Buffer 25mM Tris (pH8.3) 
192mM Glycine 
0.1% (w/v) SDS
Protein Transfer Buffer 20mM Tris (pH 8.3) 
192mM Glycine 
20% (v/v) Methanol 
0.1% (w/v) SDS
Restore Plus Western Blot Stripping Buffer (Thermo Scientific)
10% (w/v) SDS 25g SDS 
ddH20  to 250ml
20xSSC (pH 7.4) 87.6g NaCl 
44. lg Na citrate 
ddH20  to 500ml
lOx TBS (pH 7.6) 200mM Tris 
1.37M NaCl 
HC1 to pH 7.6
TBS/Tween®20 Wash Buffer 20mM Tris (pH 7.6) 
125mM NaCl 
0.1% (v/v) Tween®20
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1.5M Tris (pH 8.8)
1M Tris (pH 6.8)
Tris/Glycine/SDS lOx
2.1.4 Kits
DC Protein Assay
geNorm™ Reference Gene Selection Kit 
Immun-Star™ WestemC™ Chemiluminescent Kit 
RNase-Free DNase Set 
RNeasy® Mini
RT2 Profiler™ PCR Array System 
QuantiFast® SYBR® Green PCR Kit 
QuantiTect® Reverse Transcription Kit
2.1.5 Antibodies
Anti-Annexin V antibody [VAA-33] (FITC) 
B-Actin (13E5) Rabbit mAb 
Goat polyclonal Secondary Antibody 
to Rabbit IgG- H&L (HRP), pre-adsorbed 
p53 antibody
Phospho-p53 (Serl5) antibody
2.1.6 Molecular Weight Marker
Biotinylated Protein Ladder Detection Pack 
Precision Plus Protein™ Dual Color Standard
45.4g Tris 
ddH20  to 250ml 
HC1 to pH 8.8
30.3g Tris 
ddH20 to 250ml 
HC1 to pH 6.8
250mM Tris (pH 8.3)
1.92M Glycine 
1% (w/v) SDS
BioRad
Primerdesign
BioRad
Qiagen
Qiagen
SAbiosciences
Qiagen
Qiagen
Abeam
Cell signalling, NEB 
Abeam
Cell signalling, NEB 
Cell signalling, NEB
Cell signalling, NEB 
BioRad
39
Chapter 2
2.1.7 Primers
All primers were obtained from Sigma-Aldrich, UK.
Primer: Nucleotide Sequence:
Actin Forward 5’ GATGGCCACGGCTGCTTC 3’
Actin Reverse 5’ TGCCTCAGGGCAGCGGAA 3’
BRCA1 Forward 5’ CCTTCCTTGCAGGAAACCAGTCTCA 3’
BRCA1 Reverse 5’ TCCGCTGCTTTGTCCTCAGAGTT 3’
MSH6 Forward 5’ GCCCCCACCAGTTGTGACTTCTC 3’
MSH6 Reverse 5’ G AC A AGGCC ACC AGGGGT AACC 3’
p21 Forward 5’ GACTCTCAGGGTCGAAAACG 3’
p21 Reverse 5’ GGATTAGGGCTTCCTCTTGG 3’
Rad51C Forward 5’ AGGAGTGGCAGGTGAAGCAGTTT 3’
Rad51C Reverse 5’ TCGGTGTTCCTCTCCCTTGTGTTTT 3’
XRCC3 Forward 5’ GAACCCGCGGGAGGATGTGCAC 3’
XRCC3 Reverse 5’ CCGCGTGTTTTTGGCTGACTTGAC 3’
XRCC6BP1 Forward 5’ TGGCGTGCTCAGAGGTTCGAG 3’
XRCC6BP1 Reverse 5’ T GGCT CT GT CTCGC AC AC AAGT 3*
2.1.8 Computer software
BD FACS Diva 6.1.3.
Metafer 4, v. 3.8.5 (MSearch)
Microsoft Excel 2010
Microsoft Word 2010
Omega, Mars Data Analysis
Quantity One
SPSS 16.0.2 and 20
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2.2 Methods
2.2.1 Tissue Culture
All tissue culture manipulations were carried out in sterile Biological Safety Cabinets 
(Scanlaf Mars, VWR International Ltd., Leicestershire, UK). Only sterile equipment was 
used. Solutions, including media and PBS, were pre-warmed to 37°C in a water bath and 
sprayed with 70% ethanol before placing in the safety cabinets. When handling toxic 
chemicals appropriate safety measurements, including wearing safety equipment (lab coat, 
goggles and overarm gloves) and disposal of toxic waste material via incineration, were 
carried out.
2.2.1.1 Cell lines
In this study (at Swansea University) the human lymphoblastoid cell lines TK6, NH32, AHH- 
1 and MCL-5 were used.
TK6. The human lymphoblastoid cell line TK6 is a derivative of the WIL-2 cell line. The 
cells are heterozygous at the TK locus and contain the wild-type TP53 gene. TK6 cells were 
| acquired from the European Collection of Cell Cultures (ECACC), Salisbury, UK (Cat.-No.
! 95111735).
i
I
| NH32. The NH32 cell line was a kind gift from Prof. Dr. Gerald N. Wogan (MIT,
| Cambridge, MA, USA). Like TK6, the human lymphoblastoid cell line NH32 is a derivative
| of the WIL-2 cell line. The cells contain a double p53 knockout mutation.
f
AHH-1. AHH-1 is a human lymphoblastoid TK+/' cell line that constitutively expresses a 
high level of native CYP1A1 (Crofton-Sleigh et al., 1993). AHH-1 cells carry a heterozygous 
mutation in the TP53 locus (Morris et al., 1996; Dobo et al., 1997; Guest and Parry, 1999). 
The cells were acquired from the American Type Culture Collection (ATCC), Manassass, 
VA, USA (Cat. No. CRL-8146).
MCL-5. The human lymphoblastoid cell line MCL-5 is derived from AHH-1 by stable 
transfection with human cytochromes (CYP1A2, CYP2A6, CYP3A4 and CYP2E1) and 
microsomal epoxide hydrolase (Crofton-Sleigh et al., 1993). These are carried as cDNAs in 
plasmids and in addition the cells carry a hygromycin B resistance gene. Furthermore MCL-5 
cells carry, like AHH-1 cells, a heterozygous mutation in the TP53 locus (Guest and Parry,
I 41
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1999). MCL-5 cells were acquired from the American Type Culture Collection (ATCC), 
Manassass, VA, USA (Cat. No. CRL-10575™).
2.2.1.2 Cell culture medium
TK6, NH32, AHH-1 and MCL-5 were cultured in RPMI 1640 (Gibco®, Paisley, UK) 
supplemented with 10% donor horse serum (Gibco®, Paisley, UK) and 1% L-glutamine 
(Gibco®, Paisley, UK). For MCL-5 cells at each passage hygromycin B in acetic acid 
(35mM) was added to a final concentration of 200pg/ml to ensure plasmid retention (Crespi 
et al., 1991).
2.2.1.3 Cell culture
All cell lines used in this study were maintained in exponentially growing cultures in a 
humidified incubator at 37°C with 5%CC>2 in the air. The cell concentrations were maintained 
between 1-3 x 105 cells/ml and were not allowed to exceed 1.5 x 106 cells/ml.
Upon reaching confluency, cells were sub-cultured in order to maintain the desired 
concentrations in the culture flasks. Therefore the cell suspensions were transferred into 
multipurpose containers and spun down at 200 x g for lOmin. The supernatant was removed 
and the cells were re-suspended in fresh media, counted with the haemocytometer (Hawksley, 
Sussex, UK) or the Z1 Coulter Particle Counter (Beckman Coulter Inc., High Wycombe, UK) 
and diluted to the final concentration of roughly 1-3 x 105 cells/ml.
2.2.1.4 Measurement of cell concentration
To measure the amount of cells per ml of culture media either the haemocytometer or the Z1 
Coulter Particle Counter was used.
For the haemocytometer lOpl of cell suspension was removed from the culture flask after 
gentle shaking and placed onto the haemocytometer slide. The number of cells in each of the 
four large comer counting chambers (each compromised of 16 small squares) were scored, 
averaged and multiplied by 1 xlO4 to obtain the final cell number per ml of media.
For the Z1 Coulter Particle Counter lOOpl of cell suspension were placed into a cuvette 
containing 10ml of dilute conducting liquid. The cuvette was placed on the Z1 coulter 
Particle Counter and the cell number per ml culture was measured. The particles pass through 
an aperture of defined size and the cell number is displayed on a screen as cells/ml of media.
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2.2.1.5 Cryopreservation of cells
Cryopreservation is a process that enables storage of cell stocks over an indefinite amount of 
time at an ultra-low temperature. Cell cultures to be cryopreserved should be free of 
contamination and maintained in exponential growth phase for several days before freezing. 
Cell suspensions, which reached near-confluency were spun down in 20ml multipurpose 
containers for 10 min at 200 x g. The supernatant was removed and the pellet was re­
suspended in 3 to 4 ml of horse serum containing 10% v/v dimethyl sulfoxide (DMSO). 
Subsequently, 1.5 to 2ml of the cell suspensions were added into cryovials® for the freeze 
process. The cryovials were placed in biofreezing vessels and kept overnight in the -80°C 
freezer before long-term storage in liquid nitrogen at -196°C.
2.2.2 The in vitro MN assay
The manual and the semi-automated scoring protocol, using the Metafer-System 
(MetaSystems, Altlussheim, Germany), were performed in this study.
2.2.2.1 The manual scoring protocol for the MN assay
2.2.2.1.1 Initiation of the assay
All cell suspensions (10ml) were seeded at lx l0 5cells/ml for 24h at 37°C, 5%CC>2. For the 
CBMN-assay each cell suspension was treated with appropriately diluted chemical for 
different time points and 4.5 to 6 pg/ml cytochalasin B for one cell cycle. After the different 
incubation times the suspensions were removed from each flask and transferred into 
appropriately labelled tubes. The cells were spun down (lOmin, 200 x g) and washed with 
PBS to remove any residual chemical.
2.2.2.1.2 Manual harvest and scoring
After washing with PBS the cells were spun down (lOmin, 200 x g) and re-suspended in fresh 
culture medium. One hundred microliters of the cell suspensions were cytospun onto polished 
glass slides (5min, lOOOrpm), fixed in ice-cold 90% methanol for lOmin, stained in 20% 
Giemsa solution (VWR International Ltd., Poole, UK) and viewed under an Olympus BH2 
light microscope. A minimum of two slides per replicate were prepared.
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2.2.2.1.3 Giemsa staining
For manual scoring, cells were stained with a 20% Giemsa solution in phosphate buffer (pH 
6.8) for 11 min. The stained cells were then washed with phosphate buffer, rinsed under tap 
water and air dried.
To mount the cells the slides were placed in xylene for 10 sec. Afterwards a drop of DPX 
mounting medium (Fisher Scientific, Loughborough, UK) was added to the slide, followed 
by a coverslip. The slides were allowed to set for 12h before scoring.
2.2.2.1.4 Scoring
For the CBMN assay a minimum of 1000 binucleated cells per replicate were scored, 
whereas for the mononucleated assay a minimum of 2000 mononucleated cells per replicate 
were scored (at Swansea University). The binucleated and mononucleated cells were 
examined for MN (Figure 2.1). Furthermore mononucleated, binucleated, trinucleated, 
tetranucleated and multinucleated cells were scored.
The scoring system for MN as well as the classification for MN was adapted from Fenech et 
al. (2003).
Figure 2.1: Binucleated (A and B) and mononucleated (C and D) cells without (A/C) and 
with (B/D) MN in TK6 cells after MMC treatment stained with 20% Giemsa solution
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2.2.2.2 The Metafer-System
2.2.2.2.1 Initiation of the assay
All cell suspensions were seeded at lx l0 5cells/ml for 24h at 37°C, 5%CC>2. For the CBMN 
assay each cell suspension was treated with the appropriately diluted test chemical for 
different time points and 4.5 to 6 pg/ml cytochalasin B for one cell cycle. Test chemicals 
used were mitomycin C (MMC), cytosine arabinoside (araC) and 4-nitroquinoline 1-oxide 
(4NQO). For the MONOMn assay only TK6 cell suspensions were treated with MMC (0-0.1 
pg/ml) for 24h followed by a 24h recovery period previous to harvest.
After the different incubation times the suspensions were removed from each flask and 
transferred into appropriately labelled tubes. The cells were spun down (lOmin, 200 x g) and 
washed with PBS to remove any residual chemical.
2.2.2.2.2 Cell harvest
For semi-automated scoring, cells were prepared as described by Varga et al. (2004). Shortly, 
after washing the cells with PBS, the cells were treated with 0.56% KC1 solution and fixed 
with a methanol/acetic acid/0.09% NaCl (5:1:6) solution for lOmin. A second fixation step 
was then performed 4 times with methanol/acetic acid (5:1). The fixed cells were dropped 
across the length of slides and subsequently the cells were mounted in vectashield antifading 
solution containing 4\6-diamidino-2-phenylindole (DAPI) stain with a large coverslip.
2.2.2.2.2.1 Scanning and Classifier settings
The slides were scanned at lOx magnification with the Metafer 4 master station, coupled to 
an Olympus BX50 fluorescent microscope (Carl Zeiss), a Dell computer hub (loaded with the 
Metafer4 Version 3.8.5 software) and a high resolution megapixel charge coupled device 
(CCD) camera (Axiocam; Carl Zeiss) for image capture. A number of grid positions evenly 
distributed across the scan area determined the plane of focus and a predetermined scan area 
was used for all slides.
Classsifiers developed by MetaSystems were modified in order to detect mononucleated as 
well as binucleated cells. The search definition classifiers were used to define the size and 
shape of nuclei and MN (Table 2.1).
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Table 2.1: Classifier settings on the Metafer-System to define binucleated/mononucleated 
cells and MN
Binucleate Mononucleate
Nuclei MN Nuclei MN
Object threshold 30% 8% 20% 10%
Minimum area 20pm" 1.5pm" 10pm2 1.0pm2
Maximum area 400pm" 55pin" 400pm2 55pm2
Maximum relative concavity of 
depth
0.9 0.9 0.9 1.0
Maximum aspect ratio 1.5 4.0 2.5 3.5
Maximum distance between 30pm 25pm - 35pm
Maximum area asymmetry 70% - 90% -
2.2.2.2.2.2 Scoring
The detection and scoring process for the Metafer-System was separated into 3 steps: firstly 
the slides were scanned and binucleated or mononucleated cells were detected. Secondly 
MN-positive binucleated or mononucleated cells were validated microscopically and finally 
manual confirmation of the MN was performed in the image gallery (Figure 2.2). A minimum 
of 4000 mononucleated cells or 2000 binucleated cells per replicate were scored (at Swansea 
University) (exceptions were stated, for details see Appendix I).
Figure 2.2: Metafer image gallery (A), Binucleated cell with MN (B), Mononucleated cell 
with MN (C)
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2.2.3 Cytotoxicity
Different cytotoxicity methods in the absence of cytochalasin B (RPD, RICC and RCC) were 
compared to find the most suitable one for measurement.
RPD was determined as follows:
Number of population doublings in treated cultures
RPD = ------------------------------------------------------------------- x 100
Number of population doublings in control cultures
where
[ log (post-treatment cell number/initial cell number)]
Population doubling (PD) = ------------------------------------------------------------------------
Log2
RICC was defined as:
Increase in number of cells in treated cultures (final count-initial count)
RICC = ---------------------------------------------------------------------------------------------  x 100
Increases in number of cells in control cultures (final count-initial count)
And RCC was determined as follows:
Final cell count in treated cultures
RCC = ---------------------------------------------  x 100
Final cell count in control cultures
Cytotoxicity assessment was dependent on the measurement used. RCC slightly 
underestimated the level of cytostasis and cell death, when compared to RPD and RICC; 
while RICC slightly overestimated the level of cytostasis and cell death, when compared to 
RPD (see Table 2.2 as an example).
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Table 2.2: Cell viability of TK6 cells treated with MMC for 4h followed by 18h of 
cytochalasin B using RPD, RICC and RCC
Cell viability (%) Standard Deviation (%)
MMC
(jug/nil)
RPD RICC RCC RPD RICC RCC
0 100 100 100 0 0 0
0.002 85.33 77.35 85.76 12.79 9.42 3.87
0.004 93.70 91.35 95.03 5.77 10.90 8.95
0.006 106.05 98.93 95.43 11.99 15.46 8.52
0.008 91.04 85.42 90.51 3.09 7.61 9.17
0.01 87.57 85.99 93.16 4.81 7.94 5.81
0.02 77.22 72.39 85.50 8.87 5.62 3.30
0.04 75.83 63.05 75.11 8.77 7.07 3.19
0.06 57.58 48.85 71.09 21.99 18.57 6.07
0.08 55.79 43.12 64.03 11.56 9.41 5.84
0.1 54.21 41.49 62.87 9.64 8.60 5.20
In recent studies by Fellows et al. it was shown that RPD and RICC are the most appropriate 
measurements of toxicity in the absence of cytochalasin B (Fellows et al., 2008; Fellows et 
al., 2009).
Throughout this work it was decided to use RPD for the measurement of cytostasis and cell 
death.
2.2.4 Human Pan Centromeric Chromosome Painting
For the Human pan-centromeric chromosome staining TK6 cells treated with either MMC, 
araC or 4NQO were cytospun (5min, lOOOrpm) onto polished glass slides and fixed in ice- 
cold 90% methanol for lOmin. Afterwards the cells were pre-treated with pepsin to remove 
the cytoplasm and to allow better penetration of the probes. Both sample slides and 
300mg/ml 0.01M HC1 pepsin (pH 2.7-3) were pre-warmed for lOmin to 37°C. Several drops 
of pepsin were applied to each slide's cytodot for 30sec to lmin. To arrest the pepsin 
treatment, slides were washed in PBS for 5min, followed by another wash step in PBS/50mM 
MgCF for 5min. The slides were then dehydrated in 70%, 80% and 95% ethanol for 2min 
each to prepare them for the denaturation step.
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Meanwhile, the RTU Human pan-centromeric probe (StarFISH, Cambio, Cambridge, UK) 
was warmed up to 37°C for 5min. A 5pl aliquot of the probe per slide was added to a 
microcentrifuge tube.
Afterwards the chromosomes on the slide were denatured in 70% formamide in 2xSSC for 
2min at 70°C and immersed in ice-cold 70% ethanol. The slides were then dehydrated 
through a series of 70%, 90% and 100% ethanol washes for 5min each and air-dried at room 
temperature.
Meanwhile the probe was denatured for 10 min at 85°C and immediately chilled on ice. 
Subsequently the probe was applied to the cytodot on the slide, covered with a cover slip and 
hybridised for approximately 16 hours at 37°C in a humidified chamber.
After the hybridisation step the cover slip was removed and the slides were washed for 5min 
in 2xSSC at 37°C, followed by two washes in 50% formamide/2xSSC for 5min each time at 
37°C and two washes in 2xSSC for 5min each time. The slides were dried in the dark at room 
temperature.
The nuclei were counterstained with a DAPI + vectashield solution and 100 MN per dose (2 
replicates with 50 MN each) were scored as positive or negative for centromere(s) under an 
Olympus BX50 fluorescence microscope (Carl Zeiss).
2.2.5 RNA extraction
Total RNA was extracted from the human lymphoblastoid cell lines. All cell suspensions 
(50ml) were seeded at lx l0 5cells/ml for 24h at 37°C, 5%C02. The RNA extraction was 
performed using the Qiagen RNeasy Mini Kit (Qiagen, Sussex, UK) according to the 
manufacturers' instructions. Cells were spun down in 25ml aliquots (8min, 200 x g) and the 
supernatant was removed. After that the pellets were re-suspended in 600pl of buffer RLT. 
Subsequently the samples were homogenized by passing the lysate 3 to 4 times through a 
needle (21G). Then one volume of 70% ethanol was added and after mixing by pipetting the 
samples was applied to the columns. After spinning for 15sec at >8000 x g the on-column 
DNase digestion followed. For the DNase digestion the RNase-Free DNase Set (Qiagen, 
Sussex, UK) was used. Therefore, 350pl buffer RW1 were added and spun down for 15sec at 
>8000 x g. Then lOpl DNase I stock solution was added to 70pl buffer RDD. Afterwards the 
DNase I incubation mix (80pl) was directly added to the column membrane and placed on the 
bench top for 15min at room temperature, followed by another washing step with 350pl 
buffer RW1. After spinning (15sec, >8000 x g) 500pl buffer RPE were added to the column. 
After the centrifugation (15sec, >8000 x g) another 500pl of buffer RPE were added to the
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column followed by a centrifugation for 2min and >8000 x g. The column was then 
transferred to a fresh collection tube and spun down at full speed for lmin to be completely 
dry. The column was afterwards transferred to a fresh collection tube to remove the RNA 
from the column by adding 30pl Nuclease-free water and spun down for lmin at >8000 x g. 
After completing the RNA extraction the RNA content was measured and the purity was 
assessed (260:280 ratio) with a NanoDrop ND-1000 Spectrophotometer (Labtech 
International, Uckfield, UK). The RNA was stored at -80°C until further use.
2.2.6 RT2 Profiler™ PCR Array System
The Human DNA Repair PCR array system (PAHS-042) was acquired from SABiosciences, 
Qiagen, Sussex, UK and was used to analyse a panel of genes related to DNA repair 
pathways. Each PCR array contained a panel of 96 primer sets for a set of 84 relevant 
pathway-focused genes listed below, as well as five housekeeping genes and three RNA and 
PCR quality controls:
Base Excision Repair (BER): APEX1, APEX2, CCNO, LIG3, MPG, MUTYH, NEIL1,
i NEIL2, NEIL3, NTHL1, OGGI, PARP1, PARP2, PARP3, POLB, SMUG1, TDG, UNG,
\
| XRCC1.
Nucleotide Excision Repair (NER): ATXN3, BRIP1, CCNH, CDK7, DDB1, DDB2, ERCC1, 
ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, ERCC8, LIG1, MMS19, PNKP, POLL, RAD23A,
| RAD23B, RPA1, RPA3, SLK, XAB2, XPA, XPC.
Mismatch Repair (MMR): MLH1, MLH3, MSH2, MSH3, MSH4, MSH5, MSH6, PMS1,
| PMS2, POLD3, TREX1.I
| Double-Strand Break (DSB) Repair: BRCA1, BRCA2, DMC1, FEN1, L1G4, MRE11A,
PRKDC, RAD21, RAD50, RAD51, RAD51C, RADS IB, RAD51D, RAD52, RAD54L, XRCC2, 
XRCC3, XRCC4, XRCC5, XRCC6.
Other Genes Related to DNA Repair: ATM, ATR, EXOl, MGMT, RAD18, RFC1, TOP3A, 
TOP3B, XRCC6BP1.
To complete the PCR array procedure experimental RNA samples (RNA from TK6 cells 
treated with MMC) were converted into first strand cDNA using the RT First Strand Kit 
(SABiosciences, Qiagen, Sussex, UK). Firstly the Genomic DNA Elimination Mixture was
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prepared. For each RNA sample, the following components were combined in a sterile PCR 
tube:
Total RNA 1.6 pg
GE (5x gDNA Elimination Buffer)________ 2.0 nl
Water to a final volume of 10.0 pi
The contents were mixed gently with a pipette followed by a brief centrifugation. Afterwards 
the contents were incubated at 42°C for 5min and then immediately chilled on ice for at least 
one minute.
Thereafter the following RT Cocktail was prepared:
RT Cocktail 1 reaction 2 reactions 4 reactions
BC3 (5x RT Buffer 3) 4pl 8pl 16p 1
P2 (Primer & External Control 
Mix)
lpl 2p 4pl
RE3 (RT Enzyme Mix 3) 2pl 4pl S p
Water 3pl 6pl 12p 1
Final Volume lOpl 20pl 40pl
Afterwards the first strand cDNA synthesis reaction was performed. Therefore lOpl of RT 
cocktail were added to each lOpl Genomic DNA Elimination Mixture and mixed gently with 
a pipette. An incubation at 42°C for exactly 15min followed and then the reaction was 
immediately stopped by heating at 95°C for 5min. 91 pi of water were added to each 20pl 
cDNA synthesis reaction. The finished first strand cDNA synthesis reaction was put on ice 
until the next step or stored overnight at -20°C.
After the first strand cDNA synthesis reaction the Real-Time PCR was performed. Firstly the 
Experimental Cocktail was prepared as follows:
Plate Format: 96-well
2x SABiosciences RT" qPCR Master Mix 1350pl
Diluted First Strand cDNA Synthesis 
Reaction
102pl
Water 1248p1
Total Volume 2700m1
Afterwards the loading of the 96 -Well PCR array followed. Therefore 25pl of the 
Experimental Cocktail were added to each well of the PCR array. To remove bubbles the 
plate was centrifuged for lmin at room temperature at 1000 x g. Subsequently the Real-Time 
PCR detection was performed. The arrays were slotted into the iCycler iQ5 Thermal Cycler 
(BioRad, Hertfordshire, UK) and run the following program:
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1. 95°C for lOmin
2. 95°C for 15sec
r- x 40
3. 60°C for lmin
4. 95°C for lmin
5. 55°C for lmin
6. lOsec at each 0.5°C increase in temperature from 55°C to 95°C to generate a melt 
curve
The lOmin step at 95°C was required to activate the HotStart DNA polymerase. SYBR Green 
fluorescence was detected and recorded from every well during the annealing step of each 
cycle (Step3). Steps 4 to 6 enabled melt curve analysis.
2.2.6.1 Data analysis: AACt Method
For the analysis of the data the PCR Array Data Analysis Web Portal was used 
(w w w. SAB iosciences.com/pcrarravdataanal vsis .php). The Web Portal automatically 
performed the following calculations:
1. All Ct values reported greater than 35 or as N/A were changed to 35. At this point, 
any Ct value equal to 35 was considered a negative call.
2. The threshold cycle values of the control wells were examined.
a. Genomic DNA Control (GDC): calculate CtGDG; if the value is greater than 
35, then the genomic DNA contamination is too low to affect gene 
expression profiling results
b. Reverse Transcription Control (RTC): calculate ACt=AVG CtRTC-AVG 
Ctppc: if this value is less than 5, then no inhibition is apparent
c. Positive PCR Control (PPC): the average Ctppc value should be 20±2 on 
each PCR Array and should not vary by more than two cycles between 
PCR Arrays compared
CtO I3. The ACt for each pathway-focused gene in each plate was calculated: ACt=Cr -
q  AVG HKG
4. The AACt for each gene across two PCR Arrays (or groups) were calculated: 
AACt=ACt (group 2)-ACt (group 1); where group 1 was the control and group 2 was 
the experimental
5. The fold-change for each gene from group 1 to group 2 as 2/'(AACt)
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2.2.7 Reverse Transcription with elimination of genomic DNA for Quantitative, Real- 
Time PCR
The mRNA from the total RNA extractions (see section 2.2.5) were reverse transcribed into 
cDNA by using the QuantiTect© Reverse Transcription Kit (Qiagen, Sussex, UK). Firstly the 
genomic DNA elimination reaction was prepared and contained the following components:
Component Volume/reaction Final concentration
gDNA Wipeout Buffer, 7x 2pl lx
Template RNA iMg
Rnase-free water Variable
Total volume 14pl
The DNA elimination reaction were then incubated for 2min at 42°C and immediately placed 
on ice.
Subsequently the reverse-transcription master mix for multiple reactions was prepared, to 
ensure that the same ingredient quantities were present in each reaction. The master mix 
contained the following components:
Component Volume/reaction Final concentration
Reverse transcription Master 
Mix
Quantiscript Reverse 
Transcriptase
lpl
Quantiscript RT Buffer, 5x 4pl lx
RT Primer Mix 'Ml
Template RNA
Entire genomic DNA 
elimination reaction
14p]
Total volume 2 0 m 1
The template RNA (14pl) was added to each tube containing the reverse-transcription master 
mix. The mix was then incubated for 15min at 42°C followed by 3min at 95°C to inactivate 
the Quantiscript Reverse Transcriptase.
If 2pg RNA was used the volumes of all reaction components were doubled to a final 40pl 
reaction volume.
An aliquot of each finished reverse-transcription reaction was added to a Real-time PCR mix 
or stored at -20°C for further use.
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2.2.8 PrimerDesign geNorm Reference Gene Assay
The geNorm Reference Gene Selection Kit from PrimerDesign Ltd., Rownhams, UK was 
used to select the reference gene for the Real-time PCR experiments. The Kit contained a 
panel of 12 candidate reference genes:
• Homo sapiens actin beta (ACTB), mRNA
• Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPDH), mRNA
• Homo sapiens ubiquitin C (UBC), mRNA
• Homo sapiens beta-2-microglobulin (B2M), mRNA
• Homo sapiens phospholipase A2 (YWHAZ), mRNA
• Homo sapiens 60S ribosomal protein L 13a (RPL13A)
• Homo sapiens 18S rRNA gene
• Homo sapiens cytochrome c-1 (CYC1), mRNA
• Homo sapiens eukaryotic translation initiation factor 4A. isoform 2 (EIF4A2). mRNA
• Homo sapiens succinate dehydrogenase complex (SDHA), mRNA
• Homo sapiens topoisomerase (DNA) I (TOPI), mRNA
• Homo sapiens ATP synthase, (ATP5B), mRNA
The expression of these genes was measured by quantitative Real-time PCR and the data 
were analysed with the help of the geNorm software.
Firstly the lyophilised primers were re-suspended in 220pl RNase/DNase water. The 
reactions were then set up in a PCR hood using sterile equipment. The components of each 
reaction included:
Component 1 Reaction
Resuspended primer mix ipi
2x QuantiFast SYBR Green Master Mix 10(4l
RNase/DNase free water 4m 1
Final Volume l5 |j  1
Subsequently, 15pl of the mix was pipetted into each well of the 96-well plate according to 
the plate set up. All samples for each reference gene were run on the same plate. Six different 
cDNA samples (TK6 cells treated with MMC) per reference gene were used. After this at 
least 132pl of cDNA were prepared by diluting the RT reactions 1:10 (20pl of RT and 180pl 
of water). Five pi of the diluted cDNA was then pipetted into each well of the 96-well plate
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according to the plate layout. The final volume in each well was 20pl. After that the plate was 
slotted into the iCycler iQ5 Thermal Cycler (BioRad, Hertfordshire, UK) and run the 
following program:
1. 95°C for lOmin
2. 95°C for 15sec
3. 60°Cfor60sec
4. 95°C for lmin
5. 55°C for lmin
6. lOsec at each 0.5°C increase in temperature from 55°C to 95°C to generate a melt 
curve
2.2.8.1 GeNorm analysis in qBasePLUS
The geNorm analysis software is incorporated in to qBaseplus, which is a Real-time PCR 
analysis software provided with the Kit. The identities of the genes analysed were put into the 
software, the run files were uploaded and annotated. After the analysis was complete the 
| results appeared in the main window.
The analysis revealed the best reference gene for accurate normalisation in the experimental
I system by ranking the candidate reference genes according to their expression stability. It was
|
shown that beta actin (ACTB) would be the best reference gene to use for the Real-time PCR\
experiments (Figure 2.3).
ii!
i
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A verag*  e x p re s s io n  s tab ility  o f rem a in in g  re fe ren c e  ta rg e ts
ACTB
Figure 2.3: Graph indicates the average expression stability value (M) of the reference 
targets at each step during stepwise exclusion of the least stably expressed reference gene. 
A C TB  was the most stable gene, as can be seen on the right site of the graph (black arrow).
2.2.9 Real-Time PCR
For the Real-time PCR experiments the QuantiFast™ SYBR® Green PCR Kit (Qiagen, 
Sussex, UK) was used.
2.2.9.1 The reaction
The reactions were set up in the PCR hood using sterile equipment. The components of each 
reaction included:
Component Volume/reaction (96 well block)
2x QuantiFast SYBR Green PCR Master Mix 12.5pl
Primer A 0.25pl
Primer B 0.25pl
Template DNA or cDNA 1.5pl
RNase-free water 10.5pl
Total reaction volume 25u 1
Firstly master mixes were prepared, containing the QuantiFast SYBR Green master mix; 
primers and water to ensure that the same ingredient quantities were present in each reaction. 
These master mixes were sub-divided into aliquots of three reactions, because all samples 
were run in triplicate. Sample cDNA (1.5pl per reaction; 4.5pl in total) was added to each
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sub-divided master mix. At least 25pl of each resultant mix was aliquoted into wells of a 
sterile 96-well 0.2ml PCR plate (Sarstedt, Nuembrecht, Germany). Standard samples as well 
as negative controls were also included for each primer pair. In negative controls the cDNA 
was replaced with water.
The plates were sealed with Absolute QPCR Seal sheets (Thermo Scientific, Surrey, UK) 
after all 25pl reactions were loaded into the wells, they were briefly centrifuged to bring all 
the contents to the bottom of the wells. After that the plates were slotted into the iCycler iQ5 
thermal Cycler (BioRad, Hertfordshire, UK) and run the following program:
1. 95°C for 5min
2. 95°C for lOsec
3. 60°C for 30sec
4. 95°C for lmin
5. 55°C for lmin
6. lOsec at each 0.5°C increase in temperature from 55°C to 95°C to 
generate a melt curve
The first step activates the HotStarTaq Plus DNA polymerase. Steps 2 and 3 represent the 
PCR reaction, while steps 4 to 6 enabled melt curve analysis.
For the amplification reaction the fluorescent data were collected at step 3 as well as analysed 
in real-time, whereas for the melt curve analysis the data were collected at step 6 and 
analysed in real-time.
2.2.9.2 Data analysis
The iCycler iQ5 software version 2.1 (BioRad, Hertfordshire, UK) was used to analyse the 
data. Each sample was individually analysed.
To assign the specificity of the PCR reaction products that had been generated, the melt 
curves for all samples were analysed. When the melt temperature (Tm) was incorrect for any 
sample, this sample was removed from the analysis.
For the relative quantitation of gene expression the standard curve method was used. 
Standard samples with known template amounts were defined in the “sample setup” view. 
Therefore stock cDNA samples were diluted (10-fold dilutions with the dilution values: 1, 10, 
100 and 1000). The results from wells defined as Standards were used to generate a standard 
curve. The crossing points (C ts )  were plotted against the log of the template amount,
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resulting in a straight line. Threshold cycle (C t)  values for these samples and the standard 
curve were then used to calculate the amount of starting template in the experimental 
samples.
The samples were normalized by their respective endogenous control results to calculate a 
normalized target value:
Normalized target = Target/Endogenous control
The normalized target values were then divided by one another to calculate the fold- 
difference in target quantity:
Fold difference in target = Normalized target (treated sample)/ Normalized target (untreated 
control)
N-fold differences observed were considered as changes in gene expression if <0.5 or >1.5 as 
defined by Doak et a l (2004) and statistical analysis was conducted.
i
2.2.10 The mammalian cell HPRT gene mutation assay
The hypoxanthine phosphoribosyl transferase (HPRT) gene mutation assay detects mutations 
| which destroy the functionality of the HPRT gene and/or protein by positive selection
(Johnson, 2012).
I
| The first step of the HPRT assay was the mutant cleansing stage. Therefore 1ml of
! hypoxanthine-aminopterin-thymidine (HAT) was added to the TK6 culture (4-5x105 cells/ml)
and the cells were grown for 3 days. The aminopterin in HAT medium blocks the salvage 
pathway for the production of dNTPs for DNA synthesis. That means the cells had to rely on 
the endogenous pathway (HPRT and TK) and mutant HPRT' and TK67' mutants were 
selectively killed (Johnson, 2012). After 3 days the HAT medium was washed off with PBS. 
Therefore the cells were spun down (lOmin, 200 x g), the supernatant discarded and the pellet 
washed with PBS. Afterwards the cells were re-suspended in 50ml fresh medium and 1ml of 
hypoxanthine-thymidine (HT) was added to the culture medium for 24h, to ensure that the de 
novo nucleotide biosynthesis pathways as well as the salvage pathway were able to function 
from this step onward (Johnson, 2012). After washing off the HT medium with PBS, the TK6 
cell suspensions (10ml) were seeded at lx l0 5cells/ml for 24h at 37°C, 5%CC>2. The cell 
suspensions were then treated with the chemical and after the treatment period the chemical
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was washed off with PBS, new medium was added and the cells were sub-cultured to 1.2- 
1.5xl05cells/ml in 50ml flasks (day 1). The cells were left to grow for thirteen days to enable 
expression of the HPRT" mutants. Cells were sub-cultured at days 1, 3, 5, 7, 9 and 11 and can 
be cryogenically frozen down at days 5 and 7. After the phenotypic expression period at day 
13, the cells were added to 96-well micro plates.
For mutation frequency (MF), TK6 cells with 2.4x 107 cells in 60ml were treated with 240pl 
of 6-thioguanine (0.6pg/ml) (6-TK) for selection. Five plates per dose were used with lOOpl 
of cell suspension in each well. HPRT+ cells incorporate 6-TG into the DNA and 
consequently die, whereas HPRT" cells cannot incorporate the toxic analogue into their DNA 
and consequently survive (Johnson, 2012).
For plating efficiency (PE) approximately 200 cells in lOOpl were added to the plate per well 
with no selection. Five plates per dose were used.,
Plates were scored for colony formation after 14 days of incubation at 37°C, 5%CC>2. Scoring 
criteria specified that only colonies with 20+ cells in diameter were scored. Furthermore it 
was ensured that separate colonies were clearly apart, taking clonal expansion into account. 
The experiment was carried out in triplicate.
2.2.10.1 6-Thioguanine (6-TG)
Working solutions of lx 6-TG were prepared at 0.15mg/ml to minimise freeze/thaw cycles. 
The 30x stock of 6-TG (4.5mg/ml) was therefore diluted to a lx working solution by adding 
lml of 30x 6-TG to 29ml of 0.1M NaOH (lg  NaOH in 250ml distilled water). The lx  6-TG 
solution was then filter sterilized with 0.2pM filters and kept as 5ml aliquots at -20°C until 
use.
2.2.11 The in vitro comet assay +/-hOGGl
The comet assay is also known as the single cell gel electrophoresis assay. Cells were treated 
with the test chemical, which was then washed off with PBS and the cells were re-suspended 
in fresh media. The cell number was adjusted to 1.5xl05cells/ml. After that lml of the cell 
suspensions were sampled into labelled eppendorf tubes, centrifuged at 720rcf for 3min, the 
supernatant discarded and the cells re-suspended in lml cold lxPBS. After centrifugation 
(720rcf for 3min) the supernatant was removed from the pellet and the cells were re­
suspended with 200pl low-melting agarose and 3 x 40pl drops, resulting in 3 gels, were 
added per glass slide (pre-coated with agarose) and covered with a coverslip. Slides were 
then placed on a cold tray, which allowed for gels to set after which the coverslips were
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removed and the slides were placed in cold lysis solution (2.5M NaCl, lOOmM Na2EDTA, 
lOmM Tris buffer (pH 10), 10% DMSO, 1% Triton X-100) in a dark container over night at 
4°C. Following lysis, the slides were washed twice for 5min in lx buffer F (40mM HEPES, 
0.1M KC1, 0.5mM EDTA and 0.2mg/ml BSA (pH 8.0)) at room temperature. hOGGl 
(+hOGGl) or buffer F (-hOGGl) (60pl) were then added to each slide, topped up with a 
coverslip and incubated in a humidified box at 37°C for lOmin. After removing the coverslips 
the slides were placed in an electrophoresis platform and covered with electrophoresis buffer 
(ImM Na2EDTA, 0.3M NaOH (pH 13)) for 20min at 4°C to allow for the DNA to unwind. 
Afterwards the electrophoresis was performed at 0.7V/cm, 300mA for further 20min at 4°C. 
To neutralise, the slides were removed from the electrophoresis platform and immersed in 
three changes of neutralisation buffer (0.4M Tris-HCl (pH 7.5)) for 5min each time at room 
temperature.
Finally the slides were stained with 60pl propidium iodide (20pg/ml) for 30min, before 
scoring using a Comet IV capture system (Perceptive Instruments Ltd., Haverhill, UK). Fifty 
nuclei per gel were scored and the tail intensity (TI), which is defined as the percentage of 
DNA migrated from the head of the comet into the tail, was measured for each nucleus 
scored (Smith et al., 2006). The experiment was run in duplicate.
2.2.12 Protein extraction
All steps for the protein preparation were performed at 4°C; pre-cooled buffers and 
equipment were used.
For the total protein extraction all cell suspensions were seeded at lx l0 5cells/ml for 24h at 
37°C, 5%CC>2. Subsequently the cells were treated with the appropriately diluted test 
chemical for different time points. After chemical treatment the cell suspensions were 
transferred to centrifuge tubes and spun down at 200 x g for 8min. The cells were then 
washed with 5ml ice-cold PBS and again spun down at 200 x g for 8min. After re-suspending 
the cell pellet, 200pl ice-cold lx  radioimmuno-precipitation lysis (RIPA) buffer (Sigma- 
Aldrich, Dorset, UK) supplemented with 2pl protease inhibitor cocktail (Sigma-Aldrich, 
Dorset, UK) and 2pl phosphatase inhibitor cocktail 2 (Sigma-Aldrich, Dorset, UK) were 
added and the cell suspensions were transferred to pre-chilled micro-centrifuge tubes. After 
5min incubation at 4°C, the cells were lysed by vortexing thoroughly and spun down for 
lOmin at 10000 x g in a centrifuge pre-cooled to 4°C. Finally the supernatant was transferred 
to a new micro-centrifuge tube and after protein quantification (see section 2.2.13) aliquots of 
the protein samples were stored at -80°C.
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2.2.13 Protein quantification
The BioRad DC Protein Assay (BioRad, Hertfordshire, UK) was used for the protein 
quantification and the assay contained the reagents A, B and S. For the quantification 
dilutions of a BSA protein standard (BioRad, Hertfordshire UK) containing 0 to 2.5mg/ml of 
BSA. as well as the working reagent A were prepared, by adding 20pl of reagent S per ml of 
reagent A. All protein quantification steps were run in duplicate.
Subsequently 5pl of the protein standards and protein samples were pipetted into a clean, dry 
96-well plate. Then 25pl of the working reagent A, followed by 200pl of reagent B were 
added to each well. Afterwards the plate was gently agitated to mix the reagents for 15min. 
After the incubation, absorbance was read at 750nm with the POLARstar Omega Microplate 
Reader (BMG Labtech Ltd., Aylesbury, Bucks, UK) and the Mars Data Analysis Software 
(version 1.20.R2) was used for quantification.
2.2.14 Western blotting
With the help of the sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE) proteins could be analysed.
2.2.14.1 SDS-PAGE
The proteins were separated according to their size following denaturation (as described 
below) on a polyacrylamide gel. The gel consisted of two layers, the resolving and the 
stacking gel. The gels were prepared as seen in Table 2.3 below:
Table 2.3: Gel composition for the SDS-PAGE
Stacking Gel Resolving Gel
4%
.
10%
4 Gels “
30% Acrylamide 1.3ml
............. __  . ......
ddH20 6ml 12m.
1.5M Tris (pH 8.8) 7.5ml
lM Tris (pH 6.8) 2.5ml
..... ; . ' - ' .
10% SDS lOOpl 300ul
*
-• V .' '  . ; i ■' ' j" ;• - , ;t . /  • . .1 , ‘ v •
10% APS 50pl 150pl
Temed lOpl 30pl
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The Mini Protean® 3 Cell system from BioRad (BioRad, Hertfordshire, UK) was used for the 
SDS-PAGE. After assembling of the casting stand, the resolving gel was applied to the cast 
and left to polymerise for 30 to 60min. Subsequently the stacking gel and the comb were 
applied to the cast and again left to polymerise for 30 to 60min. The polymerised gel was 
placed into the electrode assembly and clamping frame, the comb was removed and the 
assembly filled with running buffer (25mM Tris (pH 8.3), 192mM glycine, 0.1% (w/v) SDS). 
In parallel the protein samples (40pg) were mixed in a 1:1 ratio with Laemmli Buffer (Sigma- 
Aldrich, Dorset, UK), sonicated three times for lOsec with lOsec breaks in between and 
afterwards incubated for 5min at 95°C.
Subsequently 8pl of the Dual Colour Standard and Biotinylated Ladder were loaded onto the 
gels as well as the protein samples.
The proteins were separated on the gel at 120V until the dye front reached the bottom of the 
gel.
2.2.14.2 Protein blotting
After the SDS-PAGE was completed the proteins were electroblotted onto an Immun-Blot 
PVDF membrane (BioRad, Hertfordshire, UK).
For the protein blotting the Mini Trans-Blot® Cell system (BioRad, Hertfordshire, UK) was 
used. The BioRad Immun-Blot PVDF membrane was immersed in 100% methanol until 
translucent. Afterwards fibre pads, blot paper (BioRad, Hertfordshire, UK), the 
polyacrylamide gel and the PVDF membrane were equilibrated for lOmin in transfer buffer 
(20mM Tris (pH 8.3), 192mM glycine, 20% (v/v) methanol, 0.1% (w/v) SDS)) pre-cooled to 
4°C. The transfer cassette was assembled as below:
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A n o d e
G e l  h o l d e r
F i b e r  p a d  I l l l l l l l l l l l l l l i a i l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l
F i l t e r  p a p e r  — - - - - - - —  —  —  — - - - - - - - - - _ _ _ _
P V D F  m e m b r a n e  — — — — — — — — — — — — —
G e l  i —    i
F i l t e r  p a p e r  —  —  —  —  —  —  —  —  — -- - - - - - —  —  —  —  —  — - - - - - - - - - - -
h o l d e r
C a th o d e
The proteins were transferred onto the membrane at 400mA for lhr at 4°C.
2.2.14.3 Membrane blocking and antibody incubations
After removing the PVDF membrane from the transfer cassette and washing briefly in TBS/T 
(20mM Tris (pH 7.6), 125mM NaCl, 0.1% (v/v) Tween®20) the membranes were incubated 
in blocking buffer (20mM Tris (pH 7.6), 137mM NaCl, 5% (v/v) BSA, 0.1% (v/v) 
Tween®20) for lhr at room temperature with gentle agitation.
Subsequently the blocking buffer was removed and the membranes were incubated in with 
1:1000 dilutions (p53/phospho-p53) or 1:2000 dilutions (beta-actin) of primary antibodies 
specific to p53, phospho-p53 (Serl5) and beta-actin (Cell Signalling, New England Biolabs, 
Herts, UK), diluted in 8ml blocking buffer over night at 4°C with gentle agitation.
Afterwards the membranes were washed in TBS/T for 4x5min at room temperature with 
strong agitation, then they were incubated for lh  in HRP conjugated goat polyclonal 
secondary antibody to rabbit IgG (1:1000 dilution; Abeam, Cambridge, UK) and Anti-biotin, 
HRP linked antibody (1:1000 dilution; Cell Signalling, New England Biolabs, Herts, UK) 
with gentle agitation at room temperature.
Before protein detection the membranes were washed again for 4x5min in TBS/T at room 
temperature with strong agitation.
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2.2.14.4 Protein detection
The BioRad Immun-Star WestemC Chemiluminescent kit (BioRad, Hertfordshire, UK) was 
used for protein detection. The lumino/enhancer solution and the peroxide buffer solution 
were mixed in a 1:1 ratio. The membranes were then incubated with the mixture and 
visualised using the Chemidoc XRS system (BioRad, Hertfordshire, UK). Average band 
densitometry was determined using the Quantity One version 4.6.3 software (BioRad, 
Hertfordshire, UK) and the test band densities were normalised against the corresponding 
beta-actin band density to compensate for variations in protein loading.
2.2.14.5 Stripping Membranes for Re-probing
The membranes were briefly washed in TBS/T, before incubating in 8ml Restore Western 
Blot Stripping Buffer (Thermo Scientific, Northumberland, UK) for lOmin with gentle 
agitation at room temperature. After removing the stripping buffer and briefly washing the 
membranes in TBS/T, the membranes were ready for re-use.
2.2.15 Apoptosis analysis using flow cytometry
The induction of apoptosis in cells treated with test chemicals was investigated by using an 
AnnexinV-FITC antibody (Abeam, Cambridge, UK). After the initiation of apoptosis, cells 
translocate membrane phosphatidylserine (PS) from the inner layer of the plasma membrane 
to the cell surface, where it can be detected by staining with a fluorescent conjugate of 
AnnexinV, a protein with a high affinity to PS (Elmore, 2007). Propidium iodide (PI) 
(Sigma-Aldrich, Dorset, UK) was used as a counterstain for the detection of dead cells.
All cell suspensions (10ml) were seeded at lx l0 5cell/ml for 24h at 37°C, 5%CC>2 and treated 
with the test chemicals. After the different incubation times the suspensions were removed 
from each flask and transferred into appropriately labelled tubes. The cells were spun down 
(lOmin, 200 x g), washed with PBS to remove any residual chemical and re-suspended in 
PBS, before determining the cell concentration using the Beckman Coulter Counter 
(Beckman Coulter Inc., High Wycombe, UK). The right amounts of cells (lxlO6) were 
transferred to each tube and the cells were spun down for lOmin at 200x g at 4°C. After 
removing all of the supernatant, the cell pellets were washed with 1ml of lx AnnexinV 
binding buffer (Abeam, Cambridge, UK) and spun down for lOmin at 200 x g. Afterwards 
the cell pellets were re-suspended in lOOpl of lx AnnexinV binding buffer, lOpl of 
AnnexinV-FITC antibody was added into each tube and incubated for 15min in the dark at 
room temperature. Subsequently the excess antibody was washed off with lx AnnexinV
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binding buffer, the cell pellets were re-suspended in 200pl PBS and 5pl of PI (1 mg/ml) was 
added to each tube for 5min at a final concentration of 5pg/ml, before analysing the samples 
with a BD FACS Aria™ flow cytometer (BD Biosciences, Oxford, UK).
2.2.15.1 Quantification by flow cytometry
The BD FACS Diva™ software (BD Biosciences, Oxford, UK) was used for quantification 
and AnnexinV-FITC (Ex = 488nm; Em = 530nm) was analysed using a FITC signal filter 
(530/30), while PI (Ex = 536nm; Em = 617nm) was analysed using the 585/42 filter.
The forward scatter (FSC) and side scatter (SSC) were used to identify the cells (Figure 2.4, 
A). Afterwards AnnexinV-FITC was plotted on the Y-axis against PI on the X-axis, which 
distinguished viable cells (negative for both AnnexinV-FITC and PI), early apoptotic cells 
(AnnexinV-FITC positive, PI negative), late apoptotic cells (AnnexinV-FITC and PI positive) 
and dead cells (PI positive, AnnexinV-FITC negative) (Figure 2.4,B).
Staurosporine ( lpM,  4h treatment) was used as a positive control for apoptosis induction.
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Figure 2.4: Apoptosis analysis. A: Forward vs. side scatter to identify cells. B: AnnexinV- 
FITC and PI staining of TK6 cells. Q l; early apoptotic cells (AnnexinV-FITC positive, PI 
negative), Q2; late apoptotic cells (AnnexinV-FITC and PI positive), Q3; viable cells 
(negative for both AnnexinV-FITC and PI), Q4; PI positive, AnnexinV-FITC negative)
2.2.16 Cell cycle analysis using propidium iodide (PI) staining
The cell cycle status, in cells treated with the test chemicals, was analysed by quantitation of 
DNA content using flow cytometry.
All cell suspensions (10ml) were seeded at lx l0 5cells/ml for 24h at 37°C, 5%CC>2 and treated 
with test chemicals. After the different incubation times the suspensions were removed from 
each flask and transferred into appropriately labelled tubes. The cells were spun down 
(lOmin, 200 x g), washed with PBS to remove any residual chemical and re-suspended in
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PBS, before determining the cell concentration using the Beckman Coulter Counter 
(Beckman Coulter Inc., High Wycombe, UK). The right amounts of cells (lxlO6) were 
transferred to each tube and they were spun down at 4°C for lOmin at 200 x g. After 
removing the supernatant, the cells were re-suspended in 300pl ice-cold PBS. To fix the cells, 
700pl cold ethanol (70%) were added drop-wise to the tube containing 300pl of cell 
suspension in PBS, while vortexing gently. The cells were left for lh  on ice or up to a few 
days at 4°C. Subsequently the cells were spun down, washed once with cold PBS, before re­
centrifugation and removal of the supernatant. Afterwards the cell pellet was re-suspended in 
250pl PBS, 5pl of lOmg/ml RNase A were added at a final concentration of 0.2 to 0.5mg/ml 
and the cells were incubated at 37°C for lh.
Finally lOpl of lmg/ml PI solution at a final concentration of lOpg/ml were added and the 
cells were kept in the dark at 4°C until analysed.
The DNA content was quantified using the BD FACS Aria™ flow cytometer (BD 
Biosciences, Oxford, UK) and the BD FACSDiva software (BD Biosciences, Oxford, UK)
| was used for analysis. The forward scatter (FSC) and side scatter (SSC) were measured to
identify single cells and a suitable filter (PE-A: 585/42) was chosen to measure PI (Ex = 
| 536nm; Em = 617nm). Cell count was plotted on the Y-axis, while PI was plotted on the X-
i
\ axis. PI binds in proportion to the amount of DNA present in the cell. The flow cytometric
|
! data were acquired in logarithmic scale and gates for G0/G1, S-phase and G2/M were set
| within the analysis program.
i
i
|
! 2.2.17 Statistical analysis
|
I The Kruskal-Wallis test was used to determine significant differences between groups. When
' the Kruskal-Wallis test led to significant results (p<0.05), the Mann-Whitney U test was used
for pairwise comparisons (between the control samples and the treated samples). As the final 
step the Bonferroni-Holm method was used for adjustment of the p-values for multiple 
testing.
The Chi-squared test with Yates’ continuity correction was used for the analysis of the MN 
data. Again the Bonferroni-Holm method was used afterwards for adjustment of the p-values 
for multiple testing.
Pearson’s r correlation analysis was performed for the comparison of the automated system 
Metafer and the conventional manual scoring.
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The dose regime determines the genotoxicity of mitomycin C (MMC) 
3.1 Introduction
The investigation of low dose responses in genotoxicology testing helps to improve health 
risk assessments by establishing if DNA reactive compounds follow linear or non-linear 
(thresholded) dose response relationships. The current assumption is that the relationship 
between exposure to genotoxic chemicals, DNA damage formation and the induction of 
mutagenic change is linear (Henderson et al., 2000). However, mutations are not produced 
directly by DNA adducts as DNA repair activity limits the proportion of adducts processed 
into mutational change. It is therefore possible that no observed effect levels (NOEL) may 
exist for some genotoxins (Jenkins et al., 2005). Furthermore natural defence mechanisms, 
like epithelial barriers to genotoxin entry, chemical detoxification, DNA redundancy or DNA 
repair corroborate the theory of genotoxic thresholds (Jenkins et al., 2010).
j
Biological thresholds for genotoxic mutagens or carcinogens are accepted for some genotoxic
!
| mechanisms, such as aneuploidy or indirect modes of action (Greim and Albertini, 2012).
| Further mechanisms, such as disruption of cell division and chromosome segregation,
i
| inhibition of DNA synthesis or overloading of oxidative defence mechanism might permit the
! identification of a non-linear (thresholded) genotoxic effect (Greim and Albertini, 2012).
However, thresholds of genotoxic activity have to be proven for each agent on a case-by-case
I
! basis
3.1.1 Mitomycin C (MMC)
MMC is an antineoplastic antibiotic discovered in the 1950s and was isolated from the 
industrial microorganism Streptomyces caespitosus (Hata et al., 1956; Tomasz, 1995). MMC 
has been used for clinical cancer treatments since the 1960s, because of its effectiveness 
against solid tumours (Tomasz and Palom, 1997; Paz, 2008). Examples are adenocarcinoma 
of the stomach or pancreas, superficial bladder cancer, epidermoid anal carcinomas and 
oesophageal carcinomas (Paz, 2008). MMC is in particular selective against the hypoxic 
regions of solid tumours, because these tumours are short of oxygen in comparison to normal 
tissues (Paz et al., 1999). The activation of MMC is inhibited by an oxidizing environment.
67
Chapter 3
From this it follows, that MMC has selective toxicity for solid tumours (Tomasz, 1995). The 
antibiotic is used in combination treatments with other anti-tumour drugs.
However MMC causes severe secondary effects, like myelosuppression and severe toxicities, 
such as leucopenia and anaemia (Paz, 2008). Clinical use of MMC is therefore limited. 
Further MMC is known for its wide range of specific biological effects in mammalian cells 
and microorganisms. Examples are selective inhibition of DNA synthesis, mutagenesis, and 
induction of DNA repair in bacteria (SOS response), sister-chromatid exchange, signal 
transduction and chromosome breakage (Tomasz, 1995; Tomasz and Palom, 1997; Mao et 
al., 1999). In addition MMC cross-links the complementary strands of the DNA double helix, 
first shown in 1963 (Iyer and Szybalski, 1963; Tomasz, 1995).
3.1.1.1 Mechanism of action
MMC itself can not react with DNA. However, upon enzymatic or chemical reduction of the 
quinone it is converted to a DNA-reactive species (Iyer and Szybalski, 1964; Tomasz and 
Palom, 1997; Paz, 2008). MMC consists of a pyrrolo indole ring system with an aziridine 
ring (Figure 3.1) and requires an enzymatic activation by a one-electron pathway to a 
semiquinone or by a two-electron reduction pathway to a hydroquinone (Danshiitsoodol et 
al., 2006).
o
NH
Figure 3.1: Structure of MMC (from www.sigma-aldrich.com/catalog/product/sigma/m4287)
Activation of MMC by a one-electron pathway involves enzymes such as NADPH- 
cytochrome P450 reductase, xanthine oxidase and cytochrome bs reductase; whereas 
enzymes such as NAD(P)H dehydrogenase, quinone 1 (DT-diaphorase) and xanthine oxidase 
activate MMC by a two-electron pathway (Snodgrass et al., 2010).
As a result of the reduction of the quinone and the spontaneous elimination of methanol an 
indole hydroquinone is formed, where the Cl aziridine and the CIO carbamate groups are
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highly reactive towards nucleophiles (Tomasz and Palom, 1997; Paz, 2008). The interstrand 
cross-link is then formed by the reaction of this intermediate with the 2-amino group of 
guanines in complementary strands of duplex DNA (Paz, 2008). During this process the 
initial monoadduct formation occurs at the Cl group of activated MMC, whereas the second 
arm reaction links the CIO group to a guanine in the opposite DNA strand (Paz, 2008) 
(Figure 3.2). These cross-links are formed specifically at CpG sequences, because of the 
orientation of the initial monoadduct towards the 3’ end of the opposite strand and the 
reactivity of guanine at the CpG steps (Paz, 2008).
In addition to the interstrand cross-links MMC also causes damage to DNA by monoadducts 
as well as DNA intrastrand cross-links at GpG sites (Paz et al., 1999; Paz, 2008) (Figure 3.2). 
In the case of monofunctional alkylation of DNA the Cl aziridine function reacts only with a 
guanine-N2 nucleophile while the less reactive CIO carbamate remains intact or is hydrolysed 
(Paz et al., 2004). However, the main cause of cytotoxicity is interstrand MMC-DNA cross­
links.
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Figure 3.2: MMC adducts: (1) MMC; (2,3) MMC-guanine monoadducts; (4,5) MMC-DNA 
interstrand and intrastrand cross-links (from Paz et al., 1999)
69
Chapter 3
It has been shown, that various adducts of MMC are capable of inducing different cell death 
pathways in cancer cells (Champeil et al., 2010). The evidence was deduced by a study of 
MMC and its derivatives 2,7-diaminomitosense (2,7-DAM) and decarbamoyl mitomycin C 
(DMC). 2,7-DAM is the main metabolite of MMC and forms two monoadducts with the 
DNA, whereas DMC alkylates and cross-links DNA, predominantly with chirality opposite to 
that of the DNA adducts of MMC (Champeil et al., 2010). MMC and DMC are cytotoxic and 
able to activate the p53 pathway, whereas 2,7-DAM is neither cytotoxic nor able to activate 
the p53 pathway. In comparison to MMC, DMC is more cytotoxic. Furthermore it kills p53- 
deficient cells by inducing degradation of Checkpoint 1 protein (Abbas et al., 2002; 
Bargonetti et al., 2010; Champeil et al., 2010). DNA adducts of DMC have a different 
signalling pathway, which explains the difference in the cell death pathways activated by 
MMC and DMC (Abbas et al., 2002; Bargonetti et al., 2010; Champeil et al., 2010).
3.I.I.2. Previous genotoxicity studies with MMC
The anticancer drug MMC is a known genotoxin. In previous studies MMC was therefore 
often used as a positive control in the chromosome aberration assay as well as the MN assay. 
Furthermore MMC is known to show positive responses at non-cytotoxic concentrations 
(Schuler et al., 2010). Therefore MMC was used as part of a collaborative evaluation study to 
investigate the toxicity measures recommended in the draft OECD Test Guideline 487 for the 
in vitro MN test (Elhajouji, 2010; Fowler et al., 2010; Schuler et al., 2010).
From this it follows that MMC is a useful chemical for development and validation of the in 
vitro MN assay in different cell lines as a strong inducer of MN (Sobol et al., 2012).
3.1.1.2.1 Examples of in vitro and in vivo studies
In the studies of Elhajouji (2010), Fowler et al. (2010) and Schuler et al. (2010) MMC was 
used as a one of the reference genotoxic agents tested in the in vitro MN test. The aims of 
these studies were to investigate and evaluate various cytotoxicity measurements 
recommended in the draft OECD Test Guideline 487 on “In Vitro Mammalian Cell 
Micronucleus Test” (Elhajouji, 2010; Fowler et al., 2010 and Schuler et al., 2010). These 
studies were part of an international collaborative evaluation.
In the study of Elhajouji (2010) the human lymphoblastoid cell line TK6 were treated with 
MMC for 3h followed by 27h recovery. Various concentrations between 0 to 2.0pg/ml were 
tested in the presence and absence of cytochalasin B, with at least 2000 cells per 
concentration analysed. The results showed statistically significant increases in MN
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frequencies at all analysed concentrations in the presence and absence of cytochalasin B. 
Furthermore the 50 to 60% toxicity target at the top dose was not reached (Elhajouji, 2010). 
Cytotoxicity measurements without cytochalasin B at the top dose resulted in reduction in 
RCC, RICC or RPD as low as 25.64%, 34.48% or 21.77% respectively (Elhajouji, 2010).
In the study of Schuler et al. (2010) Chinese hamster ovary (CHO) cells were treated with 
MMC for 24h in the presence and absence of cytochalasin B. Various concentrations between 
0 to 4|ig/ml were used. The results demonstrated that MMC induced significant MN 
formation at all concentrations tested with and without cytochalasin B. A range of 9.8 to 
61.8% increase in cytostasis was observed over the range of concentrations (Schuler et al., 
2010).
In the study of Fowler et al. (2010) Chinese hamster lung (CHL) cells were treated with 
MMC for 3h followed by a 21h recovery period. A range of concentrations between 0 to 
l.Opg/ml was selected. Significant increases in MN induction were observed at all 
concentrations tested. RPD, RICC and RI measurements showed 50-60% toxicity at 
0.5pg/ml, whereas RCC showed 50-60% toxicity at 0.1pg/ml (Fowler et al., 2010).
The purpose of the study by Sobol et al. (2012) was the evaluation and validation of the in 
vitro MN assay in TK6 cells, which are p53 competent. Three treatment conditions were used 
for the evaluation of MMC. The 27h continuous treatment with concentrations between 0 to 
0.1129pg/ml showed a dose-related and statistically significant increase in MN induction. In 
addition both 4h treatments with 24h recovery period (0 to 0.630pg/ml) or 48h recovery 
period (0 to 0.250pg/ml) showed significant increases in MN induction over the dose range. 
Furthermore it was shown that an extended recovery period produced higher MN frequencies 
(Sobol et al., 2012).
An example of an in vivo study is a paper published by Grawe et al. (1998), where low dose 
effects of MMC were assessed by the flow cytometric in vivo MN assay. For the experiment 
male mice (7 to 8 weeks old, weight around 25g) were used. All treatments were injected by 
a single intraperitoneal injection. Various concentrations between 0 to 0.183mg/kg were used 
and the optimum sampling time for MMC was 45h after treatment. The results showed a 
linear dose response relationship over the dose range, even in the very low dose range, which 
was defined as the dose region where the frequency of micronucleated erythrocytes was less 
than twice the baseline frequency (Grawe et al., 1998).
Previous studies with MMC, which looked at dose response relationships in vitro and in vivo 
showed linear dose responses. However concentrations and dose regime chosen in various 
studies differed depending on cell lines and cytotoxicity measurements. Further MMC was
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mainly used as a positive control and for validation purposes. Therefore no studies 
investigated the low dose response relationships of MMC with the aim of finding if NOEL 
might exist for this genotoxin. For MMC to act as a mutagen, it needs to avoid DNA repair 
and other natural defence mechanisms, such as epithelial barriers for genotoxin entry.
3.1.2 DNA repair
The integrity and stability of DNA depends on processes like DNA damage recognition, 
repair, replication, transcription and cell cycle regulation. Furthermore apoptosis contributes 
to genetic integrity by removing damaged cells (Krokan et al., 2000).
The human genome is constantly attacked by endogenous and exogenous DNA damaging 
agents, examples are environmental mutagens, endogenous reactive metabolites and 
replication errors (Christmann et al., 2003). This causes instability of the DNA, thus DNA 
repair systems are vital to maintain the genome stability.
DNA repair genes (and proteins) are either associated with signalling and regulation of DNA 
repair or with distinct repair mechanisms (Christmann et al., 2003). The main repair pathways 
are direct repair, base excision repair (BER), nucleotide excision repair (NER), mismatch 
repair (MMR) and DNA double strand break (DSB) repair.
Direct DNA repair is the simplest response to DNA damage. The lesions are removed or 
reversed in a single-step reaction. Consequently the local sequence is restored to its original 
state (Yu et al., 1999). Examples for direct DNA repair mechanisms are photoreactivation or 
the 06-methylguanine-DNA methyltransferase (MGMT) enzyme. Several photolyases in 
bacteria and yeast are known to directly reverse DNA damage resulting from UV or cisplatin 
treatment in a light-dependent way (Sancar, 1996; Yu et al., 1999). MGMT removes alkyl 
adducts from the 06-position of guanine in DNA and protect cells against the mutagenic and 
carcinogenic effects of alkylating agents (Danam et al., 2005). MGMT is expressed in all 
human cells and tissues, but its activity varies several fold between different individuals, 
organs and cell types within organs (Drablps et al., 2004).
Base excision repair (BER) targets “non-bulky” base adducts, examples are those produced 
by methylation, oxidation, reduction or fragmentation of bases (Yu et al., 1999). The lesions 
removed from DNA include incorporated uracil, fragmented pyrimidines, N-alkylated 
purines, like 7-methylguanine, 3-methyladenine and 3-methyl guanine, 8-oxo-7,8- 
dihydroguanine (8-OxoG) and thymine glycol (Christmann et al., 2003). BER is a multistep 
process, which is initiated by a damage-specific DNA glycosylase (Krokan et al., 2000). The
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DNA glycosylase removes the damaged base, which leaves an abasic site, which is then 
further processed until the correct DNA sequence is restored (Krokan et al., 2000).
Nucleoside excision repair (NER) targets bulky DNA adducts, like UV induced photolesions, 
photoproducts (6-4PPs), cisplatin-guanine, cyclobutane pyrimidine dimers, intrastrand 
crosslinks and large chemical adducts (Yu et al., 1999; Christmann et al., 2003). NER 
consists of two pathways: global genomic repair (GGR) and transcription-coupled repair 
(TCR) (Christmann et al., 2003). GGR removes lesions from non-transcribed domains of the 
genome and from the non-transcribed strand of transcribed regions, whereas TCR removes 
lesions only from the transcribed strand of expressed genes (Christmann et al., 2003). 
Mismatch repair (MMR) targets the removal of base mismatches, which are caused by 
spontaneous and induced base deamination, oxidation, methylation and replication errors 
(Modrich and Lahue, 1996; Umar and Kunkel, 1996; Christmann et al., 2003). Furthermore 
mismatched base pairs arise through formation of heteroduplexes and secondary structure 
such as imperfect palindromes (Bishop et al., 1985; Yu et al., 1999).
DNA double strand break repair (DSB) arises under physiological conditions, which include 
somatic recombinations or the overlapping of extensive excision repair tracts (Lieber, 1998; 
Yu et al., 1999). Defective DSB repair can lead to toxicity and genotoxic effects, like 
chromosomal breaks and exchanges as well as cell death (Christmann et al., 2003). Two main 
pathways are involved in DSB repair: homologous recombination (HR) and non-homologous 
end-joining (NHEJ). NHEJ occurs mainly in the G0/G1 phase of the cell cycle, whereas HR 
occurs during the late S and G2 phases of the cell cycle (Johnson and Jasin, 2000; Takata et 
al., 1998; Christmann et al., 2003).
To study the role that DNA repair plays in MMC induced DNA damage, assays are required 
to sensitively study DNA integrity and stability. In addition to the direct measurement of 
DNA damage with test assays, such as the in vitro micronucleus method, it is important to 
consider other genetic perturbations, like those involved in aberrant signalling, because they 
allow detection of abnormal gene expression.
3.1.3 The MN assay
The MN assay in vitro and in vivo is frequently used to study DNA damage at the 
chromosome level. MN are an accepted cytogenetic endpoint in mutagenicity testing. They 
are derived from chromosome fragments arising from asymmetrical structural aberrations 
(acentric fragments) or represent whole chromosomes that are not incorporated into the 
nucleus at cell division (Fenech et al., 1999; Varga et al., 2004). With the development of
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chromosome specific probes for centromeric, pericentromeric or telomeric regions of human, 
rat and mouse chromosomes the micronucleus assay became a useful tool to investigate the 
origin of MN (chromosome breakage and/or chromosome loss) as well as the distribution of 
sister chromatids between daughter cells (chromosome loss or chromosome non-disjunction) 
(Kirsch-Volders et al., 1997).
The MN test is described in detail in chapter 1 (section 1.4).
An important feature of the MN assay is how to set robust toxicity parameters to avoid the 
confounding effect of toxicity on chromosome breakage and/or whole chromosomes, which 
were unable to incorporate into the main nuclei during cell division.
3.1.4. Cytotoxicity measurements in the in vitro MN assay
Cytostasis and cell death together define the overall cytotoxicity of an agent in cell culture 
(Lorge et al., 2008). Cytostasis prevents cells from cellular growth and multiplication by 
inhibition of cell division and/or cell cycle delay. Depending on the end point (necrosis, 
apoptosis and cytostasis) estimates of cytotoxicity are known to differ (Fellows et al., 2008). 
However cytotoxicity measurements in total are mainly used for the selection of test 
concentration for genotoxicity assessment rather than to investigate the method by which 
cytotoxicity is induced (Fellows et al., 2008).
Appropriate measurements of cytotoxicity are necessary when selecting for test 
concentrations in in vitro genotoxicity assays, as underestimation of toxicity might lead to a 
selection of inappropriate toxic concentrations for analysis, which then have the potential to 
generate irrelevant positive results in the chosen assay (Fellows et al., 2008).
In the MN test different methods for measurement of cytotoxicity in the presence and absence 
of cytochalasin B are available. In the presence of cytochalasin B two main methods are 
recommended: the first one is based on the cytokinesis-block proliferation index (CBPI), 
whereas the second one is the measurement of the replication index (RI), which allows to 
measure directly the extent of cell replication in treated cultures relative to control (Lorge et 
al., 2008).
Several methods to measure cytotoxicity in the absence of cytochalasin B exist, but no clear 
recommendations have been made. Methods available are RCC, RPD and RICC.
Selection of the top concentration, when measuring for cytotoxicity, should be similar in the 
presence or absence of cytochalasin B (Lorge et al. 2008).
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To correlate genotoxicity with changes in cell biology relevant to DNA integrity methods are 
needed to study cell biology endpoints, in particular changes in gene expression due to signal 
transduction.
3.1.5 Real-time PCR
Real-time PCR was first described in the mid-1990s and is a variation of the standard PCR 
technique. The technique combines the amplification of a DNA sequence with the detection 
of the amplified products during each reaction cycle (Bonetta, 2005).
The advantages of the Real-time PCR method over the standard PCR technique are its speed, 
sensitivity and specificity in a homogenous assay (Bustin et al., 2009).
Examples for applications of the method are gene expression and copy number analysis, 
calculations of viral titers and single-nucleotide analysis (Bonetta, 2005).
Target DNA or cDNA are used as template during repeated cycles of heat denaturation, 
primer annealing and primer extension (Bonetta, 2005). The amount of template DNA 
doubles with each cycle until one of the reagents becomes saturated and the reaction reaches 
a plateau (Bonetta, 2005). Probes and dyes are used as detection reagents. They produce a 
fluorescent signal each time a double-stranded product is made (Bonetta, 2005).
Fluorescent dyes, like SYBR Green bind to double stranded DNA and become fluorescent. 
More fluorescent dye binds to DNA as the amount of PCR product increases (Bonetta, 2005). 
Probes, like TaqMan probes, consist of a single stranded oligonucleotide that is 
complimentary to a sequence within the target template. On its 5’ end it has a fluorescent dye, 
whose signal is stifled by a quencher moiety at the 3’ end (Bonetta, 2005). The probe 
hybridizes to one of the template DNA strands and is there as it extends the amplification 
primers digested by the exonuclease activity of the TaqDNA polymerase. Consequently the 
probe releases the fluorescent dye from the quencher (Bonetta, 2005).
Fewer amplification cycles are required the more copies of nucleic acid are present at the 
start of the reaction to make a sufficient product. Therefore the cycle in which a significant 
increase in fluorescence above the threshold is measured, called Cx-value, is used to calculate 
the quantity of DNA per sample (Bonetta, 2005). The calculation can be either done by 
absolute or relative quantification. Absolute quantification is using a standard curve of C t- 
values, which is obtained by a serially diluted standard solution, whereas relative 
quantification compares the difference in the Ct-values of two samples (Bonetta, 2005).
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3.1.6 Aim of study
The study was designed to assess the low dose response relationships of MMC in human 
lymphoblastoid cells using the in vitro MN assay and to compare the newly installed semi­
automated MN detection system Metafer at Swansea University to the conventional manual 
scoring.
Further the mechanism of action of MMC was investigated by testing if DNA repair up- 
regulation influences genotoxic responses.
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3.2 Material and Methods
3.2.1 Cell lines
The cell lines used in this study were TK6 and AHH-1. The human lymphoblastoid cell line 
TK6 is a derivative of the WIL-2 cell line. The cells are heterozygous at the thymidine kinase 
(TK) locus and contain the wild-type TP53 gene (Schwartz et al., 2004). AHH-1 is a human 
lymphoblastoid TK+/" cell line that constitutively expresses a high level of native CYP1A1 
(Crofton-Sleigh et al., 1993). Furthermore AHH-1 cells carry a heterozygous mutation in the 
TP53 locus (Guest and Parry, 1999).
3.2.2 Cell culture
The cell lines were cultured in RPMI 1640 (GibCo®, Paisley, UK) supplemented with 10% 
donor horse serum (GibCo®, Paisley, UK) and 1% L-glutamine (GibCo®, Paisley, UK) at 
37°C, 5%C02.
The cells were sub-cultured as described in chapter 2 (section 2.2.1).
3.2.3 Test chemical
MMC was acquired from Sigma-Aldrich, Dorset, UK. Before using, the chemical was freshly 
diluted from a stock solution (1 mg/ml MMC dissolved in water) with water.
3.2.4 Test chemical dosing regime
For the in vitro MN assay TK6 cells were treated with MMC over a range of concentrations 
between 0 and O.lpg/ml for 4h, 18h or 24h respectively, whereas AHH-1 cells were only 
treated with MMC for 4h (Table 3.1).
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Table 3.1: Dilutions of stock MMC (1 mg/ml) to result in the final concentrations (0- 
O.lpg/ml) of MMC to be applied to TK6 and AHH-1 cells
MMC Dose (pg/ml)
10ml flask- pg MMC 
needed
Volume diluted 
MMC (pi)
Volume water 
(final vol. lOOpl)
0 0 0 100
0.002 0.02 20(1:1000) 80
0.004 0.04 40(1:1000) 60
0.006 0.06 60(1:1000) 40
0.008 0.08 80(1:1000) 20
0.01 0.1 100(1:1000) 0
0.02 0.2 20(1:100) 80
0.04 0.4 40(1:100) 60
0.06 0.6 60(1:100) 40
0.08 0.8 80(1:100) 20
0.1 1 100(1:100) 0
For the PCR-Array study TK6 cells were treated with MMC for 2h (0, 0.004 and 0.08pg/ml), 
4h (0, 0.004 and 0.08pg/ml) and 24h (0 and 0.02pg/ml), whereas for the Real-time PCR 
study the cells were treated with MMC for 4h over a range of concentrations above and 
below the identified level of MN induction. Furthermore 4h treatments of MMC (Table 3.1) 
were also used for the pan-centromeric staining study.
3.2.5 The in vitro MN assay
The manual and the semi-automated scoring protocol, using the Metafer-System for the in 
vitro MN assay, were performed as described in chapter 2 (section 2.2.2). For the CBMN 
assay 1000 (manual) to 2000 (Metafer-System) cells per replicate were scored, whereas for 
the mononucleated assay 2000 (manual) to 4000 (Metafer-System) cells per replicate were 
scored (exceptions where stated; for details see Appendix I). At least two independent 
replicates were carried out for each experiment.
All cell suspensions (10ml) were seeded at lx l0 5cells/ml for 24h at 37°C, 5%CC>2. For the 
CBMN assay each cell suspension was treated with appropriately diluted MMC for different 
time points and 4.5 to 6 pg/ml cytochalasin B for one cell cycle. For the MONOMn assay
78
Chapter 3
TK6 cell suspensions were treated with MMC (0-0.1 pg/ml) for 24h followed by a 24h 
recovery period previous to harvest.
3.2.6 Cytotoxicity
RPD was used to measure cell death and cytostasis as described in chapter 2 (section 2.2.3).
3.2.7 Pan-centromeric painting
Centromeres were stained to classify if MMC was a clastogenic or aneugenic chemical with 
the RTU Human pan centromeric probe. The method is described in detail in chapter 2 
(section 2.2.4). Nuclei were counterstained with DAPI and 100 MN per dose were scored as 
positive or negative for the centromeric probe under a BX50 fluorescent (Carl Zeiss) 
microscope (exceptions where stated, for details see Appendix IV).
3.2.8 RNA extraction
Total RNA was extracted from the human lymphoblastoid cell line TK6 after MMC 
treatment. Details of the method are described in chapter 2 (section 2.2.5).
3.2.9 RT2 Profiler™ PCR Array System
The method for the PCR array system is described in detail in chapter 2 (section 2.2.6).
3.2.10 Reverse Transcription with elimination of genomic DNA for Quantitative, Real- 
Time PCR
The reverse transcription reactions are described in detail in chapter 2 (section 2.2.7).
3.2.11 PrimerDesign geNorm Reference Gene Assay
The geNorm Reference Gene Selection Kit from PrimerDesign Ltd., Rownhams, UK was 
used to select the reference gene for the Real-time PCR experiments. Details of the assay are 
described in chapter 2 (section 2.2.8)
3.2.12 Real-Time PCR
Real-time PCR was performed to quantify the gene expression of MSH6, BRCA1, Rad51C, 
XRCC3 and XRCC6BP1. For the Real-time PCR experiments the QuantiFast™ SYBR® 
Green PCR Kit (Qiagen, Sussex, UK) was used (the method is described in detail in chapter 2 
(section 2.2.9).
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Each sample in the Real-time PCR was run with primers for the (3-actin housekeeping gene 
respectively with primers for MSH6, BRCA1, XRCC3, Rad51C and XRCC6BP1.
3.2.13 Statistical analysis
The analysis method of the data sets is described in detail in chapter 2 (section 2.2.17). 
Further assessment of data used BMD modelling (Gollapudi et al., 2013).
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3.3 Results
3.3.1 Dose and time dependent genotoxic effects of MMC in TK6 cells
To explore the dose relationships of genotoxins at low doses, human lymphoblastoid cells 
were treated with the known genotoxic agent MMC and the in vitro MN assay was performed 
to investigate chromosomal damage. The in vitro MN assay can be performed with or without 
the actin polymerisation inhibitor cytochalasin B. The scoring for MN is usually done 
visually with a light or fluorescent microscope. However there are also new automated 
systems for scoring MN. One of the advanced automated systems, called the Metafer-System, 
uses fluorescent dyes specific for DNA and is used in our laboratory. A semi-automated 
scoring protocol for the Metafer-System was used for the assessment of MN preparations and 
compared to the visual Giemsa stained protocol.
As stated in the OECD guideline 487 (OECD, 2007) the test concentrations selected for the 
MN assay should cover a range of producing 50±5% toxicity to little or no toxicity. Higher 
levels may induce chromosome damage as a secondary effect of cell death. Several different 
methods to measure cytotoxicity in the presence and absence of cytochalasin B are available. 
In our studies, RPD was used to measure cell death and cytostasis (for further details see 
chapter 2 section 2.2.3).
For the comparison of the Metafer-System with manual scoring and for investigation of the 
low dose responses of MMC, TK6 cells were treated with MMC (0-0.1 pg/ml) for different 
time points. Extended treatments as well as short-term treatments were performed. For the 
extended 24h treatments of MMC, the mononucleated as well as binucleated assay were 
carried out, whereas for the extended continuous treatment of MMC and cytochalasin B as 
well as the short-term treatment only the CBMN assay was conducted (Figures 3.3 to 3.6).
For the MONOMn assay concentration-related increases in MN with both the manual and 
semi-automated method were shown from 0 to 0.04pg/ml MMC in TK6 cells. No clear 
NOEL was observed. The increase in percentage of micronucleated cells at higher 
concentrations (0.04pg/ml and above) of MMC was likely due to excessive cell death and 
cytostasis (Figure 3.3). Cytotoxicity measurements at 0.02 and 0.04pg/ml resulted in 
reduction in RPD as high as 31.2% and 62.5%.
Significant increases in MN frequency at 0.006pg/ml and 0.01 to 0.04pg/ml for the Metafer- 
System and at 0.008pg/ml and above for manually scoring were demonstrated (Figure 3.3). 
Higher concentrations were not analyzed through excessive toxicity.
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MonoMn (24+24 hours)
Automated ■ ■ M a n u a l  RPD
Figure 3.3: Effect of MMC on TK6 cells using the in vitro MN assay. TK6 cells were treated 
with MMC for 24h, followed by a 24h recovery period. Blue: Automated scoring, red: 
Manual scoring, green: Relative population doubling (RPD). Values represent mean and 
range of duplicate experiments. (*) Represents p<0.05.
For the CBMN assay TK6 cells were treated with MMC for 24h followed by one cell cycle of 
cytochalasin B (18h). As for the mononucleated assay an incremental increase in MN 
induction could be seen with each increase in concentration until 0.04pg/ml. A significant 
increase in MN frequency at 0.008pg/ml for the Metafer-System and at 0.02pg/ml for manual 
scoring was shown. The sharp increase in % micronucleated cells at higher doses (0.04pg/ml 
and above) of MMC was again likely due to excessive cell death and cytostasis (Figure 3.4). 
Cytotoxicity measurements at 0.02 and 0.04pg/ml resulted in reduction in RPD as high as 
30.6% and 60.5%.
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Figure 3.4: Effect of MMC on TK6 cells using the CBMN assay. TK6 cells were treated 
with MMC for 24h, followed by 18h of cytochalasin B. Blue: Automated scoring, red: 
Manual scoring, green: Relative population doubling (RPD). Values represent mean and 
range of duplicate experiments. (*) Represents p<0.05.
When comparing the MN frequencies for the mononucleated versus the CBMN assay for the 
extended treatment it was shown that the % of MN induction at the higher concentrations in 
the mononucleated assay was about half the % of MN induction in the CBMN assay (Figure
3.3 and 3.4).
TK6 cells, which were continuously treated with both MMC and cytochalasin B for 18h (one 
cell cycle; Figure 3.5), showed no significant increases in MN frequency at any concentration 
using both methods. In addition, treatments at higher concentrations with MMC (0.06pg/ml 
and above) showed exaggerated cell death and cytostasis (68.1% to 90.5%) (Figure 3.5).
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Figure 3.5: Effect of MMC on TK6 cells using the CBMN assay. TK6 cells were treated 
with MMC and cytochalasin B for 18h. Blue: Automated scoring, red: Manual scoring, green: 
Relative population doubling (RPD). Values represent mean ± SD (n=3).
An increase in MN induction over the background frequency level was only observed at the 
higher range of concentrations (0.02/0.04pg/ml to 0.1 pg/ml) in TK6 cells treated with 4h 
MMC followed by one cell cycle (18h) of cytochalasin B (Figure 3.6). Furthermore the cells 
showed 50±5% (45.8%) cell death and cytostasis at the highest test concentration (0.1 pg/ml) 
compared to the excessive cytotoxicity at 0.04pg/ml and above for the longer treatments 
(Figure 3.3 and 3.5).
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Figure 3.6: Effect of MMC on TK6 cells using the CBMN assay. TK6 cells were treated 
with 4h MMC followed by 18h of cytochalasin B. Blue: Automated scoring, red: Manual 
scoring, green: Relative population doubling (RPD). Values represent mean ± SD (n>3).
TK6 cells treated with MMC for all different time points showed very similar dose responses 
and MN frequencies when comparing the manual scoring with the semi-automated system 
Metafer. Pearson's r correlation analysis was performed to investigate the correlation of both 
methods and reported highly positive correlation between the manual scoring and the semi­
automated system (Table 3.2). The Metafer-System proved to be an adequate system to 
produce biologically relevant results. Therefore all further work was based on semi­
automated analysis.
Table 3.2: Comparison of the Metafer-System versus manual scoring in TK6 cells treated 
with MMC using Pearson's r correlation analysis
MMC treatment Correlation coefficient r p-value
24h+18h (CBMN assay) 0.98 1.32E-07
24h+24h (MonoMN assay) 0.90 1.37E-04
18h (CBMN assay) 0.75 0.008972
4h+18h (CBMN assay) 0.96 2.76E-06
Furthermore depending on the dose regime, TK6 cells treated with MMC showed linear and 
non-linear dose responses at the low concentration range. Therefore the dosing regime is 
crucial in describing the dose response.
0 0.0020.0040.0060.008 0.01 0.02 0.04 0.06 0.08 0.1
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3.3.2 Effect of short-term treatment of MMC in AHH-1 cells
To compare the short-term dose response seen in TK6 cells, as well as to further investigate 
the low dose response relationships of MMC, the human lymphoblastoid cell line AHH-1 was 
treated with MMC for 4h followed by one cell cycle (22h) of cytochalasin B and the CBMN 
assay was performed (Figure 3.7).
An increase in MN frequency was observed only at O.lpg/ml, when compared to the control 
sample. No increases in MN were found at the lower range of concentrations. Similarly to 
TK6 cells, AHH-1 cells treated with 4h of MMC showed up to 40% cell death and cytostasis 
only at the highest test concentration.
Like TK6 cells, AHH-1 cells treated with short-term MMC showed a similar dose-response at 
the low concentration range.
CBMN (4+22 hours)
Automated
0 0.0020.0040.0060.008 0.01 0.02 0.04 0.06 0.08 0.1
MMC (ng/ml)
Figure 3.7: Effect of MMC in AHH-1 cells using the CBMN assay. AHH-1 cells were 
treated with MMC for 4h followed by cytochalasin B for 22h. Blue: percentage 
micronucleated binucleated cells, green: Relative population doubling (RPD). Values 
represent mean ± SD (n=3).
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3.3.3 Assessment of the short-term dose response relationship of MMC in TK6 and 
AHH-1 cells
TK6 cells treated with MMC for 4h followed by 18h of cytochalasin B showed increases in 
MN frequencies only at the higher concentrations, whereas at the lower concentration range 
no increases in MN could be found (Figure 3.6). A similar dose response was observed for 
AHH-1 cells treated with MMC for 4h followed by one cell cycle of cytochalasin B (Figure 
3.7). Therefore the dose response curves were further assessed by quantitative means using 
BMD modelling.
The BMD approach estimates a dose that produces a pre-determined increase in the response 
over the control values and the BMDLio refers to the lower 90% confidence interval of a dose 
that produces a 10% increase over the fitted background level (Gollapudi et al., 2013).
For the manual T K 6  data the B M D  was calculated at 0.007pg/ml with its confidence intervals 
between 0.006pg/ml (BMD Lio)  and O.Olpg/ml, whereas for the automated data the B M D  
was calculated at 0.008pg/ml with its confidence intervals between 0.007pg/ml (BMDLio)  
and O.Olpg/ml.
The AHH-1 data set revealed a BMD at 0.02pg/ml with its confidence intervals between 
0.016pg/ml (BMDLio) and 0.03pg/ml.
The results are summarized Table 3.3 and Figures 3.8 and 3.9.
Table 3.3: The BMD analysis for the MN endpoint induced by MMC
Cell line MMC Units BMD BMDLio BMDUio
TK6 Manual data pg/ml 0.007 0.006 0.01
TK6 Metafer data Mg/ml 0.008 0.007 0.01
AHH-1 Metafer data pg/ml 0.02 0.016 0.03
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Figure 3.8: BMD dose response modelling results for MN induction in TK6 cells treated 
with MMC (4h+18h), using the manually and automated generated data set. (A) For the 
manual data the BMD was calculated at 0.007pg/ml with its confidence intervals between 
0.006 and O.Olpg/ml, whereas for (B) the automated data the BMD was calculated at 
0.008pg/ml with its confidence intervals between 0.007 (BMDLio) and O.Olpg/ml.
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Figure 3.9: BMD dose response modelling results for MN induction in AHH-1 cells treated 
with MMC (4h+22h), using the automated analysis data set. The BMD was calculated at 
0.02pg/ml with its confidence intervals between 0.016 and 0.03pg/ml.
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3.3.4 MMC - a clastogenic chemical
Human chromosome pan-centromeric staining was subsequently performed to determine if 
the MN induced by MMC originate from chromosome fragments lacking a centromere 
(clastogenicity) or whole chromosomes which were unable to incorporate into the main 
nucleus during cell division (aneuploidy).
Human chromosome pan-centromeric staining of TK6 cells (Figure 3.10 and 3.11) treated 
with 4h MMC followed by 18 h of cytochalasin B showed that MMC was a clastogenic 
chemical. The MN induced by MMC originate predominantly from chromosome fragments 
lacking a centromere and not aneuploidy, which was particularly demonstrated over the 
concentration range that presented increased MN frequencies (Figure 3.10).
Human Chromosome Pan-centromeric paint
clastogenic
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50
Q. 40
0 0.002 0.004 0.006 0.008 0.01 0.02 0.04 0.06 0.08 0.1
MMC (ng/ml)
Figure 3.10: Human chromosome pan-centromeric staining of TK6 cells treated with 4h 
MMC followed by 18h of cytochalasin B. Values represent mean and range of duplicate 
experiments.
89
Chapter 3
B
Figure 3.11: Examples of human chromosome pan-centromeric staining. (A) clastogenic MN 
with no signal (white arrows); (B) aneugenic MN with signal (white arrow).
3.3.5 DNA repair- a mechanistic study of MMC
DNA repair is believed to be mainly responsible for NOELs at low levels of DNA damage 
(Jenkins et al., 2010). Due to various DNA repair mechanisms, low levels of DNA damage at 
low concentrations can be tolerated by the cell. However at higher concentrations these 
mechanisms become saturated (Jenkins et al., 2010).
To investigate if DNA repair pathways play a role in the short-term treatment of MMC in 
TK6 cells, PCR arrays as well as Real-time PCR were performed to look at relative changes 
in gene expression of a panel of DNA repair genes.
It was hypothesized that important repair pathways may have been up-regulated in response 
to DNA damage and hence this up-regulation was sought.
The DNA Repair RT2 Profiler™ PCR Array (SABiosciences, Qiagen, Sussex, UK) profiled 
the expression of 84 genes, which are involved in various DNA repair pathways, like BER, 
NER. MMR or DSB repair.
Different treatment times for MMC (2h, 4h and 24h) and concentrations below and above the 
increases for MN induction were chosen. However, the 2h and 24h treatments showed no 
changes in gene expression when comparing the control with the MMC treated samples (data 
not shown; for details see Appendix V). Low gene expression changes in a couple of genes 
could be observed when TK6 cells were treated with MMC for 4h (Figure 3.12).
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Figure 3.12: DNA Repair RT2 Profiler™ PCR Anay Scatter Plot. Normalized expression of 
every gene of the array was compared between the control group and treated group 1 A: 
0.004pg/ml or group 2 B: 0.08pg/ml. Black dots: Genes with no changes in gene expression; 
red dots: Genes with up-regulation of gene expression; green dots: Genes with down- 
regulation in gene expression.
Based on changes at the average delta C t values (Figure 3.13) the following genes were 
chosen for further analysis by Real-time PCR: M SH 6 , BR C A 1 , R ad51C , XRC C3  and 
XRCC6BP1.
■  BRCAl ■  MSH6 ■  RAD51C XRCC3 ■  XRCC6BP1
Figure 3.13: DNA Repair RT2 Profiler™ PCR Anay Multigroup Plot. Expression changes of 
a selected set of genes across the control group and the treated groups 1 (0.004pg/ml) and 2 
(0.08pg/ml).
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When looking at the average C j values, M SH 6  was increased in TK6 treated with 0.004pg/ml 
MMC, but seemed back to control levels when treated with 0.08|jg/ml. Rad51C  showed an 
increase in the average C j  values over the control levels only in TK6 treated with 0.08pg/ml, 
whereas XRCC6BP1  showed increases in the average C/ value in both treated MMC groups 
of 0.004 and 0.08pg/ml. On the other hand XRC C 3  showed a decrease in the average C j 
values in the treated groups with MMC, when compared to the control group. Further BRCA1  
showed no changes in the average C j values, when comparing the control group with the 
treated MMC groups of 0.004 and 0.08pg/ml (Figure 3.13).
Short-term treatments with selected concentrations above and below the increased levels of 
MN induction were chosen for the Real-time PCR study. However, as can be seen in Figure 
3.14, no significant changes in gene expression of the selected genes could be observed. This 
may be because of some variation in the replicates, as can be seen with the wide error bars.
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Figure 3.14: Relative fold changes in M SH 6 , B R C A 1 , R ad51C , XRC C 3  and XRCC6BP1  gene 
expression, following exposure (4h) to increasing concentrations of MMC. Error bars 
represent SD (n=3)
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3.4 Discussion
Genetic toxicology testing is a basic component of the pre-clinical safety assessment of drug 
candidates, industrial chemicals and cosmetics. Therefore genotoxicology helps to identify 
compounds that are a potential risk for carcinogenicity and heritable mutations. It is 
important to improve health risk assessments by investigating if DNA reactive compounds 
follow linear or non-linear (thresholded) dose response relationships after exposure to low 
doses. This will allow more scientific assessment of actual risks and help to understand how 
the cells can tolerate some exposures.
In this study human lymphoblastoid cells (TK6 and AHH-1) were treated with the known 
genotoxin MMC. Chromosomal damage was quantified with the in vitro MN assay and 
further investigations into the mode of action of MMC were undertaken.
3.4.1 The Metafer-System versus manual scoring
The in vitro MN test is widely used for the assessment of genotoxic potential of drug 
substances. MN are an important endpoint in the quantification of chromosome damage. 
They are derived from chromosome fragments arising from asymmetrical structural 
aberrations (acentric fragments) or represent whole chromosomes that are not incorporated 
into the nucleus at cell division (Fenech et al., 1999; Varga et al., 2004).
Visual scoring of MN can be time consuming and the results depend on subjective 
interpretation. Therefore a high demand for automation of the MN test has been existed.
In our studies, the automated slide scoring platform Metafer, developed by MetaSystems in 
2004 was used. This advanced automated system uses fluorescent dyes specific for DNA.
For comparison purposes of the system with manual scoring, the dose response curves and 
MN frequencies obtained with the Metafer-System after treatment of TK6 cells with MMC 
were compared to the conventional manual scoring of Giemsa stained slides. This was for 
both the mono- and binucleate version of the MN assay.
TK6 cells treated with different concentrations of MMC (0-0.1 pg/ml), for different time 
points, showed very similar dose responses and MN frequencies, when comparing the manual 
scoring with the Metafer-System. Further, Pearson’s r correlation analysis revealed high 
correlation between both methods with highly significant p-values (see Table 2 for further 
details).
When looking at the Figures 3.3 to 3.6 it is notable that the mean response for the MN 
frequencies obtained with the Metafer-System was generally higher than for the manual 
scoring. However that is possibly due to subjective manual scoring and allowance of the
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system to score higher total numbers of cells as well as the classifier settings. Classifiers 
determine the parameters for the identification of the mononucleated and binucleated cells 
and the MN.
This study clearly demonstrated that the results gained with the Metafer-System are 
comparable with the results gained through visually scoring. Therefore it can be concluded 
that the Metafer-System used in our laboratory is an adequate system to produce biologically 
relevant results.
Furthermore, it is likely that the automated system can reduce the scoring subjectivity of MN 
identification. In addition, the Metafer-System allows scoring of a higher number of cells in a 
short time, when compared to manual scoring, which potentially advances the statistical 
power of the assay.
3.4.2 Dose relationships of MMC
Dependent on the treatment regime, different genotoxic responses for MMC could be 
observed. TK6 cells treated with MMC for 24h in the mononucleated as well as in the 
binucleated assay showed incremental increases in MN induction at all concentrations tested. 
Previous studies in different cell lines treated with MMC showed linear dose responses at 
relatively low concentrations of MMC (Elhajouji, 2010; Fowler et al., 2010; Schuler et al., 
2010, Sobol et al., 2012). The results are not unexpected since MMC is a cross-linking agent 
as well as an alkylating agent and therefore known to induce chromosomal aberrations 
(Abbas et al., 2002; Greenwood et al., 2004; Schuler et al., 2010). Alkylating agents induce 
DNA strand breaks as a result of the processing of lesions by various repair pathways, such 
as excision, homologous or non-homologous recombination and mismatch repair (Morales- 
Ramirez et al., 2004).
As expected, the frequency of micronucleated cells is higher in the CBMN assay than in the 
mononucleated assay. Cell division is required after damage induction for the development of 
MN. The CBMN assay detects chromosome breakage as well as chromosome loss in once 
divided binucleated cells, because cytochalasin B inhibits the actin furrow during anaphase 
(Kirsch-Volders and Fenech, 2001), whereas the mononucleated assay detects MN in 
mononucleated cells which may have gone through division.
TK6 cells continuously treated with MMC and cytochalasin B for 18h showed no increases in 
MN frequency at the chosen dose regime. It might be possible that cytochalasin B interacts 
with MMC in the continuous treatment resulting in no genotoxic effects. That cytochalasin B 
can reduce MN induction in combined treatments was shown for spindle poisons, like
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colchicine (Minissi et al., 1999). It was suggested that cytochalasin B treatment interferes 
with chromosome missegregation in human lymphocytes (Minissi et al., 1999). Further it was 
assumed that in cytokinesis-blocked cells the absence of the actin ring interferes with 
anaphase-B, which consequently leads to a shorter distance between the poles (Minissi et al., 
1999).
Another important factor is the cell cycle time. The average doubling time of TK6 cells used 
in our lab was approximately 16 to 18 hours. It seems to be very likely that the treatment time 
and cell cycle length of TK6 cells are crucial to produce genotoxic effects. It is therefore 
possible that the treatment time of 18h with no recovery time might not have been long 
enough to produce genotoxic effects. Another important factor here might be the time 
required for a lesion to be fixed as a mutation. As mentioned before MMC is an alkylating 
agent and a DNA cross-linker, which causes severe chromosomal damage and requires 
multiple DNA repair pathways including NER, DSB repair (homologous recombination) 
and/or translesion bypass repair (Drablps et al., 2004; Lee et al., 2006). It was shown that 
genotoxicity and cytoxicity of the 0 6-methylguanine lesion caused by MMS, an alkylating 
agent, is mainly due to the recognition of mispairs by the MMR system and the induction of 
futile repair cycles, resulting in the final stage in double strand breaks (Margison and 
Santibanez-Koref, 2002; Drablps et al., 2004). More than one cell cycle might be therefore 
needed for MMC to cause MN induction due to multiple rounds of error-prone lesion repair. 
Further Morales-Ramirez et al. (2004) showed that MMC induces MN in vivo mainly in the 
first division, but maybe not exclusively.
TK6 cells treated with MMC for 4h followed by 18h with cytochalasin B showed increases in 
MN frequency only at the higher concentrations. Furthermore AHH-1 cells treated with 
MMC for 4h and one cell cycle of cytochalasin B showed a similar dose response to TK6 
cells, with only the top concentration of O.lpg/ml showing increases in MN induction.
As mentioned earlier it is assumed that the relationship between exposure to genotoxic 
chemicals, DNA damage formation and the induction of mutagenic change is linear 
(Henderson et al., 2000). However mutations are not produced directly by DNA adducts as 
DNA repair activity limits the proportion of adducts processed into mutational change. It is 
therefore possible that NOEL may exist for some genotoxins (Jenkins et al., 2005). 
Furthermore natural defence mechanisms can reduce the entry and interaction of the 
genotoxin with the DNA.
Concentrations selected should have covered a range of 50±5% toxicity at the top dose to no 
toxicity in the control cultures. However extended treatments of MMC (18h and 24h) in TK6
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cells reached >50% toxicity at around 0.04(jg/ml. Increases in MN induction at higher doses 
of 0.04pg/ml were likely due to excess cell death as necrotic and apoptotic cells often contain 
chromosome fragments. MMC gave increases in MN frequency at or below the target range 
of 50±5% toxicity with the short-term treatments.
In addition pan-centromeric staining revealed that with increases in concentration, the 
proportion of centromere negative MN increased, confirming that MMC predominantly 
induces MN via chromosome breakage and not aneuploidy.
3.4.3 Dose response relationship assessment of MMC
The data for TK6 cells treated with 4h of MMC followed by 18h of cytochalasin B were 
further assessed for quantitative dose responses.
The short-term treatment data sets generated in TK6 and AHH-1 cells were analysed by the 
BMD approach, which estimates a dose that produces predetermined, biologically relevant, 
increases in the response over control (Gollapudi et al., 2013). The BMDLio refers to the 
estimate of lower 90% confidence interval of a dose that produces a 10% increase over the 
fitted background level for continuous endpoints and is considered an adequate point of 
departure (POD) for the extrapolation of dose response data (Gollapudi et al., 2013).
Table 3.3 summarizes the BMD values generated for each dataset tested and the ratio of 
BMDU io to BMDLio values provides information on the uncertainty around the BMD 
estimate. The data lined up well with the dose responses.
BMD modelling is widely used in risk assessment for other fields of toxicology to define 
POD values for cancer and non-cancer endpoints (Gollapudi et al., 2013). Determination of 
BMD values in genotoxic studies allows readily comparison to BMD values calculated for 
other toxicological endpoints and BMD modelling might therefore become the preferred 
approach when analysing genotoxic data (Gollapudi et al., 2013).
3.4.4 Mechanistic studies of MMC
Mechanistic experiments aimed to clarify if a possible NOEL over the background for MMC 
exists or not and also to understand how the cells tolerate low doses. MMC is a DNA 
interstrand cross-linking agent. As mentioned before, interstrand DNA cross-links are 
repaired by multiple repair pathways, including NER, BER and homologous recombination 
(Dronkert and Kanaar, 2001). Thus, the NOEL over the background could be due to DNA 
repair, which seems to be efficient at low doses of chemical compounds.
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DNA repair PCR arrays were used for the expression analysis of a panel of genes involved in 
DNA repair. However only in TK6 cells treated with 4h of MMC slight changes in gene 
expression in a small number of genes could be observed. MSH6, BRCA1, Rad51C, XRCC3 
and XRCC6BP1 were then chosen for further analysis by Real-time PCR. These genes are 
involved in different repair pathways. However no significance changes in gene expression of 
any genes investigated could be observed.
Limited access of the PCR arrays reduced the number of experiments to 1 replicate. It is most 
likely that more replicates are needed to get reliable results from the PCR arrays. Furthermore 
the base level expression of genes involved in DNA repair might be adequate to repair the 
damage caused by MMC to reduce DNA damage to background levels. Repair proteins can 
be modified by post-translational changes and these would not be picked up by gene 
expression approaches.
Furthermore if DNA repair does not play the crucial role in the NOEL of MMC other 
mechanisms, like cell cycle delay and apoptosis induction might. Further follow up 
experiments of the mode of action of MMC are needed to investigate the dose response.
3.5 Summary
In this chapter the dose response relationships after MMC treatment were explored at the low 
concentration range. Depending on the treatment regime different genotoxic effects were 
observed.
Furthermore the automated slide scoring platform Metafer, developed by MetaSystems was 
validated by comparing the MN frequencies obtained with the Metafer-System with the MN 
frequencies obtained with conventional manual scoring of Giemsa stained slides. The 
Metafer-System proved to be an adequate system for scoring MN.
Mechanistic studies of the short-term MMC treatment were undertaken to get a better 
understanding of the dose response relationship observed. DNA repair (at least up-regulation 
of expression) does not seem to play the crucial role in the NOEL of MMC. Further follow up 
experiments are needed to investigate the dose response.
Finally it was shown that MMC is a clastogenic chemical, which induces MN mainly due to 
chromosomal breakage and not through aneuploidy.
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Chapter 4
Detection of chromosomal damage and mutation induction after exposure to
4-nitroquinoline 1-oxide (4NQO) 
4.1 Introduction
As mentioned before, the investigation of the dose responses of genotoxins, especially in the 
low dose region helps to improve health risk assessments. In the previous chapter MMC, an 
alkylating and cross-linking agent was analysed, whereas in this chapter 4NQO, a genotoxin 
that causes bulky adducts, was investigated.
4.1.1 4-Nitroquinoline 1-oxide (4NQO)
4NQO is a known mutagen and carcinogen. It was first synthesized in 1942 and its 
carcinogenicity was first demonstrated in 1957 by Nakahara and his colleagues (Nakahara et 
al., 1957; Endo et al., 1971). Since then 4NQO was widely used in experimental oncology as 
a potent carcinogen (Sugimura et al., 1966). 4NQO has two polar groups in the molecule, the 
N-oxide and nitro group. It is therefore susceptible to nucleophilic attack in chemical 
reactions (Endo H., Ono T. and Sugimura T., 1971). Furthermore 4NQO behaves as an 
electron acceptor in the charge transfer complex formation (Endo et al., 1971) (Figure 4.1).
I
c r
Figure 4.1: The Structure of 4NQO (www.sigmaaldrich.com/catalog/product/aldrich/n8141)
4NQ0 induces cancer in various tissues of mice and rat, examples of which are lung, 
pancreas and stomach (Bailleul et al., 1989). The enzymatic reduction of its nitro group is
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believed to cause 4NQO’s carcinogenic action. 4NQO is converted into 4- 
hydroxyaminoquinoline 1-oxide (4HAQO) and 4-aminoquinoline 1-oxide (4AQO) (see 
Figure 4.2). However, only 4HAQO is believed to be carcinogenic (Bailleul et al., 1989). DT 
diaphorase, a NAD(P)H-quinolineoxidoreductase, catalyses the reaction. DT diaphorase is a 
flavoprotein, which can use either NADH or NADPH as cofactors for the reduction of 
quinone substrates (Tedeschi et al., 1995) (Figure 4.2).
4NQO and its reduced metabolite 4HAQO are able to bind to cellular macromolecules, such 
as nucleic acid and protein (Tada and Tada, 1975). Seryl-tRNA synthetase is the enzyme that 
activates 4HAQO to bind to cellular macromolecules in the presence of ATP, L-serine and 
Mg2+ (Tada and Tada, 1975). The activated 4HAQO gives rise to three main adducts by 
reacting with purines but not with pyrimidines (Tada and Tada, 1975), thus of the adducts 
two are located within the guanine base and another adenine adduct is formed (Figure 4.2). 
The structures of the adducts identified were nucleic acid bases, nucleosides or nucleotides of
0 f\N-(deoxyguanosin-8-yl)-4AQO, 3-(desoxyguanosin-N -yl)-4AQO and 3-(deoxyadenosin-N - 
yl)-4AQO (Bailleul et al., 1989; Kohda et al., 1991). The dGuo-C8-AQO adduct results from 
an attack of the nitrenium ion on the C8 position of guanine, whereas the dGuo-N2-AQO and 
the dAdo-N6-AQO adducts results from a carbocation attack on the guanine N2 and the 
adenine N6 positions, respectively (Bailleul et al., 1989).
4NQO reacts primarily with DNA at the N2 and C8 position of guanosine, and to a smaller 
extent at the N6 position of adenosine, and it was shown that NER operates on all these 
lesions (Jones et al., 1989).
Furthermore 8-hydroxydeoxyguanosine (8-OH-dG) formation was observed in cellular DNA 
treated with 4NQO (Kohda et al., 1991; Arima, et al., 2006) and it was shown that 4NQO 
induces oxidative stress and generates ROS, such as superoxide radicals or hydrogen 
peroxide, via induction of superoxide response operon (Nunoshiba and Demple, 1993; 
Kanojia and Vaidya, 2006). Consequently, a combination of reactive ROS formation and 
glutathione (GSH) depletion is involved in the 8-OH-dG formation by 4NQO (Arima et al., 
2006, Stankowsi Jr., et al., 2011) (Figure 4.2).
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Figure 4.2: Mechanism of 4NQO's reaction with DNA. Metabolic reductions to 4- 
Hydroxyaminoquinoline-1-oxide (4HAQO) results in adduct formation, while 8-hydroxy- 
deoxyguanosine (8-OH-dG) formation occurs through glutathione (GSH) depletion and 
reactive oxygen species (ROS) formation. The double arrow indicates the predominant 
pathway for genotoxicity (from Stankowski Jr. et al., 2011).
Morrow et al. (1998) showed that the resistance to 4NQO induced genotoxicity and 
cytotoxicity is affected by the Multidrug resistance protein (MRP) and glutathione S- 
transferase P (GSTP1-1) proteins (Kanojia and Vaidya, 2006). GSTP1-1 utilizes, amongst 
other GSTs, gluthathione for conjungation and 4NQO is a substrate for GSTP1-1 (Kanojia 
and Vaidya, 2006). The resultant conjugate is called 4-(glutathione-S-yl)-quinoline 1-oxide 
(QO-SG) (Morrow et al., 1998) and can be pumped out of the cell by MRP (Kanojia and 
Vaidya, 2006).
In addition, 4NQO has been referred to as a UV mimetic agent, because UV light causes 
pyrimidine dimer formation, which are bulky adducts, that are repaired by NER (Kanojia and 
Vaidya, 2006). Similarly, 4NQO causes bulky DNA adducts, but differences in the UV and 
4NQO induced damages and repair response to these adducts have been reported in previous 
studies (Jones et al., 1989; Snyderwine and Bohr, 1992; Kanojia and Vaidya, 2006).
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4.1.1.1 Examples for previous genotoxicology studies with 4NQO
4NQO is primarily used as positive control in various genotoxicology assays and has been 
shown to give clear positive results in the Ames test (Searle, 1976) and in vivo rodent studies 
(Nomura et al., 1974).
Further Jenkins et a l (1998) used the restriction site mutation (RSM) assay for the analysis of 
mutations induced by two potent genotoxins ENU and 4NQO. Human fibroblasts were 
treated with 4NQO to assess the role of DNA lesions in induced mutagenesis in vitro by the 
RSM assay and the 32P-post-labelling assay (Jenkins et al., 1998). The cells were treated with 
5pM 4NQO for 4h and DNA was extracted 24h and 4 days post-treatment. Further DNA 
extractions followed from sub-culturing flasks (sampled 24h and 4 days after sub-culturing) 
and then the process was repeated until day 80 (Jenkins et al., 1998). The results showed two 
peaks of DNA mutations at day 4 and day 46 post-exposure. The mutations then declined 
after 46 days with no mutations detected in the 64- to 80-day period (Jenkins et al., 1998). 
The base substitutions detected by RSM were GC-> AT transitions on the non-transcribed 
strand (Jenkins et al., 1998).
Valentin-Severin et a l (2003) performed a study to compare the sensitivity of the MN assay 
and the comet assay with HepG2 cells towards direct and indirect mutagens. HepG2 cells 
were treated with 1.5, 3 and 7.5pM 4NQO for 4h. 4NQO induced DNA-damage at the lowest 
range of concentrations (l-10pM) in the comet assay and showed a significant concentration- 
dependent increase between 0.1 and 2pM to reach a 3.5-fold increase of MN (Valentin- 
Severin et al., 2003).
An in vivo study by Ribeiro et a l investigated the genomic instability on blood cells during 
4NQO-induced rat tongue carcinogenesis with the help of the single cell gel (comet) and MN 
assay (Ribeiro et al., 2008). Male Wistar rats were treated with 50ppm 4NQO solution 
through their drinking water for 4, 12 and 20 weeks (Ribeiro et al., 2008). A statistically 
significant (P<0.05) increase of DNA damage was found at 4 and 20 weeks administration of 
4NQO by the mean tail moment (Ribeiro et al., 2008). Furthermore a gradual increase of MN 
frequency was observed at all period’s evaluated (Ribeiro et al., 2008).
Dertinger and colleagues evaluated two endpoints of genetic toxicity, mutation at the Pig-a 
gene and chromosomal damage in the form of micronucleated reticulocytes (MN-RET) in the 
context of a 28-day repeat-dosing study (Dertinger et al., 2010). Male Wistar Han rats were 
treated in 24h intervals on days 1 through 28 with one of the five following genotoxins: ENU, 
7, 12-dimethyl-benz[a]anthracene, 4NQO, benzo(a)pyrene and MNU. The dose levels for 
4NQO were 1.25, 2.5 and 5mg/kg/day. Flow cytometric scoring of CD59-negative
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erythrocytes (indicative of glycosylphosphatidylinositol anchor deficiency and hence Pig-a 
mutation) was performed using blood specimens obtained on days -1, 15, 29 and 56 
(Dertinger et ah, 2010). On days 4 and 29 blood specimens were collected and evaluated for 
MN-RET frequency (Dertinger et al., 2010). 4NQO showed no significant effect on MN-RET 
frequency, whereas Pig-a mutation was evident in the erythroid lineage (Dertinger et al., 
2010).
Most previous studies showed that 4NQO induces DNA damage. However no investigations 
into the low dose response curve of 4NQO have been undertaken.
Assays, such as the in vitro MN method, the HPRT assay and/or the comet assay allow direct 
measurement of DNA damage. The in vitro MN test is described in detail in chapter 1 
(section 1.4).
4.1.2. The mammalian cell HPRT gene mutation assay
The ability to detect substances that cause DNA damage is essential for human risk 
assessment, as DNA damage is an underlying cause of mutations that have the potential to 
initiate carcinogenesis. A mutation is a permanent change in the amount or structure of the 
genetic material of an organism (COM guideline, 2000) and can involve individual genes, 
blocks of genes or whole chromosomes.
The in vitro mammalian cell gene mutation test is used to screen for possible mammalian 
mutagens and carcinogens (OECD, 1997e) and allows identification of substances that lead 
specifically to point mutations. The test detects cells which are able to survive in the presence 
of a selective agent only after a new functional mutation occurs (Aaron et al., 1994).
Suitable cell lines for the test include the L5178Y mouse lymphoma cells, the CHO, AS52 
and V79 lines of Chinese hamster cells and the human lymphoblastoid cell line TK6 (OECD, 
1997e). Endpoints measured are mutation at TK, HPRT and a transgene of XPRT (Aaron et 
al., 1994; OECD, 1997e).
The HPRT gene is on the X chromosome of mammalian cells, which means male cells only 
carry a single copy of the gene and consequently it is easy to select for loss of functions 
mutants in cells derived from males, which are heterozygous for sex chromosomes (Johnson, 
2012). Mutation, that destroy the functionality of the HPRT gene and/or protein are detected 
by positive selection using a toxic analogue (Johnson, 2012). Cells deficient in HPRT are 
resistant to 6-TG (a guanine analogue), whereas HPRT proficient cells are poisoned by 6-TG, 
so mutant cells are able to proliferate in the presence of 6-TG, whereas the cellular 
metabolism of normal cells is inhibited and further cell divisions are put on hold (OECD,
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1997e). Consequently, HPRT' mutants result in viable cell colonies after continued sub- 
culturing (Johnson, 2012).
4.1.3 The comet assay
The comet or single cell gel electrophoresis assay is used in genotoxicology testing to 
measure DNA damage in eukaryotic cells at a single cell level.
Under alkaline conditions single- and double-strand breaks, incomplete repair sites, DNA 
cross-links and alkali-labile sites in single cell suspensions can be detected (Burlinson et al., 
2007; OECD, 2008; Kumaravel et al., 2009).
Electrophoresis of DNA causes it to migrate in an agarose gel matrix. Thus, cells with and 
without DNA damage can be distinguished by the fact that damaged cells take a distinctive 
comet-like shape with a nuclear region and a tail region containing DNA fragments or DNA 
strands (OECD, 2008).
Two versions of the comet assay exist. The first version was introduced by Singh et a l 
(1988) and uses alkaline electrophoresis to analyse DNA damage. The method is capable of 
detecting single-strand breaks and alkali labile sites in individual cells (Singh, et al., 1988; 
Rojas et al., 1999). The second version introduced by Olive et a l (1990) involves lysis in 
alkali treatment followed by electrophoresis at either neutral or mild alkaline conditions to 
detect single-strand breaks (Olive at al., 1990, Rojas et al., 1999).
The standard alkaline method gives limited information on the type of DNA damage, since it 
is not possible to determine if the DNA damage measured is a consequence of the direct 
action of the damaging agent or of indirect effects, such as oxidative damage or DNA repair 
(Smith et al., 2006). However the standard method can be improved by incubating the lysed 
cells with lesion-specific endonucleases, such as formamidopyrimidine DNA-glycosylase 
(FPDG), endonuclease III or human 8-hydroxyguanine DNA-glycosylase 1 (hOGGl) (Smith 
et al., 2006). This allows recognition of particular damaged bases and creation of additional 
breaks (Smith et al., 2006). The modified comet assay can therefore be used to specifically 
detect oxidative DNA damage.
4.1.4 Aim of study
This study was designed to assess the low dose response relationships of 4NQO and to 
investigate, if the genotoxin follows linear or non-linear (thresholded) dose response 
relationships.
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Chromosomal damage was investigated using the in vitro MN assay, while further gene 
mutation and DNA damage studies were carried out using the in vitro HPRT and comet 
assays.
This research was carried out at Swansea University, Swansea, UK as well as during an 
extended visit at AstraZeneca, Cheshire, UK. This allowed comparison of data generated in 
two laboratories as well as usage of a broad range of methods for the investigation into the 
low dose region of 4NQO.
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4.2 Materia] and Methods
4.2.1 Cell lines
At Swansea University the human lymphoblastoid cell lines TK6, AHH-1 and MCL-5 were 
utilized. TK6, AHH-1 and MCL-5 cells were described in detail in chapter 2 (section 2.2.1). 
For the experiments carried out at AstraZeneca the human lymphoblastoid cell line TK6 as 
well as the mouse lymphoma cell line L5178Y were used. L5178Y cells are known for their 
dysfunctional p53 activity (Storer et al., 1997; Clark et al., 2004).
The average doubling time of TK6 cells in both laboratories was approximately 16h to 18h. 
The doubling time of AHH-1 and MCL-5 cells was approximately 22h to 24h, whereas the 
L5178Y doubling time was around 11.5h.
4.2.2 Cell culture
Cell culture at Swansea University was performed as described in chapter 2 (section 2.2.1). 
TK6 cells at AstraZeneca were cultured in RPMI 1640 (Sigma-Aldrich, Dorset, UK) 
supplemented with 10% heat inactivated donor horse serum (Gibco®, Paisley, UK), 2mM L- 
glutamine (Gibco®, Paisley, UK), 2mM sodium pyruvate (Gibco®, Paisley, UK), 200IU/ml 
penicillin (Gibco®, Paisley, UK) and 200pg/ml streptomycin (Gibco®, Paisley, UK) at 37°, 
5%CC>2. L5178Y cells were cultured in RPMI 1640 supplemented with 10% heat inactivated 
donor horse serum, 2mM L-glutamine, 2mM sodium pyruvate, 1% Pluronic F68 (Gibco®, 
Paisley, UK), 200IU/ml penicillin and 200pg/ml streptomycin at 37°, 5%CC>2.
4.2.3 Test chemical
4NQO was acquired in both laboratories from Sigma-Aldrich, Dorset, UK. Before use, the 
chemical was freshly diluted from a stock solution (2.5mg/ml aliquots at Swansea University 
and 0.019mg/ml aliquots at AstraZeneca) with DMSO.
4.2.4 Test chemical dosing regime
At Swansea University the following 4NQO dosing regimens were used:
For the in vitro MN assay TK6 cells were treated with 4NQO over a range of concentrations 
between 0 and 0.03pg/ml for 4h, 24h or 48h respectively, followed by different recovery 
times. AHH-1 and MCL-5 cells were treated with 4NQO over a dose range of 0 to 0.7pg/ml 
for 4h with 22h or 46h recovery time. For the pan-centromeric staining study TK6 cells were 
treated with 4NQO for 24h over a range of concentrations between 0 and 0.03pg/ml. Further,
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TK6 cells were treated for 24h with 4NQO for the HPRT assay study with 0.0009, 0.003, 
0.01 and 0.02pg/ml 4NQO. Water was used as negative control, whereas DMSO was used as 
the solvent control. The experiment was carried out in triplicate.
The following NQO dosing regimens were used at AstraZeneca:
For the in vitro MN assay TK6 cells were treated with 4NQO for 4h plus 40h recovery period 
and 24h plus 24h recovery time over a range of concentrations between 0 to 0.03pg/ml. 
Further L5178Y cells were treated with 4NQO for 4h, followed by 24h recovery time over a 
range of concentrations between 0 and 0.05pg/ml. For the comet assay TK6 cells were 
treated with 4NQO for 3h over a range of concentrations between 0 and 0.06pg/ml 4NQO.
4.2.5 The in vitro MN assay
At Swansea University the semi-automated scoring protocol for the Metafer-System was used 
for the CBMN assay studies. The method is described in detail in chapter 2 (section 2.2.2). 
For the CBMN assay a minimum of 3000 cells per replicate were scored (exceptions where 
| stated, for details see Appendix I). Three independent experiments were carried out.
I AstraZeneca also uses the Metafer-System developed by MetaSystems for scoring MN. The
| in vitro MN test (mononucleated assay) procedure at AstraZeneca was performed as
I described below. Automated as well as manual scoring was carried out.
j
I
I
| 4.2.5.1 Initiation of the assay
I All cell suspensions (10ml) were seeded at 2xl05 cells/ml and immediately dosed with 1%
j  v/v solvent control and the test chemical as described above (section 4.2.4) at 37°C, 5%CC>2.
I After the different incubation times the cell suspensions were removed from each flask and
transferred into appropriately labelled tubes. The cells were centrifuged (5min, 200 x g), the 
supernatant discarded and the pellets washed with PBS, before re-suspending the cells in 
10ml fresh media.
4.2.5.2 Harvest and scoring
The cells were cytospun onto polished glass slides. Shandon mega-fimnels (8min, lOOOrpm) 
were used to harvest cells for the Metafer-System, whereas micro-funnels (8min, 800rpm) 
were used for the harvest for manual scoring. An appropriate volume of cells sub-cultured to 
1x10s cells/ml was used to prepare the slides. Five hundred microliter of the cell suspension
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was used for the mega-funnels, whereas lOOpl of cell suspension was used for the micro­
funnels. The cells were fixed in 100% methanol for 15min.
For the automated scoring system the slides were stained with a vectashield antifading 
solution containing DAPI stain, while acridine orange (Sigma-Aldrich, Dorset, UK) staining 
was used for manual scoring under a fluorescent microscope (Carl Zeiss).
4.2.5.3 Scanning and Classifier settings for the Metafer-System
The slides were scanned at 20x magnification using the Metafer 4 master station, coupled to a 
fluorescent microscope (equipped with a Maerzhaeuser stepping motor stage; Carl Zeiss), a 
Dell computer hub (loaded with the Metafer4 Version 3.4.102 software) and a high resolution 
megapixel charge coupled device (CCD) camera (Axiocam; Carl Zeiss) for image capture. A 
number of grid positions evenly distributed across the scan area determined the plane of focus 
and a predetermined scan area was used for all slides.
Classifiers developed by MetaSystems were optimised in order to detect mononucleated cells. 
The search definition classifiers were used to define the size and shape of nuclei and 
micronuclei (Table 4.1).
Table 4.1: Classifier settings on the Metafer-System to define mononucleated cells and MN
Mononuclear
Nuclei Micronuclei
Object threshold 20% 10%
Minimum area 10pm" 1.0pm"
Maximum area 400pm2 55pm2
Maximum relative concavity of 
depth
0.9 1.0
Maximum aspect ratio 2.5 3.5
Maximum distance between - 35pm
Maximum area asymmetry 90% -
4.2.5.4 Acridine orange staining
For manual scoring slides were stained with acridine orange. The fixed cells on the slides 
were submerged in phosphate buffer (0.66% w/v potassium phosphate monobasic + 0.32% 
w/v sodium phosphate dibasic, pH 6.4-6.5) and stained in a solution of acridine orange (AO)
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(12mg AO/100ml phosphate buffer) for lmin. The slides were transferred into phosphate 
buffer for lOmin, then the buffer was re-freshed and the slides were left in buffer for a further 
15min. Finally the slides were air-dried and stored protected from light.
4.2.5.5 Scoring
All experiments carried out at AstraZeneca were run in duplicate. 1000 mononucleated cells 
were scored per replicate for both manual and automated scoring. The manual scoring system 
for MN was as described by Fenech et a l (2003).
4.2.6 Cytotoxicity
RPD was used at Swansea University as well as AstraZeneca to measure cell death and 
cytostasis. The method is described in detail in chapter 2 (section 2.2.3).
For the Z1 Coulter Particle Counter (Beckman Coulter Inc., High Wycombe, UK) at 
AstraZeneca 1ml of cell suspension were placed into a cuvette containing 19ml of dilute 
conducting liquid.
4.2.7 Pan-centromeric painting
Centromeres were stained to classify 4NQO as a clastogenic or aneugenic chemical with 
RTU human pan-centromeric probe. The method is described in detail in chapter 2 (section 
2.2.4). Nuclei were counterstained with DAPI and 100 MN per dose were scored as positive 
or negative for the centromeric stain under a BX50 fluorescent microscope (Carl Zeiss) 
(exceptions where stated, for details see Appendix IV).
4.2.8 The mammalian cell HPRT gene mutation assay
The HPRT gene mutation assay detects mutations which destroy the functionality of the 
HPRT gene and/or protein by positive selection (Johnson, 2012). The assay is described in 
detail in chapter 2 (section 2.2.10). TK6 cells were treated with 4NQO for 24h over a range 
of concentrations between 0 and 0.02pg/ml 4NQO.
4.2.9 The in vitro comet assay +/-hOGGl
For the comet assay TK6 cells were treated with 4NQO for 3h with a range of concentrations 
between 0 and 0.06pg/ml. Details of the assay are described in chapter 2 (section 2.2.11).
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4.2.10 Statistical Analysis
The statistical analysis is described in detail in chapter 2 (section 2.2.17).
109
Chapter 4
4.3 Results
4.3.1 Chromosomal aberration induction at low doses of 4NQO in TK6 cells
Short-term and extended treatments were used for the investigation of the dose response 
curve for 4NQO at Swansea University. The work was based on semi-automated analysis 
with the Metafer-System.
TK6 cells treated for 4h with 4NQO followed by one cell cycle of cytochalasin B (18h) 
showed no significant increases in MN induction over the treatment range chosen (0 to 
0.03pg/ml). However, >50±5% (60.1% to 84.7%) cell death and cytostasis was observed at 
0.02pg/ml of 4NQO (Figure 4.3).
CBMN (4+18hours)
Autom ated
4NQO (ng/m l)
Figure 4.3: Effect of 4NQO on TK6 cells using the CBMN assay. TK6 cells were treated 
with 4NQO for 4h, followed by 18h of CytoB. Blue: percentage micronucleated binucleated 
cells, green: Relative population doubling (RPD). Values represent mean ± SD (n=3).
Extended treatments of 24h and 48h exposure to 4NQO, followed by one cell cycle of 
cytochalasin B (18h) were subsequently performed.
TK6 cells treated with 4NQO for 24h, followed by 18h of cytochalasin B showed no 
significant increases in MN frequencies. Further, >50±5% (55.5%) toxicity was observed at 
0.02pg/ml of 4NQO (Figure 4.4).
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CBMN (24+18hours)
Autom ated
4 NQO (pg/m l)
Figure 4.4: Effect of 4NQO on TK6 cells using the CBMN assay. TK6 cells were treated 
with 4NQO for 24h, followed by 18h of CytoB. Blue: percentage micronucleated binucleated 
cells, green: Relative population doubling (RPD). Values represent mean ± SD (n=3).
No significant increases in MN induction were observed when TK6 cells were treated for 48h 
with 4NQO. followed by one cell cycle of cytochalasin B (18h). At the top dose chosen 
(0.03pg/ml), only 29.5% cell death and cytostasis were observed (Figure 4.5).
CBMN (48+18hours)
Autom ated
4NQO (ng/m l)
Figure 4.5: Effect of 4NQO on TK6 cells using the CBMN assay. TK6 cells were treated 
with 4NQO for 48h, followed by 18h of CytoB. Blue: percentage micronucleated binucleated 
cells, green: Relative population doubling (RPD). Values represent mean ± SD (n=3).
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In previous studies (Sobol et al., 2012), it was proposed that an extended recovery time might 
play a critical role in MN induction. Therefore TK6 cells were treated with 4NQO for 4h, 
followed by a 24h recovery period, before adding cytochalasin B for another 18h (one cell 
cycle). Increases in MN induction only at 0.03pg/ml 4NQO could be observed. In addition at 
the top dose 60.6% toxicity was reached (Figure 4.6).
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Figure 4.6: Effect of 4NQO on TK6 cells using the CBMN assay. TK6 cells were treated 
with 4NQO for 4h, followed by a 24h recovery period and 18h of CytoB. Blue: percentage 
micronucleated binucleated cells, green: Relative population doubling (RPD). Values 
represent mean ± SD (n=3).
To compare the results gained at Swansea University and for further investigations into the 
dose response curves of 4NQO, similar experiments were carried out in a second laboratory 
at AstraZeneca, Cheshire, UK. At AstraZeneca the mononucleated MN assay was carried out. 
Cells were scored with the semi-automated system Metafer as well as manual analysis by 
visual inspection under a fluorescent microscope.
As with the previous extended treatment, TK6 cells were treated with 24h of 4NQO, followed 
by a 24h recovery period before harvesting. No significant increases in MN induction were 
observed over a range of concentrations between 0 and 0.03pg/ml 4NQO with the manual 
scoring and the Metafer-System. About 40% (38.8%) cell death and cytostasis were observed 
at the top concentration (0.03pg/ml) (Figure 4.7).
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Figure 4.7: Effect of 4NQO on TK6 cells using the in vitro MN assay. TK6 cells were 
treated with 4NQO for 24h, followed by a 24h recovery period. Blue: Automated scoring, 
red: manual scoring, green: Relative population doubling (RPD). Values represent mean and 
range of duplicate experiments.
Further, a short-term treatment of 4h with an extended recovery period of 40h was performed. 
Significant increases in MN induction were observed at 0.02 and 0.03pg/ml 4NQO with the 
manual scoring, whereas increases in MN induction were shown with the Metafer-System at 
0.02pg/ml and above. At the highest dose, 39.5% toxicity was reached (Figure 4.8).
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Figure 4.8: Effect of 4NQO on TK6 cells using the in vitro MN assay. TK6 cells were 
treated with 4NQO for 4h, followed by a 40h recovery period. Blue: Automated scoring, red: 
manual scoring, green: Relative population doubling (RPD). Values represent mean and 
range of duplicate experiments. (*) Represents p<0.05.
The work carried out at AstraZeneca, Cheshire, UK supported the studies carried out at 
Swansea University, Swansea, UK. Similar dose response curves of TK6 cells treated with 
4NQO were obtained in both laboratories. In addition Pearson's r correlation revealed highly 
positive correlation between the manual scoring and the semi-automated system Metafer at 
AstraZeneca (Table 4.2).
4.3.2 MN induction by 4NQO in the human lymphoblastoid cell lines AHH-1 and MCL- 
5 as well as the mouse lymphoma cell line L5178Y
To compare the results gained in TK6 cells against other cell lines, the human 
lymphoblastoid cell lines AHH-1 and MCL-5 were treated with 4NQO at Swansea 
University, whereas at AstraZeneca the mouse lymphoma cell line L5178Y was treated with 
4NQO.
Short-term treatments with and without prolonged recovery times were used at Swansea 
University.
AHH-1 cells treated with 4NQO for 4h over a concentration range between 0 and 0.7pg/ml, 
followed by one cell cycle of cytochalasin B (22h) showed no significant increases in MN 
induction. Further, MCL-5 cells showed no significant increases in MN induction for the 
short-term treatment over the dose range chosen. At 0.7pg/ml >50±5% toxicity in AHH-1 as
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well as MCL-5 (61% in AHH-1 and 53.5% in MCL-5) cells were observed (Figures 4.9 and 
4.10).
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Figure 4.9: Effect of 4NQO on AHH-1 cells using the CBMN assay. AHH-1 cells were 
treated with 4NQO for 4h, followed by 22h of CytoB. Blue: percentage micronucleated 
binucleated cells, green: Relative population doubling (RPD). Values represent mean ± SD 
(n=3).
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Figure 4.10: Effect of 4NQO on MCL-5 cells using the CBMN assay. MCL-5 cells were 
treated with 4NQO for 4h, followed by 22h of CytoB. Blue: percentage micronucleated 
binucleated cells, green: Relative population doubling (RPD). Values represent mean ± SD 
(n=3).
— i—  — i—  — i—  — i—
0.03 0 .07 0.1 0.3 0.7
115
Chapter 4
After prolonging the recovery time for 24h, AHH-1 cells showed increases in MN induction 
at O.lpg/ml of 4NQO and MCL-5 cells showed increases in MN induction at 0.3pg/ml 4NQO 
(Figure 4.11).
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Figure 4.11: Effect of 4NQO on AHH-1 and MCL-5 cells using the CBMN assay. AHH-1 
and MCL-5 cells were treated with 4NQO for 4h, followed by a 24h recovery period and 22h 
of CytoB. Blue: AHH-1 cells, green: MCL-5 cells. Values represent mean ± SD (n=3).
L5178Y cells are frequently used at AstraZeneca and other laboratories for genotoxicology 
studies. The cells were treated with 4NQO for 4h followed by a prolonged recovery time of 
24h prior to harvesting, over a concentration range between 0 and 0.05pg/ml. The average 
doubling time of L5178Y cell was 11.5h, hence they grow much faster than the other cell 
lines used. The cells showed significant increases in MN induction at 0.0075pg/ml and above 
with the Metafer-System and at 0.03pg/ml and above with the manual scoring. No reduction 
in cell viability could be observed over the dose range (Figure 4.12).
Pearson's r correlation revealed again highly positive correlation between the manual scoring 
and the semi-automated system Metafer (Table 4.2).
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Figure 4.12: Effect of 4NQO on L5178Y cells using the in vitro MN assay. L5178Y cells 
were treated with 4NQO for 4h, followed by a 24h recovery period. Blue: Automated 
scoring, red: manual scoring, green: Relative population doubling (RPD). Values represent 
mean and range of duplicate experiments. (*) Represents p<0.05.
Table 4.2: Comparison of the Metafer-System (AstraZeneca) versus manual scoring in TK6 
cells treated with 4NQO using Pearson's r correlation analysis
4NQO treatment Correlation coefficient r p-value
24h+24h (TK6 cells) 0.82 0.01246
4h+40h (TK6 cells) 0.74 0.03535
4h+24h (L5178Y cells) 0.99 1.933E-06
In summary, 4NQO showed little to no significant increases in MN induction in the human 
lymphoblastoid cell lines TK6, AHH-1 and MCL-5, even up to 50±5% toxicity. However, a 
linear dose response relationship was observed in the mouse lymphoma cell line L5178Y 
after 4NQO treatment, even at concentrations with no reduction in cell viability.
4.3.3 4NQO- A clastogen or an aneugen?
Human chromosome pan-centromeric staining was used to determine if the MN induced by 
4NQO were predominantly due to whole chromosomes unable to incorporate into the main 
nuclei (aneuploidy) or due to chromosome breaks (clastogenicity).
TK6 cells treated with 4NQO for 24h and 18h of cytochalasin B showed increases in pan- 
centromeric negative MN over the range of concentrations (Figure 4.13). From this it
L5178Y (4+24hours)
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followed that the MN induced by 4NQO mainly originated from chromosome fragments 
lacking a centromere (clastogenicity).
Human Chromosome Pan-centromeric paint
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Figure 4.13: Human chromosome pan-centromeric painting of TK6 cells treated for 24h with 
4NQO followed by 18h with CytoB. Values represent mean and range of duplicate 
experiments.
4.3.4 Gene mutation and DNA damage induction by 4NQO in TK6 cells
After investigating chromosomal damage of 4NQO in TK6 cells and observing somewhat 
little damage, the HPRT assay and the comet assay were performed to investigate the 
induction of gene mutations and DNA damage by 4NQO.
For the HPRT assay TK6 cells were treated with 4NQO for 24h between 0 and 0.02pg/ml. 
Water was used as negative control, while DMSO served as solvent control. Increases in gene 
mutations were observed at 0.01 and 0.02pg/ml 4NQO (Figure 4.14).
118
Chapter 4
HPRT assay (24hour)
VC
1600
1400
V  1200u
£ iooo 
§T 800
k -
c  600  
«  400  
|  200 
0 ■
H20 DMSO 0,0009 0,003
4NQO (ng/m l)
0,01 0,02
Figure 4.14: H P R T  gene mutation frequency (number of 6TG resistant clones/106 clone- 
forming cells) in TK6 cells treated with 24h of 4NQO. Values represent mean ± SD (n=3).
The modified comet assay was performed at AstraZeneca, Cheshire, UK. With the comet 
assay low levels of DNA damage can be detected. The assay was performed with and without 
hOGGl. hOGGl is an endonuclease, that recognizes oxidative DNA damage (Smith et al., 
2006). TK6 cells treated with 4NQO for 3h showed increases in DNA damage at 0.04 and 
0.06pg/ml 4NQO without hOGGl and at 0.06pg/ml 4NQO with hOGGl (Figure 4.15). At 
0.06pg/ml 4NQO, the DNA damage induced by 4NQO was higher in the samples with 
hO G G l.
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Figure 4.15: The in vitro comet assay. The effect of hOGGl on DNA tail intensity, following 
treatment of TK6 cells with 3h of 4NQO. Values represent mean and range of duplicate 
experiments.
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4.4 Discussion
4NQO is a known mutagen and carcinogen that forms stable monoadducts with purine bases 
after enzymatic reduction of its nitro group (Stankowski Jr. et al., 2011). The carcinogen is 
used as a model chemical in genotoxicology studies. However this study investigated the 
dose response relationship of 4NQO after low dose exposures.
Human lymphoblastoid cell lines (TK6, AHH-1 and MCL-5) as well as the mouse lymphoma 
cell line L5178Y were treated with low doses of 4NQO. Chromosomal damage was 
quantified with the in vitro MN assay. Further studies included the investigation of mutation 
and DNA damage induction by 4NQO.
4.4.1 Chromosomal aberration induction by 4NQO
The in vitro MN assay was used to investigate chromosomal damage. The semi-automated 
scoring protocol for the CBMN assay was carried out at Swansea University, whereas at 
AstraZeneca the mononucleated assay was used for manual and semi-automated scoring.
The in vitro MN assay can be performed with or without the actin polymerisation inhibitor 
cytochalasin B. Actin polymerisation is required for the formation of the microfilament ring 
that constricts the cytoplasm between the daughter nuclei during cytokinesis. This enables 
reliable comparisons of chromosome damage between cell populations that may differ in 
their cell division kinetics (Fenech and Morley, 1986; Kirsch-Volders et al., 2003). In the 
absence of a cytokinesis blocker it is necessary to demonstrate the analysed cells have 
undergone cell division during or after the exposure to the test substance.
MN will only be expressed in a DNA-damaged cell after at least one round of nuclear 
division. From this it follows, that cells that are not dividing cannot express MN as a sign of 
chromosome damage and so the level of MN observed is dependent on the proportion of cells 
that are dividing (Fenech, 1997). Furthermore it was reported that the MN frequencies 
decline when cells proceed through more than one nuclear division (Fenech, 1997). It is 
therefore important that the kinetics of nuclear division after a DNA insult is identical. 
Furthermore it has to be noted that an absolute value for MN frequency can only be obtained 
if MN are scored in cells that have divided once only (Fenech, 1997).
The CBMN assay at Swansea University and the mononucleated MN assay at AstraZeneca 
gave similar results. From this it follows that both assays gave reliable and comparable 
results and that both assay variants are a useful tool for genotoxicology studies.
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The research at Swansea University was based on the semi-automated scoring protocol with 
the Metafer-System (MetaSystems), whereas at AstraZeneca both the semi-automated scoring 
protocol with the Metafer-System and manual scoring were performed. The results gained 
with the Metafer-System were comparable to the results gained through manual scoring, 
proving that the Metafer-System was a rapid and accurate method to score MN. Pearson’s r 
correlation demonstrated highly positive correlation between manual scoring and the semi­
automated system Metafer. It was noted that the Metafer-System detects slightly fewer MN 
than does the manual scoring, which might be due to the intensity of staining of the main 
nuclei and the small size of MN (Doherty et al., 2011). However, the differences were 
consistent in all studies and the concentrations that caused increases in MN induction after 
4NQO treatment were similar.
Short-term treatments with and without prolonged recovery time and long term treatments 
were carried out over a concentration range of 0 to 0.03pg/ml 4NQO in TK6 cells. Short-term 
treatments (4h) without prolonged recovery time and the extended treatments (24h and 48h) 
showed little to no chromosomal damage induction up to 50±5% toxicity.
However, extending the recovery time after the short-term treatments in the CBMN assay 
from 18h to 42h and in the mononucleated assay from 24h to 40h increased the magnitude of 
MN induction at the top doses.
A study from Sobol et al. (2012) recently showed that an extended recovery time after 
treatment with compounds with direct DNA reactivity in TK6 cells increased the magnitude 
of MN induction. Further it was proposed by Islaih et al. (2005) that TK6 cells have 
prolonged cell cycle delay in response to genotoxins. Therefore it might be possible that 
damaged cells are rather stalled than eliminated through apoptosis (Sobol et al., 2012). 
Consequently the extended recovery period would allow the stalled cells to progress into 
mitosis and hence to fix damage as a MN.
In support of this, it was further noted in the present study that toxicity appeared to be higher 
in cells with the shorter recovery time than in cells with the extended recovery time, 
demonstrating higher cytostasis, which supports the proposition made by Islaih et al. (2005) 
and the findings from Sobol et al. (2012).
In addition pan-centromeric staining revealed that 4NQO predominantly induces MN via 
chromosome breakage and not aneuploidy.
To compare the results gained in TK6 cells against other cell lines, the human 
lymphoblastoid cell lines AHH-1 and MCL-5 were treated with 4NQO for 4h and the mouse 
lymphoma cell line L5178Y was treated with 4NQO for 4h.
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Like TK6 cells, AHH-1 and MCL-5 cells were treated with 4NQO for 4h with and without 
extended recovery time over a range of concentrations between 0 and 0.7pg/ml. 4NQO 
showed little to no significant increases in MN induction, even up to 50±5% toxicity. 
However, slight increases in the magnitude of MN induction were again seen after prolonging 
the recovery time.
Further, in comparison to TK6 cells, AHH-1 and MCL-5 cells could be treated with a lOx 
higher dose of 4NQO without reaching the 50±5% toxicity threshold. MCL-5 is a derivative 
of the AHH-1 cell line. Both cell lines are heterozygous for a p53 mutation at the interface 
between the codons 281 and 282 of exon 8, whereas TK6 cells are p53 competent (Guest and 
Parry, 1999).
The mouse lymphoma cell line L5178Y was treated with 4NQO for 4h (0 to 0.05pg/ml) and a 
recovery period of 24h before harvesting. The cells showed highly significant increases in 
MN induction with the Metafer-System and at 0.02pg/ml and above with the manual scoring. 
Further no decrease in cell viability could be observed. L5178Y cells are known for their 
dysfunctional p53 activity, since they have a missense mutation in exon 5 on chromosome 
11a (amino acid change from a cysteine to an arginine) and a nonsense mutation in exon 4 on 
chromosome l ib  (changing a glutamine to a stop codon) (Storer et al., 1997; Clark et al., 
2004). From this it follows that the mouse lymphoma cells have no wild-type p53 allele.
The tumour suppressor gene TP53 plays an important role in cellular integrity, with an 
integral function in transducing signals from damaged DNA to genes that control the cell 
cycle and lead to apoptosis (Guest and Parry, 1999). Abnormal DNA binding properties 
and/or transcriptional activation through p53 mutation causes mal-functions in the DNA 
damage dependent cell death pathway (Guest and Parry, 1999). Consequently, the effects of 
DNA damaging agents could become significant at low doses, where p53 competent cell lines 
would induce DNA damage dependent cell death (Guest and Parry, 1999).
In conclusion, TK6 cells showed a smaller magnitude of MN induction and more cytotoxicity 
than the human lymphoblastoid cell lines AHH-1 and MCL-5 and particular the mouse 
lymphoma cell line L5178Y. The sensitivity to MN induction and cytotoxicity is dependent 
on the cell type. However, cell lines with a p53 mutation are more likely to survive and 
replicate with DNA damage, which can lead to higher MN frequencies (Hashimoto et al., 
2011), since p53 plays an important role in cell responses, like cell cycle arrest at the G1 or 
G2 phases, apoptosis and DNA repair in response to DNA damage (Hashimoto et al., 2011). 
p53 function is therefore most likely to be a key factor for the cell-type sensitivity for 
genotoxicity and cytotoxicity (Hashimoto et al., 2011).
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The human lymphoblastoid cell lines showed little to no significant increases in MN 
induction over the background even up to 50±5% toxicity, whereas the mouse lymphoma cell 
line showed a linear dose response after 4NQO treatment at concentrations with no reduction 
in cell viability. From this it follows that 4NQO is a weak inducer of chromosomal damage in 
human lymphoblastoid cells. Therefore further investigations into the induction of gene 
mutations by 4NQO were undertaken.
4.4.2 Gene mutation and DNA damage induction by 4NQO
The HPRT gene mutation assay was used to investigate if 4NQO induces point mutations. 
Further, the comet assay was carried to investigate the DNA damage induction by 4NQO. 
Increases in point mutations over the solvent control were observed in the HPRT assay, even 
at concentrations lower than MN induction. Mutagenesis caused by 4NQO has been shown to 
be specific for base-pair substitutions, predominantly as G to A transitions, but also G to T 
conversions and rare substitutions of adenines (Bailleul et al., 1989). 4NQO induces three 
main adducts: dGuo-N2-AQO, dGuo-C8-AQO and dAdo-N6-AQO, with relative proportions 
in double stranded DNA to be around 50%, 30% and 10% respectively (Inga et al., 1994), 
which can be fixed as mutations. Further, it was shown that 4NQO induces 
apurinic/apyrimdinic sites and single-strand breaks, which originated probably from unstable 
adducts (Inga et al., 1994) and could be converted to double strand breaks and fixed as MN. 
To our knowledge, this is the first time that 4NQO was used in the HPRT assay with TK6 
cells. But, this compound has been tested before in both normal (AA8) and 4NQO-sensitive 
(UV5) Chinese hamster ovary cells to investigate the mutation spectra of 4NQO (Inga et al., 
1994). Mutation induction at the hprt locus increased linearly with 4NQO in UV5 cells over 
the tested range of concentrations (0 to 4pM 4NQO), similar to the results gained in TK6 
cells, while it levelled off at high concentrations (0 to 12pM 4NQO) in AA8 cells (Inga et al., 
1994). Mutations induced in the study by Inga et al. (1994), were base substitutions involving 
G residues localized at the splice sites on the non-transcribed strand. From this it follows that 
further sequence analysis of 4NQO induced mutations at the hprt locus in TK6 cells needs to 
be performed to determine the mutation spectra induced. However, it is most likely that the 
mutations induced by 4NQO are base substitutions.
The comet assay was used for detecting of low levels of DNA damage. Increases in DNA 
damage induction in the comet assay were observed (see Figure 4.15). The assay can detect 
single-strand breaks as initial damage as well those developed from alkali-labile sites under
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alkaline conditions (Kawaguchi et al., 2010). As mentioned above 4NQO causes 
apurinic/apyrimdinic sites and single-strand breaks (Inga et al., 1994).
In previous studies high levels of 8-hydroxydeoxyguanosine were found in 4NQO treated 
cells, which implicated the involvement of ROS in the mutagenicity of 4NQO (Bailleul et al., 
1989; Arima et al., 2006; Stankowski Jr. et al., 2011). Therefore the lysed cells in the comet 
assay were incubated with the lesion-specific endonuclease hOGGl to detect any oxidative 
DNA damage. TK6 cells treated with 4NQO for 3h showed increases in DNA damage at 0.04 
and 0.06pg/ml 4NQO without hOGGl and at 0.06pg/ml 4NQO with hOGGl. At 0.06pg/ml 
the DNA damage induction was slightly higher with hOGGl than without hOGGl, implying 
that oxidative DNA damage might be involved in the mutagenicity of 4NQO. However 
further experiments have to be undertaken to investigate the role of ROS in the mutagenicity 
of 4NQO.
4.4.3 Comparative investigations between the genotoxicity assays after 4NQO treatment
The MN assay provides a tool for detecting chromosomal damage that presents as MN, 
whereas the HPRT assay allows detection of point mutation and the comet assay detects 
DNA damage in the form of alkali-labile lesions and strand breaks.
In TK6 cells treated with 4NQO, the HPRT assay showed DNA damage at lower doses than 
the MN assay and the comet assay, while the MN assay was more sensitive than the comet 
assay. From this it follows that it is most likely that 4NQO predominantly induces gene 
mutations, more so than chromosomal damage. The difference between effects in the comet 
and MN assay could be due to variations in the type of DNA alterations that the test detects, 
while the comet assay detects primarily DNA lesions that are repairable, the MN assay 
detects irreparable lesions (Valentin-Severin et al., 2003). Furthermore DNA re-synthesis and 
re-joining events following single-strand formation can reduce the sensitivity of the comet 
assay in detecting DNA damage, like bulky base adducts (Kawaguchi et al., 2010).
4.5 Summary
In this study the dose response relationships of 4NQO at the low dose range were 
investigated. The work was carried out at Swansea University, Swansea, UK as well as 
during an extended stay at AstraZeneca, Cheshire, UK. This allowed comparisons between 
laboratories as well as usage of different methods.
The human lymphoblastoid cell lines TK6, AHH-1 and MCL-5 as well as the mouse 
lymphoma cell line L5178Y were used in this study.
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The in vitro MN assay was used for investigation of chromosomal damage. Short-term as 
well as extended treatments of 4NQO showed little to no significant increases in MN 
induction. However prolonging of the recovery time increased the magnitude of MN 
induction.
Further gene mutation induction of 4NQO was observed in the in vitro HPRT assay and the 
in vitro comet assay revealed DNA damage induction by 4NQO at the higher range of 
concentrations. In addition oxidative damage might be a cause for the mutagenicity of 4NQO.
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Induction of chromosome damage by cytosine arabinoside (araC) using the CBMN
assay
5.1 Introduction
In the previous two chapters the low dose responses for DNA damage of MMC, an alkylating 
and cross-linking agent, and 4NQO, a synthetic chemical that causes bulky adducts, were 
investigated. The research in this chapter examines the low dose response for DNA damage 
induction of the nucleoside analogue araC, using the in vitro MN assay described previously. 
AraC is used as a chemotherapeutic agent for acute non-lymphocytic leukemias and acute 
lymphoblastic leukemia.
5.1.1 Cytosine arabinoside (araC)
AraC was first synthesized in 1950 and introduced into clinical use in 1963 (Henderson, 
1982). It is a nucleoside analogue of both cytidine and deoxycytidine (Figure 5.1).
OH
Figure 5.1: Structure of araC (http://www.sigmaaldrich.com/catalog/product/sigma/cl768)
AraC is an important drug in the treatment of acute non-lymphocytic leukemias. Further the 
component is also active against acute lymphoblastic leukemia and to a smaller extent in 
chronic myelocytic leukemia and non-Hodgkin lymphomas (Henderson, 1982). AraC is 
known as a “phase-specific” anti-cancer agent, because of its ability to inhibit de novo DNA 
synthesis effectively only when cells are in S-phase of the cell cycle and because of its rapid 
in vivo detoxification (Henderson, 1982).
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Cellular effects of araC include: inhibition of cell growth, inhibition of DNA synthesis, 
proliferation-dependent cytotoxicity, progression delay and unbalanced growth (Valeriote, 
1982). The S-phase specificity of araC implicates that its cytotoxic effects should be limited 
to proliferating cells and that non-proliferating cells should be insensitive to araC (Valeriote, 
1982). Furthermore it was shown that araC slows down S-phase passage at low 
concentrations, whereas at higher concentrations araC inhibits the cell movement from G1 to 
S-phase (Valeriote, 1982). Unbalanced growth occurs when one of the three macromolecule 
syntheses (DNA, RNA, protein) are inhibited. In the case of araC it was shown, that at 
concentration at which araC inhibits DNA synthesis, both RNA and protein synthesis 
continue undiminished (Valeriote, 1982).
5.1.1.1 Mechanism of action of araC
Two mechanisms are responsible for the transport of araC through the cell membrane: a 
carrier mediated process and simple diffusion (Cheng and Capizzi, 1982). AraC is 
metabolized primarily by enzymes that metabolize deoxycytidine or cytidine, upon entry of 
araC into the cell (Cheng and Capizzi, 1982). AraC is phosphorylated with ATP as the 
phosphate donor (araC araCMP -> ara-CDP -> araCTP) and the triphosphate, araCTP, 
inhibits DNA replication (Kufe and Majot, 1982).
Two mechanisms for the inhibition of DNA replication by araC are proposed. The first model 
proposes that araC directly inhibits the enzyme DNA polymerase after its conversion to the 
5"-triphosphate (araCTP), whereas the second model proposes polynucleotide chain 
termination through incorporation of araCTP into DNA, which blocks further addition of 
deoxyribonucleotides (Momparler, 1982).
It was shown that araCTP does not induce functional alterations in the DNA polymerase 
itself, and from this it follows that araC inhibits DNA synthesis by reversible displacement of 
dCTP from the binding site on the enzyme (Kufe and Major, 1982).
Either of the two mechanisms mentioned above can produce cellular damage through any of 
the following events: faulty processing of DNA, chromosomal breaks, re-initiation of 
previously replicated DNA segments, inhibition of chain initiation and inhibition of chain 
ligation (Kufe and Major, 1982).
In addition, it was shown by Fenech and Neville (1992) that araC inhibits the gap-filling step 
during excision repair, which results in the formation of single-stranded breaks at repair sites. 
These breaks can then be converted to chromatid or chromosome breaks (Fenech and Neville, 
1992; Fenech et al., 1994).
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5.1.1.2 Examples of previous genotoxicology studies of araC
In previous studies, araC was often used as a positive control in the in vitro MN assay as well 
as for validation purposes.
For example, in 2010 araC was used as part of a collaborative evaluation study in different 
laboratories to investigate the toxicity measurements recommended in the draft OECD Test 
Guideline 487 for the in vitro MN test. Different cell lines were assessed. In the study of 
Schuler et al. (2010) Chinese hamster ovary (CHO) cells were treated with araC for 24h in 
the presence and absence of cytochalasin B. Various concentrations between 0 to lOOOpg/ml 
were used. The results demonstrated that araC induced significant MN formation between 
0.014 to lOOOpg/ml with and without cytochalasin B. Furthermore it was shown, that araC 
does not require cytotoxic concentrations to produce positive responses in the in vitro MN 
assay (Schuler et al., 2010).
L5178Y cells were used in the study of Cariou et a l (2010). The cells were treated with araC 
for 24h with no recovery time over a range of concentrations between 0 and 0.5pg/ml. A 
concentration-dependent reduction in survival was observed. Further, a significant increase in 
MN induction above the concentrations of 0.05 and 0.075pg/ml araC were shown (Cariou et 
al., 2010).
In the study of Whitwell et al, (2010) Chinese hamster V79 cells were treated with araC for 
24h+0h over a range of concentrations between 0 and 0.015pg/ml. In the absence of 
cytochalasin B, significant increases in MN induction were observed at 0.004pg/ml araC, 
inducing reductions in RCC, RICC or RPD of 24%, 33% or 21% respectively (Whitwell et 
al., 2010). In the presence of cytochalasin B significant increases in MN induction were 
observed at 0.008pg/ml (Whitwell et al., 2010)
The human lymphoblastoid cell line TK6 was used in the study of Nesslany and Marzin 
(2010). TK6 cells were treated with araC for 27h+0h or 27h+27h over a range of 
concentrations between 0 and 0.094pg/ml araC. In the 27h treatment with no recovery period, 
significant increases in MN induction were only seen at concentrations of about 65% toxicity 
and more (Nesslany and Marzin, 2010). In the 27h treatment, followed by a 27h recovery 
period significant increases in MN induction were observed at concentrations giving about 
50% toxicity or less as measured by all endpoints (Nesslany and Marzin, 2010).
All the evaluation studies mentioned above showed that RICC and RPD are useful tools for 
measuring cytotoxicity for the in vitro MN assay. In addition the studies crystallised the idea 
that different cell lines needed to be treated with different concentrations of araC to reach
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genotoxic and cytotoxic level. Furthermore, in most cell lines tested, significant increases in 
MN induction were only seen at the higher dose range.
From this it follows that studies into the low dose range of araC could reveal that a NOEL 
might exist for this genotoxin.
5.1.2 Aim of study
The study was designed to assess the low dose response relationships of the direct acting 
genotoxin araC. Human lymphoblastoid cells (TK6, AHH-1 and MCL-5) were used for this 
study. Chromosomal damage was investigated, using the in vitro MN assay and RPD was 
used to measure toxicity.
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5.2 Material and Methods
5.2.1 Cell lines
The human lymphoblastoid cell lines TK6, AHH-1 and MCL-5 were used in this study. 
MCL-5 cells are a derivative of AHH-1 cells. The cell lines were described in detail in 
chapter 2 (section 2.2.1).
5.2.2 Cell culture
Cell culture and sub-culturing was performed as described in chapter 2 (section 2.2.1).
5.2.3 Test chemical
AraC was acquired from Sigma-Aldrich, Dorset, UK. Before use, the chemical was freshly 
diluted from a stock solution (1 mg/ml aliquots) with water.
5.2.4 Test chemical dosing regime
For the in vitro CBMN assay TK6 cells were treated with araC over a range of concentrations 
between 0 and O.lpg/ml for 24h and 48h respectively, followed by one cell cycle (18h) with 
cytochalasin B (4.5pg/ml). AHH-1 and MCL-5 cells were treated for 24h with araC, followed 
by one cell cycle (22h) with cytochalasin B (4.5 to 6pg/ml). The dose range selected for 
AHH-1 cells was between 0 and 0.2pg/ml araC, whereas MCL-5 cells were treated over a 
range of concentrations between 0 and O.lpg/ml araC.
5.2.5 In vitro MN assay
The semi-automated scoring protocol for the Metafer-System was used for all CBMN assay 
studies. The method is described in detail in chapter 2 (section 2.2.2). For the CBMN assay a 
minimum of 4000 cells per replicate were scored (exceptions where stated, for details see 
Appendix I). Three independent experiments were carried out.
5.2.6 Cytotoxicity
RPD was used to measure cell death and cytostasis. The method is described in detail in 
chapter 2 (section 2.2.3).
131
Chapter 5
5.2.7 Pan-centromeric staining
Centromeres were stained to classify araC as a clastogenic or aneugenic chemical with RTU 
human pan-centromeric probe. The method is described in detail in chapter 2 (section 2.2.4). 
Nuclei were counterstained with DAPI and 100 MN per dose were scored as positive or 
negative for the centromeric stain under a BX50 fluorescent microscope (Carl Zeiss) 
(exceptions where stated, for details see Appendix IV).
5.2.8 Statistical analysis
Statistical analysis is described in detail in chapter 2 (section 2.2.17). Further assessment of 
data used the BMD model (Gollapudi et al., 2013).
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5.3 Results
The in vitro CBMN assay was used to investigate the low dose response relationships of araC 
induced DNA damage. AraC is a nucleoside analogue and used as a chemotherapeutic agent 
(Fenech et al., 1994; Cariou et al., 2010).
5.3.1 Chromosome aberration induction by araC in human lymphoblastoid cells
Extended treatments were used for the investigation of the low dose response curve for araC, 
due to the mechanism of action of araC, more than one cell cycle is needed for chromosome 
damage to be expressed. In this study all the work was based on automated analysis with the 
Metafer-System.
TK6 cells treated with araC for 24h over a range of concentrations between 0 and O.lpg/ml, 
followed by one cell cycle of cytochalasin B showed significant increases in MN induction at 
the top doses, at 0.03 and 0.07pg/ml araC. Furthermore >50±5% cell death and cytostasis 
was observed at around 0.07pg/ml (62.5% at 0.07pg/ml and 74.1% at O.lpg/ml) araC and 
above (Figure 5.2).
CBMN (24+18hours)
Autom ated
araC (pg/m l)
Figure 5.2: Effect of araC on TK6 cells using the CBMN assay. TK6 cells were treated with 
araC for 24h, followed by 18h of CytoB. Blue: percentage micronucleated binucleated cells, 
green: Relative population doubling (RPD). Values represent mean ± SD (n=3). (*)
Represents p<0.05.
133
Chapter 5
Further, TK6 cells treated with araC for 48h with 0 to O.lpg/ml araC, followed by 18h of 
cytochalasin B showed similar results to the 24h treatment experiment. A significant increase 
in MN induction was only seen at 0.07pg/ml araC. In addition, 50±5% (49.3%) toxicity were 
observed around 0.07pg/ml (Figure 5.3)
CBMN (48+18hours)
Automated
araC (pg/ml)
Figure 5.3: Effect of araC on TK6 cells using the CBMN assay. TK6 cells were treated with 
araC for 48h, followed by 18h of CytoB. Blue: percentage micronucleated binucleated cells, 
green: Relative population doubling (RPD). Values represent mean ± SD (n=3). (*) 
Represents p<0.05.
To compare the results gained in TK6 cells to other cell backgrounds, the human 
lymphoblastoid cell lines AHH-1 and MCL-5 were treated with low concentrations of araC. 
These cell lines have a heterozygous p53 mutation at codon 282 on exon 8. MCL-5 cells are a 
derivative of AHH-1 cells with metabolic capacity.
AHH-1 cells treated with araC for 24h over a range of concentrations between 0 and 
0.2pg/ml araC followed by one cell cycle of araC (22h) showed increases in MN induction at 
the top doses. At 0.2pg/ml 22% toxicity were observed (Figure 5.4). These cells were able to 
tolerate slightly higher concentrations of araC before toxicity and MN induction was seen.
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CBMN (24+22hours)
araC (ng/m l)
Autom ated —*-R PD
Figure 5.4: Effect of araC on AHH-1 cells using the CBMN assay. AHH-1 cells were treated 
with araC for 24h, followed by 22h of CytoB. Blue: percentage micronucleated binucleated 
cells, green: Relative population doubling (RPD). Values represent mean ± SD (n=3).
Further, MCL-5 cells treated with araC over a range of concentrations between 0 and 
O.lpg/ml, followed by 22h (one cell cycle) of cytochalasin B showed, like TK6 cells, 
significant increases in MN induction around 0.07pg/ml araC and above. In addition, 40.7% 
cell death and cytostasis were reached at O.lpg/ml araC (Figure 5.5), which was at a slightly 
higher concentration than in TK6 cells.
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CBMN (24h +22h CytoB)
Autom ated
araC (pg/m l)
Figure 5.5: Effect of araC on MCL-5 cells using the CBMN assay. MCL-5 cells were treated 
with araC for 24h, followed by 22h of CytoB. Blue: percentage micronucleated binucleated 
cells, green: Relative population doubling (RPD). Values represent mean ± SD (n=3). (*) 
Represents p<0.05.
The human lymphoblastoid cell lines TK6 and MCL-5 showed similar low dose responses 
after treatment with the nucleoside analogue araC. Significant increases in MN induction 
were only observed at the higher end of the concentration range with increases in cell death 
and cytostasis, whereas at the lower range of concentrations no increases in MN induction 
and/or toxicity over the background level were observed. NOELs and LOELs identified in 
TK6 and MCL-5 cells after araC treatment are summarized in Table 5.1. Further AHH-1 cells 
treated with TK6 showed only increases in MN induction at the higher range of 
concentrations.
Table 5.1: NOELs and LOELs identified after araC treatment
Treatment NOEL LOEL
TK6: 24h + 18h 0.01pg/ml 0.03pg/ml
TK6: 48h + 18h 0.03pg/ml 0.07pg/ml
MCL-5: 24h + 22h 0.03pg/ml 0.07pg/ml
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5.3.2 AraC- A clastogenic or aneugenic chemical?
Human chromosome pan-centromeric staining was used to determine if the MN induced by 
araC were predominantly due to incorporation of whole chromosomes, which were unable to 
incorporate into the main nuclei (aneuploidy) or due to chromosome breaks (clastogenicity). 
TK6 cells treated with 24h of araC, followed by one cell cycle of cytochalasin B showed a 
slight increase in pan-centromeric negative MN over the range of concentrations (0 to 
0.03pg/ml) within an acceptable toxicity range (Figure 5.6). From this it followed, that the 
MN induced by araC were predominantly originating from chromosome fragments lacking a 
centromere (clastogenic).
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Figure 5.6: Human chromosome pan-centromeric staining of TK6 cells treated with 24h of 
araC, followed by 18h of cytochalasin B. Values represent mean and range of duplicate 
experiments.
5.3.3 Assessment of the low dose response relationship of araC in human 
lymphoblastoid cells
Human lymphoblastoid cells treated with araC and one cell cycle of cytochalasin B showed 
significant increases in MN frequencies only at higher concentrations, whereas at the lower 
range of concentrations no increases in MN could be found over the background level (Figure
5.2 to 5.5). Therefore the dose responses were further assessed by quantitative means using 
BMD modelling.
137
Chapter 5
The BMD for the dose response data in TK6 cells treated with 24h of araC followed by 18h 
of cytochalasin B was calculated at O.OOlpg/ml with its confidence intervals between 0.0007 
(BMDLio) and 0.002pg/ml (Figure 5.7).
E4-CED: y = a  * [c-(c-1 )exp(-bx)]
co
o
CM
♦
♦
9 ^ o
o  y
» /
: y  &0
r 'T  ° ‘
i
i
iiiii
i i i
-3.0 -2.5 -2.0
1
-1.5
i
-1.0
version: pntast26.4 
var- 0.0943 
a- 0.051
c a >  0.00104 
c  5.81 
togl* -10.73
■s: 20 15 
oonv : 1 
x  scale factor : 1 
dtype : 1 
selected : a l  
CES 0.1
CED-LD5 0.0006702 
CED-L95 0.001093
k>g10-MWIC
Figure 5.7: BMD dose response modelling results for MN induction in TK6 cells treated 
with araC for 24h. The BMD was calculated at O.OOlpg/ml with its confidence intervals 
between 0.0007 and 0.002pg/ml.
The BMD for the dose response data in TK6 cells treated with 48h araC was calculated at 
O.OOlpg/ml, same as the 24h treatment, with its confidence intervals between 0.0008 
(BMDLio) and 0.002pg/ml (Figure 5.8).
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Figure 5.8: BMD dose response modelling results for MN induction in TK6 cells treated 
with araC for 48h. The BMD was calculated at O.OOlpg/ml with its confidence intervals 
between 0.0008 and 0.002pg/ml.
The BMD for the dose response data generated in AHH-1 cells was calculated at 0.007pg/ml 
with its confidence intervals between 0.004 (BMDLio) and O.Olpg/ml (Figure 5.9).
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Figure 5.9: BMD dose response modelling results for MN induction in AHH-1 cells treated 
with araC for 24h. The BMD was calculated at 0.007pg/ml with its confidence intervals 
between 0.004 and O.Olpg/ml.
The BMD for the dose response data in MCL-5 cells was calculated at 0.005pg/ml with its 
confidence intervals between 0.003 (BMDLio) and 0.008pg/ml (Figure 5.9).
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Figure 5.10: BMD dose response modelling results for MN induction in MCL-5 cells treated 
with araC for 24h. The BMD was calculated at 0.005pg/ml with its confidence intervals 
between 0.003 and 0.008pg/ml.
The assessment of the low dose response relationship of araC in the human lymphoblastoid 
cells TK6, AHH-1 and MCL-5 provided similar results. Non-linear dose responses after araC 
treatment were observed. The assessment results are summarized in Table 5.2.
Table 5.2: The BMD analysis for the MN endpoint induced by araC
araC Cell line Units BMD BMDLio BMDUio
24+18h TK6 pg/ml 0.001 0.0007 0.002
48+18h TK6 Mg/ml 0.001 0.0008 0.002
24+22h AHH-1 pg/ml 0.007 0.004 0.01
24+22h MCL-5 pg/ml 0.005 0.003 0.008
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5.4 Discussion
The human lymphoblastoid cell lines TK6, AHH-1 and MCL-5 were treated with araC to 
investigate the low dose response for this chemical, using the in vitro MN assay.
5.4.1 Low dose response relationships of araC
Non-linear dose responses of araC were observed after extended treatments in TK6, AHH-1 
and MCL-5 cells. Significant increases in MN induction were only seen at the higher dose 
range. TK6 cells treated with araC for 24h or 48h and MCL-5 cells treated with 24h of araC, 
followed by one cell cycle of cytochalasin B showed a LOEL at 0.03 to 0.07 pg/ml araC.
Two mechanisms are responsible for the transport of araC into the cell: a carrier-mediated 
process and simple diffusion (Cheng and Capizzi, 1982). The carrier-mediated transport 
mechanism predominates at low concentrations of araC. However the efficiency of this 
process depends on the binding affinity of araC for the carrier, the number of molecules of 
the carrier in the membrane and the presence of competing nucleosides (Cheng and Capizzi, 
1982). Simple diffusion is the predominant mechanism for cell entry at higher concentration 
of araC (Cheng and Capizzi, 1982). Therefore, at low concentrations of araC cells might be 
resistant to araC due to the decreased efficiency of the carrier-mediated transport, whereas at 
higher concentrations araC might simply pass though the cell membrane by diffusion. 
Furthermore two main hypotheses for the inhibitory effect of araCTP on DNA synthesis were 
proposed. The first one proposes that araC inhibits the DNA polymerase by competing with 
the binding of dCTP to this enzyme (Kufe and Major, 1982). However kinetic studies 
revealed that araCTP is a weak competitive inhibitor, with the binding affinity of araCTP and 
dCTP for the catalytic site of DNA polymerase being the same (Momparler, 1982). From this 
it follows that at low concentrations of araC the inhibition of DNA syntheses might be low. 
The second hypotheses proposes the inhibition of DNA synthesis by araCTP through its 
incorporation into the DNA strand, which could result in either chain termination or slowing 
of chain elongation (Kufe and Major, 1982). However, it was shown that low concentrations 
of araC can inhibit DNA synthesis without producing cell death (Momparler, 1982). From 
this it follows that DNA repair mechanisms may exist, which can reduce the cytotoxic action 
of this chemical by removing it enzymatically from DNA (Momparler, 1982). In conclusion, 
NOELs may exist for the nucleoside analogue araC.
Increases in MN induction were observed at the higher range of concentrations chosen in all 
cell lines tested. It was shown by Fenech and Neville (1992) that araC inhibits the gap-filling
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step during excision repair, which results in the formation of single-strand breaks at repair 
sites. The single-strand breaks could then be converted to chromatid or chromosome breaks 
and subsequently into MN on completion of nuclear division (Fenech and Neville, 1992; 
Fenech et al., 1994). Two possible ways of MN induction through araC were proposed. 
Excision-repairable DNA lesions on the DNA, caused endogenous or exogenous, are repaired 
in the presence of araC, which inhibits the gap-filling step, resulting in a single-strand break 
at the lesion side. The single-strand break can then be converted to a double-strand break at 
S-phase or can be converted to a double-strand break following endonuclease attack 
following S-phase, resulting in acentric chromatid fragments, which can be expressed as a 
micronucleus (Fenech et al., 1994). Further araC can induce MN directly by inhibiting the 
repair and/or re-joining of DNA strand breaks (Fenech et al., 1994).
Furthermore Fenech et a l (1994) showed that the majority of araC induced MN originate 
from acentric fragments using anti-kinetochore antibodies. This was confirmed in this study 
through pan-centromeric painting. With increases in concentration, the proportion of 
centromere negative MN increased, even though there was overall low MN induction, 
confirming that araC predominantly induces MN via chromosome breakage and not 
aneuploidy.
In addition, the study revealed that TK6 cells were a more sensitive test system compared to 
MCL-5 and particularly AHH-1 cells. MCL-5 and AHH-1 cells showed less cytotoxicity than 
TK6 cells. TK6 cell are p53 competent, whereas AHH-1 and its derivative MCL-5 are 
heterozygous for TP53 (Guest and Parry, 1999). The tumour suppressor gene TP53 is an 
important regulatory molecule, because of its involvement in the response to DNA damaging 
agents (Morris et al., 1996). p53 is involved in maintaining the integrity of the Gi checkpoint 
in the cell cycle by up-regulating the synthesis of p22WAF~1/IP~1 gene product and further in the 
signalling of damaged or unwanted cells into apoptosis (Morris et al., 1996). It is therefore 
likely that MCL-5 and AHH-1 cells are less susceptible to the induction of cell death 
(apoptosis). However Guest and Parry (1999) showed that the presence of the mutation in 
AHH-1 and MCL-5 cells has no influence of the DNA damage induced cell death pathway 
and that the reduced capacity of the G0/G1 checkpoint after p53 induction through a chemical 
exposure may not mean that the TP53 gene has lost its function. Further it is known that 
sensitivity to MN induction and cytotoxicity are highly dependent on the cell type.
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5.4.2 Dose response relationship assessment of araC
The data for all the cell lines tested were further assessed for quantitative dose using BMD 
modelling (Table 5.2 and Figures 5.7 to 5.10).
As previously mentioned, BMD modelling estimates a dose that produces predetermined 
biologically relevant increases in the response over the control and the BMGLjo refers to the 
estimate of lower 90% confidence interval of a dose that produces a 10% increase over the 
fitted background level for continuous endpoints (Gollapudi et al., 2013). The BMGLio in 
TK6 cells treated with araC was 0.0007/0.0008pg/ml, in AHH-1 0.004pg/ml and in MCL-5 
cells 0.003pg/ml, which was in line with the observed genotoxicity data gained in this study 
(Figures 5.2 to 5.5).
In conclusion, the dose response data in this study for TK6, MCL-5 (and MCL-5) cells 
treated with araC showed clear NOELs and LOELs. Mechanistic experiments have to be 
applied to prove if araC causes no adverse effects over the background at the low dose range.
5.5 Summary
In this chapter the dose response relationships after araC treatment were explored at the low 
dose range in the human lymphoblastoid cell lines TK6, AHH-1 and MCL-5. Non-linear dose 
responses, with increases in MN induction only at the higher dose range, were observed in all 
cell lines tested. Further clear NOELs and LOELs were identified in TK6 and MCL-5 cells 
treated with araC.
RPD was used to set robust toxicity parameters to avoid the confounding effect of toxicity on 
chromosome breakage and/or whole chromosomes, which were unable to incorporate into the 
main nuclei during cell division.
In addition, it was observed that araC is a clastogenic chemical that induces MN mainly due 
to chromosomal breakage and not through aneuploidy.
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Chapter 6
The role of p53 in the low dose mutagenic relationships of MMC and araC 
6.1 Introduction
The human lymphoblastoid cell lines TK6, AHH1 (and MCL-5) showed non-linear dose 
responses in DNA damage induction after treatment with MMC and araC at the low dose 
range (see chapter 3 and 5).
Natural defence mechanisms, like epithelial barriers to genotoxin entry, chemical 
detoxification, DNA redundancy or DNA repair corroborate the theory of genotoxic 
thresholds (Jenkins et al., 2010). In addition the tumour suppressor gene TP53 plays a key 
role in cellular integrity, because of its involvement in the response to DNA damaging agents, 
with an integral function in transducing signals from damaged DNA to genes that control the 
cell cycle and/or lead to apoptosis (Guest and Parry, 1999).
Therefore in this chapter, the role and involvement of p53 in the low dose response 
relationships after treatment with MMC and araC was investigated.
6.1.1 p53
The tumour suppressor gene TP53 plays an essential role in cellular integrity and inactivation 
of the gene by mutations is the most frequent alteration in human cancers (Kato et al., 2003). 
p53 is a transcriptional activator that regulates the expression of various genes involved in 
cell cycle arrest and apoptosis in response to genotoxic and cellular stress, which prevents 
damaged DNA from being replicated (Arrowsmith, 1999).
The TP53 gene encodes a 53kD phospho-protein, which is involved in cellular processes, 
such as gene transcription, DNA repair, cell cycle regulation, genomic stability, chromosomal 
segregation, senescence and apoptosis (Harris, 1996).
The human p53 protein consists of 393 amino acids with 4 highly conserved domains, which 
contribute to the DNA damage response (Harris, 1996; Amundson et al., 1998; Joerger and 
Fersht, 2007).
The N terminal region (residues 1-62), which is required for transcriptional transactivation, 
contains the transactivation domain, followed by a proline-rich region (residues 63-94) 
(Amundson, 1998; Joerger and Fersht, 2007). The transactivation domain interacts with 
regulatory proteins, like MDM2 (a regulator of cellular levels of p53), or components of the
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transcription initiation complex and acetyltransferases, which act as co-activators and 
regulate p53 function through acetylation of the p53 C-terminus, while the proline-rich region 
contains SH3-domain binding motifs (Joerger and Fersht, 2007). The central core domain 
(residues 94-292) is a sequence-specific DNA binding domain and binds specifically to 
double-stranded DNA, while the C-terminus, which interacts directly with single-stranded 
DNA, contains the tetramerization domain (residues 325-356) and the negative auto- 
regulatory domain. The tetramerization domain regulates the oligomerization state of p53, 
while the negative auto-regulatory domain contains acetylation sites and binds DNA non- 
specifically (Amundson et al., 1998; Joerger and Fersht, 2007). The cellular p53 protein 
levels are tightly regulated and post-translational modification of the protein as well as 
alternative splicing and binding of regulatory proteins modulate the activity of p53 (Pucci et 
al., 2000; Joerger and Fersht, 2007). Thus, mutations in the gene disrupt the ability of p53 to 
bind to DNA and consequently to transactivate downstream genes (Kato et al., 2003). 
p53 predominately acts at the DNA damage checkpoint in the cell cycle, influencing cell 
proliferation. p53 is activated by DNA damage and initiates the transcription of p21, which 
results in G1 cell cycle arrest (Schafer, 1998; Pucci et al., 2000). It can also act at the G2/M 
checkpoint, inducing cell-type specific G2 arrest. The G2/M checkpoint seems to be activated 
when DNA synthesis is blocked to prevent segregation of damaged or incompletely 
synthesised DNA (Pucci et al., 2000).
Furthermore p53 is involved in the spindle checkpoint through inhibition of entry into S- 
phase and plays a role in centrosome duplication, by preventing mitotic failure through 
regulation of the number of centrosomes (Pucci et al., 2000).
In addition, p53 plays a major role in inducing apoptosis by DNA damage, hypoxia or 
withdrawal of growth factors (Pucci et al., 2000).
6.1.2 The cell cycle
The cell cycle is a complex process involved in cell growth and proliferation, regulation of 
DNA repair, tissue hyperplasia as a result of injury and diseases like cancer (Schafer, 1998). 
Numerous mechanisms control the cell cycle to ensure correct cell division. Cell division is 
characterised by DNA replication and segregation of replicated chromosomes into two 
separate cells (Vermeulen et al., 2003). Cell division consists of two stages: mitosis (M- 
phase) and interphase.
Mitosis is the process of nuclear division and stages of mitosis include prophase, metaphase, 
anaphase and telophase. During mitosis the chromosomes condense and after spindle
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assembling they attach to the spindle, align at the cell equator and move as spindle 
microtubules retreat towards opposite poles of the cell, where they get surrounded by a 
nuclear membrane, resulting in two identical daughter cells (Nature Education, 2012).
The interphase is composed of the G l, S and G2 phase. S-phase is preceded by a gap (Gl) 
during which the cells prepare for DNA synthesis and is followed by another gap (G2) during 
which the cells prepare for mitosis (Vermeulen et al., 2003). During S-phase DNA gets 
synthesized and therefore cells have a DNA content between 2N and 4N (Schafer, 1998). 
Furthermore cells can enter a resting state (called GO) in Gl before commitment to DNA 
replication. Cells in GO are non-growing and non-proliferating cells (Vermeulen et al., 2003).
6.1.2.1 Regulation of the cell cycle
The standard cell cycle consists of the phases G l, S, G2 and M and the transition from one 
phase to another occurs in order and is regulated by cellular proteins. Cyclin-dependent 
kinases (CDK) are the key regulatory proteins of the cell cycle (Vermeulen et al., 2003). 
CDKs, a family of serine/threonine protein kinases, are activated at specific points in the cell 
cycle, through cyclins. The CDK protein levels remain stable, while cyclin protein levels rise 
and fall during the cell cycle, resulting in periodical activation of CDK (Vermeulen et al., 
2003).
Different cyclins are required at different phases of the cell cycle (Figure 6.1). Cells can only 
enter the next cell cycle stage, if the appropriate cyclin of the previous phase is degraded, and 
the cyclin of the next phase is synthesized (Schafer, 1998).
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Figure 6.1: Regulation of the cell cycle by cyclin dependent protein kinases (CDKs) and 
cyclins
The CDK-cyclin D complexes are essential for the entry in G l, while cyclin E, which 
associates with CDK2, regulates the progression from Gl into S phase. Further the CDK2- 
cyclin A complex is required during S phase, while in late G2 and early M, the CDK1-cyclin 
A complex promotes the entry into mitosis and the CDK1-cyclin B complex regulates mitosis 
(Vermeulen, et al., 2003).
Further CDK inhibitors (CKI) can regulate CDK activity through binding to CDK alone or 
CDK-cyclin complexes. Two families of CKIs have been discovered: the INK4 family and 
Cip/Kip family. The INK4 family (pl5, pl6, p i8 and pl9) forms stable complexes with the 
CDK enzyme before cyclin binding, while the Cip/Kip family (p21, p27, p57) inactivate 
CDK-cyclin complexes (Vermeulen et al., 2003).
6.1.2.2 Cell cycle restriction point and checkpoints
After passing the restriction point, which is a point of no return in G l, the cell is committed 
to enter the cell cycle. Cell cycle checkpoints (DNA damage and spindle checkpoints) then 
monitor progression through the cell cycle and act as gatekeepers to ensure the process occurs 
accurately at all stages (Vermeulen et al., 2003).
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Cell cycle arrest in response to DNA damage provides time for DNA repair. There are two 
main DNA damage checkpoints, which are positioned before the cell enters the S phase (Gl- 
S checkpoint) and/or after DNA replication (G2-M checkpoint) (Vermeulen et al., 2003). 
Arrest in Gl allows repair before DNA replication, while arrest in G2 allows repair before 
chromosome separation in mitosis. In addition cells can also arrest in S-phase, resulting in a 
prolonged S-phase with slowed DNA synthesis (Schafer, 1998).
The cell cycle arrest induced by DNA damage at the Gl-S checkpoint is p53 dependent. 
Activated p53 stimulates the transcription of important genes, such as p21, Mdm2 and Bax, 
which leads in the case of p21 (a CKI) to CDK inhibition and cell cycle arrest, preventing the 
replication of damaged DNA (Vermeulen et al., 2003). However in cases of severely 
damaged cells, p53 induces apoptosis by activating genes, like Bax, which are involved in 
apoptotic signalling (see Figure 6.2) (Vermeulen et al., 2003).
Cell cycle arrest at the G2-M checkpoint can be initiated in the presence or absence of p53. 
The entry into mitosis is inhibited through inhibitory phosphorylation or by sequestration of 
components of the CDK 1-cyclin B complex outside the nucleus by protein kinases Chkl and 
Chk2, which are activated by DNA damage (Vermeulen et al., 2003).
The spindle checkpoint arrests the cell cycle in metaphase after detecting improper alignment 
of the chromosomes on the mitotic spindle (Vermeulen et al. 2003). It was shown, that the 
mitotic arrest deficient (Mad) and the budding uninhibited by benomyl (Bub) proteins are 
activated after defects in microtubule attachment, resulting in the inhibition of the Cdc20 
subunit of the anaphase-promoting complex, preventing metaphase-anaphase transition 
(Vermeulen, et al., 2003).
6.1.3 Apoptosis
Apoptosis or programmed cell death occurs normally during development, ageing and as a 
homeostatic mechanism to maintain cell populations in tissues (Fulda and Debatin, 2006; 
Elmore, 2007). Further apoptosis is also used as a defence mechanism in immune reactions or 
after cell damage by disease or noxious agents (Elmore, 2007).
Morphological changes of the cell include shrinkage and pyknosis, which is the result of 
chromatin condensation (Majno and Joris, 1995; Elmore, 2007). Furthermore plasma 
blebbing occurs, followed by karryorrhexis and separation of cell fragments into apoptotic 
bodies, which are then phagocytosed by macrophages, parenchymal cells or neoplastic cells 
(Elmore, 2007).
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The apoptosis process is energy-dependent and involves the activation of a group of cysteine 
proteases (caspases). Caspases have proteolytic activity, they are synthesized as inactive 
proforms, but upon activation they cleave proteins at aspartic residues (Fulda and Debatin, 
2006). The proteases are categorized into initiators (caspase-2,-8,-9,-10), effectors (caspase- 
3,-6,-7) and inflammatory caspases (caspase-1,-4,-5) (Elmore, 2007).
Two main apoptotic pathways are described: the extrinsic or death receptor pathway and the 
intrinsic or mitochondrial pathway (Elmore, 2007).
Transmembrane receptor-mediated interactions are involved in the extrinsic pathway (Figure 
6.2), including death receptors, which are members of the tumour necrosis factor (TNF) 
receptor gene superfamily, containing more than 20 proteins with various biological functions 
(Fulda and Debatin, 2006; Elmore, 2007). The best characterised ligands and corresponding 
death receptors are FasL/FasR, TNF-a/TNFRl, Apo3L/DR3, Apo2L/DR4 and Apo2L/DR5 
(Elmore, 2007). Upon ligand binding to the receptors, cytoplasmic adapter proteins are 
recruited. In the case of Fas ligand binding to Fas receptor, the adapter protein Fas-associated 
death domain (FADD) is recruited, whereas TNF ligand binding to the TNF receptor results 
in binding of the adapter protein TRADD (Elmore, 2007). Subsequently FADD associates 
with procaspase-8 and the death-inducing signalling complex (DISC) is formed, resulting in 
auto-catalytic activation of procaspase-8 (Elmore, 2007). The execution phase of apoptosis is 
then triggered, after caspase-8 is activated, by activating downstream effector caspases, such 
as caspase-3 (Fulda and Debatin, 2006).
The intrinsic pathway (Figure 6.2) involves non-receptor stimuli, specifically mitochondrial- 
initiated events that produce intracellular signals and act directly on target (Elmore, 2007). 
Negative signals, such as absence of growth factors or hormones and/or positive stimuli, like 
radiation or viral infection, can trigger apoptosis. The stimuli cause changes in the inner 
mitochondrial membrane, resulting in an opening of the mitochondrial permeability transition 
pore and releasing of two main groups of pro-apoptotic proteins from the intermembrane 
space into the cytosol (Elmore, 2007).
The first group contains cytochrome C, Smac/DIABLO and the serine protease HTrA2/Omi 
and activates the caspase-dependent mitochondrial pathway by cytochrome C binding and 
activation of Apaf-1 and procaspase-9, which leads to caspase-9 activation (Elmore, 2007). 
Caspase-3 activation is triggered through the formation of the cytochrome C/Apaf-l/caspase- 
9 apoptosome complex (Fulda and Debatin, 2006).
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The second group of pro-apoptotic proteins (AIF, endonuclease G and CAD) are released 
from the mitochondria during apoptosis and cause DNA fragmentation and/or chromatin 
condensation after translocation to the nucleus (Elmore, 2007).
Members of the Bcl-2 protein family control and regulate the apoptotic mitochondrial events, 
while the tumour suppressor protein p53 plays a crucial role in regulating the proteins of the 
Bcl-2 family (Elmore, 2007). The Bcl-2 proteins regulate mitochondrial membrane 
permeability by cytochrome C release and can be either pro-apoptotic (Bax, Bak, Bid) or 
anti-apoptotic (Bcl-2, Bcl-x, BAG) (Elmore, 2007).
Furthermore the extrinsic and intrinsic pathway can also interact (Figure 6.2). An example is 
that mitochondrial damage in the Fas pathway is mediated by the caspase-8 cleavage of Bid 
(Elmore, 2007).
Both pathways end at the execution phase, which is considered the final pathway of 
apoptosis. Effector caspases, such as caspase-3 and caspase-6 activate the cytoplasmic 
endonuclease, which results in DNA fragmentation, degradation of cytoskeletal and nuclear 
proteins, formation of apoptotic bodies, expression of ligands for phagocytic cell receptors 
and lastly uptake by phagocytic cells (Elmore, 2007).
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Figure 6.2: Schematic presentation of the extrinsic and the intrinsic pathway of apoptosis. 
The extrinsic pathway involves transmembrane receptor-mediated interactions, where upon 
ligand binding to the receptors, cytoplasmic adapter proteins are recruited; in the case of Fas 
ligand binding to Fas receptor, the adapter protein FADD is recruited and subsequently 
FADD associates with procaspase-8 and the DISC complex is formed, resulting in auto- 
catalytic activation of procaspase-8, which causes activation of either caspase-3 or truncation 
of Bid. The intrinsic pathway involves activation of the caspase-dependent mitochondrial 
pathway by cytochrome C binding and activation of Apaf-1 and procaspase-9, which leads to 
caspase-9 activation; caspase-3 activation is then triggered through the formation of the 
cytochrome C/Apaf-1 /caspase-9 apoptosome complex (from Bruin et al., 2008).
6.1.4 Aim of study
The previous chapters assessed the low dose response relationships of MMC and araC in 
human lymphoblastoid cells, which were either p53 proficient (TK6) or heterozygous for p53 
(AHH-1 and MCL-5), using the in vitro MN assay.
This study was designed to investigate the role of the tumour suppressor gene TP53 in the 
low dose relationships of MMC and araC, using p21 gene and p53/phospho(Scil5)-p53 protein 
expression analysis, as well as flow cytometry for analysis of apoptosis and cell cycle status. 
Furthermore DNA damage induction in MMC and araC treated cultures were compared in 
TK6 and NH32 cells (TK6 cells, which are p53 deficient), using the in vitro MN assay.
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6.2 Material and Methods
6.2.1 Cell lines
The human lymphoblastoid cell lines TK6 (proficient for p53), AHH-1 (heterozygous for 
p53), MCL-5 (derivative of AHH-1, metabolically active, heterozygous for p53) and NH32 
(TK6 cells deficient in p53) were used in this study. The cell lines were described in detail in 
chapter 2 (section 2.2.1).
NH32 cells are a derivative of TK6 cells with a double p53 knockout through a promoterless 
gene targeting approach (Chuang, et al., 1999; Hashimoto et al., 2011). The NH32 cell line 
was a kind gift from Prof. Dr. Gerald N. Wogan (MIT, Cambridge, MA, USA).
6.2.2 Cell culture
Cell culture and sub-culturing was performed as described in chapter 2 (section 2.2.1). NH32 
cells were cultured in the same manner as TK6 cells.
6.2.3 Test chemical
; MMC and araC were freshly diluted from a stock solution (1 mg/ml aliquots) with water.
I 6.2.4 Test chemical dosing regime
i
| For the Real-time PCR and Western Blot sections of work, TK6 and AHH-1 cells were 
treated with MMC for 4h with 0, 0.004, 0.008, 0.02, 0.04 and 0.08pg/ml MMC, whereas 
TK6, AHH-1 and MCL-5 cells were treated with araC for 24h with 0, 0.007, 0.005, 0.01,
| 0.07 and O.lpg/ml araC.
i
j Flow cytometry was used for the analysis of apoptosis and cell cycle status in TK6 cells.
Therefore TK6 cells were treated with MMC for 4h and araC for 24h (with and without
recovery time of 18h for the cell cycle study) over a range of concentrations between 0 and
O.lpg/ml.
! For the in vitro CBMN assay NH32 cells were treated with MMC for 4h and with araC for
24h, followed by one cell cycle of cytochalasin B. NH32 cells were treated with MMC over a 
range of concentrations from 0 to 0.06pg/ml and araC with a dose range between 0 and 
0.03pg/ml.
i
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6.2.5 In vitro MN assay
The semi-automated scoring protocol for the Metafer-System was used for all CBMN assay 
studies. The method is described in detail in chapter 2 (section 2.2.2). For the CBMN assay a 
minimum of 4000 cells (NH32 cells) per replicate was scored (exceptions where stated, for 
details see Appendix I).Three independent experiments were carried out.
6.2.6 Cytotoxicity
RPD was used to measure cell death and cytostasis. The method is described in detail in 
chapter 2 (section 2.2.3).
6.2.7 RNA extraction
Total RNA was extracted from the human lymphoblastoid cell lines TK6 and AHH-1 after 
MMC treatment and TK6, AHH-1 and MCL-5 cells after araC treatment. The method is 
described in detail in chapter 2 (section 2.2.5).
After completing the RNA extraction the RNA content was measured and the purity was 
assessed (260:280 ratio) with a NanoDrop ND-1000 Spectrophotometer (Labtech 
International, Uckfield, UK). The RNA was stored at -80°C until further use.
6.2.8 Reverse Transcription with elimination of genomic DNA for Quantitative, Real- 
Time PCR
The mRNA from the total RNA extractions (see section 6.2.7) were reverse transcribed into 
cDNA by using the QuantiTect® Reverse Transcription Kit (Qiagen, Sussex, UK). The 
method is described in detail in chapter 2 (section 2.2.7).
6.2.9 Real-Time PCR
Real-time PCR was performed to quantify the gene expression of p21. For the Real-time PCR 
experiments the QuantiFast™ SYBR® Green PCR Kit (Qiagen, Sussex, UK) was used. The 
method is described in detail in chapter 2 (section 2.2.9).
6.2.10 Total protein extraction
All steps for the protein preparation were performed at 4°C; pre-cooled buffers and 
equipment were used. Details of the method are described in chapter 2 (section 2.2.12).
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6.2.11 Protein Quantification
The BioRad DC Protein Assay (BioRad, Hertfordshire, UK) was used for the protein 
quantification and the details of the assay are described in chapter 2 (section 2.2.13).
6.2.12 Western blotting
With the help of the sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS- 
PAGE) proteins could be analysed. They were separated according to their size and details of 
the method are described in chapter 2 (section 2.2.14).
6.2.13 Apoptosis analysis using flow cytometry
The induction of apoptosis in TK6 cells treated with either MMC or araC was investigated by 
using an AnnexinV-FITC antibody (Abeam, Cambridge, UK). After the initiation of 
apoptosis, cells translocate membrane phosphatidylserine (PS) from the inner layer of the 
plasma membrane to the cell surface, where it can be detected by staining with a fluorescent 
conjugate of AnnexinV, a protein with a high affinity to PS (Elmore, 2007). PI was used as a 
counterstain for the detection of dead cells.
The method is described in detail in chapter 2 (section 2.2.15).
6.2.14 Cell cycle analysis using PI staining
The cell cycle status, in TK6 cells treated with the test chemicals MMC and araC, was 
analysed by quantitation of DNA content using flow cytometry. Details of the method are 
described in chapter 2 (section 2.2.16).
6.2.15 Statistical analysis
The analysis of the data sets is described in detail in chapter 2 (section 2.2.17).
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6.3 Results
In the previous chapters it was shown that human lymphoblastoid cell lines (TK6, AHH-1 
and MCL-5) treated with MMC and/or araC follow non-linear dose responses for DNA 
damage induction, using the in vitro MN assay.
To summarize, TK6 and AHH-1 cells treated with MMC (0 to O.lpg/ml) for 4h, followed by 
one cell cycle of cytochalasin B (see Figures 3.6 and 3.7), as well as TK6, AHH-1 and MCL- 
5 cells treated with araC (0 to O.lpg/ml and up to 0.2pg/ml for AHH-1 cells) for 24h, 
followed by one cell cycle of cytochalasin B (see Figures 5.2, 5.4 and 5.5), showed increases 
in MN induction only at the higher concentrations, whereas at the lower range of 
concentrations no increases were observed. Further follow up experiments of the mechanism 
of action of the chemicals were needed for a better understanding of the dose response 
relationships. Consequently, in this chapter, the role and involvement of p53 was 
investigated.
6.3.1 p53 activation after MMC treatment
p53 stimulates the transcription of different genes, such as p21. The induction of p21, a 
cytokine kinase inhibitor (CKI), results in cytokine dependent kinase (CDK) inhibition and 
cell cycle arrest (Vermeulen et al., 2003). Thus, p53 activation was investigated by p21 gene 
expression and p53/phospho-p53 (Seri 5) protein expression analysis.
TK6 and AHH-1 cells were treated with MMC for 4h over a range of concentrations (0, 
0.004, 0.008, 0.02, 0.04 and 0.08pg/ml) below and above the increase in MN induction 
observed in TK6 cells and below the increase in MN induction observed in AHH-1 cells for 
chromosome damage induction. No significant increases in p21 gene expression were 
observed in either TK6 or AHH-1 cells (Figure 6.3).
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Figure 6.3: Relative fold change in p21 gene expression in TK6 and AHH-1 cells, following 
exposure to increasing concentrations of MMC. Values represent mean ± SD (n=3)
However, an overall increase in phospho-p53 in TK6 cells with increasing doses of MMC 
was noticed (Figure 6.4). No increases in protein expression of either p53 and/or phospho- 
p53 (Seri 5) were observed in AHH-1 cells (Figure 6.5).
Chapter 6
A:
p53
p-actin
'CV & pg/ml
phospho-p53
(3-actin
B:
cuW>
m 3 
.c  u
1  ^
p53 p h osp h o-p 53(S er15)
•  d  i  I 1 i  ■
0 0.004 0.008 0.02 0.04 0.08
MMC pg/m l)
Figure 6.4: TK6 cells. A: Representative Western Blot for p53 and phospho-p53 (Seri5) 
following MMC treatment. B: Relative fold change in protein expression (represents the ratio 
of (3-actin normalised treated band density to the untreated control band density. Values 
represent mean ± SD (n=3)
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Figure 6.5: AHH-1 cells. A: Representative Western Blot for p53 and phospho-p53 (Seri5) 
following MMC treatment. B: Relative fold change in protein expression (represents the ratio 
of (3-actin normalised treated band density to the untreated control band density). Values 
represent mean ± SD (n=3)
No p53 activation was observed in AHH-1 cells at doses which caused no chromosomal 
damage induction in the in vitro MN assay (see Chapter 3), whereas an overall increase in 
phospho-p53 (Seri5) was observed in TK6 cells at doses which caused increases in MN 
induction (see Chapter 3).
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6.3.2 p53 activation after araC treatment
p53 activation was, as above, investigated by p21 gene expression and p53/phospho-p53 
(Seri 5) protein expression analysis following exposure of cells to araC.
TK6, AHH-1 and MCL-5 cells were treated with araC for 24h over a range of concentrations 
(0, 0.0007, 0.005, 0.01, 0.07 and O.lpg/ml) below and above the LOEL observed in TK6 and 
MCL-5 cells for chromosomal damage induction.
No significant increases in p21 gene expression were observed in any of the cell lines 
investigated (Figure 6.6). However, an overall increase in p21  gene expression, in particular 
in TK6 cells, was noticed with increasing doses of araC.
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Figure 6.6: Relative fold change in p21 gene expression in TK6, AHH-1 and MCL-5 cells, 
following exposure to increasing concentrations of araC. Values represent mean ± SD (n=3)
In addition, TK6 cells treated with araC for 24h showed high increases in p53 and phospho- 
p53 (S eri5) protein expression over the range of concentrations (Figure 6.7), whereas AHH-1 
cells showed only increases in p53 protein expression at O.lpg/ml araC (Figure 6.8), while 
MCL-5 cells treated with araC for 24h showed increases in p53 and phospho-p53 (Seri5) 
protein expression at the top concentrations of 0.07 and O.lpg/ml (Figure 6.9).
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Figure 6.7: TK6 cells. A: Representative Western Blot for p53 and phospho-p53 (Seri5) 
following araC treatment. B: Relative fold change in protein expression (represents the ratio 
of P-actin normalised treated band density to the untreated control band density). Values 
represent mean ± SD (n=3)
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Figure 6.8: AHH-1 cells. A: Representative Western Blot for p53 and phospho-p53 (Seri5) 
following araC treatment. B: Relative fold change in protein expression (represents the ratio 
of p-actin normalised treated band density to the untreated control band density). Values 
represent mean ± SD (n=3)
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Figure 6.9: MCL-5 cells. A: Representative Western Blot for p53 and phospho-p53 (Seri5) 
following araC treatment. B: Relative fold change in protein expression (represents the ratio 
of p-actin normalised treated band density to the untreated control band density). Values 
represent mean ± SD (n=3)
p53 activation was observed in TK6 and MCL-5 cells at concentrations that caused increases 
in MN induction (see Chapter 5), whereas in AHH-1 cells an increase in total p53 was shown 
even at a concentration below the increase in MN frequency for chromosomal damage 
induction (see Chapter 5).
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6.3.3 Induction of apoptosis in TK6 cells
Cell death (apoptosis) was investigated in TK6 cells treated with MMC (0 to O.lpg/ml) for 4h 
or with araC (0 to O.lpg/ml) for 24h at concentrations above and below the DNA damage 
induction. AnnexinV-FITC antibody staining was used for the detection of early apoptotic 
cells, while PI was used as a counterstain for dead cells. This allowed distinction on the flow 
cytometer between viable cells (negative for both AnnexinV-FITC and PI), early apoptotic 
cells (AnnexinV-FITC positive, PI negative), late apoptotic cells (AnnexinV-FITC and PI 
positive) and dead cells (PI positive, AnnexinV-FITC negative). Staurosporin was used as a 
positive control for early and late apoptotic cells.
TK6 cells treated with MMC for 4h showed 25% to 30% dead cells in all cultures, with no 
significant increases of dead cells over the background to the top dose of O.lpg/ml MMC. 
Further no detection of apoptosis could be observed with the MMC treatment (Figure 6.10).
_  40
£  35 
j/> 30
"53 25
£ 20
»“ 15
10
5
0
Figure 6.10: Flow cytometric analysis of apoptosis in TK6 cells treated with 4h of MMC. 
The graph shows the % of dead, late and early apoptotic cells in TK6 cultures treated with 
MMC. Staurosporin was used as a positive control. Values represent mean ± SD (n=3)
TK6 cells treated with araC for 24h showed increases in dead cells over the background 
levels at the top two concentrations at 0.07pg/ml and O.lpg/ml araC, as well as an increase in 
late apoptotic cells at 0.07 and O.lpg/ml araC (Figure 6.11).
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Figure 6.11: Flow cytometric analysis of apoptosis in TK6 cells treated with 24h of araC. 
The graph shows the % of dead, late and early apoptotic cells in TK6 cultures treated with 
araC. Staurosporin was used as a positive control. Values represent mean ± SD (n=3)
6.3.4 Cell cycle analysis in TK6 cells
PI was used as a DNA marker for the cell cycle analysis using flow cytometry. TK6 cells 
were treated with MMC for 4h over a range of concentrations between 0 and O.lpg/ml. No 
significant changes in any of the cell cycle phases were observed, when comparing the 
control sample with the MMC treated samples (Figure 6.12).
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Figure 6.12: Cell cycle analysis in TK6 cells treated with MMC for 4h. A: Representative 
cell cycle plots for MMC (0 to O.lpg/ml; from left to right) showing cells in G0/G1, S and 
G2/M phase. B: Graph presenting the % of cells in G0/G1, S and G2/M phase. Values 
represent mean ± SD (n=3)
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In contrast, TK6 cells treated with MMC for 4h, followed by a recovery period of 18h, 
showed a decrease in the percentages of cells in the GO/G1 phase at the top concentration of 
O.lpg/ml, with more cells being in the G2/M phase, when compared to the control (Figure 
6.13).
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Figure 6.13: Cell cycle analysis in TK6 cells treated with MMC for 4h, followed by a 
recovery period of 18 h. A: Representative cell cycle plots for MMC (from left to right: 0, 
0.006, 0.02, 0.06 and O.lpg/ml) showing cells in G0/G1, S and G2/M phase. B: Graph 
presenting the % of cells in G0/G1, S and G2/M phase. Values represent mean ± SD (n=3)
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No induction of apoptosis was observed in TK6 cells even at concentrations where 
chromosomal damage induction was observed (see Figure 6.10 and Chapter 3). However, an 
accumulation of cells at the G2/M checkpoint was shown at the higher range of 
concentrations in TK6 cells treated with MMC for 4h, followed by an 18h recovery period. 
TK6 cells treated with araC for 24h over a range of concentrations between 0 and O.lpg/ml 
showed an increase of cells in the G0/G1 phase and a decrease of cells in the G2/M phase at 
the higher concentration range, when compared to the control sample (Figure 6.14). However 
high toxicity was observed, when TK6 cells were treated above 0.07pg/ml of araC (see 
Chapter 5).
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Figure 6.14: Cell cycle analysis in TK6 cells treated with araC for 24h. A: Representative 
cell cycle plots for araC (0 to O.lpg/ml; from left to right) showing cells in G0/G1, S and 
G2/M phase. B: Graph presenting the % of cells in G0/G1, S and G2/M phase. Values 
represent mean ± SD (n=3)
Furthermore, TK6 cells treated with araC for 24h, followed by a recovery period of 18h, 
showed similar results as above, where an increase of cells in G0/G1 phase was observed, 
while cells in G2/M phase decreased (Figure 6.15).
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Figure 6.15: Cell cycle analysis in TK6 cells treated with araC for 24h, followed by a 
recovery period of 18 h. A: Representative cell cycle plots for araC (from left to right: 0, 
0.0005, 0.009, 0.03, 0.07 and O.lpg/ml) showing cells in G0/G1, S and G2/M phase. B: 
Graph presenting the % of cells in G0/G1, S and G2/M phase. Values represent mean ± SD 
(n=3)
Induction of apoptosis and an accumulation of cells at the G1/G0 checkpoint were observed 
in TK6 cells at doses where chromosomal damage induction and p53 activation was shown 
(see Figure 6.7, 6.11 and Chapter 5).
6.3.5 Chromosome aberration in NH32 cells after MMC and araC treatment
NH32 cells are a derivative of TK6 cells with a double p53 knockout (Chuang, et al., 1999; 
Hashimoto et al., 2011). p53 expression was checked in TK6 and NH32 cells after treatment 
with araC for 24h (0, 0.01 and O.lpg/ml). As expected no p53 protein expression was 
observed in NH32 cells, whereas p53 was expressed in TK6 cells (Figure 6.16).
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Figure 6.16: TK6 and NH32 cells. Representative Western Blot for p53 protein expression 
following araC treatment.
To compare the results gained in TK6 cells (p53 proficient) and to investigate the role of p53, 
NH32 cells (p53 deficient) were treated with MMC for 4h or with araC for 24h and 
chromosomal damage was examined, using the in vitro MN assay. The semi-automated 
scoring protocol for the Metafer-System (MetaSystems) was applied.
TK6 cells treated with MMC (0 to O.lpg/ml) for 4h, followed by one cell cycle of
cytochalasin B (18h) showed increases in MN induction at 0.04 to 0.06pg/ml and above. 
Further 45.8% toxicity was observed at O.lpg/ml MMC (see Figure 3.6).
In comparison, NH32 cells treated with MMC for 4h, followed by one cell cycle of
cytochalasin B (18h), showed increases in MN induction at 0.02 and 0.04pg/ml. Further
54.3% cell death and cytostasis were observed at 0.06pg/ml MMC (Figure 6.17).
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Figure 6.17: Effect of MMC on NH32 cells using the CBMN assay. NH32 cells were treated 
with MMC for 4h, followed by 18h of CytoB. Blue: percentage micronucleated binucleated 
cells, green: Relative population doubling (RPD). Values represent mean ± SD (n=3)
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TK6 cells treated with araC (0 to O.lpg/ml) for 24h, followed by one cell cycle of 
cytochalasin B (18h) showed significant increases in MN induction at 0.03pg/ml and above. 
Further >50±5% (62.5%) cell death and cytostasis were observed at 0.07pg/ml araC (see 
Figure 5.2).
In comparison, NH32 cells, treated with 24h of araC, followed by 18h of cytochalasin B, 
showed significant increases in MN induction at 0.007pg/ml and above, while >50±5% 
(90.6%) toxicity were observed at 0.03pg/ml araC (Figure 6.18).
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Figure 6.18: Effect of araC on NH32 cells using the CBMN assay. NH32 cells were treated 
with araC for 24h, followed by 18h of CytoB. Blue: percentage micronucleated binucleated 
cells, green: Relative population doubling (RPD). Values represent mean ± SD (n=3). (*) 
Represents p<0.05.
NH32 cells (p53 deficient) thus demonstrated to be more sensitive to toxicity than the p53 
proficient parental cell line TK6. Furthermore NH32 cells treated with araC showed a higher 
magnitude for MN induction than TK6 cells treated with the analogue. However, NH32 cells 
treated with MMC showed a lower to a similar magnitude of MN induction compared to the 
parent TK6 cells line treated with the cross-linker.
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6.4 Discussion
The role of the tumour suppressor gene TP53 in the low dose region of MMC and araC 
exposure was investigated in this study. TP53 encodes a phospho-protein, which is involved 
in cellular processes, such as cell cycle control (predominantly at the DNA damage 
checkpoint) and prevention of uncontrolled cell proliferation through apoptosis; thus the 
protein plays a crucial role for cellular integrity (Yang and Duerksen-Hughes, 1998; 
Arrowsmith, 1999). Inactivation of the gene by mutations is the most frequent alteration in 
human cancers (Kato et al., 2003).
6.4.1 p53 activation after genotoxic stress
It is well known that cellular stress including DNA damage, activate the p53 response. 
Increases in p53 protein levels as well as structural changes in the protein are hallmarks of 
p53 activation (Salazar et al., 2009). Furthermore post-translational modifications, like 
phosphorylation at serine residues ensure p53 stabilization and accumulation in the nucleus, 
allowing p53 to interact with sequence-specific sites on target genes (Joerger and Fersht, 
2007; Salazar et al., 2009). Target genes include p21, which is involved in cell cycle arrest at 
the Gl/S checkpoint, Gadd45, which plays a role in triggering DNA repair and Bax, which is 
involved in the apoptotic pathway (Yang and Duerksen-Hughes, 1998).
In this study p53 activation was investigated by p21 gene expression and p53/ phospho-p53 
(Seri5) protein expression analysis.
No significant increases in p21 gene expression were observed in any of the cell lines after 
MMC or araC treatment. However increases in p21 gene expression over the background 
with increasing concentrations were observed in TK6 cells treated with araC (see Figure 6.6). 
DNA damage induction triggers p53 activation, which leads to downstream signalling to 
target genes. p21 gene expression was analysed in AHH-1 cells below the threshold for DNA 
damage induction level described in the previous chapters. Consequently, p53 protein levels 
might have been maintained at low levels, resulting in no p53 activation in AHH-1 cells at 
the low dose levels. Furthermore chromosomal damage was more strongly induced in TK6 
cells treated with araC, when compared to the MMC treatment, resulting in increasing levels 
of p21 in TK6 cells treated with araC. In addition p21 is not the only target gene activated in 
the p53 response, suggesting that other target genes, like Gadd45 or Bax, need to be 
investigated.
173
Chapter 6
In parallel to the p21 gene expression assessment, p53 activation was investigated by p53 and 
phopho-p53 (Seri5) protein expression analysis. As mentioned before DNA damage induces 
phosphorylation of p53 at serine residues, such as serine 15 or 20 (Lakin and Jackson, 1999). 
No increases in the protein levels of p53 and/or phospho-p53 (Seri 5) were observed in AHH- 
1 cells treated with MMC for 4h. The results confirm that p53 is most likely not activated in 
AHH-1 cells at the low dose levels chosen. Natural defence mechanisms, like epithelial 
barriers to genotoxin entry, chemical detoxification, DNA redundancy or DNA repair 
(Jenkins et al., 2010) are most likely responsible for the low levels of MN induction seen in 
AHH-1 cells treated with MMC. Increases in phospho-p53 (Seri 5) levels were observed in 
TK6 cells treated with MMC for 4h, showing that DNA damage occurs. However the overall 
p53 induction after MMC treatment was low. It was shown by Nelson and Kastan (1994) that 
DNA strand breaks might be critical to trigger p53 induction. They suggested that agents 
capable of directly causing strand breaks, in particular after short-term treatments, were more 
effective in activating p53 than agents that cause DNA cross-links (such as MMC), that 
induce DNA base modifications, intercalate into the DNA or cause interference with the cell 
cycle or cellular metabolism (Nelson and Kastan, 1994). DNA strand breaks, in particular 
DNA double strand breaks, can cause various problems for the cell, like relaxation of the 
torsional super helical strain in the DNA template required for transcriptional regulation, 
gene expression effects or chromosomal damage (Nelson and Kastan, 1994).
In addition, only the short-term treatment for MMC was investigated for p53 activation. 
Extended treatments, which showed high rates of chromosomal damage induction after MMC 
treatment might activate p53 more strongly, since it was shown previously that MMC is able 
to activate the p53 pathway (Champeil et al., 2010).
TK6 cells treated with araC for 24h showed high increases in p53 and phospho-p53 (Seri 5) 
protein expression at 0.07pg/ml araC and above, whereas MCL-5 cells treated with araC for 
24h showed high increases in p53 and phospho-p53 (Seri5) protein expression only at the top 
dose of O.lpg/ml, while AHH-1 cells showed increases in p53 protein expression at O.lpg/ml 
araC. These results suggest a direct relationship between p53 levels and the induction of MN. 
Significant increases in p53 expression were observed at concentrations that were found to be 
statistically significant for MN induction. Salazar et a\. (2009) showed a direct relationship 
between p53 levels and the induction of MN in RKO cells treated with genotoxic chemicals, 
indicating that the level of p53 might be associated with chromosomal damage. Further, p53 
binds directly to sites of DNA damage, such as mismatches and single-stranded DNA,
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showing the potential of p53 as a direct DNA damage detector (Amundson et al., 1998) and 
as an endpoint for genotoxicity testing (Salazar et al., 2009).
In addition, it was shown by Fenech and Neville that araC inhibits the gap-filling step during 
excision repair, which results in the formation of single-strand breaks at repair sites. The 
single-strand breaks could then be converted to chromatid or chromosome breaks, confirming 
that DNA strand breaks might be critical to trigger for p53 induction (Fenech and Neville, 
1992). Downstream effector genes transactivated by p53 determine the final outcome of p53 
activation.
6.4.2 Cell cycle analysis and apoptosis in TK6 cells after MMC and araC treatment
Activation of p53 can lead to cell cycle arrest to prevent the proliferation of damaged cells 
and to allow DNA repair before replication and mitosis or induce apoptosis to eliminate 
irreparable damaged cells (Amundson et al., 1998).
TK6 cells exposed to MMC for 4h showed no changes in any phases of the cell cycle. 
However TK6 cells treated with MMC for 4h, followed by a recovery time of one cell cycle 
showed G2/M arrest in particular at O.lpg/ml MMC.
A study by Islaih et a l (2005) analysed the cell cycle in TK6 cells after treatment with 
different genotoxins, such as MMC. The cells were exposed for 4h and cell cycle analysis 
was performed at 4h and 20h following treatment. Cells collected at the 8h time point showed 
significant increases in the percentage of cells in S phase, whereas cells collected at the 24h 
time point showed a strong G2/M arrest (Islaih et al., 2005). Furthermore a study by 
Lukamowicz et a l (2011) revealed a dose-dependent accumulation of cells in G2/M phase 
after MMC treatment. The G2/M checkpoint seems to be activated, when DNA synthesis is 
blocked to prevent segregation of damaged or incompletely synthesised DNA (Pucci et al., 
2000). The cyclinB 1/Cdc2 complex is the main regulatory factor for the entry into M phase 
and phosphorylation of cdc2 or inhibition of cyclinB 1 can cause G2 arrest (Amundson et al., 
1998). In addition p53-regulated genes can regulate the G2 arrest to a certain extent. Further 
experiments are required to clarify the mechanism behind the G2/M arrest induced by MMC. 
TK6 cells exposed to araC for 24h with and without an extended recovery period of one cell 
cycle, showed dose-dependent increases in the percentage of cells in G1/G0 phase. p53 
predominately acts at the DNA damage checkpoint in the cell cycle, influencing cell 
proliferation. The sequence-specific transactivation function of p53 clearly mediates the G1 
arrest. Activation of p53 in this study was shown after araC treatment by increases in p21 
gene expression as well as p53 and phospho-p53 (Seri 5) protein expression. p53 is activated
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by DNA damage induced by araC and initiates the transcription of p21, a G1 cyclin 
dependent kinase inhibitor (CKI), which results in G1/G0 cell cycle arrest (Amundson et al., 
1998; Pucci et al., 2000). Cell cycle progression is prevented by inhibition of phosphorylation 
of CDK2/cyclin-complexes by p21 and inhibition of further downstream signalling 
(Amundson et al., 1998). Hence the data support a general link between araC induced 
chromosome damage, p53 activation and Gl/S phase block.
Activation of p53 can also lead to apoptosis to eliminate irreparable damaged cells. TK6 cells 
treated with MMC for 4h showed no induction of apoptosis over the low range of 
concentrations. Furthermore no increase in dead cells over the background level was 
observed. In contrast, TK6 cells treated with araC for 24h showed increases in dead cells at 
0.07pg/ml araC and above, as well an increase in apoptotic cells at O.lpg/ml araC.
It was proposed by Islaih et al. (2005) that TK6 cells have a prolonged cell cycle delay in 
response to genotoxins. Therefore it might be possible that damaged cells are rather stalled 
than eliminated through apoptosis (Sobol et al., 2012). However, it is important to note that 
the final outcome of p53 activation depends on many factors, such as the presence of growth 
factors and is mediated through the action of downstream effector genes, which are 
associated with growth control, cell cycle checkpoints, DNA repair and/or apoptosis 
| (Amundson et al., 1998).
6.4.3 Chromosome aberration in NH32 (p53 deficient) cells after MMC and araC 
treatment
The human lymphoblastoid cell line TK6 has been extensively used in recent genotoxicity 
assays to examine its suitability for genotoxicology testing. Most studies revealed lower fold 
MN increase in TK6 cells than in the commonly used rodent cell lines (L5178Y, CHO and 
CHL) (Hashimoto et al., 2011). This was also confirmed is this study, when TK6 and 
L5178Y cells were treated with low doses of 4NQO (see Chapter 4). TK6 cells treated with 
4NQO showed little to no induction of chromosome damage, while L5178Y showed 
significant increases in MN induction at very low doses, using the in vitro MN assay (see 
Chapter 4). TK6 cells are p53 proficient, whereas the rodent cell lines are p53 compromised 
and therefore more likely to survive and replicate with DNA damage, resulting in higher MN 
frequencies (Hashimoto et al., 2011). Furthermore, in our group it was observed that the 
human lymphoblastoid cell lines AHH-1 and MCL-5, which are heterozygous for TP53, 
showed a lower sensitivity to toxicity than TK6 cells and therefore allowed treatment with a
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higher dose range (see Chapters 3 to 5). Consequently, p53 function might be a key factor for 
the cell-type dependent sensitivity for genotoxicity and cytotoxicity (Hashimoto et al., 2011). 
NH32 cells are an isogenic derivative of TK6 cells with a double TP53 knockout (Li et al., 
2006). Thus, the DNA damage induction in TK6 and NH32 cells after MMC and araC 
treatment was compared to investigate, if p53 plays a central role in the low dose responses in 
human lymphoblastoid cells.
NH32 cells were more sensitive to cytotoxicity after both MMC and araC treatment than the 
proficient parent cell line TK6. Further NH32 cells treated with MMC for 4h showed a lower 
to a similar magnitude of MN induction compared to the parent TK6 cells line, when treated 
with the cross-linker MMC, whereas NH32 cells treated with araC for 24h showed a higher 
magnitude for MN induction than TK6 cells treated with the nucleoside analogue araC.
A study by Hashimoto et al. (2011) showed no differences in sensitivity to MN induction and 
cytotoxicity between p53 competent TK6 cells and p53-null NH32 cells after short and/or 
extended treatments with genotoxins. Further it was reported by Yu et al. (1997) that p53-null 
cells have similar characteristics to p53-competent cells, while p53-mutated cells show 
different characteristics, suggesting a dominant negative effect of abnormal p53 function (Yu 
et al., 1997; Hashimoto et al., 2011).
These results are in line with the results gained for MMC in our study. However it was shown 
that p53 induction in TK6 cells treated with MMC for 4h was low, suggesting that p53 might 
be insignificant under the chosen short treatment condition (because of low concentration). 
Natural defence mechanisms, like DNA repair seem to be responsible for the low DNA 
damage induction of MMC in NH32 cells. Furthermore NH32 cells were more sensitive to 
DNA damage and cytotoxicity after araC treatment, when compared to TK6 cells. p53 was 
highly activated in TK6 cells treated with araC for 24h and the cells showed G1 arrest in the 
cell cycle analysis, suggesting a central role for p53 in the dose response, since p53 plays an 
important function in cellular responses, such as cell cycle arrest at the G1 phase. In 
conclusion, p53 was more prominent in araC treated cell cultures and therefore p53 deficient 
cells showed a greater effect.
6.5 Summary
In this chapter the role of p53 in the low dose response relationships after treatment with the 
genotoxins MMC and araC was investigated by gene and protein expression analysis as well 
as apoptosis and cell cycle studies. Furthermore MN induction was compared between p53 
competent TK6 cells and p53-null NH32 cells.
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Low levels of p53 induction were observed in TK6 cells treated with MMC for 4h, since no 
significant increases in either p21 gene expression or p53/ phospho-p53 (Seri 5) protein 
expression were detected. Furthermore no cell cycle changes or induction of cell death were 
observed, suggesting that other defence mechanisms play a major role in the MMC dose 
response. This was further confirmed by the low DNA damage induction in NH32 cells.
On the other hand high p53 activity was shown in TK6 cells treated with araC for 24h. 
Increases in p21 gene expression as well as high increases in total p53 and phospho-p53 
(Ser53) were detected. Further the percentage of cells in G1/G0 phase increased over the dose 
range, suggesting a G1 arrest after araC treatment. In addition NH32 cells showed a higher 
magnitude of MN induction than TK6 cells. Consequently p53 played a central role in the 
DNA damage response in human lymphoblastoid cells treated with araC.
Furthermore the results gained in TK6, AHH-1 and MCL-5 cells suggested a direct 
relationship between the p53 levels and the induction of MN. High increases in p53 
expression were only observed at concentrations that were found to be statistically significant 
for MN induction, showing the potential of p53 as a direct DNA damage detector and as a 
potential endpoint for genotoxicity testing.
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Chapter 7 
General Discussion
Genotoxicology deals with investigating the DNA damaging effects of substances that 
humans are exposed to and DNA damage is an underlying cause of mutations that have the 
potential to initiate carcinogenesis. The investigation of low dose responses in 
genotoxicology testing helps to improve health risk assessments by establishing if DNA 
reactive compounds follow linear or non-linear (thresholded) dose response relationships. 
The concepts of thresholds in genotoxicology have been discussed substantially and have 
been mainly accepted for aneuploidy based mechanistic experimental evidence (Elhajouji et 
al., 2011). However the assumption for direct acting genotoxins (including clastogens), such 
as MMC and 4NQO is that the relationship between exposure to these genotoxic chemicals, 
DNA damage formation and the induction of mutagenic change is linear (Henderson et al., 
2000). Yet mutations are not produced directly by DNA adducts as DNA repair activity limits 
the proportion of adducts processed into mutational change. It is therefore possible that no 
observed effect levels (NOEL) may exist for some genotoxins (Jenkins et al., 2005). 
Furthermore, natural defence mechanisms, like epithelial barriers to genotoxin entry, 
chemical detoxification or DNA repair corroborate the theory of genotoxic thresholds 
(Jenkins et al., 2010).
The main aim of this thesis was therefore to assess low dose response relationships in vitro 
for a number of genotoxic agents (MMC, 4NQO and araC) and to establish if the DNA 
reactive compounds follow linear or non-linear (thresholded) dose responses, since it is 
important to investigate the biological significance of low dose exposures to improve health 
risk assessments. These studies used the newly installed semi-automated MN detection 
system at Swansea University to investigate DNA damage induction at the chromosomal 
level. Furthermore, the mechanism of action of each test component was further investigated 
by follow up experiments to gain mechanistic understanding of the dose response 
relationships, such as expression of DNA repair enzymes using Real-time PCR or protein 
analysis using Western blotting as well as cell cycle status analysis.
7.1 The Metafer-System: a semi-automated method for scoring MN
The in vitro and in vivo MN assay has been extensively used in genotoxicity studies and 
contributed to our understanding of the dose-relationships of genotoxins (Elhajouji et al.,
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2011). A high demand for the automation of the MN assay exists, because visual scoring of 
MN can be time consuming and the results depend on subjective interpretation. Two types for 
automated MN scoring are commonly used: flow cytometry and MN scoring by image 
analysis (Varga et al., 2004). Several systems are commercially available, such as Metafer 
and Cellomics (Doherty et al., 2011).
One of the advantages of flow cytometry is the possibility of scoring a very large number of 
cells over a very short time. However the disadvantage of the methodology is, that no 
individual cells can be examined in detail to determine whether or not MN are the result of 
aneugenic or clastogenic events and furthermore samples cannot be re-analysed (Doherty et 
al., 2011). Consequently, it was decided to use the automated slide scoring platform Metafer 
in this laboratory. Advantages of the system are visual inspection of the images and cells, 
which allows MN distinction from other DNA fragments and slide preparations can be re­
examined by conventional microscopy to clarify results (Doherty et al., 2011). In addition the 
Metafer software contains classifiers, which can be modified to determine the size and shape 
of nuclei and MN, allowing screening for MN in mononucleated and/or binucleated cells 
(Doherty et al., 2011).
The dose response curves and MN frequencies obtained with the Metafer-System after 
treatment of TK6 cells with MMC were compared to the conventional manual scoring of 
Giemsa stained slides (Chapter 3). Both the mono- and binucleated MN assay was performed. 
Very similar dose responses and MN frequencies were observed in TK6 cells treated with 
different doses of MMC for different time points, when comparing manual scoring with the 
Metafer-System for both the mononucleated and binucleated assay. Further both methods 
showed high correlation (see Chapter 3 and 4). Therefore the MMC study clearly 
demonstrated that the Metafer-System is an adequate system to provide rapid and accurate 
assessment of MN. Furthermore, the system proved to enhance reliability of results and to 
reduce scoring subjectivity of MN identification. In addition, the possibility to score high 
numbers of cells (between 2000 and 4000 cells per replicate were chosen in this study) in a 
short time advances the statistically power of the assay.
Minor difficulties were encountered in our laboratory during automated scoring with the 
Metafer-System due to the loss of cytoplasmic boundaries. Examples were the careful 
attention that needs to be paid to the distance of MN from the main nuclei and attention to the 
staining pattern and intensities of the two nuclei was required. Consequently, although the 
Metafer-System can be used as a fully automated system, it was decided to use a semi­
automated approach with the final assessment being performed by visual examination under
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the microscope. Further, it was notable that the mean response for the MN frequencies 
obtained with the Metafer-System was generally higher than for manual scoring. However 
that is possibly due to subjective manual scoring and the ability of the system to score higher 
total numbers of cells, coupled to the classifier settings, which determine the parameters for 
the identification of the mononucleated and binucleated cells and the MN. The slight 
increases in MN frequency were consistent across the different doses and different chemical 
treatments and so did not interfere with the low dose studies described here.
Further development of the technology was implemented in Chapter 4, where the human 
lymphoblastoid cell lines (TK6, AHH-1 and MCL-5) and the mouse lymphoma cell line 
L5178Y were treated with low doses of 4NQO. At AstraZeneca (Cheshire, UK) the 
mononucleated MN assay was performed and analysed by manual scoring and the Metafer- 
System. The results gained with the Metafer-System were again comparable to the results 
gained through manual scoring, proving once more that the Metafer-System was a 
biologically relevant method to score MN. It was noted that the Metafer-System at 
AstraZeneca detects slightly fewer MN than does the manual scoring, which might be due to 
the intensity of staining of the main nuclei and the small size of MN (Doherty, et al., 2011). 
However, the differences were consistent in all studies and the doses that caused significant 
increases in MN induction after 4NQO treatment were similar. However, clearly system setup 
in each laboratory influenced the performance of the Metafer-System and this requires 
attention in any new laboratory acquiring this equipment.
In conclusion, the Metafer-System is a very promising tool for improving risk assessment of 
human populations exposed to mutagens and thus the semi-automated scoring protocol for 
the Metafer-System was used for the assessment of chromosomal damage throughout this 
thesis.
7.2 Genotoxic thresholds for MMC, 4NQO and araC?
Dose response thresholds for genotoxins have implications for the setting of safe exposure 
levels. A threshold of genotoxic activity indicates that a compound will not produce 
mutations below a critical exposure level. Furthermore it reduces the risk for the induction of 
cancer or congenital abnormalities at these exposures. The main endpoints analysed for 
threshold dose responses have been DNA adduct formation, gene mutation and chromosomal 
aberration (Kirsch-Volders et al., 2003; Jenkins et al., 2010).
Redundant targets and protective mechanisms in the cells are the main mechanisms which 
can lead to genotoxic thresholds. Aneugens (non-DNA reactive genotoxins) show
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thresholded dose response curves. Low levels of the compounds are tolerated, because 
deactivation of multiple targets is required to induce aneuploidy. However, thresholds of 
genotoxic activity have to be proven for direct acting genotoxins on a case-by-case basis. 
Experimental evidence (to date) of thresholded responses has only be demonstrated for 
spindle poisons, ionizing radiation, alkylating agents (methylmethanesulfonate (MMS), 
ethylmethanesulfonate (EMS)), topoisomerase II inhibitors and ROS inducers (Jenkins et al., 
2005; Doak et al., 2007).
In this thesis the low dose response relationships of the direct acting agents MMC, 4NQO and 
araC in human lymphoblastoid cells were investigated. MMC cross-links the complementary 
strands of the DNA double helix, while 4NQO causes bulky DNA adducts and araC is a 
nucleoside analogue of both cytidine and deoxycytidine. Short-term as well as extended 
treatments were undertaken.
TK6 cells treated with MMC (0-0.1pg/ml) for 4h followed by 18h with cytochalasin B 
showed increases in MN frequency only at the higher doses (Chapter 3). Quantitative dose 
response assessment with the BMD model indicated a BMDLio for the manual data at 
0.006pg/ml, whereas for the automated data the BMDLio was calculated at 0.007pg/ml. The 
BMDLio is considered an adequate point of departure (POD) for the extrapolation of dose 
response data (Gollapudi et al., 2013).
In conclusion, the short-term treatment of MMC in TK6 cells showed a clear non-linear dose 
response. In addition AHH-1 cells treated with MMC for 4h and one cell cycle of 
cytochalasin B showed a similar dose response to TK6 cells. Mechanistic experiments had to 
be applied to prove if MMC causes no adverse effects over the background at the low dose 
range in the short-term treatment.
Non-linear dose responses of araC were observed after extended treatments with the chemical 
in TK6, AHH-1 and MCL-5 cells with increases in MN induction only seen at the higher 
dose range (Chapter 5). Assessment with the BMD approach indicated a BMDLio in TK6 
cells treated with araC at 0.0007|ig/ml, in AHH-1 at 0.004pg/ml and in MCL-5 cells at 
0.003pg/ml, which was in line with the observed genotoxicity data gained in this study.
Little to no chromosomal damage induction was observed in TK6 cells treated with 4NQO 
for short-term or extended treatment periods (Chapter 4). However, extending the recovery 
time after the short-term treatments in the CBMN assay from 18h to 42h and in the 
mononucleated assay from 24h to 40h increased the magnitude of MN induction at the top 
doses to a significant level. No induction of MN was observed in the low dose region with 
regard to any treatment regime. Furthermore AHH-1 and MCL-5 cells showed similar dose
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response curves to TK6 cells. However gene mutation induction of 4NQO was observed in 
the in vitro HPRT assay and the in vitro comet assay revealed DNA damage induction by 
4NQO at the higher dose region. Oxidative damage might be a cause for the mutagenicity of 
4NQO. Further investigations into the mechanism of 4NQO have to be undertaken to get an 
understanding of the dose response relationships of 4NQO, such as DNA repair assays and 
gene and protein expression approaches. 4NQO induces three main adducts: dGuo-N2-AQO, 
dGuo-C8-AQO and dAdo-N6-AQO, which can be fixed as mutations (Inga et al., 1994). 
Further, it was shown that 4NQO induces apurinic/apyrimdinic sites and single-strand breaks, 
which originated probably from unstable adducts (Inga et al., 1994) and could be converted to 
double strand breaks and fixed as MN. Therefore studies investigating the adduct formation 
and mutation spectrum in TK6 cells after 4NQO treatment might help to understand the dose 
response of 4NQO. In conclusion, it was shown in this study that 4NQO is a weak clastogen 
in human lymphoblastoid cells, but has the potency to induce gene mutations and DNA 
damage.
These studies clearly demonstrated that direct acting genotoxic agents could exhibit 
thresholds or non-linear dose responses for chromosome aberrations in vitro. MMC, 4NQO 
and araC displayed dose ranges where there was no elevation of chromosomal damage above 
background levels and thus safe exposure levels might exist for these genotoxins. 
Investigations into the mechanisms of the thresholded effects are however needed to provide 
explanations for the results.
DNA repair is one of the natural defence mechanisms to cope with the exposure to 
genotoxins (Jenkins et al., 2010). MMC is a DNA cross-linking agent and the lesions induced 
are repaired by multiple repair pathways, including NER, BER and homologous 
recombination (Dronkert and Kanaar, 2001). Thus, the NOEL observed, could be due to 
DNA repair, which seems to be efficient at low doses of chemical compounds. Genes 
involved in different repair pathways were investigated for changes in gene expression 
(Chapter 3). However no significant changes in gene expression of any genes investigated 
could be observed. The base level expression of genes involved in DNA repair might be 
adequate to repair the damage caused by MMC to reduce DNA damage to background levels. 
In addition repair proteins could be modified by post-translational changes and these would 
not be picked up by gene expression approaches.
Apoptosis is another defence mechanism and the tumour suppressor gene TP53 encodes a 
phospho-protein, which is involved in cellular processes, such as cell cycle control and the 
prevention of uncontrolled cell proliferation through apoptosis. Therefore the role of p53 was
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investigated in the low dose response of the genotoxins MMC and araC (Chapter 6). Low 
levels of p53 induction were observed in TK6 cells treated with MMC for 4h, since only 
small increases in either, p21 gene expression or p53/ phospho-p53 (Seri5) were detected. 
Furthermore no cell cycle changes or induction of apoptosis were observed, suggesting that 
other defence mechanisms play a major role in the MMC dose response. Cellular and nuclear 
membranes might reduce the access of MMC to the nucleus. Consequently more studies into 
the mechanistic basis of the thresholded dose response of MMC need to be conducted.
MMC causes DNA damage through monofunctional DNA alkylation products and DNA 
cross-links (Abbas et al., 2002). However, the main cause of cytotoxicity is the interstrand 
MMC-DNA cross-links (Paz et al., 2004). Therefore investigations into MMC-induced 
adduct formation should be conducted. DNA cross-links cause damage to chromosomal DNA 
by blocking key DNA metabolisms, such as DNA replication and transcription (Lee et al.,
2006). Further, alkylating agents, such as MMC are not capable of directly inducing strand 
breaks; thus they are rather the result of processing of lesions by different repair pathways 
(Morales-Ramirez et al., 2004). Therefore more investigations into the repair pathways 
induced by MMC have to be undertaken, by protein expression approaches or for example by 
the use of cell lines, which are deficient for certain repair pathways.
In addition, it was shown previously that MMC can activate the p53 pathway (Abbas et al., 
2002; Champed et al., 2010). However, only the short-term treatment for MMC was 
investigated for p53 activation here. Extended treatments, which showed high rates of 
chromosomal damage induction after MMC treatment might activate p53 more strongly than 
the short-term treatment.
High p53 activity was demonstrated in TK6 cells treated with araC. Increases in p21 gene 
expression as well as increases in total p53 and phospho-p53 (Seri 5) were detected. Further, 
the percentage of cells in G1/G0 phase increased over the dose range, suggesting a G1 arrest 
after araC treatment. Therefore p53 seems to play a central role in the DNA damage response 
in TK6 treated with araC, demonstrating the involvement of DNA repair pathways and 
apoptosis in the non-linear dose response relationships of araC. It was shown previously that 
araC slows down S-phase passage at low doses, whereas at higher concentrations araC 
inhibits the cell movement from G1 to S-phase (Valeriote, 1982). Further, araC is known for 
its inhibition of DNA synthesis in proliferating cells by incorporation into elongating DNA 
strands, resulting in retardation of DNA elongation as well as chain termination (Grant, 1998; 
Besirli et al., 2003). In addition, araC can inhibit enzymes involved in DNA synthesis and 
repair and furthermore can increase the generation of ROS (Grant, 1998; Besirli et al., 2003).
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However, the exact mechanism of toxicity caused by araC is still unknown. Therefore more 
mechanistic studies need to be conducted to investigate the non-linear dose response of araC, 
such as investigating if DNA repair is involved in the dose responses seen.
In conclusion natural defence mechanisms seem to play an important role in the response of 
cells to exposure with direct acting genotoxins at the low dose level.
7.3 Importance of dose regime, accurate toxicity measurement and choice of cell type
Improvement of the in vitro mammalian cell assays is one of the priorities in genotoxicolgy 
testing because of the high rate of misleading positive results (Fowler et al., 2012; Fowler et 
al., 2012). It has become apparent that a number of chemicals that are not in vivo genotoxins 
lead to positive results in vitro. Reasons include the absence of detoxification processes in 
vitro, extreme culture conditions, which disturb the physiological conditions of the cell or 
DNA damage that can be inflicted through non-DNA target and processes within the cell 
(Scott et al., 1991; Fowler et al., 2012).
In this thesis the in vitro MN assay was used to investigate the low dose response 
relationships of genotoxins. Short-term as well as extended exposures of the chemical in the 
presence and absence of cytochalasin B are commonly used with this assay (OECD 487,
2007). However, dependent on the dose regime, linear and non-linear dose response 
relationships for MMC could be observed (Chapter 3). An extended treatment schedule of 
24h in TK6 cells followed by one cell cycle of cytochalasin B (18h) showed significant 
increases in MN induction at low doses of MMC, demonstrating a linear dose response for 
MMC in the mononucleated and binucleated assay. The results are not unexpected since 
MMC is a cross-linking agent as well as an alkylating agent and therefore known to induce 
chromosomal aberrations (Greenwood et al., 2004; Schuler et al., 2010). Yet, an extended 
concurrent treatment of MMC and cytochalasin B in TK6 cells for one cell cycle showed no 
significant increases in MN frequency at the chosen dose regime. A possible interaction of 
cytochalasin B with MMC in the continuous treatment accounts for the lack of genotoxic 
effects. Cytochalasin B can reduce MN induction in combined treatments and has been 
shown for spindle poisons, like colchicine (Minissi et al., 1999). Cytochalasin B treatment 
might therefore interfere with the chromosome missegregation in human lymphocytes 
(Minissi et al., 1999).
Furthermore the cell cycle time might play a crucial role in the dose response of MMC. The 
average doubling of TK6 cells used in our lab was approximately 16 to 18 hours. It seems to 
be very likely that the treatment time and cell cycle length of TK6 cells are important to
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produce genotoxic effects. It is therefore possible that the treatment time of 18h (one cell 
cycle) with no recovery time might not have been long enough to produce genotoxic effects 
and that at least 1.5 cell cycles are essential for DNA damage induction to be shown. In 
addition the time required for a lesion to be fixed as a mutation might play a role, as it was 
shown for alkylating agents in vitro (MMS) and in vivo (BCNU and Bus) that more than one 
cell division is needed to cause MN induction due to multiple rounds of error-prone lesion 
repair (Drabl0s et al., 2004; Morales-Ramirez et al., 2004).
TK6 cells treated with MMC for 4h (short-term exposure) followed by one cell cycle with 
cytochalasin B showed a non-linear dose response.
Consequently, the dose regime seems to play a crucial role in the response of the cell to the 
exposure of genotoxins and in the induction of genotoxicity and cytotoxicity. Furthermore, a 
recent study from Sobol et al. (2012) showed that an extended recovery time after treatment 
with compounds with direct DNA reactivity in TK6 cells increased the magnitude of 
micronucleus induction. Similar observations were made in this study after the treatment of 
TK6 cells with 4NQO (Chapter 4). Short-term treatments (4h) and extended treatments (24h 
and 48h) without prolonged recovery time showed little to no chromosomal damage 
induction, whereas extending the recovery time after the short-term treatments in the CBMN 
assay from 18h to 42h and in the mononucleated assay from 24h to 40h increased the 
magnitude of MN induction at the top doses, demonstrating yet again the importance of the 
dose regime. TK6 cells might have a prolonged cell cycle delay in response to genotoxins 
(Islaih et al., 2005), resulting in the possibility of damaged cells being rather stalled than 
eliminated through apoptosis (Sobol et al., 2012). Consequently the extended recovery period 
would allow the stalled cells to progress into mitosis and hence to fix damage as a MN. In 
addition toxicity appeared to be higher in cells with the shorter recovery time than in cells 
with the extended recovery time, demonstrating higher cytostasis, which supports the 
proposition made by Islaih et a l (2005) and the findings from Sobol et al. (2012). 
Consequently, cell cycle length, dose range, treatment time and recovery regimes should be 
taken into account when investigating dose response relationships and DNA damage 
induction.
Cytostasis and cell death together define the overall cytotoxicity of an agent in cell culture 
(Lorge et al., 2008). Appropriate measurements of cytotoxicity are crucial when selecting for 
test concentrations in in vitro genotoxicity assays, as underestimation of toxicity might lead 
to a selection of inappropriate toxic concentrations for analysis, which have the potential to 
generate misleading positive results in the chosen assays (Fellows et al., 2008).
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Concentrations selected should have a maximum of 50±5% toxicity at the top dose, because 
necrotic and apoptotic cells often contain chromosome fragments. Different toxicity measures 
are available for the in vitro MN assay, including CBPI or PI for experiments with 
cytochalasin B and RPD, RICC and RCC for experiments with or without cytochalasin B 
(Fowler et al., 2012). RICC and RPD are appropriate measures of toxicity when compared 
with RI and CBPI (Schuler et al., 2010; Fowler et al., 2012), while RCC seems to 
underestimate toxicity and consequently higher concentrations for subsequent MN assay 
analysis could be selected (Fellows et al., 2008; Fowler et al., 2012). In the studies described 
in this thesis RPD was selected as the most suitable method to measure in toxicity, because of 
recent publications (Lorge et al., 2008; Fellows et al., 2008) and results gained in our 
laboratory (data not shown).
Another factor in the high rate of misleading positive results seems to be the choice of cell 
type and in particular the numbers of deficiencies that the cell lines carry, such as lack of 
normal metabolism, altered DNA-repair capability and impaired p53 function (Fowler et al., 
2012).
A study by Fowler et al. (2012) showed that rodent cell lines, which are p53 deficient, were 
more susceptible to cytotoxicity and MN induction than p53 competent cells, resulting in 
misleading positive results (Fowler et al, 2012). In addition the mouse lymphoma cell line 
L5178Y treated with 4NQO in this thesis (Chapter 4) showed highly significant increases in 
MN induction with no decreases in cell viability, while the human lymphoblastoid cell lines 
TK6, AHH-1 and MCL-5 showed little to no induction of MN even up to 50±5% toxicity 
after 4NQO treatment. L5178Y cells are known for their dysfunctional p53 activity, since 
they have a missense mutation in exon 5 on chromosome 11a (amino acid change from a 
cysteine to an arginine) and a nonsense mutation in exon 4 on chromosome 1 lb (changing a 
glutamine to a stop codon) (Storer et al., 1997; Clark et al., 2004). From this it follows that 
the mouse lymphoma cells have no wild-type p53 allele. On the other hand TK6 cells are p53 
competent, while AHH-1 and MCL-5 cells are heterozygous for p53 at the interface between 
the codons 281 and 282 of exon 8 (Guest and Parry, 1999).
The tumour suppressor gene TP53 is a transcriptional activator that regulates the expression 
of various genes involved in cell cycle arrest and apoptosis in response to genotoxic and 
cellular stress, which prevents damaged DNA from being replicated and plays an essential 
role in cellular integrity (Arrowsmith, 1999). Abnormal DNA binding properties and/or 
transcriptional activation through TP53 mutation can cause mal-functions in the DNA 
damage dependent cell death pathway (Guest and Parry, 1999). Consequently, the effects of
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DNA damaging agents could become significant at low doses, where p53 competent cell lines 
would induce DNA damage dependent cell death (Guest and Parry, 1999).
Furthermore the DNA damage induction of MMC and araC in NH32 cells, which are an 
isogenic derivative of TK6 cells with a double p53 knockout were compared with TK6 cells 
(Li et al., 2006) (Chapter 6). NH32 cells were more sensitive to cytotoxicity after both MMC 
and araC treatment than the proficient parent cell line TK6. Furthermore NH32 cells showed 
a higher magnitude of MN induction than TK6 cells after araC treatment, demonstrating yet 
again that p53 plays a central role in the DNA damage response in human lymphoblastoid 
cells.
In conclusion in Chapter 4, it was shown that TK6 cells are more susceptible to cytotoxicity 
and further showed a smaller magnitude of MN induction than AHH-1 and MCL-5 cells and 
in particular to the mouse lymphoma cell line L5178Y. Cell lines with p53 mutations are 
more likely to survive and replicate with DNA damage, which can lead to higher MN 
frequencies, since p53 plays an important role in cell responses, like cell cycle arrest, 
apoptosis and DNA repair in response to DNA damage (Hashimoto et al., 2011). p53 
function seems to be a key factor for the cell-type sensitivity for genotoxicity and cytotoxicity 
(Hashimoto et al., 2011). Subsequently, it is necessary to compare the ability of different cell 
types to lead to true positive and negative results (Fowler et al., 2012).
The data presented in this study demonstrated clearly the importance of dose-regime, 
accurate toxicity measurements and the choice of cell type for genotoxicity testing to reduce 
the detection of misleading positive compounds.
7.4 Conclusion
Non-linear dose response relationships after low dose exposure have been demonstrated for 
MMC (a cross-linking agent) and araC (a nucleoside analogue of cytidine and 
desoxycytidine), while 4NQO (a bulky adduct inducer) revealed to be a weak clastogen by 
investigating chromosomal damage, using the in vitro MN assay. The semi-automated 
scoring protocol for the Metafer-System proved to be an accurate protocol for scoring MN, 
when compared to the visually scoring protocol. However, dose regime, accurate toxicity 
measurements and choice of cell type are crucial for defining the dose response relationships 
and the induction of genotoxicity and cytotoxicity; thus they have to be taken into account 
when designing and analysing genotoxicology experiments.
DNA repair plays most likely a major role in these non-linear (thresholded) responses by 
removing genetic damage induced at low levels. Furthermore p53 was shown to be involved
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in the DNA damage response in human lymphoblastoid cells, through cell cycle delay and the 
induction of apoptosis. In addition the potential of p53 as a direct DNA damage detector and 
as a potential endpoint for genotoxicity testing was noted and needs to be further validated.
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Appendix I
Micronucleus assay raw data tables
Terminology for data tables:
Mono - number of mononucleated cells scored
Bi -  number of binucleated cells scored
Tri -  number of trinucleated cells scored
Tetra -  number of tetranucleated cells scored
Multi -  number of multinucleated cells scored
Tot Multi -  total number of multinucleated cells scored
Total -  total cells sored altogether
% Bi -  frequency of binucleated cells
% Mono -  frequency of mononucleated cells
MnBn -  number of micronuclei scored in binucleated cells
%MnBn -  frequency of micronuclei in binucleated cells
Mono -  number of micronuclei scored in mononucleated cells
% MnMono -  frequency of micronuclei in mononucleated cells
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Table A.2: Results from MMC in TK6 cells (CBMN assay 4+18h; automated data)
MMC (jug/ml) Bi MnBn %MnBn
0 2016 10 0.496032
0 2008 10 0.498008
0 2000 1 1 0.55
0 5013 41 0.817874
0 2101 12 0.571157
0 2876 17 0.591099
0 2669.00 16.83 0.59
0.002 41 19 37 0.898276
0.002 4102 25 0.609459
0.002 4204 28 0.666032
0.002 2107 7 0.332226
0.002 3633.00 24.25 0.63
0.004 4112 23 0.559339
0.004 2002 6 0.2997
0.004 4202 26 0.618753
0.004 2113 13 0.615239
0.004 3107.25 17.00 0.52
0.006 4107 16 0.389579
0.006 41 10 26 0.632603
0.006 4076 29 0.71 1482
0.006 21 10 1 1 0.521327
0.006 3600.75 20.50 0.56
0.008 4181 24 0.574025
0.008 4108 18 0.438169
0.008 4206 27 0.64194
0.008 2105 12 0.570071
0.008 3650.00 20.25 0.56
0.01 2008 6 0.298805
0.01 2013 10 0.496771
0.01 2102 15 0.713606
0.01 2110 1 1 0.521327
0.01 2058.25 10.50 0.51
0.02 5900 49 0.830508
0.02 4102 25 0.609459
0.02 6310 37 0.586371
0.02 5109 48 0.939518
0.02 5355.25 39.75 0.74
0.04 41 1 1 31 0.754074
0.04 4194 42 1.001431
0.04 4121 36 0.873574
0.04 2102 25 1.189343
0.04 3632.00 33.50 0.95
0.06 2006 25 1.246261
0.06 2134 34 1.593252
0.06 5699 45 0.789612
0.06 2029 38 1.872844
0.06 2967.00 35.50 1.38
0.08 3701 57 1.540124
0.08 3605 42 1.165049
0.08 3781 50 1.322401
0.08 2111 31 1.468498
0.08 3299.50 45.00 1.37
0.1 2128 32 1.503759
0.1 2137 34 1.591015
0.1 2405 33 1.372141
0.1 2385 38 1.593291
0.1 2263.75 34.25 1.52
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Table A.4: Results from MMC in TK6 (CBMN assay: 24+18h; automated data)
MMC ((jg/ml) Bi MnBn %MnBn
0 201 1 27 1.342616
0 2004 26 1.297405
0 2008 30 1.494024
0 2010 28 1.393035
0 2008.25 27.75 1.38
0.002 2007 38 1.893373
0.002 2007 41 2.04285
0.002 2007.00 39.50 1.97
0.004 2005 46 2.294264
0.004 2012 58 2.882704
0.004 2008.50 52.00 2.59
0.006 2024 52 2.56917
0.006 2023 61 3.015324
0.006 2023.50 56.50 2.79
0.008 2001 63 3.148426
0.008 2009 83 4.131409
0.008 2005.00 73.00 3.64
0.01 2014 72 3.574975
0.01 2007 66 3.28849
0.01 2010.50 69.00 3.43
0.02 2010 155 7.71 1443
0.02 2009 135 6.719761
0.02 2009.50 145.CK) 7.22
0.04 2064 260 12.5969
0.04 2198 294 13.3758
0.04 2131.00 277.00 12.99
0.06 1691 326 19.27853
0.06 1324 245 18.50453
0.06 1507.50 285.50 18.89
0.08 1487 302 20.30935
0.08 1286 234 18.19596
0.08 1386.50 268.00 19.25
0.1 1088 286 26.28676
0.1 1326 267 20.13575
0.1 1207.00 276.50 23.21
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Table A.6: Results from MMC in TK6 cells (Mononucleated assay: 24+24h; automated data)
MMC (pg/ml) Mono MonoMn % MonoMn
0 3929 47 1.19623314
0 3864 51 1.31987578
0 3915 38 0.9706258
0 3864 41 1.0610766
0 3893.00 44.25 1.14
0.002 3886 96 2.47040659
0.002 3898 65 1.66752181
0.002 3892.00 80.50 2.07
0.004 3899 81 2.07745576
0.004 3873 64 1.65246579
0.004 3886.00 72.50 1.86
0.006 3905 121 3.09859155
0.006 3873 94 2.42705913
0.006 3889.00 107.50 2.76
0.008 3927 131 3.33587981
0.008 3881 86 2.21592373
0.008 3904.00 108.50 2.78
0.01 3909 194 4.9629061 1
0.01 3919 160 4.08267415
0.01 3914.00 177.00 4.52
0.02 3987 290 7.27363933
0.02 3937 242 6.14681229
0.02 3962.00 266.00 6.71
0.04 4334 519 11.9750808
0.04 3962 243 6.13326603
0.04 4148.00 381.00 9.05
0.06 3975 444 11.1698113
0.06 3968 241 6.07358871
0.06 3971.50 342.50 8.62
0.08 3640 387 10.6318681
0.08 3747 351 9.367494
0.08 3693.50 369.00 10.00
0.1 2829 242 8.55425946
0.1 5187 431 8.30923463
0.1 4008.00 336.50 8.43
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Table A.8: Results from MMC in TK6 cells (CBMN assay: 18h combined; automated data)
MMC (pg/ml) Bi MnBn %MnBn
0 2107 14 0.664452
0 2014 16 0.794439
0 2007 14 0.697559
0 2009 10 0.49776
0 2006 15 0.747757
0 2028.60 13.80 0.68
0.002 2112 13 0.61553
0.002 2005 1 1 0.548628
0.002 2009 20 0.99552
0.002 2042.00 14.67 0.72
0.004 2105 10 0.475059
0.004 2015 16 0.794045
0.004 2010 7 0.348259
0.004 2043.33 1 1.00 0.54
0.006 2105 10 0.475059
0.006 2004 20 0.998004
0.006 2006 7 0.348953
0.006 2038.33 12.33 0.61
0.008 2107 1 1 0.522069
0.008 201 1 9 0.447539
0.008 2008 13 0.64741
0.008 2042.00 1 1.00 0.54
0.01 2106 20 0.949668
0.01 1999 5 0.250125
0.01 2010 12 0.597015
0.01 2038.33 12.33 0.60
0.02 4207 18 0.427858
0.02 2012 23 1.143141
0.02 2013 16 0.794834
0.02 2744.00 19.00 0.79
0.04 2101 20 0.951928
0.04 2272 34 1.496479
0.04 2006 13 0.648056
0.04 2126.33 22.33 1.03
0.06 2312 24 1.038062
0.06 2478 23 0.928168
0.06 2355 25 1.061571
0.06 2381.67 24.00 1.01
0.08 2100 19 0.904762
0.08 2050 34 1.658537
0.08 2506 30 1.197127
0.08 2218.67 27.67 1.25
0.1 2325 17 0.731183
0.1 2078 32 1.539942
0.1 2729 37 1.355808
0.1 2377.33 28.67 1.21
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Table A.9: Results from MMC in AHH-1 cells (CBMN assay: 4+22h; automated data)
MMC ((jg/ml) Bi MnBn % MnBn
0 2098 32 1.525262
0 2105 28 1.330166
0 2105 29 1.377672
0 2102.67 29.67 1.41
0.002 2109 37 1.754386
0.002 2105 36 1.710214
0.002 2103 28 1.331431
0.002 2105.67 33.67 1.60
0.004 2101 31 1.475488
0.004 2102 25 1.189343
0.004 2105 29 1.377672
0.004 2102.67 28.33 1.35
0.006 2100 27 1.285714
0.006 2105 30 1.425178
0.006 2113 22 1.041174
0.006 2106.00 26.33 1.25
0.008 2104 27 1.28327
0.008 4205 75 1.783591
0.008 4213 66 1.56658
0.008 3507.33 56.00 1.54
0.01 2107 33 1.566208
0.01 4205 76 1.807372
0.01 4189 55 1.312963
0.01 3500.33 54.67 1.56
0.02 2106 31 1.471985
0.02 2101 39 1.856259
0.02 2103 33 1.569187
0.02 2103.33 34.33 1.63
0.04 2101 27 1.285102
0.04 2101 35 1.665873
0.04 2101 33 1.570681
0.04 2101.00 31.67 1.51
0.06 2192 42 1.916058
0.06 2111 48 2.273804
0.06 2105 41 1.947743
0.06 2136.00 43.67 2.05
0.08 2028 34 1.676529
0.08 4210 66 1.567696
0.08 4205 112 2.663496
0.08 3481.00 70.67 1.97
0.1 2112 43 2.035985
0.1 2100 56 2.666667
0.1 2100 47 2.238095
0.1 2104.00 48.67 2.31
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Table A.10: Results from 4NQO in TK6 cells (CBMN assay: 4+18h; automated data)
4NQO (|jg/ml) Bi MnBn % MnBn
0 3000 38 1.266667
0 3008 40 1.329787
0 3010 20 0.664452
0 3006.00 32.67 1.09
0.0005 3042 38 1.249178
0.0005 3008 25 0.831117
0.0005 3015 19 0.630182
0.0005 3021.67 27.33 0.90
0.0007 3153 38 1.205201
0.0007 3007 31 1.030928
0.0007 3012 19 0.63081
0.0007 3057.33 29.33 0.96
0.0009 3005 30 0.998336
0.0009 3016 23 0.762599
0.0009 3012 12 0.398406
0.0009 3011.00 21.67 0.72
0.001 3066 37 1.206784
0.001 3148 37 1.175349
0.001 3019 18 0.596224
0.001 3077.67 30.67 0.99
0.003 3199 39 1.219131
0.003 3010 35 1.162791
0.003 3010 28 0.930233
0.003 3073.00 34.00 1.10
0.005 3094 37 1.195863
0.005 2997 25 0.834168
0.005 3018 23 0.762094
0.005 3036.33 28.33 0.93
0.007 3167 52 1.641932
0.007 3005 37 1.231281
0.007 3003 32 1.065601
0.007 3058.33 40.33 1.31
0.009 3029 67 2.211951
0.009 3038 26 0.855826
0.009 3018 27 0.894632
0.009 3028.33 40.00 1.32
0.01 3075 49 1.593496
0.01 3001 37 1.232922
0.01 3008 18 0.598404
0.01 3028.00 34.67 1.14
0.02 3150 53 1.68254
0.02 3138 34 1.083493
0.02 3044 33 1.0841
0.02 3110.67 40.00 1.28
0.03 3053 55 1.801507
0.03 3087 46 1.49012
0.03 3015 56 1.85738
0.03 3051.67 52.33 1.72
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Table A . l l :  Results from 4NQO in TK6 cells (CBMN assay: 24+18h; automated data)
4NQO (pg/ml) Bi MnBn °/c MnBn
0 4231 27 0.638147
0 4219 37 0.876985
0 4213 26 0.617137
0 4221.00 30.00 0.71
0.0005 4214 26 0.616991
0.0005 4215 33 0.782918
0.0005 4215 29 0.688019
0.0005 4214.67 29.33 0.70
0.0007 4215 24 0.569395
0.0007 4226 39 0.922858
0.0007 4204 29 0.689819
0.0007 4215.00 30.67 0.73
0.0009 4198 18 0.428776
0.0009 4221 34 0.805496
0.0009 4208 24 0.570342
0.0009 4209.00 25.33 0.60
0.001 4212 25 0.593542
0.001 4207 39 0.927026
0.001 4210 24 0.570071
0.001 4209.67 29.33 0.70
0.003 4192 24 0.572519
0.003 4202 40 0.951928
0.003 4208 28 0.665399
0.003 4200.67 30.67 0.73
0.005 4198 18 0.428776
0.005 4204 36 0.856327
0.005 4211 31 0.736167
0.005 4204.33 28.33 0.67
0.007 4212 20 0.474834
0.007 4220 40 0.947867
0.007 4214 40 0.949217
0.007 4215.33 33.33 0.79
0.009 4228 27 0.6386
0.009 4207 48 1.140956
0.009 4213 33 0.78329
0.009 4216.00 36.00 0.85
0.01 4202 24 0.571157
0.01 4226 72 1.703739
0.01 4196 37 0.881792
0.01 4208.00 44.33 1.05
0.02 4226 30 0.709891
0.02 4212 72 1.709402
0.02 4203 94 2.236498
0.02 4213.67 65.33 1.55
0.03 4208 63 1.497148
0.03 4221 52 1.231936
0.03 4202 61 1.45169
0.03 4210.33 58.67 1.39
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Table A.12: Results from 4NQO in TK6 cells (CBMN assay: 48+18h; automated data)
4NQO (|jg/ml) Bi MnBn % MnBn
0 4204 22 0.523311
0 4220 40 0.947867
0 4206 37 0.879696
0 4210.00 33.00 0.78
0.0005 4204 24 0.570885
0.0005 4032 38 0.94246
0.0005 4209 30 0.712758
0.0005 4148.33 30.67 0.74
0.0007 4216 22 0.521822
0.0007 4213 29 0.688346
0.0007 4217 23 0.545411
0.0007 4215.33 24.67 0.59
0.0009 4198 23 0.54788
0.0009 4203 34 0.808946
0.0009 4207 34 0.808177
0.0009 4202.67 30.33 0.72
0.001 4200 20 0.47619
0.001 4217 33 0.782547
0.001 4213 35 0.830762
0.001 4210.00 29.33 0.70
0.003 4219 24 0.568855
0.003 4201 26 0.6189
0.003 4209 27 0.641483
0.003 4209.67 25.67 0.61
0.005 4216 24 0.56926
0.005 4208 17 0.403992
0.005 4227 31 0.733381
0.005 4217.00 24.00 0.57
0.007 4193 21 0.500835
0.007 4215 26 0.616845
0.007 4217 35 0.829974
0.007 4208.33 27.33 0.65
0.009 4198 20 0.476417
0.009 4223 45 1.065593
0.009 4218 37 0.877193
0.009 4213.00 34.00 0.81
0.01 4228 33 0.780511
0.01 4210 31 0.736342
0.01 4212 46 1.092118
0.01 4216.67 36.67 0.87
0.02 4213 21 0.498457
0.02 4218 33 0.782361
0.02 4217 26 0.616552
0.02 4216.00 26.67 0.63
0.03 4203 38 0.904116
0.03 4213 34 0.807026
0.03 4202 58 1.380295
0.03 4206.00 43.33 1.03
224
T able A.13: Results from 4NQO in TK6 cells (CBMN assay: 4+42h; automated data)
4NQO ((j g/ml Bi MnBn % MnBn
0 4220 37 0.876777
0 4213 29 0.688346
0 4228 50 1.182592
0 4220.33 38.67 0.92
0.001 4219 26 0.61626
0.001 4204 26 0.618459
0.001 4218 48 1.13798
0.001 4213.67 33.33 0.79
0.003 4208 26 0.617871
0.003 4194 33 0.786838
0.003 4216 48 1.13852
0.003 4206.00 35.67 0.85
0.01 4210 38 0.902613
0.01 4215 48 1.13879
0.01 4209 29 0.689
0.01 421 1.33 38.33 0.91
0.03 4209 64 1.520551
0.03 4217 57 1.351672
0.03 4212 71 1.68566
0.03 4212.67 64.00 1.52
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Table A.14: Results from 4NQO in AHH-1 cells (CBMN assay: 4+22h; automated data)
4NQO (|jg/ml) Bi MnBn % MnBn
0 4214 36 0.854295
0 4213 31 0.735818
0 8429 81 0.960968
0 5618.67 49.33 0.85
0.003 4217 28 0.663979
0.003 4215 34 0.806643
0.003 8419 86 1.021499
0.003 5617.00 49.33 0.83
0.007 4218 38 0.900901
0.007 4214 32 0.759374
0.007 4212 17 0.403609
0.007 4214.67 29.00 0.69
0.01 4206 34 0.808369
0.01 4216 38 0.901328
0.01 4197 32 0.762449
0.01 4206.33 34.67 0.82
0.03 4244 47 1.107446
0.03 4216 22 0.521822
0.03 4199 24 0.571565
0.03 4219.67 31.00 0.73
0.07 4207 45 1.069646
0.07 4214 28 0.664452
0.07 4199 28 0.666825
0.07 4206.67 33.67 0.80
0.1 4224 27 0.639205
0.1 4212 52 1.234568
0.1 4222 40 0.947418
0.1 4219.33 39.67 0.94
0.3 4213 62 1.471635
0.3 3455 49 1.418234
0.3 4206 55 1.307656
0.3 3958.00 55.33 1.40
0.7 4078 35 0.858264
0.7 1470 17 1.156463
0.7 4205 58 1.37931
0.7 3251.00 36.67 1.13
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T able A.15: Results from 4NQO in MCL-5 cells (CBMN assay: 4+22h; automated data)
4NQO (jag/ml) Bi MnBn % MnBn
0 4148 34 0.819672
0 4204 37 0.880114
0 4209 58 1.378
0 4187.00 43.00 1.03
0.003 4201 29 0.690312
0.003 4209 30 0.712758
0.003 4217 51 1.209391
0.003 4209.00 36.67 0.87
0.007 4195 56 1.334923
0.007 4216 29 0.687856
0.007 4221 55 1.303009
0.007 4210.67 46.67 1.11
0.01 4018 41 1.020408
0.01 4203 35 0.832739
0.01 4207 54 1.283575
0.01 4142.67 43.33 1.05
0.03 4202 67 1.594479
0.03 4209 51 1.21 1689
0.03 4205 41 0.97503
0.03 4205.33 53.00 1.26
0.07 4207 59 1.402425
0.07 3864 28 0.724638
0.07 4207 58 1.378655
0.07 4092.67 48.33 1.17
0.1 4213 51 1.210539
0.1 3908 45 1.151484
0.1 4203 72 1.713062
0.1 4108.00 56.00 1.36
0.3 4778 70 1.465048
0.3 3276 34 1.037851
0.3 3981 84 2.110023
0.3 4011.67 62.67 1.54
0.7 2866 34 1.186322
0.7 3489 14 0.401261
0.7 3348 54 1.612903
0.7 3234.33 34.00 1.07
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T able A.16: Results from 4NQO in AHH-1 cells (CBMN assay: 4+46h; automated data)
4NQO (|jg/ml) Bi MnBn % MnBn
0 4207 41 0.974566
0 4213 29 0.688346
0 4237 39 0.920463
0 4219.00 36.33 0.86
0.003 4212 47 1.1 15859
0.003 4199 28 0.666825
0.003 4204 24 0.570885
0.003 4205.00 33.00 0.78
0.03 4220 45 1.066351
0.03 4208 50 1.188213
0.03 4218 67 1.588431
0.03 4215.33 54.00 1.28
0.1 4200 102 2.428571
0.1 4206 65 1.54541 1
0.1 4224 85 2.01231 1
0.1 4210.00 84.00 2.00
0.3 4464 59 1.321685
0.3 6316 96 1.519949
0.3 3951 100 2.531005
0.3 4910.33 85.00 1.79
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Table A.17: Results from 4NQO in MCL-5 cells (CBMN assay: 4+46h; automated data)
4NQO (jjg/ml) Bi MnBn % MnBn
0 4207 34 0.808177
0 4211 43 1.021135
0 3914 29 0.74093
0 4110.67 35.33 0.86
0.003 4210 45 1.068884
0.003 4213 52 1.234275
0.003 4197 43 1.024541
0.003 4206.67 46.67 1.1 1
0.03 4213 52 1.234275
0.03 4215 30 0.711744
0.03 4195 61 1.454112
0.03 4207.67 47.67 1.13
0.1 4224 57 1.349432
0.1 4214 47 1.11533
0.1 4209 84 1.995723
0.1 4215.67 62.67 1.49
0.3 3731 72 1.929778
0.3 4202 106 2.522608
0.3 2565 63 2.45614
0.3 3499.33 80.33 2.30
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Table A.19: Results from 4NQO in TK6 cells (MonoMn assay (AZ): 24+24h; automated
data)
4NQO (jjg/ml) Mono MonoMn %MonoMn
0 1649 8 0.4851425
0 2263 12 0.5302696
0 1956.00 10.00 0.51
0.0025 2322 1 1 0.4737295
0.0025 2315 12 0.5183585
0.0025 2318.50 11.50 0.50
0.005 2309 14 0.6063231
0.005 2372 10 0.4215852
0.005 2340.50 12.00 0.51271 1
0.0075 2373 12 0.505689
0.0075 2374 13 0.547599
0.0075 2373.50 12.50 0.53
0.01 2129 15 0.7045561
0.01 2274 15 0.6596306
0.01 2201.50 15.00 0.68
0.015 2325 17 0.731 1828
0.015 2093 13 0.62 HI 8
0.015 2209.00 15.00 0.68
0.02 2249 12 0.5335705
0.02 2378 24 1.0092515
0.02 2313.50 18.00 0.77
0.03 2337 19 0.8130081
0.03 2317 16 0.6905481
0.03 2327.00 17.50 0.75
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T able A.21: Results from 4NQO in TK6 cells (MonoMn assay (AZ): 4+40h; automated data)
4NQO (|jg/ml) Mono MonoMn %MonoMn
0 1697 9 0.53034767
0 2374 15 0.63184499
0 2035.50 12.00 0.58
0.0025 2375 18 0.75789474
0.0025 2255 16 0.70953437
0.0025 2315.00 17.00 0.73
0.005 2308 23 0.9965338
0.005 2170 17 0.78341014
0.005 2239.00 20.00 0.89325592
0.0075 2397 19 0.79265749
0.0075 2321 9 0.38776389
0.0075 2359.00 14.00 0.59
0.01 2395 20 0.83507307
0.01 2316 14 0.6044905
0.01 2355.50 17.00 0.72
0.015 1972 13 0.65922921
0.015 2390 18 0.75313808
0.015 2181.00 15.50 0.71
0.02 2327 24 1.03137086
0.02 2320 29 1.25
0.02 2323.50 26.50 1.14
0.03 2294 24 1.0462075
0.03 2288 27 1.18006993
0.03 2291.00 25.50 1.11
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Table A.23: Results from 4NQO in L5178Y cells (MonoMn assay (AZ): 4+24h; automated
data)
4NQO (|jg/ml) Mono MonoMn %MonoMn
0 2339 4 0.171013
0 2350 5 0.212766
0 2344.50 4.50 0.19
0.005 2305 8 0.347072
0.005 2192 7 0.319343
0.005 2248.50 7.50 0.33
0.0075 2243 10 0.445831
0.0075 2290 9 0.393013
0.0075 2266.50 9.50 0.419148
0.01 2362 11 0.465707
0.01 2340 9 0.384615
0.01 2351.00 10.00 0.43
0.02 2349 15 0.63857
0.02 2282 16 0.701139
0.02 2315.50 15.50 0.67
0.03 2267 29 1.279224
0.03 2276 22 0.966608
0.03 2271.50 25.50 1.12
0.04 2291 35 1.527717
0.04 2221 30 1.350743
0.04 2256.00 32.50 1.44
0.05 2233 45 2.015226
0.05 2324 37 1.592083
0.05 2278.50 41.00 1.80
235
Table A.24: Results from araC in TK6 cells (CBMN assay: 24+18h; automated data)
araC (|ag/ml) Bi MnBN %MnBn
0 4218 38 0.900901
0 4218 32 0.758653
0 4208 24 0.570342
0 4214.67 31.33 0.74
0.0001 4210 33 0.783848
0.0001 4219 46 1.090306
0.0001 4206 12 0.285307
0.0001 4211.67 30.33 0.72
0.0003 4214 29 0.688182
0.0003 4226 28 0.662565
0.0003 4233 23 0.54335
0.0003 4224.33 26.67 0.63
0.0005 4203 25 0.594813
0.0005 4210 47 1.11639
0.0005 4199 24 0.571565
0.0005 4204.00 32.00 0.76
0.0007 4214 40 0.949217
0.0007 4208 42 0.998099
0.0007 4199 31 0.738271
0.0007 4207.00 37.67 0.90
0.0009 4199 30 0.714456
0.0009 4204 34 0.808754
0.0009 4195 26 0.619785
0.0009 4199.33 30.00 0.71
0.001 4219 32 0.758474
0.001 4200 36 0.857143
0.001 4212 20 0.474834
0.001 4210.33 29.33 0.70
0.003 4218 23 0.545282
0.003 4217 53 1.256818
0.003 4209 17 0.403896
0.003 4214.67 31.00 0.74
0.005 4223 35 0.828795
0.005 4222 43 1.018475
0.005 4224 30 0.710227
0.005 4223.00 36.00 0.85
0.007 4230 57 1.347518
0.007 4074 60 1.472754
0.007 4221 29 0.687041
0.007 4175.00 48.67 1.17
0.009 4202 42 0.999524
0.009 4155 58 1.395909
0.009 421 1 30 0.71242
0.009 4189.333 43.33 1.04
0.01 4222 43 1.018475
0.01 4217 72 1.707375
0.01 4225 52 1.230769
0.01 4221.33 55.67 1.32
0.03 4202 96 2.284626
0.03 4211 139 3.300879
0.03 4200 95 2.261905
0.03 4204.33 110.00 2.62
0.07 4207 102 2.424531
0.07 4235 182 4.297521
0.07 421 1 132 3.134647
0.07 4217.67 138.67 3.29
0.1 4155 105 2.527076
0.1 2468 92 3.727715
0.1 4032 118 2.926587
0.1 3551.67 105.00 3.06
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Table A.25: Results from araC in TK6 cells (CBMN assay: 48+18h; automated data)
araC
( M g / m l ) Bi MnBN %MnBn
0 4220 25 0.592417
0 4207 35 0.831947
0 4212 26 0.617284
0 4213.00 28.67 0.68
0.0001 4211 27 0.641178
0.0001 4217 19 0.450557
0.0001 4213 22 0.522193
0.0001 4213.67 22.67 0.54
0.0003 4222 22 0.52108
0.0003 4200 31 0.738095
0.0003 4203 26 0.618606
0.0003 4208.33 26.33 0.63
0.0005 4215 24 0.569395
0.0005 4021 9 0.223825
0.0005 4213 13 0.308569
0.0005 4149.67 15.33 0.37
0.0007 4209 18 0.427655
0.0007 4170 16 0.383693
0.0007 4222 31 0.734249
0.0007 4200.33 21.67 0.52
0.0009 4224 19 0.44981 1
0.0009 4201 26 0.6189
0.0009 4212 30 0.712251
0.0009 4212.33 25.00 0.59
0.001 4202 22 0.52356
0.001 4212 31 0.735992
0.001 4226 32 0.757217
0.001 4213.33 28.33 0.67
0.003 4204 26 0.618459
0.003 4211 37 0.878651
0.003 4189 26 0.620673
0.003 4201.33 29.67 0.71
0.005 4217 32 0.758833
0.005 4221 34 0.805496
0.005 4223 46 1.089273
0.005 4220.33 37.33 0.88
0.007 4222 25 0.592136
0.007 4212 35 0.830959
0.007 4215 44 1.043891
0.007 4216.33 34.67 0.82
0.009 3987 51 1.279157
0.009 3728 33 0.885193
0.009 4206 30 0.713267
0.009 3973.667 38 0.959206
0.01 4207 31 0.736867
0.01 4199 44 1.047869
0.01 4201 37 0.880743
0.01 4202.33 37.33 0.89
0.03 4218 61 1.446183
0.03 4173 71 1.701414
0.03 4196 73 1.739752
0.03 4195.67 68.33 1.63
0.07 4203 88 2.093743
0.07 3809 137 3.596745
0.07 4198 100 2.382087
0.07 4070.00 108.33 2.69
0.1 3459 103 2.977739
0.1 4568 199 4.356392
0.1 4070 95 2.334152
0.1 4032.33 132.33 3.22
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Table A.26: Results from araC in AHH-1 cells (CBMN assay: 24+22h; automated data)
araC
(Mg/ml) Bi MnBN %MnBn
0 8428 61 0.723778
0 8422 63 0.748041
0 8425 56 0.664688
0 8425.00 60.00 0.71
0.0001 4205 41 0.97503
0.0001 4214 41 0.972947
0.0001 4195 19 0.45292
0.0001 4204.67 33.67 0.80
0.0003 4220 40 0.947867
0.0003 4224 38 0.899621
0.0003 4195 25 0.595948
0.0003 4213.00 34.33 0.81
0.0005 4220 30 0.7109
0.0005 4220 28 0.663507
0.0005 4208 17 0.403992
0.0005 4216.00 25.00 0.59
0.0007 4218 27 0.640114
0.0007 4208 34 0.807985
0.0007 4198 20 0.476417
0.0007 4208.00 27,00 0.64
0.0009 4200 24 0.571429
0.0009 4211 39 0.926146
0.0009 4204 31 0.737393
0.0009 4205.00 31.33 0.74
0.001 4212 30 0.712251
0.001 4219 31 0.734771
0.001 4208 23 0.546578
0.001 4213.00 28.00 0.66
0.003 4208 31 0.736692
0.003 4219 26 0.61626
0.003 4192 24 0.572519
0.003 4206.33 27.00 0.64
0.005 4204 22 0.523311
0.005 4238 25 0.589901
0.005 4207 40 0.950796
0.005 4216.33 29.00 0.69
0.007 4209 33 0.784034
0.007 4218 26 0.616406
0.007 4196 29 0.691134
0.007 4207.67 29.33 0.70
0.009 41 19 23 0.558388
0.009 4219 32 0.758474
0.009 4202 24 0.571157
0.009 4180 26.33333 0.629339
0.01 4211 37 0.87865 1
0.01 4204 26 0.618459
0.01 4197 21 0.500357
0.01 4204.00 28.00 0.67
0.03 4214 44 1.044139
0.03 4216 49 1.162239
0.03 4210 24 0.570071
0.03 4213.33 39.00 0.93
0.07 41 13 99 2.407002
0.07 4218 45 1.066856
0.07 4207 43 1.022106
0.07 4179.33 62.33 1.50
0.1 4212 93 2.207977
0.1 421 1 67 1.591071
0.1 421 1 34 0.807409
0.1 421 1.33 64.67 1.54
0.12 4230 85 2.009456
0.12 4068 60 1.474926
0.12 4123 92 2.231385
0.12 4140.33 79.00 1.91
0.15 4218 61 1.446183
0.15 4116 99 2.405248
0.15 4266 91 2.133146
0.15 4200.00 83.67 1.99
0.2 2882 40 1.387925
0.2 5575 82 1.470852
0.2 4266 124 2.906704
0.2 4241.00 82.00 1.92
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Table A.27: Results from araC in MCL-5 cells (CBMN assay: 24+22h; automated data)
araC
(Mg/ml) Bi MnBN %MnBn
0 4224 40 0.94697
0 4198 33 0.786089
0 4208 28 0.665399
0 4210.00 33.67 0.80
0.0001 4221 33 0.781805
0.0001 4214 43 1.020408
0.0001 4219 31 0.734771
0.0001 4218.00 35.67 0.85
0.0003 4218 36 0.853485
0.0003 4200 44 1.047619
0.0003 4203 40 0.951701
0.0003 4207.00 40.00 0.95
0.0005 4207 34 0.808177
0.0005 4199 45 1.071684
0.0005 4202 44 1.04712
0.0005 4202.67 41.00 0.98
0.0007 4210 29 0.688836
0.0007 4197 34 0.810102
0.0007 4208 30 0.712928
0.0007 4205.00 31.00 0.74
0.0009 4227 29 0.686066
0.0009 4206 43 1.022349
0.0009 4217 24 0.569125
0.0009 4216.67 32.00 0.76
0.001 4203 38 0.9041 16
0.001 4204 40 0.951475
0.001 4201 27 0.642704
0.001 4202.67 35.00 0.83
0.003 4201 41 0.975958
0.003 4217 35 0.829974
0.003 4211 24 0.569936
0.003 4209.67 33.33 0.79
0.005 4200 38 0.904762
0.005 4204 48 1.14177
0.005 4214 37 0.878026
0.005 4206.00 41.00 0.97
0.007 4206 41 0.974798
0.007 4210 42 0.997625
0.007 4209 40 0.950344
0.007 4208.33 41.00 0.97
0.009 4197 42 1.000715
0.009 4202 47 1.118515
0.009 4216 30 0.711575
0.009 4205 39.66667 0.943602
0.01 4202 54 1.285102
0.01 4206 40 0.951022
0.01 4222 58 1.373757
0.01 4210.00 50.67 1.20
0.03 4203 68 1.617892
0.03 4204 80 1.90295
0.03 4205 106 2.520809
0.03 4204.00 84.67 2.01
0.07 4030 122 3.027295
0.07 4206 96 2.282454
0.07 4201 101 2.404189
0.07 4145.67 106.33 2.57
0.1 4209 151 3.58755
0.1 4195 83 1.978546
0.1 4097 132 3.22187
0.1 4167.00 122.00 2.93
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Table A.28: Results from MMC in NH32 cells (CBMN assay: 4+18h; automated data)
MMC
(Mg/ml) Bi MnBN %MnBn
0 4203 19 0.452058
0 4207 23 0.546708
0 4222 45 1.065846
0 4210.67 29.00 0.69
0.0006 4212 26 0.617284
0.0006 4212 19 0.451092
0.0006 4221 38 0.900261
0.0006 4215.00 27.67 0.66
0.0008 4327 24 0.554657
0.0008 4227 31 0.733381
0.0008 4214 19 0.450878
0.0008 4256.00 24.67 0.58
0.001 4213 18 0.427249
0.001 4200 31 0.738095
0.001 4214 32 0.759374
0.001 4209.00 27.00 0.64
0.002 4193 25 0.596232
0.002 4216 31 0.735294
0.002 4219 19 0.450344
0.002 4209.33 25.00 0.59
0.004 4178 20 0.478698
0.004 4205 32 0.760999
0.004 4244 30 0.70688
0.004 4209.00 27.33 0.65
0.008 4278 27 0.631136
0.008 4217 43 1.019682
0.008 4217 36 0.853687
0.008 4237.33 35.33 0.83
0.01 4157 20 0.481116
0.01 4203 29 0.689983
0.01 4200 20 0.47619
0.01 4186.67 23.00 0.55
0.02 4134 60 1.451379
0.02 4205 50 1.189061
0.02 4234 38 0.897496
0.02 4191.00 49.33 1.18
0.04 4124 50 1.212415
0.04 4222 58 1.373757
0.04 4222 60 1.421127
0.04 4189.33 56.00 1.34
0.06 4374 71 1.623228
0.06 4210 26 0.617577
0.06 4221 40 0.947643
0.06 4268.333 45.66667 1.062816
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Table A.29: Results from araC in NH32 cells (CBMN assay: 24+18h; automated data)
araC
( M g / m l ) Bi MnBN %MnBn
0 4219 35 0.82958
0 4216 34 0.806452
0 4223 37 0.876154
0 4219.33 35.33 0.84
0.0005 4207 47 1.1 17186
0.0005 4228 34 0.804163
0.0005 4215 47 1.115065
0.0005 4216.67 42.67 1.01
0.0007 4204 41 0.975262
0.0007 4225 54 1.278107
0.0007 4231 55 1.299929
0.0007 4220.00 50.00 1.18
0.0009 4220 37 0.876777
0.0009 4219 50 1.185115
0.0009 4225 46 1.088757
0.0009 4221.33 44.33 1.05
0.001 4209 50 1.187931
0.001 4210 60 1.425178
0.001 4212 46 1.0921 18
. 0.001 4210.33 52.00 1.24
0.003 4207 53 1 .259805
0.003 4228 65 1.53737
0.003 4223 65 1.53919
0.003 4219.33 61.00 1.45
0.005 4212 95 2.255461
0.005 4222 91 2.155377
0.005 4212 84 1.994302
0.005 4215.33 90.00 2.14
0.007 4294 132 3.074057
0.007 4216 108 2.56167
0.007 4215 96 2.27758
0.007 4241.67 112.00 2.64
0.009 4169 147 3.526025
0.009 4207 148 3.517946
0.009 4215 149 3.534994
0.009 4197.00 148.00 3.53
0.01 4215 168 3.985765
0.01 4222 151 3.576504
0.01 4214 153 3.630755
0.01 4217.00 157.33 3.73
0.03 4200 224 5.333333
0.03 4171 176 4.219612
0.03 4096 175 4.272461
0.03 4155.667 191.6667 4.608469
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Appendix II
HPRT assay raw data table
Table A.30: HPRT assay data set for TK6 cells treated with 4NQO for 24h
4NQO (|jg/ml) MF PE
H 20 75 84.40
H 20 136 48.34
H 20 33 130.93
H 20 81.33 87.89
DMSO 109 138.63
DMSO 171 29.66
DMSO 171 59.18
DMSO 150.33 75.82
0.0009 185 103.10
0.0009 122 88.35
0.0009 124 73.40
0.0009 143.67 88.28
0.003 103 120.40
0.003 364 42.57
0.003 234 71.33
0.003 233.67 78.10
0.01 386 94.16
0.01 944 18.63
0.01 558 80.59
0.01 629.33 64.46
0.02 871 55.05
0.02 1081 17.83
0.02 337 137.30
0.02 976.00 36.44
Terminology for data table: 
MF -  Mutation frequency *10~6 
PE -  Plate effiency
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Appendix III
Comet assay raw data table
Table A.31: Comet assay data for TK6 cells treated with 4NQO for 3h (AZ)
4NQO (fjg/ml) %TI %TI
-hOGGl +hOGG 1
0 1.711076 1.37494
0 0.92976 0.916257
0 1.320418 1.145599
0.007 2.367384 4.050035
0.007 0.72723 1.71772
0.007 1.547307 2.883877
0.009 4.464567 3.76769
0.009 1.512453 1.314716
0.009 2.98851 2.541203
0.02 1.631675 2.151925
0.02 1.066499 1.55795
0.02 1.349087 1.854937
0.04 5.442586 5.535046
0.04 4.091848 2.951205
0.04 4.767217 4.243126
0.06 6.757332 8.284068
0.06 7.584607 10.01188
0.06 7.17097 9.147972
Terminology for data table: 
%TI -  % Tail intensity
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Appendix IV
Pan centromeric staining raw data tables
Terminology for data table:
MN- -  Micronuclei without staining (clastogenic)
%Mn- -  Frequency of micronuclei without staining (clastogenic) 
MN+ -  Micronuclei with staining (aneugenic)
%Mn+ -  Frequency of micronuclei with staining (aneugenic) 
Total -  Total number of micronuclei scored
Table A.32: Results from MMC in TK6 cells (Pan centromeric staining: 4+18h)
MMC (jjg/ml) MN - MN + Total % MN - % MN +
0 30 21 51 58.82353 41.17647
0 27 25 52 51.92308 48.07692
0 28.50 23.00 51.50 55.37 44.63
0.002 38 21 59 64.40678 35.59322
0.002 28 22 50 56 44
0.002 33.00 21.50 54.50 60.20 39.80
0.004 34 19 53 64.15094 35.84906
0.004 26 24 50 52 48
0.004 30.00 21.50 51.50 58.08 41.92
0.006 23 12 35 65.71429 34.28571
0.006 27 26 53 50.9434 49.0566
0.006 25.00 19.00 44.00 58.33 41.67
0.008 48 14 62 77.41935 22.58065
0.008 28 21 49 57.14286 42.85714
0.008 38.00 17.50 55.50 67.28 32.72
0.01 45 8 53 84.90566 15.09434
0.01 33 24 57 57.89474 42.10526
0.01 39.00 16.00 55.00 71.40 28.60
0.02 38 14 52 73.07692 26.92308
0.02 37 16 53 69.81132 30.18868
0.02 37.50 15.00 52.50 71.44 28.56
0.04 42 1 1 53 79.24528 20.75472
0.04 41 10 51 80.39216 19.60784
0.04 41.50 10.50 52.00 79.82 20.18
0.06 46 7 53 86.79245 13.20755
0.06 36 13 49 73.46939 26.53061
0.06 41.00 10.00 51.00 80.13 19.87
0.08 49 11 60 81.66667 18.33333
0.08 39 11 50 78 22
0.08 44.00 11.00 55.00 79.83 20.17
0.1 45 9 54 83.33333 16.66667
0.1 37 12 49 75.5102 24.4898
0.1 41.00 10.50 51.50 79.42 20.58
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Table A.33: Results from 4NQO in TK6 cells (Pan centromeric staining: 24+18h)
4NQO ((jg/ml) MN - MN + Total % MN - % MN +
0 34 19 53 64.15094 35.84906
0 31 22 53 58.49057 41.50943
0 32.50 20.50 53.00 61.32 38.68
0.0007 34 17 51 66.66667 33.33333
0.0007 36 14 50 72 28
0.0007 35.00 15.50 50.50 69.33 30.67
0.001 39 11 50 78 22
0.001 31 19 50 62 38
0.001 35.00 15.00 50.00 70.00 30.00
0.005 37 14 51 72.54902 27.45098
0.005 35 16 51 68.62745 31.37255
0.005 36.00 15.00 51.00 70.59 29.41
0.009 37 13 50 74 26
0.009 38 13 51 74.5098 25.4902
0.009 37.50 13.00 50.50 74.25 25.75
0.02 47 10 57 82.45614 17.54386
0.02 43 7 50 86 14
0.02 45.00 8.50 53.50 84.23 15.77
0.03 42 10 52 80.76923 19.23077
0.03 40 12 52 76.92308 23.07692
0.03 41.00 1 1.00 52.00 78.85 21.15
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Table A.34: Results from araC in TK6 cells (Pan centromeric staining: 24+18h)
araC (pg/ml) MN - MN + Total % MN % MN +
0 32 20 52 61.53846 38.46154
30 20 50 60 40
0 31.00 20.00 51.00 60.77 39.23
0.0001 25 21 46 54.34783 45.65217
31 20 51 60.78431 39.21569
0.0001 28.00 20.50 48.50 57.57 42.43
0.0003 31 50 62 38
0.0003 35 15 50 70 30
0.0003 33.00 17.00 50.00 66.00 34.00
0.0005 30 20 50 60 40
0.0005 32 18 50 64 36
0.0005 31.00 19.00 50.00 62.00 38.00
0.0007 34 16 50 68 32
0.0007 35 16 51 68.62745 31.37255
0.0007 34.50 16.00 50.50 68.31 31.69
0.0009 32 19 51 62.745 1 37.2549
0.0009 28 23 51 54.90196 45.09804
0.0009 30.00 21.00 51.00 58.82 41.18
0.001 37 14 51 72.54902 27.45098
0.001 31 19 50 62 38
0.001 34.00 16.50 50.50 67.27 32.73
0.003 34 52 65.38462 34.61538
0.003 33 17 50 66 34
0.003 33.50 17.50 51.00 65.69 3 4 .3 1
0.005 38 1 2 50 76 24
0.005 36 14 50 72 28
0.005 37.00 13.00 50.00 74.00 26.00
0.007 34 17 51 66.66667 33.33333
0.007 34 52 65.38462 34.61538
0.007 34.00 17.50 51.50 66.03 33.97
0.009 45 14 59 76.271 19 23.7288:
0.009 36 15 51 70.58824 29.41176
0.009 40.50 14.50 55.00 73.43 26.57
0.01 46 15 61 75.40984 24.59016
0.01 37 13 50 74 26
0.01 41.50 14.00 55.50 74.70 25.30
0.03 40 16 56 71.42857 28.57143
0.03 38 12 50 76 24
0.03 39.00 14.00 53.00 73.71 26.29
0.07 36 15 51 70.58824 29.41176
0.07 33 17 50 66 34
0.07 34.50 16.00 50.50 68.29 31.71
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Appendix V
RT2 Profiler™ PCR Array (PAH-042)
The Human DNA Repair RT2 Profiler™ PCR Array profiles the expression of 84 key genes 
encoding the enzymes that repair damaged DNA (http://www.sabiosciences.com)
Array Layout
APEX1
A 01
APEX2
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A 03
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A 04
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A 05
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A 06
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Figure A.l: DNA Repair RT2 Profiler™ PCR Array Scatter Plot of TK6 cells treated with 
MMC for 2h. Normalized expression of every gene of the array was compared between the 
control group and treated group 1 A: 0.004pg/ml or group 2 B: 0.08pg/ml. Black dots: Genes 
with no changes in gene expression; red dots: Genes with up-regulation of gene expression; 
green dots: Genes with down-regulation in gene expression.
■  B R C A l ■  M SH6 ■  R A D 5 1C [ XRCC 3 ■  XRCC6BP1
Figure A.2: DNA Repair RT2 Profiler™ PCR Array Multigroup Plot of TK6 cells treated 
with MMC for 2h. Expression changes of a selected set of genes across the control group and 
the treated groups 1 (0.004pg/ml) and 2 (0.08pg/ml).
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Figure A.3: DNA Repair RT2 Profiler™ PCR Array Scatter Plot of TK6 cells treated with 
MMC for 24h. Normalized expression of every gene of the array was compared between the 
control group and treated group 1 A: 0.02pg/ml. Black dots: Genes with no changes in gene 
expression; red dots: Genes with up-regulation of gene expression; green dots: Genes with 
down-regulation in gene expression.
■  B R C A l ■  MSH6 ■  RAD5 1C XRCC3 ■  XR CC 6B P1
Figure A.4: DNA Repair RT2 Profiler™ PCR Array Multigroup Plot of TK6 cells treated 
with MMC for 24h. Expression changes of a selected set of genes across the control group 
and the treated group 1 (0.02pg/ml).
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Appendix VI
Real-time PCR raw data
Table A.35: Cx-values of XRCC3 gene expression, following exposure (4h) with increasing 
concentrations of MMC in TK6 cells
Cj-values
Replicate 1 Replicate 2 Replicate 3
beta-actin XRCC3 beta-actin XRCC3 beta-actin XRCC3
Standard 14.98 26.71 14.02 26.70 7.77 24.17
Standard 14.98 26.34 13.97 26.33 7.57 24.04
Standard 15.32 26.75 14.36 26.75 7.63
Standard (10-1) 19.40 30.76 18.43 30.75 12.04 26.69
Standard (10-1) 17.58 29.72 16.65 29.71 11.85 26.63
Standard (10-1)
Standard (10-2) 21.61 33.42 20.66 33.41 16.17 30.10
Standard (10-2) 21.55 34.25 20.59 34.24 15.44 29.94
Standard (10-2) 21.47 32.69 20.48 32.68
Standard (10-3) 25.12 36.33 24.13 36.32 20.11 32.69
Standard (10-3) 24.87 36.56 23.87 36.55 19.86 32.83
Standard (10-3) 24.70 36.97 23.72 36.97 19.52
Opg/ml 15.91 24.66 12.58 23.99 7.55 23.68
Ojig/ml 15.82 25.09 12.47 24.14 7.61 23.70
Opg/ml 15.76 25.81 12.44 24.21 7.78 23.79
0.004jjg/ml 15.47 25.45 12.53 23.30 8.69 23.58
0.004pg/ml 15.32 25.38 12.90 23.28 7.56 23.52
0.004|jg/ml 15.61 25.67 13.16 23.46 7.85 23.42
0.008pg/ml 15.71 25.15 13.70 24.75 8.78 23.79
0.008pg/ml 15.18 25.09 13.43 24.67 7.79 23.72
0.008pg/ml 15.45 25.37 13.78 24.79 7.80 23.98
0.02|ig/ml 14.19 24.79 12.81 24.76 7.55 22.11
0.02|ig/ml 14.11 24.69 13.22 24.91 7.87 21.76
0.02|jg/ml 14.55 24.70 13.30 24.92 7.63 22.48
0.04iig/ml 14.55 25.47 13.12 24.68 7.83 23.82
0.04pg/ml 14.45 25.31 12.94 24.60 7.66 23.67
0.04pg/ml 14.56 25.51 12.97 24.58 8.47 23.84
0.08pg/ml 14.11 23.94 13.72 23.39 7.81 24.22
0.08jig/ml 14.21 24.08 13.23 23.70 7.60 24.10
0.08|ig/ml 14.53 23.97 13.33 23.86 7.78 24.43
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Table A.36: Relative fold changes in XRCC3 gene expression, following exposure (4h) with
increasing concentrations of MMC in TK6 cells
Replicate 1 SQ mean
MMC (pg/ml) Beta actin XRCC3 Normalization Fold change
0 6.05E-01 3.01E+00 4.98E+00 1
0.004 7.83E-01 2.31E+00 2.95E+00 0.59225993
0.008 8.03E-01 2.84E+00 3.53E+00 0.70941145
0.02 1.82E+00 3.93E+00 2.16E+00 0.43311328
0.04 1.53E+00 2.42E+00 1.58E+00 0.3171478
0.08 1.82E+00 6.52E+00 3.57E+00 0.71696133
Replicate 2 SQ mean
MMC (Mg/ml) Beta actin XRCC3 Normalization Fold change
0 3.260579 5.97233 1.831677781 1
0.004 2.551601 10.15145 3.978463888 2.172032619
0.008 1.45473 3.881497 2.668189662 1.456691614
0.02 2.130362 3.555878 1.669142557 0.911264293
0.04 2.259236 4.210245 1.863569712 1.017411322
0.08 1.696445 8.294559 4.889375902 2.669342803
Replicate 3 SQ mean
MMC (pg/ml) Beta actin XRCC3 Normalization Fold change
0 1.05E+00 1.23E+00 1.18E+00 1
0.004 8.71E-01 1.46E+00 1.68E+00 1.4289034
0.008 8.25E-01 1.14E+00 1.38E+00 1.1718763
0.02 1.03E+00 4.46E+00 4.33E+00 3.6853925
0.04 8.81E-01 1.19E+00 1.35E+00 1.1453629
0.08 1.00E+00 8.19E-01 8.17E-01 0.6953486
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Table A.37: Ct-values of Rad51C gene expression, following exposure (4h) with increasing
concentrations of MMC in TK6 cells
CT-values
Replicate 1 Replicate 2 Replicate 3
beta-actin XRCC3 beta-actin XRCC3 beta-actin XRCC3
Standard 14.98 26.71 14.02 26.70 7.77 24.17
Standard 14.98 26.34 13.97 26.33 7.57 24.04
Standard 15.32 26.75 14.36 26.75 7.63
Standard (10-1) 19.40 30.76 18.43 30.75 12.04 26.69
Standard (10-1) 17.58 29.72 16.65 29.71 11.85 26.63
Standard (10-1)
Standard (10-2) 21.61 33.42 20.66 33.41 16.17 30.10
Standard (10-2) 21.55 34.25 20.59 34.24 15.44 29.94
Standard (10-2) 21.47 32.69 20.48 32.68
Standard (10-3) 25.12 36.33 24.13 36.32 20.11 32.69
Standard (10-3) 24.87 36.56 23.87 36.55 19.86 32.83
Standard (10-3) 24.70 36.97 23.72 36.97 19.52
Opg/ml 15.91 24.66 12.58 23.99 7.55 23.68
0|ig/ml 15.82 25.09 12.47 24.14 7.61 23.70
0|ig/ml 15.76 25.81 12.44 24.21 7.78 23.79
0.004|jg/ml 15.47 25.45 12.53 23.30 8.69 23.58
0.004pg/ml 15.32 25.38 12.90 23.28 7.56 23.52
0.004|jg/ml 15.61 25.67 13.16 23.46 7.85 23.42
0.008pg/ml 15.71 25.15 13.70 24.75 8.78 23.79
0.008|ig/ml 15.18 25.09 13.43 24.67 7.79 23.72
0.008|ig/ml 15.45 25.37 13.78 24.79 7.80 23.98
0.02|jg/ml 14.19 24.79 12.81 24.76 7.55 22.11
0.02|jg/ml 14.11 24.69 13.22 24.91 7.87 21.76
0.02|jg/ml 14.55 24.70 13.30 24.92 7.63 22.48
0.04pg/ml 14.55 25.47 13.12 24.68 7.83 23.82
0.04pg/ml 14.45 25.31 12.94 24.60 7.66 23.67
0.04|ig/ml 14.56 25.51 12.97 24.58 8.47 23.84
0.08pg/ml 14.11 23.94 13.72 23.39 7.81 24.22
0.08pg/ml 14.21 24.08 13.23 23.70 7.60 24.10
0.08pg/ml 14.53 23.97 13.33 23.86 7.78 24.43
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Table A.38: Relative fold changes in Rad51C gene expression, following exposure (4h) with
increasing concentrations of MMC in TK6 cells
Replicate 1 SQ mean
MMC (pg/ml) Beta actin Rad51C Normalization Fold change
0 7.39E-01 7.59E-01 1.03E+00 1
0.004 5.22E-01 2.35E-01 4.51E-01 0.4392208
0.008 1.10E+00 7.83E-01 7.13E-01 0.6943003
0.02 1.18E+00 7.57E-01 6.39E-01 0.6218035
0.04 9.24E-01 6.74E-01 7.30E-01 0.7099223
0.08 1.52E+00 9.20E-01 6.05E-01 0.5886604
Replicate 2 SQ mean
MMC (pg/ml) Beta actin Rad51C Normalization Fold change
0 3.01E+00 1.10E+00 3.67E-01 1
0.004 2.03E+00 8.30E-01 4.09E-01 1.11560277
0.008 1.30E+00 7.48E-01 5.77E-01 1.57415662
0.02 2.10E+00 1.22E+00 5.82E-01 1.58684942
0.04 2.23E+00 9.66E-01 4.34E-01 1.18287783
0.08 1.61E+00 8.49E-01 5.28E-01 1.44091701
Replicate 3 SQ mean
MMC (pg/ml) Beta actin Rad51C Normalization Fold change
0 1.05E+00 1.39E+00 1.32E+00 1
0.004 8.71E-01 1.27E+00 1.45E+00 1.09811002
0.008 8.25E-01 1.37E+00 1.66E+00 1.25568453
0.02 1.03E+00 1.26E+00 1.22E+00 0.92140745
0.04 8.81E-01 1.12E+00 1.27E+00 0.96178885
0.08 1.00E+00 1.52E+00 1.52E+00 1.15028963
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Table A.39: C t - values of MSH6 gene expression, following exposure (4h) with increasing
concentrations of MMC in TK6 cells
Cj-values
Replicate 1 Replicate 2 Replicate 3
beta-actin MSH6 beta-actin MSH6 beta-actin MSH6
Standard 14.58 20.08 12.18 23.65 11.20 18.81
Standard 14.36 19.88 11.96 23.47 11.43 18.62
Standard 14.61 19.93 12.42 23.50 11.72 18.77
Standard (10-1) 19.13 25.03 15.95 27.57 14.93 22.28
Standard (10-1) 18.99 24.77 15.56 27.04 14.60 22.19
Standard (10-1) 18.36 24.46 14.26 21.72
Standard (10-2) 22.32 29.36 18.84 30.72 17.99 26.01
Standard (10-2) 21.99 28.64 18.61 30.57 17.99 25.71
Standard (10-2) 21.91 27.63 18.61 30.44 17.66
Standard (10-3) 25.97 32.35 22.07 34.01 21.90 29.45
Standard (10-3) 25.70 32.67 21.91 34.43 21.38 29.40
Standard (10-3) 24.71 31.83 21.76 33.88 21.00 28.39
0|ig/ml 13.49 19.05 12.92 24.14 11.68 18.39
0|jg/ml 13.76 19.16 12.19 23.88 11.36 18.31
Opg/ml 13.89 19.68 12.76 24.46 11.47 18.88
0.004|ig/ml 13.11 19.16 12.75 24.42 11.16 18.58
0.004pg/ml 13.39 18.88 12.83 24.00 10.96 18.64
0.004|jg/ml 13.73 19.32 12.60 24.56 11.09 18.77
0.008pg/ml 14.29 19.17 13.69 24.49 11.21 18.35
0.008jjg/ml 14.10 18.96 13.54 24.25 10.89 18.24
0.008gg/ml 14.20 19.39 12.91 24.53 11.17 18.70
0.02|ig/ml 14.03 19.24 13.55 24.19 11.27 18.80
0.02pg/ml 13.81 19.18 12.70 24.13 11.52 18.34
0.02|ig/ml 14.45 19.53 12.97 24.14 11.50 18.80
0.04pg/ml 14.66 19.63 12.65 24.67 11.20 18.71
0.04pg/ml 14.22 19.28 12.23 24.64 11.20 18.56
0.04|ig/ml 14.84 19.91 12.99 24.67 11.86 18.73
0.08pg/ml 14.12 19.26 13.15 25.04 11.42 18.68
0.08jjg/ml 15.11 19.49 13.16 24.85 11.32 18.69
0.08|ig/ml 15.47 19.64 13.76 24.98 11.65 18.94
255
Table A.40: Relative fold changes in MSH6 gene expression, following exposure (4h) with
increasing concentrations of MMC in TK6 cells
Replicate 1 SQ mean
MMC (pg/ml) Beta actin MSH6 Normalization Fold change
0 2.02E+00 1.76E+00 8.68E-01 1
0.004 2.47E+00 1.93E+00 7.81E-01 0.89940381
0.008 1.48E+00 1.87E+00 1.26E+00 1.45534746
0.02 1.59E+00 1.72E+00 1.08E+00 1.24443378
0.04 1.18E+00 1.47E+00 1.25E+00 1.43758815
0.08 1.01E+00 1.59E+00 1.57E+00 1.80910599
Replicate 2 SQ mean
MMC (pg/ml) Beta actin MSH6 Normalization Fold change
0 8.06E-01 7.05E-01 8.75E-01 1
0.004 7.31E-01 6.32E-01 8.64E-01 0.98806
0.008 4.72E-01 5.88E-01 1.24E+00 1.423209
0.02 5.89E-01 6.99E-01 1.19E+00 1.356298
0.04 8.07E-01 5.01E-01 6.22E-01 0.710719
0.08 4.75E-01 4.14E-01 8.71E-01 0.995261
Replicate 3 SQ mean
MMC (pg/ml) Beta actin MSH6 Normalization Fold change
0 9.08E-01 1.14E+00 1.25E+00 1
0.004 1.22E+00 1.03E+00 8.42E-01 0.670742914
0.008 1.21E+00 1.21E+00 1.00E+00 0.796919787
0.02 9.52E-01 1.05E+00 1.10E+00 0.878764726
0.04 9.77E-01 1.03E+00 1.05E+00 0.836789746
0.08 9.33E-01 9.60E-01 1.03E+00 0.820284645
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Table A.41: Gr-values of BRCA1 gene expression, following exposure (4h) to increasing
concentrations of MMC in TK6 cells
Cj-values
Replicate 1 Replicate 2 Replicate 3
beta-actin BRCA1 beta-actin BRCA1 beta-actin BRCA1
Standard 14.58 20.65 12.18 22.82 11.20 21.82
Standard 14.36 20.43 11.96 22.91 11.43 21.79
Standard 14.61 20.56 12.42 23.10 11.72 22.19
Standard (10-1) 19.13 24.98 15.95 26.93 14.93 25.74
Standard (10-1) 18.99 25.01 15.56 27.10 14.60 24.49
Standard (10-1) 18.36 24.30 26.65 14.26
Standard (10-2) 22.32 28.37 18.84 30.56 17.99 29.11
Standard (10-2) 21.99 28.04 18.61 30.30 17.99 27.81
Standard (10-2) 21.91 18.61 30.00 17.66 32.51
Standard (10-3) 25.97 31.67 22.07 33.95 21.90 31.65
Standard (10-3) 25.70 31.11 21.91 33.64 21.38 31.64
Standard (10-3) 24.71 30.88 21.76 33.62 21.00
0(ig/ml 13.49 18.88 12.92 23.14 11.68 21.25
0|jg/ml 13.76 19.14 12.19 23.02 11.36 21.28
Opg/ml 13.89 19.46 12.76 23.26 11.47 22.11
0.004pg/ml 13.11 18.86 12.75 23.18 11.16 21.59
0.004pg/ml 13.39 18.86 12.83 23.20 10.96 21.50
0.004pg/ml 13.73 19.19 12.60 23.38 11.09 21.76
0.008|ig/ml 14.29 19.09 13.69 23.94 11.21 21.34
0.008|ig/ml 14.10 18.90 13.54 23.75 10.89 21.24
0.008(ig/ml 14.20 19.25 12.91 23.75 11.17 21.77
0.02|ig/ml 14.03 18.90 13.55 23.10 11.27 21.80
0.02pg/ml 13.81 19.13 12.70 23.15 11.52 21.85
0.02pg/ml 14.45 19.72 12.97 23.14 11.50 22.56
0.04pg/ml 14.66 19.00 12.65 23.67 11.20 21.55
0.04pg/ml 14.22 19.19 12.23 23.56 11.20 21.66
0.04|ig/ml 14.84 19.88 12.99 23.76 11.86 21.95
0.08|ig/ml 14.12 19.14 13.15 23.59 11.42 21.73
0.08pg/ml 15.11 19.16 13.16 23.61 11.32 21.75
0.08pg/ml 15.47 19.53 13.76 23.96 11.65 22.06
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Table A.42: Relative fold changes in BRCA1 gene expression, following exposure (4h) to
increasing concentrations of MMC in TK6 cells
Replicate 1 SQ mean
MMC (pg/ml) Beta actin BRCA1 Normalization Fold change
0 2.02E+00 3.06E+00 1.51E+00 1
0.004 2.47E+00 3.43E+00 1.39E+00 0.918286
0.008 1.48E+00 3.19E+00 2.16E+00 1.427359
0.02 1.59E+00 2.91E+00 1.83E+00 1.208449
0.04 1.18E+00 2.73E+00 2.32E+00 1.534094
0.08 1.01E+00 2.81E+00 2.78E+00 1.842273
Replicate 2 SQ mean
MMC (pg/ml) Beta actin BRCA1 Normalization Fold change
0 8.06E-01 9.73E-01 1.21E+00 1
0.004 7.31E-01 9.05E-01 1.24E+00 1.025691
0.008 4.72E-01 6.32E-01 1.34E+00 1.1093
0.02 5.89E-01 9.78E-01 1.66E+00 1.375556
0.04 8.07E-01 6.94E-01 8.60E-01 0.712509
0.08 4.75E-01 6.74E-01 1.42E+00 1.175801
Replicate 3 SQ mean
MMC (pg/ml) Beta actin BRCA1 Normalization Fold change
0 9.08E-01 1.30E+00 1.43E+00 1
0.004 1.22E+00 1.20E+00 9.80E-01 0.687028
0.008 1.21E+00 1.35E+00 1.12E+00 0.782901
0.02 9.52E-01 8.97E-01 9.42E-01 0.660405
0.04 9.77E-01 1.12E+00 1.15E+00 0.803423
0.08 9.33E-01 1.02E+00 1.10E+00 0.770086
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Table A.43: CT-values of XRCC6BP1 gene expression, following exposure (4h) with
increasing concentrations of MMC in TK6 cells
Cj-values
Replicate 1 Replicate 2 Replicate 3
beta-actin XRCC6BP1 beta-actin XRCC6BP1 beta-actin XRCC6BP1
Standard 12.38 24.84 11.76 19.18 14.27 22.76
Standard 12.10 24.72 11.79 19.03 13.94 22.68
Standard 24.94 11.78 19.12 14.14 22.59
Standard (10-1) 15.04 27.95 15.87 22.55 16.37 26.55
Standard (10-1) 14.64 28.38 15.42 22.60 15.65 26.11
Standard (10-1) 27.87 14.60
Standard (10-2) 18.07 31.14 18.55 26.48 19.20 29.92
Standard (10-2) 17.95 30.65 18.13 25.86 19.18 29.52
Standard (10-2) 18.14 25.56 18.61
Standard (10-3) 20.99 35.35 21.83 30.02 22.19 32.58
Standard (10-3) 21.22 35.88 21.87 30.24 21.86 33.12
Standard (10-3) 21.67 22.24 32.88
Opg/ml 11.95 23.07 12.69 19.08 10.83 21.51
Opg/ml 12.01 23.13 12.33 18.89 10.60 21.34
Opg/ml 11.92 23.06 12.20 18.62 10.80 21.45
0.004pg/ml 10.74 22.56 12.15 19.38 10.49 21.34
0.004pg/ml 10.41 22.47 11.89 19.42 10.43 21.32
0.004pg/ml 10.43 22.22 11.93 19.27 10.66 21.38
0.008pg/ml 10.81 22.09 12.55 19.55 10.39 21.30
0.008pg/ml 10.67 22.31 11.71 19.52 10.38 21.34
0.008pg/ml 10.61 22.48 19.69 10.29
0.02|ig/ml 10.76 22.56 12.04 19.30 10.80 20.83
0.02pg/ml 10.77 22.38 11.88 18.99 10.79 21.32
0.02pg/ml 9.89 22.36 11.92 19.03 10.72
0.04pg/ml 11.42 23.83 12.34 19.67 10.49 21.59
0.04pg/ml 11.43 23.88 12.23 19.04 10.61 21.55
0.04pg/ml 11.43 23.64 12.59 10.32 21.68
0.08pg/ml 11.22 23.15 11.95 18.70 10.71 21.28
0.08pg/ml 11.31 22.83 12.63 19.19 10.86 21.55
0.08|ig/ml 10.86 22.41 12.65 19.55 11.19 21.97
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Table A.44: Relative fold changes in XRCC6BP1 gene expression, following exposure (4h)
with increasing concentrations of MMC in TK6 cells
Replicate 1 SQ mean
MMC (pg/ml) Beta actin XRCC6BP1 Normalization Fold change
0 1.11E+00 2.77E+00 2.51E+00 1
0.004 3.37E+00 4.34E+00 1.29E+00 0.51335614
0.008 2.94E+00 4.71E+00 1.60E+00 0.63896158
0.02 3.69E+00 4.28E+00 1.16E+00 0.46105969
0.04 1.67E+00 1.76E+00 1.05E+00 0.41878544
0.08 2.12E+00 3.43E+00 1.62E+00 0.64354456
Replicate 2 SQ mean
MMC (pg/ml) Beta actin XRCC6BP1 Normalization Fold change
0 6.79E-01 1.10E+00 1.62E+00 1
0.004 9.00E-01 8.00E-01 8.89E-01 0.549336
0.008 8.47E-01 6.90E-01 8.14E-01 0.503048
0.02 9.25E-01 9.39E-01 1.02E+00 0.627327
0.04 6.82E-01 8.15E-01 1.20E+00 0.738833
0.08 6.86E-01 9.34E-01 1.36E+00 0.84141
Replicate 3 SQ mean
MMC (pg/ml) Beta actin XRCC6BP1 Normalization Fold change
0 1.44E+01 2.50E+00 1.74E-01 1
0.004 1.74E+01 2.66E+00 1.53E-01 0.87851011
0.008 2.00E+01 2.70E+00 1.35E-01 0.77619614
0.02 1.40E+01 3.23E+00 2.31E-01 1.32612183
0.04 1.82E+01 2.22E+00 1.22E-01 0.7027906
0.08 1.25E+01 2.27E+00 1.82E-01 1.0457999
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Table A.45: Cj-values of p21 gene expression, following exposure (4h) with increasing
concentrations of MMC in TK6 cells
Cj-values
Replicate 1 Replicate 2 Replicate 3
beta-actin p21 beta-actin p21 beta-actin p21
Standard 13.78 20.77 12.60 18.57 15.73 20.69
Standard 13.86 20.83 13.59 19.25 15.91 20.95
Standard 20.61
Standard (10-1) 17.99 24.76 17.88 24.14 18.26 24.80
Standard (10-1) 17.55 24.15 17.85 23.87 18.15 24.55
Standard (10-1) 17.48
Standard (10-2) 21.67 27.48 20.54 27.12 21.40 26.89
Standard (10-2) 21.38 27.32 20.29 26.25 20.77 26.59
Standard (10-2) 20.65
Standard (10-3) 23.58 30.69 23.59 30.03 23.96 31.28
Standard (10-3) 23.61 30.66 23.49 29.72 23.89 30.98
Standard (10-3) 23.23 23.65
Opg/ml 14.31 19.89 16.13 21.00 14.21 20.06
Opg/ml 14.35 19.76 15.94 20.70 14.34 19.74
0|ig/ml 14.87 19.61 16.90 20.64 14.51 20.16
0.004|ig/ml 13.82 20.16 15.47 19.13 15.02 20.00
0.004jjg/ml 14.01 20.05 15.34 19.12 14.98 19.53
0.004|jg/ml 14.37 20.11 15.50 18.89 15.18 19.56
0.008|ig/ml 14.13 19.78 13.57 19.27 14.97 20.22
0.008|jg/ml 13.91 19.83 14.67 19.62 15.17 19.83
0.008pg/ml 14.36 19.76 15.84 20.82
0.02pg/ml 13.91 19.86 16.00 20.53 14.67 19.38
0.02pg/ml 13.95 19.66 16.08 20.38 14.73 19.13
0.02|ig/ml 14.57 19.60 16.34 20.93 14.85 19.65
0.04pg/ml 14.33 19.81 15.64 20.36 13.81 18.41
0.04pg/ml 14.22 19.82 15.93 20.27 13.50 18.37
0.04iig/ml 14.51 19.69 20.18 13.83 18.67
0.08pg/ml 13.28 18.97 12.96 17.87 14.07 17.84
0.08|jg/ml 13.16 19.02 13.10 18.17 13.91 17.99
0.08pg/ml 13.71 19.25 13.43 18.28 14.70 18.60
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Table A.46: Relative fold changes in p21 gene expression, following exposure (4h) with
increasing concentrations of MMC in TK6 cells
Replicate 1 SQ mean
MMC (pg/ml) Beta actin p21 Normalization Fold change
0 8.65E-01 2.18E+00 2.516313 1
0.004 1.18E+00 1.69E+00 1.426477 0.56689167
0.008 1.12E+00 2.11E+00 1.879715 0.7470114
0.02 1.13E+00 2.24E+00 1.986417 0.78941554
0.04 9.53E-01 2.14E+00 2.24004 0.89020693
0.08 1.94E+00 3.48E+00 1.796278 0.71385305
Replicate 2 SQ mean
MMC (pg/ml) Beta actin p21 Normalization Fold change
0 1.76E-01 4.49E-01 2.554029 1
0.004 3.10E-01 1.37E+00 4.432752 1.735592
0.008 6.22E-01 1.07E+00 1.71805 0.672682
0.02 1.93E-01 5.04E-01 2.614411 1.023642
0.04 2.45E-01 6.21E-01 2.532755 0.99167
0.08 1.48E+00 2.53E+00 1.71544 0.67166
Replicate 3 SQ mean
MMC (pg/ml) Beta actin p21 Normalization Fold change
0 3.11E+00 1.90E+00 0.610326 1
0.004 1.69E+00 2.33E+00 1.378748 2.259035
0.008 1.68E+00 1.59E+00 0.945399 1.549006
0.02 2.21E+00 2.89E+00 1.306243 2.140239
0.04 5.40E+00 5.40E+00 1.001071 1.640224
0.08 3.58E+00 6.99E+00 1.952407 3.198958
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Table A.47: C t - values of p21 gene expression, following exposure (4h) with increasing
concentrations of MMC in AHH-1 cells
CT-values
Replicate 1 Replicate 2 Replicate 3
beta-actin p21 beta-actin p21 beta-actin p21
Standard 13.78 20.77 12.60 18.57 15.73 20.69
Standard 13.86 20.83 13.59 19.25 15.91 20.95
Standard 20.61
Standard (10-1) 17.99 24.76 17.88 24.14 18.26 24.80
Standard (10-1) 17.55 24.15 17.85 23.87 18.15 24.55
Standard (10-1) 17.48
Standard (10-2) 21.67 27.48 20.54 27.12 21.40 26.89
Standard (10-2) 21.38 27.32 20.29 26.25 20.77 26.59
Standard (10-2) 20.65
Standard (10-3) 23.58 30.69 23.59 30.03 23.96 31.28
Standard (10-3) 23.61 30.66 23.49 29.72 23.89 30.98
Standard (10-3) 23.23 23.65
Opg/ml 12.79 19.69 12.52 18.50 13.75 19.80
Opg/ml 12.79 19.62 12.58 19.02 13.87 19.69
Opg/ml 13.41 19.99 13.62 20.03 14.27 20.00
0.004|jg/ml 12.84 19.65 14.47 21.66 13.85 19.72
0.004|ig/ml 12.84 19.41 14.38 21.76 13.74 19.77
0.004pg/ml 13.19 19.67 14.34 22.14 14.03 20.30
0.008pg/ml 12.55 19.35 13.31 18.91 14.99 20.26
0.008pg/ml 12.30 19.20 13.54 19.18 14.73 20.06
0.008pg/ml 12.50 19.60 13.81 19.51 15.34 20.64
0.02jjg/ml 13.46 19.95 14.01 19.48 14.69 20.06
0.02pg/ml 13.27 19.96 13.90 19.58 14.61 20.12
0.02pg/ml 13.72 19.97 14.23 19.50 15.37 20.54
0.04|ig/ml 13.91 20.08 13.81 20.23 15.04 20.45
0.04pg/ml 13.83 20.26 13.97 20.93 14.86 20.60
0.04|ig/ml 14.50 20.11 14.82 20.76 15.15 20.81
0.08pg/ml 13.41 19.70 14.38 19.83 16.05 20.94
0.08|ig/ml 13.06 19.80 13.91 19.72 16.05 21.16
0.08|jg/ml 13.75 19.86 14.72 20.07 16.65 21.64
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Table A.48: Relative fold changes in p21 gene expression, following exposure (4h) with
increasing concentrations of MMC in AHH-1 cells
Replicate 1 SQ mean
MMC (pg/ml) Beta actin p21 Normalization Fold change
0 2.572307 2.15745 0.838722 1
0.004 2.608381 2.456625 0.94182 1.12292236
0.008 3.740781 2.817722 0.753244 0.89808581
0.02 1.792782 1.875219 1.045983 1.24711541
0.04 1.184305 1.64485 1.388874 1.65594038
0.08 1.914941 2.117818 1.105944 1.3186068
Replicate 2 SQ mean
MMC (pg/ml) Beta actin p21 Normalization Fold change
0 1.85E+00 1.36E+00 0.735704 1
0.004 6.31E-01 2.25E-01 0.35642 0.484461
0.008 1.13E+00 1.26E+00 1.107045 1.504742
0.02 8.05E-01 1.01E+00 1.255649 1.706731
0.04 7.54E-01 4.98E-01 0.660799 0.898186
0.08 6.75E-01 8.05E-01 1.194012 1.622952
Replicate 3 SQ mean
MMC (pg/ml) Beta actin p21 Normalization Fold change
0 4.407694 2.106465 0.477906 1
0.004 4.707765 1.98525 0.421697 0.882384
0.008 1.791605 1.513517 0.844783 1.767673
0.02 2.033471 1.592654 0.783219 1.638854
0.04 1.762811 1.216742 0.690229 1.444275
0.08 0.625903 0.797646 1.274393 2.666615
i
t
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Table A.49: C t - values of p21 gene expression, following exposure (24h) with increasing
concentrations of araC in TK6 cells
Cx-values
Replicate 1 Replicate 2 Replicate 3
beta-actin p21 beta-actin p21 beta-actin p21
Standard 12.96 22.02 12.59 22.50 14.42 16.85
Standard 12.94 22.54 12.72 22.53 14.13 16.81
Standard 12.66 22.39 17.20
Standard (10-1) 17.21 27.10 18.18 28.05 17.07 20.14
Standard (10-1) 17.06 25.78 17.85 27.22 16.28 19.99
Standard (10-1) 17.07 17.74
Standard (10-2) 20.17 29.59 20.95 31.27 20.21 23.11
Standard (10-2) 19.74 29.19 20.78 30.59 19.71 22.64
Standard (10-2) 20.58 19.53 22.22
Standard (10-3) 22.98 32.65 23.04 34.37 24.15 26.57
Standard (10-3) 22.55 32.92 22.82 33.62 23.48 26.36
Standard (10-3)
0|ig/ml 13.37 21.54 12.74 22.23 16.25 17.44
0|jg/ml 13.17 21.38 12.73 21.66 15.87 17.38
0|ig/ml 13.37 21.16 12.87 21.67 16.16 17.38
0.0007|ig/ml 13.09 20.94 12.81 21.41 15.40 17.05
0.0007|ig/ml 13.13 20.66 12.72 21.18 15.33 16.76
0.0007|jg/ml 13.24 20.42 12.96 21.24 16.07 17.01
0.005pg/ml 12.21 19.75 13.05 21.31 15.19 16.88
0.005pg/ml 12.13 19.54 12.79 20.99 15.55 16.91
0.005gg/ml 12.31 19.50 12.87 21.09 15.90 17.12
O.Oljjg/ml 13.24 20.04 12.93 22.11 15.74 16.86
0.01|ig/ml 13.16 20.32 12.88 21.90 16.61 16.48
0.01 pg/ml 13.45 20.95 12.79 22.17 16.48 16.98
0.07pg/ml 12.03 18.87 12.59 20.48 15.84 16.44
0.07pg/ml 12.08 18.78 12.43 20.14 15.84 16.42
0.07|ig/ml 12.54 18.73 12.59 20.27 16.10 16.36
0.1 jig/ml 11.90 19.33 11.42 18.95 15.85 15.78
0.1 pg/ml 12.79 19.33 11.54 18.80 15.74 15.82
0.1 pg/ml 13.84 19.33 12.12 19.03 16.55 16.01
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Table A.50: Relative fold changes in p21 gene expression, following exposure (24h) with
increasing concentrations of araC in TK6 cells
Replicate 1 SQ mean
araC (pg/ml) Beta actin p21 Normalization Fold change
0 1.11E+00 2.24E+00 2.022245417 1
0.0007 1.23E+00 3.56E+00 2.890254164 1.429230172
0.005 2.42E+00 7.25E+00 2.99636522 1.48170207
0.01 1.12E+00 4.26E+00 3.786876183 1.872609601
0.07 2.45E+00 1.24E+01 5.05478457 2.499590073
0.1 1.79E+00 8.65E+00 4.820452615 2.383712963
Replicate 2 SQ mean
araC (pg/ml) Beta actin p21 Normalization Fold change
0 1.58E+00 1.92E+00 1.22E+00 1
0.0007 1.52E+00 2.68E+00 1.76E+00 1.445972
0.005 1.45E+00 2.93E+00 2.02E+00 1.656356
0.01 1.49E+00 1.68E+00 1.13E+00 0.929404
0.07 1.85E+00 4.81E+00 2.60E+00 2.13737
0.1 3.31E+00 1.09E+01 3.29E+00 2.70406
Replicate 3 SQ mean
araC (pg/ml) Beta actin p21 Normalization Fold change
0 1.98E-01 6.76E-01 3.413017 1
0.0007 2.91E-01 9.57E-01 3.291488 0.964392
0.005 3.00E-01 9.35E-01 3.118143 0.913603
0.01 1.79E-01 1.09E+00 6.102837 1.788106
0.07 2.23E-01 1.42E+00 6.350254 1.860598
0.1 2.1 IE-01 2.13E+00 10.09687 2.958341
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Table A.51: Gp-values of p21 gene expression, following exposure (24h) with increasing
concentrations of araC in AHH-1 cells
Cj-values
Replicate 1 Replicate 2 Replicate 3
beta-actin p21 beta-actin p21 beta-actin p21
Standard 12.96 22.02 12.54 19.61 12.91 19.57
Standard 12.94 22.54 12.26 19.64 12.99 19.60
Standard 12.65 20.02 12.73 19.66
Standard (10-1) 17.21 27.10 17.13 24.53 16.20 22.99
Standard (10-1) 17.06 25.78 17.02 24.34 15.42 22.76
Standard (10-1) 17.07 15.96 23.68 22.20
Standard (10-2) 20.17 29.59 20.10 27.23 19.63 26.27
Standard (10-2) 19.74 29.19 19.62 26.95 18.69 25.32
Standard (10-2) 19.24 26.60 18.62
Standard (10-3) 22.98 32.65 23.22 30.70 22.38 29.61
Standard (10-3) 22.55 32.92 22.95 29.45 21.91 29.24
Standard (10-3)
0|ig/ml 11.10 21.15 12.36 20.38 12.66 18.82
0|ig/ml 10.87 20.99 12.75 20.38 12.65 18.73
0|ig/ml 11.08 21.09 12.80 20.56 13.02 18.60
0.0007|jg/ml 11.99 21.85 12.69 19.76 12.61 18.83
0.0007pg/ml 11.93 21.83 12.43 20.57 12.64 18.61
0.0007pg/ml 12.01 21.81 12.97 21.38 12.95 18.49
0.005Mg/ml 12.82 21.84 13.65 20.30 12.10 19.03
0.005pg/ml 12.61 21.73 13.60 20.55 12.14 18.70
0.005pg/ml 12.86 21.80 13.67 20.99 12.27 18.46
0.01|ig/ml 12.28 21.26 13.15 19.46 12.18 18.07
0.01 pg/ml 12.04 21.44 13.29 19.79 12.20 18.52
0.01 jig/ml 12.18 21.34 14.02 20.16 12.35 18.36
0.07|ig/ml 12.97 21.87 14.06 20.94 12.71 18.44
0.07pg/ml 13.01 21.91 14.07 20.93 12.69 18.19
0.07|ig/ml 13.37 21.88 14.60 20.73 12.93 18.02
0.1(jg/ml 10.86 20.48 14.17 20.45 13.66 19.28
0.1|ig/ml 10.74 20.50 14.03 21.35 13.59 18.62
0.1 pg/ml 11.07 20.67 14.70 20.46 13.62 18.31
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Table A.52: Relative fold changes in p21 gene expression, following exposure (24h) with
increasing concentrations of araC in AHH-1 cells
Replicate 1 SQ mean
araC (pg/ml) Beta actin p21 Normalization Fold change
0 5.74E+00 2.70E+00 0.469849065 1
0.0007 2.87E+00 1.62E+00 0.565511724 1.203602956
0.005 1.63E+00 1.67E+00 1.022824181 2.176920754
0.01 2.51E+00 2.25E+00 0.897359587 1.909889055
0.07 1.28E+00 1.57E+00 1.229710472 2.617245757
0.1 6.29E+00 3.83E+00 0.60885054 1.295842825
Replicate 2 SQ mean
araC (pg/ml) Beta actin p21 Normalization Fold change
0 1.095581 0.830061 0.757645 1
0.0007 1.053292 0.834506 0.792284 1.045719
0.005 0.559313 0.749696 1.340388 1.76915
0.01 0.636871 1.296683 2.03602 2.687301
0.07 0.380185 0.620268 1.63149 2.153371
0.1 0.368611 0.69544 1.88665 2.490151
Replicate 3 SQ mean
araC (pg/ml) Beta actin p21 Normalization Fold change
0 1.05E+00 1.74E+00 1.67E+00 1
0.0007 1.08E+00 1.84E+00 1.71E+00 1.025488153
0.005 1.63E+00 1.75E+00 1.07E+00 0.641065661
0.01 1.55E+00 2.34E+00 1.51E+00 0.904441648
0.07 1.04E+00 2.50E+00 2.40E+00 1.440217606
0.1 5.50E-01 1.79E+00 3.24E+00 1.944379143
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Table A.53: Cx-values of p21 gene expression, following exposure (24h) with increasing
concentrations of araC in MCL-5 cells
CT-values
Replicate 1 Replicate 2 Replicate 3
beta-actin p21 beta-actin p21 beta-actin p21
Standard 12.50 21.49 11.61 19.56 12.59 22.50
Standard 12.29 21.79 11.52 19.40 12.72 22.53
Standard 11.79 19.58 12.66 22.39
Standard (10-1) 16.82 26.01 14.88 23.38 18.18 28.05
Standard (10-1) 16.32 25.95 14.79 23.06 17.85 27.22
Standard (10-1) 14.60 22.67 17.74
Standard (10-2) 19.99 29.50 17.65 25.85 20.95 31.27
Standard (10-2) 19.63 28.91 17.59 25.99 20.78 30.59
Standard (10-2) 17.62 25.58 20.58
Standard (10-3) 22.36 33.12 20.92 29.68 23.04 34.37
Standard (10-3) 22.48 32.79 21.01 29.37 22.82 33.62
Standard (10-3) 21.88
Opg/ml 13.10 21.28 13.60 22.80 12.52 21.98
Opg/ml 12.79 21.87 13.67 22.49 12.73 22.34
Opg/ml 13.21 22.09 13.87 22.62 12.96 22.77
0.0007pg/ml 12.65 21.48 13.56 22.92 12.32 23.08
0.0007pg/ml 11.90 21.34 13.51 22.77 12.29 22.88
0.0007pg/ml 12.46 21.36 13.59 22.98 12.82 22.83
0.005pg/ml 12.20 21.83 13.64 22.01 12.80 22.97
0.005pg/ml 12.57 21.55 13.41 21.81 12.81 23.04
0.005pg/ml 12.66 21.13 13.79 21.96 12.98 23.30
0.01 pg/ml 12.04 21.12 12.88 20.96 12.29 23.01
0.01 pg/ml 12.18 21.14 13.02 20.94 12.57 22.70
0.01 pg/ml 12.47 21.58 13.02 21.20 13.05 23.12
0.07pg/ml 12.70 20.88 13.11 20.88 12.54 22.06
0.07pg/ml 12.47 20.84 12.96 20.85 12.55 21.67
0.07pg/ml 12.66 20.84 13.53 20.77 12.93 22.00
0.1 pg/ml 11.67 20.10 12.80 19.76 12.76 22.07
0.1 pg/ml 11.63 20.05 12.72 20.33 12.75 21.91
0.1 pg/ml 12.12 20.38 13.23 20.30 12.84 22.01
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Table A.54: Relative fold changes in p21 gene expression, following exposure (24h) with
increasing concentrations of araC in MCL-5 cells
Replicate 1 SQ mean
araC (pg/ml) Beta actin p21 Normalization Fold change
0 8.95E-01 1.11E+00 1.235675 1
0.004 1.50E+00 1.34E+00 0.895119 0.724397
0.008 1.33E+00 1.27E+00 0.955133 0.772965
0.02 1.59E+00 1.46E+00 0.916573 0.741759
0.04 1.20E+00 1.88E+00 1.559399 1.261982
0.08 2.16E+00 2.87E+00 1.329965 1.076306
Replicate 2 SQ mean
araC (pg/ml) Beta actin p21 Normalization Fold change
0 2.10E-01 1.15E-01 0.545692 1
0.0007 2.36E-01 9.55E-02 0.404323 0.740937
0.005 2.27E-01 1.89E-01 0.829647 1.520359
0.01 3.65E-01 3.55E-01 0.97324 1.783498
0.07 3.12E-01 4.08E-01 1.305081 2.39161
0.1 3.86E-01 6.82E-01 1.769863 3.24334
Replicate 3 SQ mean
araC (pg/ml) Beta actin p21 Normalization Fold change
0 1.63E+00 1.42E+00 8.73E-01 1
0.0007 1.95E+00 9.99E-01 5.13E-01 0.587396
0.005 1.49E+00 8.99E-01 6.04E-01 0.692178
0.01 1.77E+00 9.94E-01 5.63E-01 0.644797
0.07 1.70E+00 1.84E+00 1.08E+00 1.237394
0.1 1.57E+00 1.74E+00 1.11E+00 1.270464
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Appendix VII
Western Blots
Figure A.5: Representative Western Blots for p53 and phosphos-p53 following MMC 
treatment in TK6 cells (Replicate 1 to 3)
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Figure A.6: Representative Western Blots for p53 and phosphos-p53 following MMC
treatment in AHH-1 cells (Replicate 1 to 3)
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Figure A.7: Representative Western Blots for p53 and phosphos-p53 following araC
treatment in TK6 cells (Replicate 1 to 3)
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Figure A.8: Representative Western Blots for p53 and phosphos-p53 following araC
treatment in AHH-1 cells (Replicate 1 to 3)
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Figure A.9: Representative Western Blots for p53 and phosphos-p53 following araC
treatment in MCL-5 cells (Replicate 1 to 3)
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Appendix VIII
Apoptosis results
Table A.55: Flow cytometric analysis of apoptosis in TK6 cells treated with 4h of MMC. 
Staurosporin was used as a positive control.
MMC (pg/ml) % early apoptotic % late apoptotic %dead cells
0 0.205581778 2.804680183 24.4112812
0.002 0.169598731 3.22034498 27.1388548
0.004 0.127322486 2.115392439 23.1531928
0.006 0.286247854 3.45387751 23.7130678
0.008 0.153506919 3.150629666 27.2894347
0.01 0.202130496 3.002960705 24.5793689
0.02 0.159741045 2.93954491 24.626641
0.04 0.188918268 2.920127671 26.244557
0.06 0.20734541 2.407648329 23.4933976
0.08 0.169269517 2.72810154 25.5900046
0.1 0.161842952 3.578054799 31.7730298
l|iM  Staurosporine (FTTC-pos) 5.712631356
I Table A.56: Flow cytometric analysis of apoptosis in TK6 cells treated with 24h of araC. 
Staurosporin was used as a positive control.
araC (pg/ml) % early apoptotic % late apoptotic % dead cells
0 0.05663 1.595473 25.05149
0.0001 0.055515 1.890797 23.62957
0.0003 0.053539 1.270249 29.08727
0.0005 0.048329 1.385316 31.02858
0.0007 0.031296 1.050755 26.78154
0.0009 0.028512 1.22981 28.2823
0.001 0.038313 1.216312 29.66936
0.003 0.069749 1.870813 29.13842
0.005 0.061986 1.424695 24.666
0.007 0.048805 1.132638 33.16454
0.009 0.072746 1.447228 32.58757
0.01 0.078127 1.545029 29.30622
0.03 0.048481 1.963403 34.51287
0.07 0.081076 3.095258 44.52838
0.1 0.069369 5.24765 46.5181
lpM  Staurosporine (FTTC-pos) 3.931486
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Appendix IX
Cell cycle results
Table A.57: Cell cycle analysis in TK6 cells treated with MMC for 4h
MMC (Mg/ml) G0/G1 S-phase G2/M
0 47.3 13.7666667 37.3
0.002 50.1333333 14.5 33.8333333
0.004 50.7333333 14.6666667 33.2666667
0.006 47.5 14.4333333 36.8333333
0.008 47.2 14.6 36.7333333
0.01 46.4 14.4333333 37.5333333
0.02 46.7 14.7 37.1666667
0.04 45 15.1 38.5
0.06 45.1333333 16.5333333 37.1
0.08 44.3333333 16.8666667 37.4333333
0.1 42.6666667 16.4333333 39.7
Table A.58: Cell cycle analysis in TK6 cells treated with MMC for 4h +18h recovery
MMC (pg/ml) G1/G0 S-phase G2/M
0 48.7666667 13.1666667 36.5
0.006 45.7 11.6666667 40.4
0.02 45.1666667 11.2666667 41.4333333
0.06 41.6333333 11.3 44.6333333
0.1 32.2666667 12.2 52.5666667
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Table A.59: Cell cycle analysis in TK6 cells treated with araC for 24h
araC (|ig/ml) G0/G1 S-phase G2/M
0 48.8666667 13.2 36.1666667
0.0001 49.6 13.9666667 34.1333333
0.0003 47.7 14.0333333 36.4
0.0005 47.0333333 13.9666667 37.3333333
0.0007 45.0666667 14.4 38.8
0.0009 47.7 14.4 35.8666667
0.001 48.9 14.6 34.4666667
0.003 47.9333333 16.1 34.0333333
0.005 46.1 16.0333333 35.7
0.007 49.3666667 17.1333333 31.6333333
0.009 47.2666667 16.6666667 33.4
0.01 46.5333333 16.8666667 34.1666667
0.03 52.9333333 16.0333333 26.8333333
0.07 57.4 12.1666667 20.8666667
0.1 49.6666667 13.4 27.2333333
Table A60: Cell cycle analysis in TK6 cells treated with araC for 24h +18h recovery
araC (pg/ml) G1/G0 S-phase G2/M
0 53.2 10.2 34.7666667
0.0005 53.3666667 10.9 33.8
0.009 57.8 11.2333333 29
0.03 59.1333333 10.1666667 28.2333333
0.07 56.7333333 10.1666667 26.4
0.1 60 10.1666667 20.7
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